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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) is one of the European Union’s decentralised 
agencies. Established in 1993 and based in Lisbon, it is the 
central source of comprehensive information on drugs and 
drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, 
objective, reliable and comparable information on drugs and 
drug addiction. In doing so, it provides its audiences with an 
evidence-based picture of the drug phenomenon at European 
level.
The Centre’s publications are a prime source of information 
for a wide range of audiences including policy-makers and 
their advisers; professionals and researchers working in the 
drugs field; and, more broadly, the media and general public.
EMCDDA monographs are comprehensive scientific 
publications containing thematic papers prepared in the 
context of the Centre’s activities. Topics cover a wide range 
of issues relating to science, policy, epidemiology and best 
practice.
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Introduction
Smoked, eaten, imbibed — or just talked about — it seems the world has a strong 
appetite for cannabis. An estimated one in five European adults have tried it. Thirteen 
million Europeans have consumed it in the past month. Globally, nearly 50 000 tonnes 
of cannabis herb or resin is produced for consumption each year. Little wonder, then, 
that cannabis has become a controversial cultural and commercial phenomenon. Today, 
cannabis has a unique ability to divide opinion among policymakers, scientists, law 
enforcers, drugs professionals and consumers.
This EMCDDA cannabis monograph addresses one basic question. How can I find 
quality information on cannabis, amid all the bias and opinion? During the editing of 
this monograph it soon became clear that the EMCDDA was entering an area crowded 
with general guides, even competing cannabis monographs. This is where the idea of 
a cannabis ‘reader’ emerged. Our audience — researchers, parliamentarians, drugs 
professionals, students, European citizens — is currently faced with an overload of 
professional publications. Added to this is the daily flood of information on the Internet, 
often crusading in nature, and sometimes misleading. This threatens to obscure the 
genuine progress made in cannabis research during the past two decades.
The EMCDDA cannabis reader underlines the point that cannabis is not just a static, 
unchanging plant, but a dynamic product that is subject to gradual evolution in potency, 
prevalence, cultivation, legislative and public health concerns. In this monograph, 
leading experts provide short, sharp insights on a range of cannabis topics while 
offering advice on further reading for each topic. Brief editorial notes provide concise 
introductions to each topic, occasionally drawing attention to political sensitivities and 
the need for a ‘critical eye’. So this cannabis reader has a value, both as a shortcut to 
researchers entering the area and a synthesis for experts.
You will find a wide range of views expressed in the chapters in this monograph, not 
all of them in agreement. The arguments, tone and conclusion of each chapter is the 
responsibility of the author alone, and is not necessarily endorsed or supported by the 
EMCDDA. This reflects the wider discourse on cannabis where different positions and 
perspectives often lead to different conclusions being drawn from the same evidence. 
We believe each chapter represents a useful contribution to the overall debate, even if 
their individual perspectives differ.
Introduction
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Two volumes, multiple audiences: policymakers, 
enforcers, researchers, professionals
The monograph is divided into two volumes, each comprising three sections. There are 
a number of reasons for the two-volume approach. While complementary, each has a 
slightly different audience. The first volume centres on political, legislative, commercial 
and social developments relating to cannabis. Its core audience thus comprises 
policymakers, sociologists, historians, journalists and those involved in enforcement. 
The second volume is very much centred on drugs professionals working in the fields of 
treatment, prevention and healthcare.
Volume 1
Cannabis in the past•	
Policies, legislation and control strategies•	
Supply and production issues•	
Volume 2
Epidemiology•	
Health effects of cannabis use•	
Prevention and treatment•	
Changing perspectives: from global issues to local 
experiences
What unites both volumes is an attempt to fuse general chapters with specific case 
studies. Within each section, you will encounter a progression from a ‘top level’ to a 
‘close-up’ view of the subject. So each section begins with chapters providing a general 
introduction to a single cannabis issue, often of an encyclopaedic nature, together with a 
summary of the current state of scientific research. The monograph then ‘zooms in’ with 
a case study about a specific aspect of cannabis.
In Volume 1 ...
In Volume 1 we can read an autobiographical article on events in the United Kingdom 
in the late 1960s, recent cannabis developments in the EU’s new Member States, the 
cannabis resin trade linking Morocco to northern Europe, the closure of Pusher Street 
in the Copenhagen commune of Christiania, and information on how coffee shops 
developed in the Netherlands. While these articles focus only on smaller pieces of the 
cannabis puzzle, they provide insights into the many different ways Europe has dealt 
with cannabis.
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Foreword
Cannabis is Europe’s most-consumed illicit drug. An estimated 13.4 million European 
adults have used cannabis in the last month. Cannabis also supports a multibillion euro 
market across the EU, with the share of cannabis resin in many markets losing ground 
to herbal cannabis. Moreover, treatment demand for cannabis use is rising in many 
Member States. Such facts underline the importance of having a clear understanding of 
what is known about cannabis in Europe, for example its impact on public health, how 
cannabis controls are enforced and the implications of cannabis use for public health 
responses.
Cannabis is also, perhaps, Europe’s most heavily debated illicit drug. Reviews of 
the health effects and legal status of cannabis have been carried out by numerous 
governments and agencies over recent decades. And there is frequent, sometimes 
heated, discussion about cannabis in the political arena, amongst others in relation 
to mental health problems, the therapeutic potential of cannabinoids, policing and 
enforcement, legislation and sentencing.
So it is with great pleasure that I introduce this important body of work on cannabis. It is 
the most comprehensive publication the EMCDDA has ever produced, and the first time 
the Centre has attempted to review a single substance in such an all-encompassing way. 
We must extend our gratitude to all authors who have contributed to this monograph. 
Excellent work was carried out by Sorad in Sweden, together with reviewers from the 
EMCDDA’s Scientific Committee, and two independent scientific editors, John Witton 
and Wendy Swift. The result is a ‘cannabis reader’: a genuine navigational aid to 
research, debate and policy-making on the substance. The reader approaches cannabis 
from many angles, and will appeal to a wide audience, ranging from ‘beginners’ 
approaching the subject from other disciplines to drug researchers and professionals 
who are familiar with the literature and who may appreciate some synthesis of the state-
of-the-art in current research or practice.
A cannabis ‘reader’
While cannabis is the most consumed illicit drug worldwide, politically cannabis is a 
great divider. The illegality of the drug means that the evidence base is often patchy. 
Lobbyists, libertarians, prohibitionists, think-tanks and commercial interests all by 
definition speak to the issue from divergent positions. Even research in this area can 
sometimes appear to be influenced by a political as well as a scientific agenda. The 
information base in this area is considerable and this fact alone poses a serious 
challenge to any reader who attempts to navigate it. The goal of this publication is to 
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gather knowledge that will provide a base for improved policy approaches to cannabis 
in the future. In reaching this goal, leading experts have been asked to clarify what is 
known and what is not known about cannabis; on which issues scientists agree and 
which issues are still under debate.
In the development of the monograph the EMCDDA has been keen to provide a non-
judgemental, non-partisan approach to the evidence. However, our aim has also been 
to enable each author’s ideas to be fully expressed. As leading experts in the field, they 
are qualified to make judgements where they feel fit, and while most of the monograph 
is analytical and descriptive, the nature of the subject matter means that, in places, 
opinions and views are expressed which may be perceived as controversial. Not all the 
views expressed here are in agreement.
Chapters have been peer-reviewed by the EMCDDA’s Scientific Committee and further 
edited by qualified scientific editors. The EMCDDA has introduced each chapter, and 
where opinions are expressed, references to counter-arguments are given, together with 
a reading list, for those seeking to explore the subject further. Authors have also been 
given the opportunity to adapt their chapters based on peer feedback. Nonetheless, the 
chapters remain very much the work of the respective authors. They should be read with 
the proviso that any views expressed should neither be considered those of the EMCDDA 
nor the EU institutions in relation to cannabis.
Maximising the shelf-life of the monograph
One of the challenges with working on illicit drugs is that the field is in constant 
evolution. Use patterns and prevalence, use context and even routes of administration 
and potency of product can change substantially over time. This is particularly the case 
for a drug like cannabis, where our understanding of the public health impact of the 
use of the drug is growing almost daily. Another example of this difficulty is the field of 
medicinal cannabis, where a number of new medicines are currently being developed 
in various parts of the world, with considerable uncertainty as to the scope and range of 
potential therapeutic applications.
What is certain is that this will not be the last monograph published on cannabis. There 
is a publication cycle of one governmental or think-tank monograph on cannabis every 
few weeks, and this is likely to continue. Around 20 major books on cannabis are 
produced by commercial publishers each year, in different languages, with many more 
in the specialised and scientific literature. So the first volume of the monograph includes 
an Appendix that sketches a brief history of cannabis monographs and grey literature, 
referring to the large range of monographs on cannabis. The EMCDDA monograph 
hopes to (i) identify the producers of literature on cannabis, (ii) illustrate the range in 
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thematic focus of publications and (iii) provide a one-stop research resource for recent 
major publications on cannabis. This Appendix will reside in a more dynamic form on 
our website. We hope it will provide an important stepping stone to information on 
cannabis, published at national, European and global levels.
What this reader adds to the literature
Each chapter is preceded by a section entitled ‘Setting the context’. These are provided 
to guide readers through the monograph, to offer suggestions for further reading, 
and to draw attention to the cycles of reporting on cannabis — often annual — by 
organisations such as the UNODC, the EMCDDA and our Reitox National focal points.
Readers will be interested in knowing what they will gain from this publication. The 
first is the multidimensional approach to the subject matter. It describes cannabis as 
seen from different perspectives: historical and cultural, pharmacological, sociological, 
legal and policy-related, and treatment- and practitioner-related. The second is 
the monograph’s supranational and European focus. While numerous cannabis 
monographs have been written at a national or multilateral level in Europe in the 
past decade, this one can claim EU-wide relevance. It is backed by the EMCDDA’s 
epidemiological statistics, based on reporting from the Reitox network and the Centre’s 
privileged position of being able to select a strong team of authors for the monograph. 
Thirdly, the monograph reflects emerging trends, for example in legislative approaches, 
treatment demand and provision and cannabis potency.
We hope you will appreciate the effort invested in this monograph. It provides a step 
back from the EMCDDA’s annual monitoring activities. This wider perspective is both 
refreshing and eye-opening, even to those of us who are seasoned experts in the field.
Wolfgang Götz
Director, EMCDDA
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Overview of Volume 1
Part I: Cannabis in the past
 1 Cannabis as medicine in Europe in the 19th century 
Manfred Fankhauser
 2 The re-emergence of the therapeutic use of cannabis products: recent developments 
and future prospects 
John Witton
 3 The pharmacology of cannabis: issues for understanding its use 
Desmond Corrigan
 4 Soma, the Wootton Report and cannabis law reform in Britain during the  
1960s and 1970s 
Stephen Abrams
 5 Cannabis’s role in drawing attention to ‘the drugs problem’ in Sweden  
Börje Olsson
 6 Enlargement 2005: cannabis in the new EU Member States  
Jacek Moskalewicz, Airi-Alina Allaste, Zsolt Demetrovics, Danica Klempova and 
Janusz Sierosławski with Ladislav Csemy, Vito Flaker, Neoklis Georgiades, Anna 
Girard, Vera Grebenc, Ernestas Jasaitis, Ines Kvaternik Jenko, Richard Muscat, 
Marcis Trapencieris, Sharon Vella and Alenka Žagar
Our understanding of cannabis today is bound up in an understanding of the past. We 
begin this monograph by looking back on how cannabis was used and understood in 
the past. Throughout human history, cannabis has been used for many purposes such as 
recreation, therapy, art, religion, medicine and as a textile.
The first two chapters in this section examine the role of cannabis as a medicine in 
Europe in the 19th century, together with more recent developments in developing 
cannabis as a medicine. In the past two decades, great efforts have been made to 
assess the usefulness of cannabis as medicine, as cannabis is currently being used in 
a small way as medicine. Nevertheless, the role cannabis plays in medicine today is 
modest compared with the past, and although there are reviews on the subject, well-
established and secure conclusions of the extent to which cannabis is a reliable and 
useful medicine remain uncertain. Many have pointed out that there is a need for further 
research on the subject.
Rödner Sznitman and Olsson
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Moving on from a historical and contemporary perspective on cannabis as medicine, a 
general introduction to the pharmacology of cannabis is also presented. Although the 
psychoactive effects of cannabinoids have long been known, it was not until the 1980s 
that the first evidence for the manner in which tetrahydrocannabinol (THC) acts on the 
brain became known and, as Corrigan’s chapter highlights, important advances have 
been made since then.
This section proceeds to focus on two case studies that discuss the role of cannabis in 
youth cultures in the 1960s. As Abrams and Olsson show, cannabis became widely 
known as a recreational drug with the youth cultures of the 1960s. Government 
responses to the increased use of cannabis were probably as much concerned with a 
response to the youth cultures as they were a response to the substance use in its own 
right.
The section ends with development in the more recent past: the enlargement of the 
European Union in 2005, to embrace 10 countries in Eastern Europe, the Baltic States 
and the Mediterranean Islands. This round of enlargement is an event that remains fresh 
in the minds of those who will read this monograph in Europe. Yet with the subsequent 
addition of Bulgaria and Romania, and the welcoming of new candidate countries, these 
Member States are beginning to become more firmly integrated within the fabric of the 
EU. Time will tell whether the large variations currently seen in cannabis use across 
these countries will evolve to reflect those in pre-2005 Member States.
The different chapters included in this section constitute only a limited presentation of 
cannabis in the past. Nevertheless, we hope that the section facilitates the beginning of 
an understanding of present-day processes. As people living in contemporary society 
with contemporary concerns, we sometimes neglect the importance of the past. We hope 
that these introductory chapters illuminate that although much of this monograph is 
based on up-to-date data, our understanding of cannabis today is partly a product of its 
past.
Part II: Policies, legislation and control strategies
 7 Cannabis control in Europe  
Danilo Ballotta, Henri Bergeron and Brendan Hughes
 8 In thinking about cannabis policy, what can be learned from alcohol and tobacco? 
Robin Room
 9 An open front door: the coffee shop phenomenon in the Netherlands 
Dirk Korf
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 10 Cannabis policy: tightening the ties in Denmark  
Vibeke Asmussen
 11 Cannabis: a harm reduction perspective  
Andrew Bennett
There are three main UN drug conventions, two of which are significant for cannabis. 
The 1961 Single Convention on Narcotic Drugs provides for controls over cannabis, 
as well as other drugs. The 1988 Convention Against Illegal Traffic in Narcotic Drugs 
and Psychotropic Substances strengthened the international scope and framework of 
cooperation against drug trafficking, including trafficking in cannabis. All EU members 
are signatories of the three UN conventions on illicit drugs, and the EU itself is a 
signatory of the 1988 Convention. Consequently, all countries within the EU have 
adopted some sort of legal prohibition against cannabis, and the UN conventions have 
played a role in constraining national legal experimentation on drug law and policies. 
The international UN conventions on drugs are unique. There is no other issue where 
one can find a universalised discourse translated into such similar legislation around the 
world.
Nevertheless, and as made apparent in this section, the appearance of harmony in 
the EU is to a large extent not a reality. Wide room for manoeuvre within illicit drug 
legislation has been taken within the EU. Individual national legislation is possible 
despite the UN conventions, as treaties allow for discretion. Additionally, national 
variations in drug use policies are accommodated within the EU organisational structure. 
Although the EU has launched several drug action plans, full harmonisation has not 
materialised. And though the EU takes complementary measures, there is no coherent 
holistic approach to drug issues in the EU. The EU considers drugs to be mainly an 
internal security concern. This implies that there is little overarching influence from 
the EU on national drug policies. Individual countries are relatively free to experiment 
with different drug-related policy regimes. Especially prominent is the case of cannabis 
liberalisation policies, explored by Ballotta et al. in this section. The chapter makes 
evident that many EU Member States have gone their own way in terms of how to 
interpret the UN global control regime on cannabis.
The different approaches to cannabis-related issues are often discussed in terms of a 
philosophical shift between zero tolerance approaches and harm reduction approaches, 
or in terms of criminalisation and decriminalisation or repressive versus liberal regimes. 
This is, however, too simplistic a notion of the issue at hand. Clearly, as shown in 
Ballotta et al.’s chapter, there exist multiple approaches to legislation regarding 
cannabis within the European Union today, and specific legislative categories are often 
difficult to determine. The Netherlands, for instance, which is often thought of as a 
liberal regime, is still a prohibitionist country. The Netherlands uses roughly two-thirds 
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of its budget for drug problems on criminal action. As noted in Korf’s chapter, although 
possession for personal use and use of cannabis is decriminalised in the Netherlands, 
production and supply of cannabis are prohibited, and criminal sanctions are enforced. 
Seen from this perspective, it might be informative to think of the various issues related 
to cannabis control as continuous and blurred, rather than a case of dichotomy of 
liberal or repressive.
In terms of the effectiveness of the various cannabis policies which exist in the EU, 
evidence is scarce. As Room points out, the drug field has much to learn from the 
tobacco and alcohol fields, in which policy measures are more rigorously examined and 
there is a relatively well-developed evidence base on which strategies work and which 
are most effective in terms of reducing the harms. In comparison, the policy impact 
literature is relatively undeveloped with respect to illicit drug use. Indeed, different drug 
control regimes are rarely rigorously evaluated. Despite scarce evidence, a modest 
research literature exists which remains sceptical about the effectiveness of cannabis 
prohibition. Korf suggests, for instance, that cannabis possession laws have little 
influence on cannabis prevalence rates and are thereby not an effective way to deter 
use.
It is also generally agreed that there is a gap between formal policies and policy as 
implemented. As is shown by Ballotta et al., the most common penalties for cannabis 
possession range from fine to incarceration. Nevertheless, reports suggest that in 
practice most detections lead to a fine. Additionally, evidence of a ‘net widening effect’ 
exists. Researchers have noted that a relaxation of policies may not have the intended 
effect of less severe consequences of cannabis prosecution. Some have suggested, for 
instance, that cannabis reclassification in the UK might have led to offenders that were 
previously dealt with informally being subject to on-the-spot formal warnings, recorded 
as such by the police force. Since there are few long-term data on cannabis policies 
as implemented and the effects they have, it is difficult to determine the impact of 
‘decriminalisation’ policies.
Researchers generally agree that the harm to the defendant in drug cases extends far 
beyond the cost of the actual criminal justice sentence or caution. Exactly what the 
impact of a cannabis prosecution entails is, however, far from clear. Administrative 
measures do not necessarily mean a more gentle approach than criminal measures, 
as administrative measures might be associated with additional costs for the individual 
user, for instance through a reduction or withdrawal of a student’s loan or difficulties in 
employment opportunities. While evidence of this is available in the literature for the US 
and Australia, little evidence exists for European countries.
Harm reduction policies, as mentioned by Bennett, start from a recognition that 
substance use has been and will continue to be part of human experience. Acceptance 
Overview of Volume 1
xxi
of this fact leads harm reduction approaches to develop strategies with the aim of 
moving people towards safer forms of substance use, possibly with abstinence as the 
ideal. In this way harm reduction is a radical move away from more traditional illicit 
drug strategies that solely aim at abstinence. Another distinct feature of harm reduction 
is its emphasis on respecting drug users and on moving away from paternalistic models 
of care.
A strength of harm reduction strategies is the firm focus on secondary as well as primary 
harms of cannabis use. In addition to the attempt to reduce primary and adverse health 
effects of cannabis use, harm reduction strategies recognise that harm also arises as a 
consequence of legislation, policies and police strategies. Unfortunately, the secondary 
harms are far less researched than the primary harms of cannabis use, and this poses 
a challenge for future research efforts. Indeed, and as pointed out already, the current 
evidence base on the impact of drug policy regimes is weak. In order to learn more 
about the relation between policies and effects, there is a need for carefully designed 
studies that are able to determine the impacts, primary and secondary, of cannabis use. 
The most appropriate way to go about such work is through quasi-experimental designs, 
and where possible true experiments.
One criticism of harm reduction strategies has been that it sends out the ‘wrong’ 
messages. This claim can be countered by a variety of responses, for example, that 
public health approaches in other fields such as sex education have adopted a harm 
reduction approach, that the community understands harm reduction messages, and 
that they are not an encouragement to use drugs. But symbolic values can be as 
important as evidence and the emphasis on symbolic values might be a useful starting 
point for reaching an understanding of how cannabis policies have developed and how 
they may develop in the near future.
What the future holds in terms of drug law harmonisation is, however, impossible to 
predict. What is clear is that a possible harmonisation, if occurring at all, is likely to 
be very slow, and national and regional distinctions within the EU in terms of cannabis 
policies are likely to continue to be the rule rather than the exception.
Part III: Supply and production issues
 12 Global cannabis cultivation and trafficking 
Ted Leggett and Thomas Pietschmann
 13 Monitoring cannabis availability in Europe: issues, trends and challenges 
Chloé Carpentier, Meredith Meacham and Paul Griffiths
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 14 Understanding cannabis potency and monitoring cannabis products in Europe 
Leslie King
 15 Multinational export–import ventures: Moroccan hashish into Europe through Spain 
Juan Francisco Gamella and Maria Luisa Jiménez Rodrigo
 16 An analysis of the significance of supply and market factors for variations in 
European cannabis use 
Leif Lenke
The market
Current research shows that the main supplier of cannabis to the EU is Morocco. This 
claim is based to a great extent on research efforts made by the United Nations Office 
on Drugs and Crime (UNODC), as shown by Pietschmann and Leggett. Gamella 
and Jiménez Rodrigo have provided an in-depth analysis of the cannabis trade from 
Morocco to Europe. As they point out, hashish is generally taken from Morocco to Spain 
and Portugal and is thereafter exported across Europe. This should come as no surprise 
in view of the geographical location of the countries. It must, however, also be noted 
that cannabis on the European market travels through other routes as well.
Although it is clear that Morocco plays an important role in the European cannabis 
market, it must not be forgotten that there are other significant supply sources of 
cannabis. As is mentioned by Pietschmann and Leggett, cannabis in Europe also derives 
from Thailand, Afghanistan and Pakistan. Various central Asian states and former parts 
of the Soviet Union are also suppliers of cannabis resin to the European market. This 
suggests that there is a strong correlation between poverty and the drug trade. In a 
poor region such as Morocco, cannabis production constitutes an important means for 
families to reach a sustainable standard of living.
It should also be highlighted that over the last decade, domestic cultivation of cannabis 
has started to change the shape of the cannabis market, so that home cultivation has 
in some countries become an important part of the cannabis supply. The Netherlands 
has long been known to be a producer of marijuana, or ‘netherweed’. Netherweed is 
produced for domestic as well as international consumption, and in the last few years 
‘netherweed’ has been seized in the UK, Scandinavia, Germany, Belgium and France. 
New evidence also indicates that the supply of cannabis produced elsewhere in Europe 
is on the rise. Switzerland has, for instance, reported a sharp increase in illegal cannabis 
cultivation. A 1999 Swiss EKDT report argued that in 1998 more than 100 tonnes 
of cannabis were harvested for the drug trade, and it was plausible that Switzerland 
became the second largest European exporting country after the Netherlands. An 
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increase in domestic cultivation has also been noted in the UK, with some arguing 
that cannabis cultivated in England and Wales may now make up well over half of the 
consumption there.
Owing to the illegality of cannabis, both use and trade are mostly hidden. Carpentier 
et al. demonstrate a certain degree of uncertainty when it comes to measuring and 
researching the cannabis market. One can never really know if seizures are indications 
of general trends or of the extent of law enforcement. The trend of an increase in 
domestically grown sinsemilla at the European level is possible, but currently relatively 
undocumented. While international trafficking, mainly from Morocco, evidently occurs, 
it is unclear what share of the market home-produced cannabis actually comprises. 
Although much domestic cannabis cultivation is small-scale production for personal 
use, it should not be neglected, as it contributes to the European cannabis market and 
it might make up a larger proportion in the future. Seen from this perspective, although 
continued attention to Morocco and other international suppliers is important, there is 
a need for more research on domestic cultivation. Too strong a focus on Morocco may 
indeed produce a partly distorted picture of the European cannabis market today.
If cannabis production is to an increasing extent produced on European soil this raises 
new and important questions. Apart from the issue of THC potency, as discussed above, 
a geographical change in the production of cannabis is also connected to questions 
regarding the relationship between the industrial and the developing world. As Gamella 
and Jímenez Rodrigo point out, the cannabis market is an important economic asset to 
poor farmers in Morocco. A possible turnover of the market, with a shift of production 
to Europe, may have negative implications for peasant farmers in the developing world. 
Further, European domestic cultivation has implications for national criminal justice 
responses. At the moment heated debates regarding cannabis are usually confined to 
the issue of possession and not cultivation. As the geographical production of cannabis 
changes it might, however, also change the focus of the public debate towards more 
emphasis on appropriate responses to cultivation. Indeed, EU Member States might 
increasingly have to deal with criminal justice issues such as cultivation for personal 
use, and commercial cultivation, as well as medical growers. We might expect new 
policy initiatives, and with these a need for scientific investigation into how the market is 
evolving and how it responds to new developments.
Potency
From time to time, a wave of media interest across Europe contends that cannabis in 
contemporary society is stronger and thus more harmful than it was in the 1960s and 
1970s. Claims have been made that cannabis consumed today is 30 % stronger than 
in the past. This belief, though strongly held, is something of an urban myth. As King in 
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this section notes, the myth has been fuelled by media and politicians, and researchers 
have suggested that the figures come from misinterpretation of the data which, when 
calculated in accurate terms, actually translate to a 1 % increase.
Clearly, there are controversies concerning cannabis potency, and in-depth and careful 
investigation is required in order to explore properly the issue of THC potency. King 
investigates data from seven European countries. When using potency data combined 
with data on resin and herbal cannabis consumption, a weighed mean potency is found. 
Following this strategy, King finds a potency increase only in the Netherlands and he 
thus concludes that no overall upward trend is found except from indoor-cultivated 
Dutch resin, which is thought to make up a small share of the market. But despite 
King’s reassurance that overall cannabis potency has not increased dramatically, there 
is evidence which challenges this view. This is, for instance, pointed out by Leggett and 
Pietschmann in this section, who point towards a possible trend for indoor domestic 
cultivation of sinsemilla to increase in several European countries. Claims have been 
made that this type of cannabis is easily modified and does often imply an increase in 
potency. At present the size of the European domestically produced cannabis market is, 
however, unclear. Additionally, it is unclear to what extent domestic production actually 
implies an increase in cannabis potency.
Clearly, contradictions prevail, and we may conclude that at present it is difficult to 
gain adequate data on the issue of trends in cannabis potency. Forensic data provide 
only a weak basis for evaluating potency trends, largely due to problems associated 
with standardising definitions of cannabis products and sampling issues. Additionally, 
analysis based on drug enforcement seizures may be anomalous in a number of ways, 
including a disproportionate focus on large cultivators and seizures. Finally, it is evident 
that the discussion has been contaminated by scare tactics and ignoring of sound 
evidence. Thus, there is clearly a need to pursue these issues further in order to create 
an improved knowledge base from which the potency issue may be further explored and 
better understood.
In order to facilitate an informed policy debate, there is also a need to explore issues 
indirectly linked to the issue of THC potency, for instance, to investigate adverse short- 
and long-term health effects that might arise from a potential increase in potency. 
Indeed, as pointed out by King, THC potency increase does not necessarily mean that 
there will be an increase in adverse health effects, as an increase in potency may lead 
to an adaptation by the users to smoke less cannabis. In turn this would lead to less 
inhaled smoke in lungs and thus decreased risk of respiratory diseases.
Knowledge of potency as well as the dose consumed by individual users is an important 
and sometimes neglected area in the research literature. As is well accepted in the 
alcohol and tobacco field, the effects of cannabis must be considered in relation to type 
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of cannabis consumed, and pattern of consumption, and hence also THC levels. There 
is little disagreement that there is a difference between drinking a full glass of vodka 
and a full glass of wine and that intense, prolonged use of alcohol is deleterious to both 
physical and psychological well-being. In the case of cannabis, on the other hand, there 
seems to be little effort made to ascertain actual dose rates and hence lifetime intake of 
cannabinoids. Thus, little account is taken of the wide range of concentrations of THC 
and related compounds in smoked cannabis and differences of smoking habits from one 
individual to another. This poses a challenge for future research.
Sharon Rödner Sznitman
Sorad
Börje Olsson
Sorad
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Setting the context
Cannabis has been the subject in recent years of substantial historical study. Overviews 
include Abel (1980), Grinspoon and Bakalar (1993), Mathre (1997), Sloman (1998), 
Matthews (1998, revised 2003), Rätsch (2001), Grotenhermen (2002), Wujastyk (2002), 
Green (2002), Booth (2003), Allegret (2006) and Russo (2007).
This explosion in historical interest is firmly rooted in the present. Reasons for this 
interest include: a wider vogue in historical publishing towards single product histories 
(cod, salt, opium, etc.); advocates of medicinal cannabis research and the hemp industry 
seeking historical legitimacy and lineage; cannabis use among the middle-aged (the 
core audience for history of any kind); cannabis’ emergence as a legislative hot potato; 
lively debate among botanists on the classification of Cannabis sativa (1); not to mention 
the explosion of both encyclopaedic texts and drugs-related historical source documents 
on the Internet. Cannabis has even evolved to have its own portal on Wikipedia.
Rather than retread the all-encompassing historical scope of such studies, this chapter 
provides a focused view of how cannabis aroused interest among pharmacists in 
Europe. It also provides brief reflections on the contemporary revival in research 
into medical applications of cannabis over the past two decades. Analogies can be 
drawn with today’s cannabis debate: for example, European experience of far-flung 
cultures — the past’s Napoleonic soldiers in Egypt, today’s backpackers in Thailand and 
(1) See Watts, G. (2006), ‘Science commentary: cannabis confusions’, in British Medical Journal 332: 
175–176 (available at: www.bmj.com/cgi/reprint/332/7534/175.pdf).
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Morocco; availability of information — the past’s national botanic encyclopaedias and 
pharmacopoeia, today’s cannabis discussion forums and online growguides.
This chapter remains historical in scope. While mentioning recent developments, it does 
not explore in detail current developments in medicinal cannabis. However, a short 
chapter has been added by John Witton, providing a summary of recent developments 
in medicinal cannabis.
Further reading
Histories
Abel, E. L. (1980), Marihuana: the first twelve thousand years, Plenum Press, New York  
www.druglibrary.org/Schaffer/hemp/history/first12000/abel.htm
Allegret, S. (2006), ‘Histoire du chanvre’, in P. Boulloc (ed.), Le Chanvre industriel — production et 
utilisation, Editions France agricole, Paris.
Booth, M. (2003), Cannabis: a history, Doubleday, London.
Green, J. (2002), Cannabis, Pavilion, London.
Grinspoon, L., Bakalar, J. B. (1993), Marihuana, the forbidden medicine, Yale University Press, New 
Haven.
Rätsch, C. (2001), Marijuana medicine: a world tour of the healing and visionary powers of cannabis, 
Healing Arts Press, Rochester.
Russo, E. (2007), ‘History of cannabis and its preparations in saga, science, and sobriquet’, Chemistry 
and Biodiversity, 4: 1614–1646.
Sloman, L. (1998), Reefer madness: a history of marijuana, St. Martin’s Press, New York.
Zuardi, A. (2006), ‘History of cannabis as a medicine: a review’, Revista Brasileira de Psiquiatría, 
28: 153–157.
For primary historical materials, a bibliography of historical mentions of cannabis was compiled in 
1951 in two volumes of the United Nations’ Bulletin on Narcotics (2).
See also the grey literature list in the Appendix to Volume 1 of this monograph (p. 300).
(2) United Nations (1951), Bulletin on narcotic drugs (available at: www.unodc.org/unodc/en/bulletin/
bulletin_1951-01-01_1_page007.html (accessed 11 October 2007)).
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Cannabis as medicine in Europe 
in the 19th century
Manfred Fankhauser
As in the previous centuries, hemp was predominantly used in the 19th century as a 
fibre material. Herbal cannabis played a marginal role as a medicinal plant, although 
its seeds were used medicinally, mostly in the form of pressed oils or hemp milk as 
medicine against gonorrhoea or cystitis. In tandem with prevailing interest in plants, 
products and culture from the Orient, medicinal use of cannabis arrived in Europe from 
the East during the 18th century.
Much has been written on the historical knowledge in Europe of the psychoactive 
properties of hemp prior to the 18th century: among readers of Herodotus’ description 
of Scythian cannabis-incensed burial rites; by alchemists, in particular the herb 
Pantagruelion lauded by author François Rabelais; via knowledge of Islamic medicine 
via al-Andalus, and elsewhere (Bennett et al., 1995; Booth, 2003; Mercuri et al., 2002). 
However, widespread scientific writings on its psychoactive properties came later. For 
example, Gmelin wrote in 1777 of the Eastern use of bhang for stupefying (‘etwas 
Betaeubendes’), mind-clouding (‘Benebelung des Verstandes’) and intoxicating effects 
(Fankhauser, 2002); and in 1786 the Comte d’Angiviller thanked a certain Boulogne 
for his sending of Indian hemp plants with the prophetic words ‘Cette plante sera peut-
être un présent intéressant pour l’Europe’. At the end of the 18th century, the French 
naturalist Sonnerat informed Lamarck’s 1873 Encyclopédique de botanique of Cannabis 
indica (Emboden, 1974) and brought Indian hemp home to France after a journey 
to the Orient. Napoleonic campaigns in Egypt and the Near East introduced colonial 
troops — notably the scientists Silvestre de Sacy, Rouyer and Desgenettes — to hashish 
(Abel, 1980; Booth, 2003).
European interest in this ‘new’, or rather rediscovered, plant grew only hesitantly. The 
first comprehensive description of the medical usefulness of Indian hemp in Europe was 
written in 1830 by the German pharmacist and botanist Friedrich Ludwig Nees von 
Esenbeck. Until that point in time, use of hemp for medical purposes had remained 
at a low level. This situation changed significantly prior to the middle of the 19th 
century. William B. O’Shaughnessy (1809–1889/90), an Irish medical doctor stationed 
in Calcutta, India, published in 1839 a comprehensive study on Indian hemp. Thanks 
mainly to his On the Preparations of the Indian Hemp or Gunjah, Cannabis indica now 
also became recognised within European-school medicine. O’Shaugnessy used various 
hemp compounds in his investigations, partly with great success, against the following 
indications: rheumatism, rabies, cholera, tetanus, convulsions and delirium tremens. 
With hashish he had found a well-suited medicine to give his patients relief, and in the 
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case of cramps, even total disappearance of symptoms. For concluding remarks, he 
wrote: ‘The presented cases are a summary of my experience with cannabis indica, and 
I believe that this medicine is an anticonvulsivum of great value’ (O’Shaughnessy, 1839).
Europe reacted promptly to this new knowledge from India. This is not surprising as until 
then no adequate treatment existed against recognised diseases such as rabies, cholera 
or tetanus. Great hopes were based on O’Shaughnessy’s results. The French were 
the first to engage themselves intensively with the plant. As early as 1840, the French 
medical doctor Louis Aubert-Roche (1809–1874), who resided in Egypt, used hashish 
seemingly successfully against pestilence (Hirsch, 1884–1886). Nearly simultaneously, 
his compatriot and friend, the psychiatrist Jaques Joseph Moreau de Tours (1804–1884), 
began to experiment with hashish. He started out with experimenting upon doves and 
hares, giving them large doses of hashish extracts with their fodder. Then he tested 
hashish on friends, colleagues, patients and himself. He was convinced that hashish was 
the supreme medicament for use in psychiatry. His book, Du Hachich et de l’aliénation 
mentale (1845), caused a great sensation at the time, and is still understood as the 
origin of experimental psychiatry and psychopharmacology (Weber, 1971).
The works of Moreau de Tours had an impact not only in medical circles, but also 
among writers and artists. The poet Théophile Gauthier (1811–1872), for instance, 
received hashish samples from Moreau de Tours. In 1843 he described extensively a 
self-experienced hashish intoxication in the Paris newspaper La Presse under the title 
‘Le Club des Hachichins’. The club of hashish eaters, of which Gauthier was one of 
the founders, had regular meetings in Hôtel Pimodan on the Seine island of St Louis. 
He and Charles Baudelaire (1821–1867) shared a penthouse in the hotel for several 
years. Other prominent club members were Alexandre Dumas (1802–1870) and Honoré 
Daumier (1808–1879) (Moreau, 1904). Further well-known contemporaries such as 
Honoré de Balzac (1799–1850), Gustave Flaubert (1821–1880) and Victor Hugo 
(1802–1885) participated occasionally (Behr, 1982).
Inspired by Moreau de Tours and later by pharmacy professor Eugène Soubeiran 
(1797–1859), the pharmacist Edmond de Courtive published in 1848 his widely noted 
dissertation, Haschish. In addition to chemical analysis, he carried out self-experiments 
with miscellaneous hashish compounds and gave exact descriptions of their physical and 
psychic effects (De Courtive, 1848).
Many medical doctors took advantage of the promising results of the pioneers 
O’Shaughnessy, Aubert-Roche and Moreau de Tours and used these new drugs for 
therapeutic purposes. Initially, primarily doctors from the colonial powers of England 
and France showed interest in the use of compounds made of Indian hemp. The 
necessary commodities or compounds were imported in great quantities to Europe from 
the colonies, especially from India (Smith and Smith, 1847). Hemp was in this period 
sold to Europe primarily in three commercial variations:
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Ganjah•	 : consists solely of the blooming tips of the female, carefully cultivated plant. 
Mostly 24 blooming tips are bundled in a length of approximately 1 m, and 11 cm 
thickness.
Charras•	 : consists of the resin, which is extracted foremost from the blossom, but 
also from leaves and stalks of the female plant. Today, the extracted resin is called 
hashish.
Bhang•	 : extracted from the leafless stalks of the female hemp plant. Bhang was 
predominantly exported to Europe in powder form.
In Europe ganjah was the first to be pharmaceutically exploited. Initially, the fields 
of application known to O’Shaughnessy were adopted. Later on, the therapeutic 
application of hashish was considerably extended. In particular, the English and French 
medics applied this new wonder drug against tetanus (Martius, 1844). Encouraged 
by many positive reports, especially from England, the Bulgarian medic Basilus Beron 
intensively engaged in this problem in a dissertation. His work concludes:
I was so contented that, after having used almost all known antitetanic drugs without result, 
the sick person that had been assigned to me was totally cured after use of the Indian hemp 
(...) wherefore the Indian hemp is strongly recommended against tetanus.
(Beron, 1852)
Homeopathy, founded by Samuel Hahnemann (1755–1843) and rapidly advancing in 
this period, was also quick to include Indian hemp in its medical catalogue. Towards 
the middle of the 19th century, in addition to the illnesses already mentioned, Indian 
hemp was mainly used against neuralgia and other pains, chorea, hysteria, insanity, 
haemorrhage and insomnia. Since prepared products did not yet exist, cannabis extracts 
and tinctures were mostly used.
The real success story of cannabis as a medicine began in the second half of the 
19th century after the publication of Beron’s dissertation in 1852. In the same year, 
Franz von Kobylanski published a dissertation on the effect of cannabis as an oxytocic 
(1852). Four years later, the German Georg Martius wrote his comprehensive work 
Pharmakognostisch-chemische Studien über den Hanf, which attracted much attention. 
Interest was also aroused by the experiments of the Viennese Carl Damian Ritter 
von Schroff (1802–1887). Martius was among the few who did not deem cannabis 
compounds as harmless. He wrote that:
the Indian hemp and all its compounds show great diversity concerning the degree and type 
of effect according to individual differences in healthy as well as in pathological conditions. It 
therefore belongs to the unsafe agents, and the medic should under all circumstances use it 
with great care.
(Von Schorff, 1858)
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At the same time, Ernst Freiherr von Bibra (1806–1878) published his standard work, 
Die narkotischen Genussmittel und der Mensch. Here, he discussed hashish for over 30 
pages. In addition to experiences of others, he describes a self-experiment with hashish. 
His concluding judgement was as follows: ‘Recent experiments and experiences made 
on the medical effect of the hemp plant and its compounds very much point to their 
advantage’ (von Bibra, 1855).
In this period, most European countries, as well as the USA, included Indian hemp 
in their national pharmacopoeia. The monographs Herba Cannabis indicae, Tinctura 
Cannabis indicae and Extractum Cannabis indicae enjoyed increased prominence, 
whereas Semen/Fructus Cannabis and Oleum Cannabis became more and more rare. 
It was first of all France and England, and to a lesser extent the USA, that significantly 
contributed to the definitive breakthrough of the drug into Western medicine.
The study of Indian hemp was even pursued in Germany. A comprehensive work of 
Bernhard Fronmüller, written in 1869, is frequently cited. He had studied the qualities 
of the hemp plant for a long time, and carried out cannabis experiments within the 
framework of ‘clinical studies on the euthanising effect of the narcotic drugs’ with 
exactly 1 000 test patients. These test patients suffered from heavy insomnia due to 
various illnesses. The results of his investigation were positive. Thus, he concluded in 
his work: ‘The Indian hemp is, among the known anaesthetic drugs, the narcosis which 
most perfectly achieves a replacement of natural sleep, without particular repression of 
expulsions, without bad repercussions, without paralyses’ (Fronmüller, 1869).
Well-known medical experts or pharmacologists of the time wrote more-or-less 
comprehensive essays on Cannabis indica. Some of these articles criticise the 
unreliability of hemp compounds. Indeed, the standardisation problem continued to 
be an issue for cannabis compounds until they disappeared. Kobert is one of very few 
who discussed the dangers of long-term consumption: ‘The habitual consumption of 
any effective hemp compound deprives the human being and brings him to a mental 
institution’ (Kobert, 1897).
The period 1880 to 1900 can be considered a peak in the medical use of cannabis. 
The use of hashish compounds had become commonplace in almost all European 
countries and in the USA. Nonetheless, it was still scientists from England, France, 
Germany and the USA who persistently continued cannabis research. It is, therefore, not 
a coincidence that most of the products on the market (‘specialities’) originated in these 
countries. It is first of all through the contribution of the company E. Merck of Darmstadt, 
Germany, that cannabis compounds became more widely used in Europe towards the 
end of the 19th century. One of the preferred source materials in the production of 
cannabis compounds in this period was Cannabinum tannicum Merck. In addition, the 
company Burroughs, Wellcome & Co. in England produced cannabis compounds. In 
Chapter 1
9
the USA, cannabis compounds were manufactured by Squibb and sons in New York 
(‘Chlorodyne and Corn Collodium’), and, later, Parke-Davis & Co. in Detroit (‘Utroval’ 
and ‘Casadein’) and Eli Lilly (‘Dr Brown’s Sedative Tablets’, ‘Neurosine’ and ‘The One 
Day Cough Cure’). These companies delivered sufficient quantities of high-quality raw 
materials and produced compounds for the market. Probably the most-used hemp 
compound was the sleeping pill Bromidia, of the American company Battle & Co. This 
was a combined drug, that is, in addition to cannabis extract it contained bromine 
potassium, chloral hydrate and henbane. While single compounds dominated during 
the 19th century, combination compounds were preferred in the 20th century. Most 
cannabis drugs were for internal use, but there existed topical compounds, for instance, 
creams or the common clavus tinctures.
In the meantime, France continued its 50-year tradition and honoured medical doctors 
and pharmacists with doctoral degrees based upon works on hashish. In 1891 Georges 
Meurisse (born 1864) published his work Le Haschich, and five years later Le chanvre 
indien by Hastings Burroughs (born 1853) appeared. The latter is strongly based on 
Villard’s work, but also upon his own therapeutic experiments. He summarises: ‘In 
therapeutic doses, the Indian hemp is safe and would deserve to be more frequently 
used’ (Burroughs, 1896).
In Germany, the PhD students H. Zeitler (‘On Cannabis indica’, 1885) and M. Starck 
(‘How to apply the new cannabis compounds’, 1887) first wrote their graduation 
dissertations, before the pharmacist Leib Lapin in 1894 published his dissertation, ‘A 
contribution to the knowledge of Cannabis indica’, under the guidance of the leading 
figures Johan Georg Dragendorff (1836–1898) and Rudolf Kobert (1854–1918). In the 
first part of his work, he gives an overview of ‘common, manufactured and officinal 
hemp compounds’ in use at the time. In the second part he describes the pharmacology 
of ‘cannabindon’, a cannabis derivate first studied by him. In the preamble of his 
investigation, he makes a remark which shows the uncertainty that existed regarding the 
medical safety of Indian hemp:
Had it been so simple to solve the hashish question, it would certainly have been solved by 
one of the numerous previous investigators. I believe that I have contributed to the definitive 
resolution, and this belief gives me the courage to publish the following as a dissertation.
(Lapin, 1894)
A scientific contribution of extraordinary importance within the cannabis research of the 
19th century was the so-called Indian Hemp Report of 1894. This census, carried out by 
Great Britain in its colony India, primarily studied the extraction of drugs from cannabis, 
the trade in these drugs and the implications for the total population. Additionally, the 
study set out to clarify whether prohibition of the compounds might be justified, and an 
expert commission was established for this purpose. Its report impressively shows the 
significance of the stimulant and drug cannabis in India towards the end of the 19th 
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century. The main conclusion of the commission was: ‘Based upon the effects of the 
hemp drugs, the commission does not find it necessary to forbid the growing of hemp, 
nor the production of hemp drugs and their distribution’ (Leonhardt, 1970).
Towards the 20th century, Indian hemp enjoyed an important position in the materia 
medica of Western medicine. Evidence of misuse of cannabis compounds was practically 
non-existent until then. Kunkel writes:
The chronical misuse of cannabis compounds — cannabism — is believed to be widespread in 
Asia and Africa. It results in chronic, heavy disruption of the entire organism, especially mental 
disorder — attacks of raving madness and a subsequent condition of weakness. It is not 
observed in Europe, Indian doctors report however daily frequent cases of this disease.
(Kunkel, 1899)
To sum up, hashish played a significant role as a medicine in Europe and in the USA 
towards the end of the 19th century. The most important applications were against pain, 
especially migraine and dysmenorrhoea, pertussis, asthma and insomnia. Additionally, 
hashish was relatively frequently used as an additive in clavus supplements. Rare 
applications were stomach ache, depressions, diarrhoea, diminished appetite, pruritus, 
haemorrhage, Basedow syndrome and malaria. Cannabis compounds were also used 
in numerous single cases, partly with good results. These were, however, of smaller 
significance.
Typically, doctors who worked intensively with cannabis drugs for years would classify 
them as valuable medicines. Others criticised them, and frequently looked upon them as 
worthless or even dangerous. However, both groups agreed on the unpredictable effect 
of cannabis compounds.
After keen use of cannabis compounds around the turn of the century, they disappeared 
completely in the middle of the 20th century. The main reasons for the disappearance 
of hashish medicaments are medical developments. Even before the 20th century, new, 
specific medicines were introduced for all main applications of cannabis compounds. 
Vaccines were developed for the treatment of infectious diseases (cholera, tetanus, etc.), 
which not only fought the symptoms as cannabis did, but also gave protection against 
infections. Other bacterial illnesses, such as gonorrhoea, that were frequently treated 
with cannabis could somewhat later be treated successfully with chemotherapeutica. 
Cannabis indica received competition as a sleeping and tranquillising drug in the form 
of chemical substances such as chloral hydrate or barbiturate. Contrary to the numerous 
opium drugs, cannabis compounds were also replaced as analgesics by chemical 
substances. In this area, aspirin achieved great importance shortly after its introduction 
in 1899.
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Another reason for the decline of cannabis as medicine was pharmaceutical instability. 
The varying effectiveness of the hashish compounds has often been noted. Very different 
factors, such as origin, age, storage and galenic preparation, affected effectiveness 
of the medicine. Unlike, for instance, alkaloid drugs such as opium, the isolation of 
active ingredients was not successful until the middle of the 20th century. This resulted 
in standardisation problems. There were also legal constraints. The use of cannabis 
compounds became more and more restricted in international and national law. 
Hashish compounds were defined as anaesthetics some time in the 20th century. This 
complicated their use enormously, until finally a general ban made it impossible to 
apply them.
Finally, economic aspects contributed to the decline in use of medical cannabis. Import 
into Europe of high-quality Indian hemp became more and more difficult due to 
constraints in the producing countries (mainly India) and the influences of the two world 
wars. Laws of supply and demand also applied to cannabis, resulting in a massive price 
increase for raw materials (e.g. herba Cannabis indicae) as well as for compounds (e.g. 
extractum Cannabis indicae).
Cannabis as medicine — the contemporary situation
As already mentioned, hemp compounds were still frequently used at the beginning 
of the 20th century, and scientific research on the plant was promoted. However, its 
standing declined rapidly, and towards the middle of the 20th century cannabis as a 
medicine gradually faded into insignificance. Finally, the use of cannabis was prohibited 
worldwide through international agreements.
In particular, use of cannabis as a medicine was made impossible by the Convention on 
Narcotic Drugs of 1961 (see Ballotta et al., this monograph). Only lately have individual 
countries begun to stretch the application of this regime, as in Holland, where since 
September 2003 cannabis can be bought in pharmacies on prescription. In specific 
cases, cannabis can be used as medicine in Canada and in some US states without 
sanctions against the patients. In Canada, the cannabis medicine Sativex as a spray was 
licensed for treatment of neuropathic pain for multiple sclerosis patients in April 2005. 
Until then, only the two cannabinoids, THC and Nabilon, had been legally traded since 
the 1960s (IACM-News, 2005). Other European countries, such as the United Kingdom, 
Spain, and more recently Switzerland and Italy, have for some time undertaken efforts to 
explore possible benefits of cannabis for medical purposes (see Witton, this monograph).
In spite of the ban on cannabis, research on the medical effects of this ancient drug 
plant has not stood still. In many countries, scientific work with cannabis was and is 
allowed. The discovery of ∆9-tetrahydrocannabinols (THCs) in 1964 and the cannabinoid 
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receptors (CBs) in 1988 are important milestones in cannabis research. Four years 
later, the existence of endocannabinoids was proven, that is substances produced by 
the human body that function as agonists to cannabinoid receptors. Presently, the first 
selectively working CB1 receptor antagonist rimonabant is being clinically tested (phase 
III). It seems that this receptor may be used against overweight and metabolic risk 
factors, as well as with tobacco withdrawal (Heinzl, 2005).
Since the cannabinoid system was discovered, agents that make use of the therapeutic 
effects of the cannabinoids have been intensively searched for, thereby avoiding the 
psychotropic side-effects. Just in the years following the discovery and investigation of 
the chemical structure of THCs until 1986, approximately 6 000 scientific studies of the 
chemistry, pharmacology, clinical properties and metabolism of the THCs have been 
published (Mechoulam, 1986). During the last 20 years, research on the hemp plant 
has intensified. It is hardly possible to provide an overview the abundance of data and 
scientific publications. Presently, various clinical studies of the effects of hemp on certain 
illnesses are being undertaken.
A summary of research focal points and possible fields of cannabis application is given 
below. According to Grotenhermen (2004), therapeutic effects of cannabis or segregated 
THC (or dronabinol) may, based on current science, be divided as follows:
 1 Established effect: nausea and vomiting, anorexia and loss of weight.
 2 Relatively well-proven effect: spasms, pain conditions, movement disturbances, asthma, 
glaucoma.
 3 Unproven effect: allergies, itchiness, inflammations and infections, epilepsy, depressions, 
and anxiety disturbances.
 4 Basic research: auto-resistant diseases, cancer, neuroprotection, fever and blood 
pressure disturbances.
As previously mentioned, some of these applications had already been in use for a long 
time based on experience. Interestingly, long-proven indications have more recently 
been scientifically documented. In spite of the ban on cannabis, it is frequently used 
by patients in the form of tea or tinctures and sometimes recommended by medical 
doctors against the law. In practical terms, some multiple sclerosis patients successfully 
use cannabis as an antispastic, and some migraine patients frequently use it as a pain 
reliever.
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Setting the context
The previous chapter looked at the history of medicinal use of cannabis. It is interesting 
to consider that, a century ago, the patent medicine J. Collis Browne’s Chlorodyne 
(a mixture of laudanum, tincture of cannabis, and chloroform) could be purchased 
at chemists and was marketed as ‘the most wonderful and remarkable remedy ever 
discovered’ (1). Yet historical anecdotes about medicinal use of cannabis are gradually 
being displaced by a wealth of international research on cannabinoids and their role 
in therapeutics. This brief chapter — which may be perceived as a postscript to the 
previous one — provides a summary of recent developments in medicinal cannabis.
Researchers in this area are highly productive, and so this chapter is likely to suffer 
from almost instant obsolescence. Nonetheless, the chapter reveals that, at the time 
of writing in late 2007, there are relatively few cannabis-derived medicines that have 
received regulatory approval. Forecasts dating from the early 2000s that cannabinoids 
may become the new blockbuster branch of the pharmaceutical industry seem to 
be premature. Yet a recent market report by Visiongain (2) remains upbeat, valuing 
the global cannabis medicines market at USD 700 million. Besides interest from the 
pharmaceutical industry, there is an increasing body of research on ‘self-medication’ 
using herbal cannabis. The knowledge base is increasing, following relaxation of 
legislation relating to medicinal use of cannabis in some US states and the Netherlands, 
together with grassroots organisations focusing on medicinal use of herbal cannabis in 
Canada and several European countries.
(1) Advertisement for J. Collis Browne’s Chlorodyne, 1891.
(2) www.visiongainintelligence.com/reportDetail.aspx?reportId=1359
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The re-emergence of the 
therapeutic use of cannabis 
products: recent developments 
and future prospects
John Witton
The past two decades have seen renewed and concerted interest in the therapeutic 
potential of cannabis. Tetrahydrocannabinol (THC), the active and most significant 
constituent of cannabis, and other closely related compounds were identified in the 
1960s. However, it was not until the mid-1980s and 1990s that research accelerated, 
when understanding increased of the biology of the body’s endocannabinoid system 
and how cannabis works on the brain. These discoveries opened up possibilities to 
exploit cannabis-based products for medical use. This renewed scientific interest in the 
cannabinoids is evidenced by (i) the increase in the number of research papers on the 
biology of cannabinoids, from 200–300 per year through the 1970s to nearly 6 000 in 
2004, and (ii) the number of cannabinoid drugs under pharmaceutical development, 
rising from 2 in 1995 to 27 in 2004 (Pacher et al., 2006).
The identification of a natural cannabinoid receptor–neuromodulator system in the body 
was the key to pharmacological and therapeutic developments. Receptors are the sites 
of action for brain chemicals, called neurotransmitters, and often the sites of action 
of drugs. Binding of the neurotransmitter or drug to the brain cell receptor causes a 
response in the cell. Two cannabis receptors (termed CB1 and CB2) have been found 
(Pertwee, 1997). CB1 receptors are distributed in discrete areas of the brain, particularly 
concentrated in the hippocampus and cerebral cortex (areas concerned with memory 
and cognition), olfactory areas, basal ganglia and cerebellum (areas concerned with 
motor activity and posture control) and the spinal cord. CB2 receptors are found 
peripherally and are closely linked with cells in the immune system (Kumar et al., 2001). 
With the discovery of cannabis receptors it became possible to develop cannabinoid 
agonists or antagonists — that is, agents that activate or bind but do not activate the 
receptors — that might act as therapeutic tools or help determine the roles of the 
cannabinoid receptors and the body’s own endogenous cannabinoids (British Medical 
Association, 1997). Two major endocannabinoids have been identified and isolated: 
anandamide and 2-arachidonoyl glycerol. This endogenous cannabinoid system is 
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involved in analgesia, cognition, memory, locomotor activity, appetite, vomiting and 
immune control (Kumar et al., 2001).
As the structure–activity relationships of the cannabis receptors and endocannabinoid 
system unfolded, the potential for cannabis-based medicines became clearer. But in a 
review of these developments, a leading neuropharmacologist, Professor Leslie Iversen, 
suggested that pharmaceutical companies faced a range of substantial obstacles in 
developing cannabis-based medications. These obstacles were: development costs would 
be high; only synthetic cannabinoids could be patented rather than the natural product; 
products would be likely to be niche drugs rather than ‘blockbuster’ drugs used to treat 
common health problems; there were already medicines available to treat the problems 
that cannabinoids might be used for; and finally, the vast US marketplace would be 
difficult to enter, with the US having strict regulatory requirements to introduce a drug 
that is derived from or chemically related to a prohibited substance (Iversen, 2003).
Over the last 30 years, widely reported use of illicitly smoked cannabis for self-
medication for a range of illnesses has brought normally law-abiding citizens into 
conflict with their country’s legal system. Surveys have found that the common 
indications for cannabis use include depression, multiple sclerosis, pain, migraine, 
asthma and cancer-related anorexia/cachexia (Schnelle et al., 1999; Gorter et al., 
2005). The ethical dilemmas surrounding this issue were among the factors that led to 
a number of enquiries examining the therapeutic potential of cannabis products. The 
British Medical Association’s 1997 report Therapeutic Uses of Cannabis and the 1998 
report Cannabis: the Scientific and Medical Evidence from a Select Committee of the 
House of Lords both called for the setting up of clinical trials to evaluate the potential 
therapeutic use of cannabinoids. The prestigious US Institute of Medicine published 
its report Medical Use of Marijuana in 1999. Together, these reports established the 
evidence base to support the further examination of cannabis products for medical use. 
Medical and political interest intensified in several European countries and the medical 
use of cannabis was legalised in the Netherlands in 2003 (Grotenhermen and Russo, 
2002; Gorter et al., 2005) and extended for a five-year period in 2007.
Naturally, cannabis products are subject to the same rigorous clinical testing and 
regulatory processes as any other potential medicine. Clinical trials for new medications 
normally follow three phases. In phase I the safety of the drug is established. In phase II 
the efficacy of the drug is established through giving the medication to a small group of 
potential patients who have the condition targeted by the medication. Finally, phase III 
trials use large studies involving hundreds of patients.
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Two synthetic cannabinoid receptor agonists, dronabinol and nabilone, have already 
passed these stringent tests. They have been available and approved for medical use 
since the 1980s. However, neither has been widely prescribed. The effective dose for 
these cannabinoids is close to a dose that causes sedation or intoxication, limiting 
the amount of the drug that can be given to patients (Iversen, 2000). Moreover, their 
therapeutic potential has been superseded by more powerful medications.
Dronabinol is the non-proprietary name for tetrahydrocannabinol. Marinol capsules 
containing dronabinol were approved for use by the US Food and Drug administration 
for nausea and vomiting associated with cancer chemotherapy for patients who had not 
responded to conventional antiemetic medications. Marinol was also approved for use in 
anorexia associated with weight loss in patients with AIDS. Dronabinol is also available 
on prescription in a number of countries outside the USA. Dronabinol is manufactured 
by two German companies, THC Pharm and Delta 9 Pharma, and may be bought 
by pharmacies to produce dronabinol capsules or solutions. The second cannabinoid 
receptor agonist, nabilone, a synthetic derivative of dronabinol, was also approved 
by the FDA in 1986 for use in treatment of nausea and vomiting associated with 
chemotherapy. It is delivered in the form of Cesamet capsules. Nabilone was originally 
developed by Eli Lilly in the USA but was not marketed there, but is available in the UK 
and other European countries.
Two more cannabis-related drugs have become available more recently. The British 
biotech firm GW Pharmaceuticals has developed Sativex, a cannabis plant extract, 
consisting of equal amounts of dronabinol (THC) and cannabidiol, another important 
cannabinoid. Sativex is delivered as an oral spray. Using a spray for delivery provides 
a consistent quality to the medication and enables doctors to set standard dosages. The 
spray technique also avoids the carcinogenic smoke normally associated with cannabis 
use. It also allows for flexible dosing, important when people with MS experience 
variable amounts of pain.
In 2005 Sativex received approval as an adjunctive treatment for the relief of 
symptomatic pain related to muscular sclerosis in Canada through the governmental 
Health Canada’s Notice of Compliance with Conditions policy. This policy is applied to 
products which Health Canada considers as addressing a serious medical condition for 
which there are no currently approved products and where data from clinical trials to 
date appear to be promising. The condition to be satisfied is a need for confirmatory 
phase II study to further verify the clinical benefit of the product. In June 2007 Sativex 
was approved by the Canadian regulatory authority for use in cancer-related pain. More 
recently, GW has reached an agreement with the Japanese pharmaceutical firm Otsuka 
to develop and market Sativex in the USA, where it will be initially trialled for cancer 
pain.
The re-emergence of the therapeutic use of cannabis products
22
In Europe, in November 2005 Sativex and the Catalan Health Authority reached 
agreement to supply Sativex to up to 600 patients suffering from multiple sclerosis under 
a compassionate access programme. Initial results from a patient study suggested that 
65 % of the patients had experienced an improvement in quality of life and a decrease 
in pain. In the UK, the Home Office permitted the prescription of Sativex to individual 
patients as an unlicensed medicine. Thus, Sativex can be supplied on a named patient 
basis from the drug’s manufacturing site and dispensed by local pharmacies to patients. 
At the time of writing (end of 2007), Sativex is awaiting approval as a prescription drug 
for multiple sclerosis in Spain, Denmark and the Netherlands.
The second new drug, the cannabinoid receptor antagonist rimonabant, received a 
positive recommendation for approval by the European Medicines Agency in 2006. 
Available in the United Kingdom for the treatment of obesity under the name Acomplia, 
a Cochrane review found rimonabant use with diet and exercise led to modest weight 
loss at one year follow-up in the four studies under review. However the review authors 
suggested caution in interpreting the results of their review because of methodological 
shortcomings in the studies reviewed, high drop-out rates among participants and the 
need for longer term follow-up (Curioni and André, 2007). In the USA, rimonabant 
(planned to be marketed under the name Zimulti) was rejected by the Food and Drug 
Administration in June 2007. The FDA cited concerns on side-effects such as depression, 
anxiety and sleep problems when taking the drug.
Another cannabis-related product under investigation in clinical trials is Cannador, 
containing dronabinol and other cannabinoids. Studies have examined Cannador’s 
value in treating spasticity and other symptoms related to multiple sclerosis and post-
operative pain (Holdcroft et al., 2006; Zajicek et al., 2006). Further trials with Cannador 
have been undertaken at the Institute for Clinical Research in Berlin. There has been 
some interest in investigating the potential of cannabidiol as an antipsychotic (Zuardi et 
al., 2006).
Away from pharmaceutical cannabis-related preparations, the use of its natural form for 
medicinal purposes has also progressed recently. While cannabis remains illegal under 
federal law in the US, 13 states have made available the medical use of cannabis under 
their state laws. The latest to legalise medical use of cannabis is New Mexico, where 
1 742 patients are authorised to possess dried cannabis as a medication. 1 040 are 
licensed to grow their own cannabis and 167 people are licensed to grow cannabis for 
the use of authorised patients. Here the state’s health ministry buys the cannabis from 
these licensed growers and sells it on to the patient.
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In terms of very recent developments, in Finland the Ministry of Social Affairs and 
Health in December 2007 sought to clarify legislation on prescribing cannabis to 
sufferers of chronic pain, based on the implications of a test case involving an individual 
who had obtained special permission from the ministry for using cannabis for pain 
relief. A Canadian pharmaceutical research company called Cannasat Therapeutics 
is developing three candidate medicines, named CAT 210, CAT 310 and CAT 320, 
for which it forecast Phase II testing for the lead candidate, CAT 310, ‘by the end of 
2008’. In late 2007, a Dutch company called Echo Pharmaceuticals, based in Weesp, 
announced funding aimed at developing a cannabis-based pill called Namisol, targeting 
numerous therapeutic applications. The company is partnering with the cannabis grower 
Bedrocan, as well as the companies Farmalyse and Feyecon, to develop a pill.
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Setting the context
To understand cannabis, it is helpful to have a knowledge of the pharmacology of 
the drug. What are the psychoactive effects of the substance, and what physical and 
neurological changes are brought about by the product? What can be said about the 
varying effects of dosage, route of administration, the type of product (herb, resin, oil), 
and the use environment?
Scientific knowledge about the pharmacology of cannabis has seen substantial progress 
in the last three decades. In addition to substantial work in neuroscience, cannabinoid 
research accelerated following the discoveries in the late 1980s of cannabinoid-like 
chemicals produced by the body, known as ‘endocannabinoids’.
As with much science, much of the literature on cannabis is technically challenging, 
especially for those approaching drugs from disciplines such as sociology and political 
science. In addition, there is a glut of information in the scientific journals: a Medline 
search on ‘cannabis pharmacology’ reveals over 3 500 articles, and many more are 
published each month. Meanwhile, users seeking to explore the science of cannabis are 
likely, sooner or later, to encounter disinformation and inaccuracy. User reports are by 
nature subjective, and growshop information is compromised by the incentive to sell. 
Pro-cannabis lobbying information is skewed towards innocuous and euphoric effects 
or favourable comparisons with alcohol. Prohibitionist literature emphasises the risks 
of cannabis smoking without placing sufficient emphasis on the sought-after effects of 
cannabis.
Fortunately, help is at hand for those first approaching the subject. A number of 
initiatives have sought to provide information that is simultaneously accurate and 
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accessible, and valuable publications exist for a variety of audiences (see Further 
reading, below). One of the products of a more didactic approach is the simplified 
summary above by Kumar et al., republished in a number of government monographs 
since its first appearance in 2001 (Table 1). The chapter that follows, by a leading 
authority based at Trinity College Dublin, provides a short summary of what is known 
to date about the pharmacology of cannabis. A glossary is provided to assist non-
specialists.
Table 1: Summary of the effects of cannabinoids
System Effect
Central nervous system (CNS)
Psychological effects Euphoria, dysphoria, anxiety, depersonalisation, 
aggravation of psychotic states
Effects on perception Heightened sensory perception, distortion of space and 
time sense, misperceptions, hallucinations
Sedative effects Generalised CNS depression, drowsiness, sleep, additive 
effect with other CNS depressants
Effects on cognition and psychomotor 
performance
Fragmentation of thoughts, mental clouding, memory 
impairment, global impairment of performance
Effects on motor function Increased motor activity followed by inertia and 
uncoordination, ataxia, dysarthria, tremulousness, 
weakness and muscle twitching
Analgesic effects Similar in efficacy to codeine
Antiemetic effects In acute doses, effect reversed with larger doses or chronic 
use, increased appetite
Tolerance To most behavioural and somatic effects, including the 
‘high’ with chronic use
Dependence, abstinence syndrome Rarely observed but has been produced experimentally 
following prolonged intoxication or administration of 
antagonists
Cardiorespiratory system
Heart rate Increased with acute dosage, decreased with chronic use
Peripheral circulation Vasodilation, conjuctival redness and postural hypotension
Cardiac output Increased output and myocardial oxygen demand
Cerebral blood flow Increased in the short term and decreased with chronic use
Breathing Small doses stimulate, larger doses depress coughing but 
tolerance develops
Airways obstruction Due to chronic smoking
Eye Decreased intraocular pressure
Immune system Impaired activity of bactericidal macrophages in lung and 
spleen
Reproductive system Decreased sperm count and sperm motility in males, 
suppression of ovulation, complex effects on prolactin 
secretion, increased obstetric risks
Source: R. Kumar, W. Chambers, R. Pertwee (2001), ‘Pharmacological actions and therapeutic uses of cannabis and 
cannabinoids’, Anaesthesia 56(11): 1059–1068.
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issues for understanding its use
Desmond Corrigan
Abstract
The drug products obtained from the plant Cannabis sativa contain many different 
chemicals. The most active are the phytocannabinoids, such as THC, which exert their 
psychoactive effects by binding to specific receptors within the brain and other parts of 
the body. The existence of a complex endocannabinoid system within humans and other 
animals and the interaction between the phytocannabinoids and this system explains 
many of the rewarding, dependence-producing effects of cannabis drugs as well as 
their influence on movement, coordination, reactions, memory and learning, especially 
since the brain regions implicated in these effects are richest in cannabinoid receptors. 
Cannabinoids are highly fat-soluble and their metabolism and slow excretion from the 
body distinguishes them from other drugs, such as alcohol. The slow elimination of THC 
explains the low intensity of withdrawal symptoms and also why urine tests following 
consumption test positive for cannabinoids for much longer than for most other 
psychoactive drugs (up to two weeks).
Cannabis drugs
The plant Cannabis sativa L. is the source of a number of drug products. While herbal 
cannabis (or marijuana) consists of dried plant parts, the main ingredient in cannabis 
resin (or hashish) is the resin secreted by the glandular hairs found all over the plant 
but mainly around the flowers. In addition to these two kinds of preparation, which 
have been used since time immemorial, hashish oil is extracted by use of a solvent (e.g. 
acetone) and evaporated. In addition, the cannabis plant can be used as a source of 
hemp fibres, as well as hemp seeds and fatty oil.
The flowering tops and leaves of the plant Cannabis sativa secrete a resin containing 
about 60 terpenophenolic compounds which are called cannabinoids, to distinguish 
the plant compounds from the endogenously occurring endocannabinoids found in 
most animals, especially humans. The highest amount of cannabinoids has been 
found in the flowering tops, followed by the leaves, whereas only small amounts are 
found in the stem and roots. While for many years herbal cannabis typically showed a 
lower cannabinoid content than preparations (resin and oil), innovation in cultivation 
techniques, pruning and seed selection have enabled marijuana growers to match or 
exceed the potency of resin (see King, this monograph).
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Glossary
Endocannabinoids Cannabinoids produced by the body, such as anandamide.
Free radical An atom or group of atoms with at least one unpaired electron; in the body 
it is usually an oxygen molecule that has lost an electron and will stabilise 
itself by stealing an electron from a nearby molecule.
Ganglia 
(singular: ganglion)
Tissue mass which provides relay points and connections between different 
neurological structures in the body, such as the central nervous system.
Neurones Nerve cells found in the brain, spinal cord and peripheral nerves. They 
communicate with one another using a complex of chemical and electrical 
signals.
Neurotransmitters Chemicals which are used by neurones to communicate or signal to one 
another. Examples include dopamine and serotonin.
Phagocytosis The ability of certain white blood cells (leucocytes), especially macrophages, 
to scavenge foreign material (especially bacteria) within the body as a first-
line defence against infection.
Pharmacodynamic 
effects
What the drug does to the body, its organs, tissues and cells.
Pharmacokinetics What the body does to the drug, that is, the speed at which it is absorbed 
into the bloodstream, transported to the site of action, metabolised and 
excreted from the body.
Phytochemical A chemical compound containing carbon, hydrogen, oxygen and sometimes 
nitrogen produced by plants. Some are ubiquitous, such as starch. Some 
are pharmacologically active, such as morphine. Some are restricted to just 
one plant species, for example tetrahydrocannabinol in cannabis.
Receptors Drugs act by binding to specific proteins located on the surface of cells. 
Once bound they can elicit a response (agonist effect) by causing an 
electrical impulse to be generated or the release of a signalling chemical 
within the cell. Sometimes drugs can prevent a response from the receptor, 
that is, act as an antagonist.
T lymphocyte A small lymphocyte developed in the thymus; it orchestrates the immune 
system’s response to infected or malignant cells.
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Phytocannabinoids
The main cannabinoid is ∆9–tetrahydrocannabinol (THC), which is recognised as 
the major psychoactive euphoriant responsible for the characteristic intoxication 
(‘high’) which follows the smoking or ingestion of cannabis. High THC doses produce 
hallucinogenic effects. In addition to THC, several less potent metabolites and related 
compounds, such as the also psychoactive ∆8-THC and cannabinol are found in the 
cannabis plant. Another major compound is cannabidiol (CBD), which has antagonistic 
effects to THC because it is a sedative compound. The ratio of THC to CBD in the plant 
is significant in terms of psychoactivity and is genetically determined.
A number of chemotypes exist within cannabis. These are plants which are visually 
and botanically identical but which are chemically dissimilar. One type referred to 
as the fibre- or hemp-type contains predominantly CBD and only trace amounts of 
THC (less than 0.3 % THC according to Commission Regulation (EC no. 327/2002)). 
Conversely, drug-type plants produce predominantly THC with trace quantities of CBD. 
The issue is further complicated by the existence of an intermediate plant which contains 
approximately equal amounts of both THC and CBD. The concentrations of these and 
other cannabinoids vary enormously in practice depending on plant breeding and 
cultivation techniques and on post-harvest handling. The question of the potency of 
cannabis drugs, usually expressed in terms of THC content, is dealt with in the chapter 
by King (this monograph, p. 239). THC is a highly unstable compound, breaking 
down in air and light to a number of inactive molecules, one of which, cannabinol 
(CBN), is commonly found in cannabis products as they age. Other relatively abundant 
cannabinoids include cannabigerol (CBG) and cannabichromene (CBC) but in general 
little is known about the biological activities of these and the remaining less frequently 
occurring molecules.
Most pharmacological research has focused on THC and CBD. However, while THC is 
responsible for many of the effects of cannabis drugs, it is important to bear in mind 
that THC and cannabis are not synonymous for a number of reasons.
Firstly, THC does not exist as such in the plant material but rather it is found as an acid 
(THCA), as is CBD. These acids (THCA and CBDA) decompose slowly during storage to 
the corresponding chemically neutral but pharmacologically potent THC and CBD. This 
conversion is speeded up by the high temperatures involved in smoking and to a lesser 
extent by cooking or baking the drugs. Secondly, the THC/CBD ratio can markedly 
alter the effects of the drugs. Thirdly, some of the non-cannabinoid compounds from 
the plant may modulate the pharmacological effects of the cannabinoids. Terpenoids, 
which are responsible for the characteristic smell of cannabis, have been postulated as 
influencing the effects yet experimental evidence is scarce. Some 1 % by weight of the 
plant is composed of a mixture of 20 flavonoid compounds which are well known as 
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antioxidants and which also scavenge damaging free radicals. Whether the quantities 
which survive the pyrolysis reactions involved in smoking cannabis are sufficient for 
activity is unknown (Musty, 2004).
Pharmacokinetics and metabolism
The dose of THC needed to produce effects in humans ranges from 2 to 22 mg (Adams 
and Martin, 1996). It is estimated that only 1 % of the THC content of a ‘joint’ is found 
in the brain after smoking; hence, only 2–44 µg of THC enters the brain in humans. 
Given the significant variation in cannabinoid content in the crude drugs and also in 
the weights of those crude drugs incorporated into ‘joints’ (Buchanan and O’Connell, 
1998), there is little comparability or standardisation of dosages of THC and the other 
cannabinoids in practice.
THC is rapidly absorbed after inhalation of cannabis smoke and it is detectable in 
plasma within seconds. Between 10 and 50 % of the THC in the drug reaches the 
bloodstream. Losses due to burning account for 30 %, while sidestream smoke, 
incomplete absorption and retention within the cigarette (‘joint’) also produce significant 
losses. Inexperienced and infrequent smokers absorb approximately 10–14 % of the 
available THC whereas regular users absorb double that amount, probably because 
their more efficient smoking technique allows them to hold the smoke longer in their 
lungs. For the other major cannabinoids, the amounts absorbed range from 31 % for 
CBD to 38 % for CBN.
When cannabis is smoked, the effects start within seconds, reach a peak around 20 
minutes and last for two to three hours (Figure 1). In contrast, if the drug is eaten, the 
effects are delayed and last longer, reaching a maximum about 3–4 hours after drug 
ingestion, and lasting for six to eight hours (Grotenhermen, 2003). After smoking, THC 
is detectable in the plasma only seconds after the first puff of a cannabis cigarette, 
with peak plasma level being measured 3–10 minutes after the first puff. This reflects 
the conversion of THC to its metabolites. This metabolism takes place in the liver and 
involves different enzymes, some of which are inhibited by CBD, which can thus affect 
the metabolism of THC. THC is further metabolised to a non-psychoactive molecule, 
which is excreted in urine as its glucuronide, although more than 100 different 
metabolites of THC have been identified (Hawksworth and McArdle, 2004). Only traces 
of the original THC are found in urine.
Because THC is highly fat soluble (lipophilic), plasma levels of THC fall rapidly after 30 
minutes. However, its many metabolites are only slowly eliminated from the body as they 
are stored in fatty tissues. Complete elimination may take up to five weeks. So repeated 
cannabis use leads to an accumulation of cannabinoids in lipid-rich tissues including 
The pharmacology of cannabis
34
the brain. THC is slowly released from fatty tissues into the bloodstream. There is, 
however, no simple relationship between the level of THC and its metabolites in blood 
and behavioural effects, such as psychomotor impairment (Agurell et al., 1986). This 
is because there is a delay between the subjective ‘high’ and THC in blood, and there 
are also large variations in individual psychoactive effects experienced at the same THC 
level in blood (see Figure 1).
The endocannabinoid system
THC and other cannabinoids act by binding to specific cannabinoid receptors found 
on the surface membranes of various cells located chiefly in the brain and in the 
immune system. Two receptors have been identified. The first cannabinoid receptor, 
CB1 (Matsuda et al., 1990), is expressed in the brain, in nerve cells, the reproductive 
system, some glandular systems and the microcirculation (Howlett et al., 2002, 2004; 
de Fonseca et al., 2005). The second cannabinoid receptor, CB2, is expressed in the 
peripheral tissues, principally in the immune system (Munro et al., 1993; Felder and 
Glass, 1998; Pertwee, 1999).
The discovery of these receptors — and there may be others in the body — led to the 
identification of a family of ‘endocannabinoids’. These molecules are arachidonic acid 
derivates which have potent actions at the cannabinoid receptors. The discovery of 
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Figure 1: Distribution of THC in the body over time
Source: Nahas (1975), quoted and commented in Ashton (2001).
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cannabinoid receptors and their endogenous ligand, the endocannabinoids, suggested 
the existence of an endogenous cannabinoid system. Subsequent elaboration of the 
biosynthesis, release, transport and degradation of these endocannabinoids within 
the body led to the realisation that they formed part of a new signalling system within 
the body termed the ‘endocannabinoid system’. This has interactions with other 
neurotransmitters including gamma-aminobutyric acid (GABA), the opioid receptors 
and the dopamine system. The endogenous cannabinoid system seems to act as a 
neuromodulatory system, generally inhibiting the release of other neurotransmitters. 
CBD, on the other hand, does not bind to the CB receptors but may exert its sedating, 
hypnotic effects through other cannabinoid receptors which are believed, but not proven, 
to exist.
Cannabinoid receptors control cell differentiation in the developing brain. One of 
their most remarkable features is their high concentration within the brain, with 
densities 10–50 times greater than those of the classical neurotransmitter receptors, for 
example those for dopamine and opioids. CB1 receptors are expressed at particularly 
high densities in the cerebellum, hippocampus and in the basal ganglia (striatum, 
globus pallidum and substantia nigra). The presence of cannabinoid receptors in the 
hippocampus and the cortex suggested their involvement in the learning and memory 
process, whereas cannabinoids appear to mediate effects on motor activity, coordination 
and reactions through receptors in the basal ganglia and cerebellum. CB1 receptors are 
also found in the nucleus accumbens and frontal cortex, which is believed to account for 
the reinforcing effect of cannabinoids. Indeed, the endocannabinoid system controls the 
motivation for appetite stimuli, including food and drugs. Drugs of dependence tend to 
activate dopamine-producing nerve cells in the ventral tegmental area (VTA) and THC 
is no different because it increases dopamine release in the nucleus accumbens and 
prefrontal cortex.
The numerous investigations into the endocannabinoid receptor system and its 
interactions with other neuronal systems have resulted in a large body of scientific 
evidence which indicates that CB1 receptors, especially in the striatum, nucleus 
accumbens and the prefrontal cortex, mediate virtually all of the behavioural and 
neurochemical properties of THC and other cannabinoids. In particular, rewarding 
effects, tolerance and physical dependence have been ascribed to the brain 
endocannabinoid system and its interactions with the opioid, glutamate, GABA and 
especially the dopaminergic systems (Tanda and Goldberg, 2003). Gardner (2002) 
concluded that cannabinoids act on brain reward processes and related behaviours in 
ways that are remarkably similar to other addictive drugs. Studies with CB1 antagonists 
have shown the importance of these receptors in the whole phenomenon of craving. 
Ongoing studies highlight the significance of the endocannabinoid system in alcohol 
dependence, smoking cessation, weight loss, and self-administration of cocaine and 
opioids.
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The CB1 receptor has also been identified in both male and female reproductive 
systems including the ovaries, the uterine endometrium, the testis, sperm, vas deferens 
and urinary bladder. Recent studies reviewed by Park et al. (2004) have demonstrated 
that marijuana, THC and other exogenous cannabinoids exert potent effects on 
the endocannabinoid system in both the gonads and during pregnancy. Current 
understanding indicates that endocannabinoids may be critical for embryo implantation 
and miscarriage.
The CB2 receptor has been detected in the spleen, tonsils and thymus gland, which 
are the major tissues involved in immune cell production. Cannabinoids including 
THC — which activate these receptors (agonists) generally — suppress the functions 
of lymphocytes, natural killer cells, macrophages and mast cells. Roth et al. (2002) 
summarised knowledge concerning CB2 receptors and cells involved in the immune 
system. They suggest a dynamic interaction between the receptors and the immune 
system, particularly leucocytes. Receptor expression is markedly altered in habitual 
cannabis smokers and the pattern of T lymphocyte responses to THC and the resulting 
immunological events may explain epidemiological reports linking cannabis use to 
opportunistic infections, AIDS and respiratory tract cancers. Nevertheless, as Witton 
(this monograph) points out, the evidence is not conclusive. Roth et al. (2002) observe 
that the most convincing evidence of immunosuppression comes from examining 
the antimicrobial activity of alveolar macrophages. Those from herbal cannabis 
smokers exhibit defective phagocytosis, are impaired in their ability to produce key 
immunological chemicals (interleukins, tumour necrosis factor, etc.) and in their ability to 
exhibit effective antibacterial activity when challenged with pathogenic bacteria. Because 
cannabinoid receptors are not found in significant numbers in the brain stem, cannabis 
is not considered to be a drug with fatal overdose risks.
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Chapter 4
Soma, the Wootton Report and 
cannabis law reform in Britain 
during the 1960s and 1970s
Keywords: 1960s – autobiography – the Beatles – cannabis – legislation  
– lobbying – protest movements – social protest – sociology  
– Wootton Report
Setting the context
This chapter provides a first-person account of a significant event in the history of 
cannabis policymaking in Europe: the publication of the UK’s Wootton Report in 1969. 
There was some debate about whether to include this chapter in the monograph. The 
chapter is self-evidently personal in tone. Yet it is also interesting and anecdotal, and we 
believe the monograph benefits from its inclusion with few significant editorial changes. 
However, it should be read for what it is: an oral history, told from an individual’s 
standpoint, with which others might disagree.
Recent literature has tended to play down the level of drug use in the 1960s. Prevalence 
statistics are not available, but cannabis use was likely much lower than today. A recent 
survey suggests that today’s 50-somethings exaggerate their participation in 1960s 
counterculture in order to appear cool to their offspring. Nonetheless, several decades 
on, there is little doubt that the high-profile celebrities of the late 1960s still hold cultural 
resonance in today’s global cannabis culture.
Nostalgia, anachronisms and the Beatles aside, Soma in many ways established the 
prototype for contemporary, often more fragmented, cannabis advocacy groups. It 
was a well-organised, erudite and media-aware pressure group. It had a talent for 
both publicity and linking debate to other contentious issues. Moreover, it was able 
to leverage the polarisation between political liberals and hardliners in the 1960s. 
Similarly, today there is sometimes political capital to be won from taking an extreme 
view, be it for or against cannabis use (see Hall, this monograph). The Soma campaign 
thus remains relevant to contemporary debate on cannabis.
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In recent years, the nature of pro-marijuana activism and lobbying has been subjected 
to some study, amongst others by Calafat et al. (2000), Matthews (2003) and Iversen 
(2004). The key pro and con arguments have been summarised by Scheerer (1993) 
and Wodak et al. (2002). An analysis of recent government reports on cannabis, with 
specific reference to European legislative reforms, is provided by Ballotta et al. later in 
this monograph. Most recently, considerable discussion has focused on the potency of 
1960s and 1970s cannabis vis-à-vis that available today. King explores this issue, and 
suggests that some of the more outlandish claims made of today’s ‘skunk’ should be 
viewed with a critical eye.
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Soma, the Wootton Report and 
cannabis law reform in Britain 
during the 1960s and 1970s
Stephen Abrams
In April 1970 the British government introduced legislation which sharply reduced the 
penalties for simple possession of cannabis. This was done to implement a proposal by 
the Home Office Advisory Committee on Drug Dependence (the ‘Wootton Report’) that 
casual users of cannabis should not face the prospect of imprisonment. This reform, 
under new legislation (The Misuse of Drugs Act 1971) was a step in the direction of 
decriminalisation and marked a limited toleration of cannabis smoking.
Declaration of interest
The author of this chapter was head of the Soma Research Association (Soma (1)), 
which campaigned from 1967 for cannabis law reform. The article therefore expresses 
an insider’s perspective on the reform process. On 24 July 1967 Soma set out its 
proposals for decriminalisation in a full-page advertisement in The Times (Figure 1). 
The issue was debated in Parliament and referred to the Hallucinogens Sub-Committee 
(the so-called ‘Wootton Committee’(2)) of the Advisory Committee. In January 1969, 
the Home Office published the Advisory Committee Report on Cannabis, the so-called 
‘Wootton Report’. The report endorsed the proposals in the advertisement. The Home 
Secretary of the day denounced the report and the advertisement. However, a year later 
he introduced legislation to implement the main proposals of the report. This article 
describes the background to the appearance of the advertisement and describes the 
subsequent reform process up to 1979, when the Home Office advisors proposed the 
‘reclassification’ of cannabis.
A brief history of cannabis convictions in the United 
Kingdom
Cannabis was prohibited in Britain in 1928 under the Dangerous Drugs Act, which 
remained in force during the 1960s. Under the Act, cannabis was classified as a 
(1) Soma was chosen to have associations with the soma of the Rig Vedas, the nectar of the gods and 
the problematic tranquilliser in Aldous Huxley’s novel Brave New World.
(2) The Advisory Committee on Drug Dependence was headed by Sir Edward Wayne, Professor of 
Practice of Medicine at the University of Glasgow. The ‘Wootton’ subcommittee on hallucinogens was 
led by Baroness Wootton of Abinger, a sociologist.
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Figure 1: Advertisement in The Times, 24 July 1967
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narcotic and offences were subject to penalties essentially identical to those for heroin 
and cocaine. The maximum penalties were one year on summary conviction and 10 
years on indictment (3). No distinction was made between possession and supply, 
and most offenders were sent to prison. On the other hand, up to the mid-1960s 
enforcement was lax and directed mainly at black immigrants from the Caribbean. 
The first year in which a minority of offenders (48%) were imprisoned, 1964, was also 
the first year in which white offenders outnumbered black offenders (UK Home Office, 
1968).
During the 1950s there was little evidence of increased use of cannabis in the United 
Kingdom. In 1951 there were 127 convictions and this figure was not exceeded until 
1959, when it rose to 185. A plateau of about 600 convictions was reached in 1962 
and not exceeded until 1966, when a figure of 1 119 was reached. In 1967 convictions 
doubled again to 2 393. That year the total seizures by police and customs amounted 
to 295 kg and 457 plants. For a comparison, 30 years later, in 1997, the year of peak 
enforcement, seizures amounted to about 150 000 kg and 115 000 plants (The Police 
Foundation, 2000), an increase by a factor of 500 and 250 respectively.
1967: a watershed year for cannabis
Witnesses heard by the Wootton subcommittee in December 1967 variously estimated 
the prevalence of cannabis use at between 30 000 and 300 000 persons. Perhaps the 
lower figure corresponds roughly to the number of regular users at the beginning of the 
year. However, there must have been a very dramatic increase in cannabis smoking in 
1967, when the subject was widely and favourably publicised. By the end of the decade, 
a government-funded study indicated that nearly a million people had tried cannabis (4). 
The scale of cannabis use had by then probably reached a level where it was self-
sustaining and could not be moderated by widespread enforcement. The sanction of 
imprisonment was still applied in a quarter of cases heard in 1967, the great majority 
of them for simple possession of small quantities. Seventeen per cent of first offenders 
were imprisoned (UK Home Office, 1968). The possibility of jailing tens, if not hundreds 
of thousands, of people for minor cannabis offences was both unthinkable and quite 
impractical.
In the first half of the 1960s in the United Kingdom, cannabis smoking was a feature 
of the half-world, where it was used by jazz musicians, artists and writers and, 
increasingly, in the universities. In January 1967 an article estimated that 5 % of Oxford 
(3) ‘Summary conviction’ means conviction in a magistrates court. Cases of possession for personal use 
would normally be heard in a magistrate’s court. If the accused elected trial by jury the case would 
be heard in a Crown court and higher penalties would apply.
(4) A survey by Market Advertising and Products Study Ltd (MAPS), commissioned in 1969 by the Home 
Office and the Registrar General’s Office of Population Synthesis and Survey.
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undergraduates smoked pot from time to time (Abrams, 1967). This converted into 
a figure of 500 and was debated in the broadsheet newspapers. At the instigation of 
the Oxford Committee on Student Health, the Vice Chancellor wrote to the then Home 
Secretary Roy Jenkins on 28 February, asking him to commission a national inquiry into 
cannabis and LSD (UK Home Office, 1968). This led to the appointment on 7 April of 
the Hallucinogens Sub-Committee (the so-called ‘Wootton Committee’) of the Advisory 
Committee on Drug Dependence.
Up to the beginning of 1967, cannabis received little publicity and nearly all of this 
was negative. Though prevalence remained low, cannabis use among 1960s celebrities 
and pop stars served to publicise the substance. For example, the arrest of the Scottish 
singer Donovan in mid-1966 was widely reported. Following a denunciation in the mass 
circulation newspaper the News of the World, Mick Jagger and Keith Richards of the 
Rolling Stones were arrested in February 1967 and sent for trial at the end of June for 
minor drugs offences. On 1 June 1967 the Beatles, at the zenith of their creative power 
and influence, released their Sgt. Pepper album, which was saturated with references 
to cannabis and LSD. The last track, ‘A Day in the Life’ (5), was banned from airplay 
on the BBC. The Beatles, and Paul McCartney in particular, were advocates of LSD: 
a serious confrontation was brewing between fashionable alternative society and the 
Establishment.
Soma was looking for a way to put the topic of cannabis law reform on the political 
agenda, and also to influence the terms of the deliberations of the Wootton Committee. 
In particular, the aim was to persuade the subcommittee to report on cannabis alone, 
rather than in conjunction with LSD. This in turn was based on the assumption that 
there was a consensus of informed opinion that cannabis was less harmful than 
stimulants, sedatives and alcohol and confidence that the committee would discover 
this for themselves. The gesture which occurred to me was to take a page of The Times 
newspaper for a paid advertisement in support of the decriminalisation of cannabis. 
The advertisement would draw its force from a number of influential people who would 
put their names to it. Barry Miles (6) mentioned this proposal to Paul McCartney on 2 
June. McCartney immediately realised that the advertisement would have the effect of 
switching the focus from LSD to cannabis and associating the Beatles with prominent 
authorities in a legitimate protest ‘within the system’. Following a meeting between 
McCartney, Miles and myself on 5 June, the Beatles agreed to add their names to the 
(5) The song’s lyrics include the lines ‘Found my way upstairs and had a smoke/Somebody spoke and I 
went into a dream’.
(6) Barry Miles was an author and co-runner of London’s Indica bookshop and gallery, later biographer 
of Allan Ginsberg and Paul McCartney.
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advertisement and McCartney guaranteed the funding, finally credited to a Beatles 
advertising account (7).
At the end of June, as the preparation of the advertisement neared completion, Mick 
Jagger and Keith Richards were convicted and sentenced to imprisonment. There was 
a public outcry, including three nights of demonstrations in Fleet Street against the 
newspaper the News of the World, who were accused by Michael Havers, Jagger’s 
counsel, of sending in an agent provocateur. After spending two nights in prison, Jagger 
and Richards were released on bail on 30 June. Jagger had been sentenced to three 
months for possession of amphetamines and Richards was sentenced to a year for the 
‘absolute’ offence that cannabis had been smoked at his home, with or without his 
knowledge (8).
On the following day, 1 July, The Times published a famous leading article with the 
felicitous title, ‘Who breaks a butterfly on a wheel?’. This leader has been much 
misunderstood, not least by its author, William Rees-Mogg, who claims that it ‘helped 
to get Jagger out of prison on a minor drugs charge’ (9). Also, the official history of The 
Times says that the leader was delivered to Jagger in prison by a warder with the advice 
that he would soon be freed on bail (10). As mentioned above, Jagger was freed a day 
before the leader appeared. Many, if not most, accounts of the case, including the most 
recent one in The Times and others in The Guardian, The Independent and on the BBC, 
assert that Jagger was convicted of possession of cannabis (11). Rees-Mogg’s leader 
made it clear that he considered amphetamine to be a ‘soft’ drug and Jagger’s offence 
to be trivial. However, he seemed to regard cannabis as a dangerous narcotic and was 
not, therefore, prepared to question the sentence of a year in prison for Richards. The 
Times got cold feet and postponed the publication of the advertisement, which finally 
appeared on 24 July. In the interim, a Legalise Pot Rally was held in Hyde Park on 16 
July, attended by 10 000 people, marking the colourful advent of ‘flower power’. Most 
national newspapers covered the event with a two-page spread. There were no arrests.
(7) B. Miles, Paul McCartney: many years from now, Secker & Warburg, London, 1997, pp. 386–395; 
S. Abrams, ‘The Wootton Retort’; D. Taylor, It was twenty years ago today, Bantam Press, London, 
1987, pp. 122–127.
(8) T. Hewat (ed.), Rolling Stones file: the trials of Mick Jagger and Keith Richards, Panther Record, 
London, 1967, p. 128.
(9) In a news article, ‘We’ve got to face it, Britain’s gone to pot’ (The Times, 2 July 2001), Lord Rees-
Mogg finally expressed the view that ‘prohibition has not proved to be the answer’.
(10) John Grigg in The Times Magazine, 30 October 1993, p. 39.
(11) Lewis Smith in The Times, 2 August 2005: [Jagger was] convicted of possessing cannabis in 1967 
in a case that became a cause célèbre when first he was jailed for a year and then freed on appeal 
three days later after a leading article in The Times headlined ‘Who breaks a butterfly on a wheel’.
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Paragraph 2 of the Wootton Report reads:
Our first enquiries were proceeding — without publicity — into the pharmacological and 
medical aspects, when other developments gave our study new and increased significance. 
An advertisement in The Times on 24th July, 1967 represented that the long-asserted 
dangers of cannabis were exaggerated and that the related law was socially damaging, if not 
unworkable. This was followed by a wave of debate about these issues in Parliament, the Press 
and elsewhere, and reports of enquiries, e.g. by the National Council for Civil Liberties. This 
publicity made more explicit the nature of some current ‘protest’ about official policy on drugs; 
defined more clearly some of the main issues in our study; and led us to give greater attention 
to the legal aspects of the problem. Government spokesmen made it clear that any future 
development of policy on cannabis would have to take account of the Advisory Committee’s 
Report. Accordingly, we decided to give first priority to presenting our views on cannabis.
The advertisement in The Times (Figure 1) was published by the Soma Research 
Association and signed by 65 people, including the Nobel Laureate Francis Crick, 
novelist Graham Greene, 15 doctors of medicine, one member of the Wootton 
Committee, members of Parliament and the Beatles (12). The advertisement was the 
subject of an adjournment debate in Parliament in the week of its appearance (on 28 
July), when the Minister of State referred the issue to the Wootton Committee (13). The 
Wootton Report was submitted on 1 November 1968 and published in January 1969.
The advertisement in The Times described the existing law as ‘immoral in principle 
and unworkable in practice’ but it stopped short of advocating the legalisation of 
cannabis. Instead, it proposed that users of cannabis should not face the prospect of 
imprisonment. Specifically, the advertisement said that possession of a small amount 
should not be punished by anything more than a relatively small fine of £25. The 
question of supply was ignored. This position has become known as ‘decriminalisation’.
The Advisory Committee Report included many echoes of the advertisement, that:
(…) The long term consumption of cannabis in moderate doses has no harmful effects (…) 
Cannabis is less dangerous than the opiates, amphetamines and barbiturates, and also less 
dangerous than alcohol. (…) An increasing number of people, mainly young, in all classes of 
(12) The Soma Research Association was founded in January 1967, incorporated in 1969 and disbanded 
in 1971. The directors were Dr David Cooper; Francis Crick, FRS; Francis Huxley; Dr R. D. Laing; 
The Rev. Kenneth Leech; Dr Anthony Storr; Professor Norman Zinberg and the present writer. The 
secretary, from 1968, was Don Aitken. Staff included Adam Parker-Rhodes, pharmacologist; Dick 
Pountain, chemist; Derek Blackburn, psychologist; and Sam Hutt and Ian Dunbar, physicians. 
Premises (in London) were at 438 Fulham Road (from 1968) and 4 Camden High Street (from 1969). 
Soma was funded by private donations and subscriptions. The total expenditure did not exceed 
£5 000. This figure does not include the cost of advertisement, which was £1 800.
(13) On 31 July the Court of Appeal quashed Richards’s conviction. This was remarkable because 
Richards had no case to argue. However, the court ignored the fact that the premises offence was 
‘absolute’. Jagger’s conviction was upheld but he was let off with a conditional discharge.
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society are experimenting with this drug, and substantial numbers use it regularly for social 
pleasure. There is no evidence that this activity is causing violent crime, or is producing in 
otherwise normal people conditions of dependence or psychosis requiring medical treatment 
(…) there are indications that (cannabis) may become a functional equivalent of alcohol.
The burden of proof thus passed from the campaigners to the government’s own 
expert advisors; and this was regarded by many as a green light for the consumption 
of cannabis. The Advisory Committee appeared also to accept the principle of 
decriminalisation. The main proposal in the report was that ‘possession of a small 
amount of cannabis should not normally be regarded as a serious crime to be punished 
by imprisonment’. The accompanying letter of submission to the Home Secretary said: 
‘The committee is generally of the view that imprisonment is no longer an appropriate 
punishment for those who are unlawfully in possession of a small amount.’
The Home Secretary of the day, James Callaghan, suggested he would reject the report. 
He told Parliament that on his reading, the committee had been ‘over-influenced’ by the 
‘lobby’ for ‘legalisation’ responsible for ‘that notorious advertisement’, adding, ‘it was 
wrong for the committee to report on one drug in isolation in the way that it did’ (14). 
However, a year later he introduced comprehensive new consolidating legislation that 
had the effect of implementing Wootton’s proposal (15).
Callaghan’s Misuse of Drugs Bill increased the penalties for most drugs offences, 
including trafficking in cannabis. However, this legislation introduced a distinction not 
drawn by Wootton between penalties for use and supply. The penalties for possession 
of cannabis were sharply reduced, by 50 %, to five years on indictment and six months 
on summary conviction. The Wootton Report noted that offences with a maximum 
sentence on summary conviction of six months or less were not normally punished by 
imprisonment, and that such sentences as were passed were suspended as a matter of 
routine. They opted for a maximum sentence on summary conviction of four months.
Callaghan’s legislation perished in the General Election of 1970. However, it was 
soon reintroduced by the incoming Conservative government and became law as 
The Misuse of Drugs Act (1971). When the act received the Royal Assent in 1973, the 
Lord Chancellor, Hailsham, instructed magistrates on sentencing. He said, ‘Set aside 
your prejudice, if you have one, and reserve the sentence of imprisonment for suitably 
flagrant cases of large scale trafficking’ (16).
(14) Hansard, 27 January 1969.
(15) One account suggests James Callaghan got cold feet and tried at the last moment to alter the 
legislation, but he was outvoted in cabinet: entry for 26 February 1970 in A. Howard (ed.) (1979), 
The Crossman Diaries, London.
(16) The Times, 12 October 1973.
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The operation of the new law in its first four years was made the subject of a special 
in-depth statistical analysis by the Advisory Council on the Misuse of Drugs (ACMD), 
prepared in December 1978 and published in 1979 (17). This study showed that the 
law was working as intended and that, with a handful of exceptions, the courts had 
abandoned custodial sentences for cannabis users. During this period, there was a 
further reduction, under the Criminal Justice Act (1977), of 50 % in the maximum 
sentence on summary conviction, to three months’ imprisonment, one month less than 
the maximum proposed by the Wootton Report.
Subsequently, in 1978 the Advisory Council on the Misuse of Drugs (the successor to the 
Advisory Committee) proposed to ‘reclassify’ cannabis, moving it to the weakest of three 
punishment regimes. It took 25 years to implement this recommendation. However, in 
the 1980s the Thatcher government moved sharply in the direction of decriminalisation 
by introducing ‘cautioning’: an offender who was cautioned would escape without a 
fine or a criminal conviction. By the beginning of the 1990s, the majority of minor cases 
were dealt with by means of the caution, so that in 1992, when The Times itself came 
out in support of legalisation, on the 25th anniversary of the Soma advertisement, the 
leader could conclude that the law was ‘all but unenforced’.
In 2000 the question of reclassification was revived in the Report of the Independent 
Police Foundation Inquiry. In response, the Home Secretary sought advice from the 
Advisory Council and from the House of Commons Select Committee on Home Affairs 
(see Ballotta et al., this monograph). The interesting point, perhaps, is that all three 
bodies stressed that the importance of reclassification (which did not directly affect the 
penalty on summary conviction) was that it demonstrated the fact that cannabis is less 
dangerous than amphetamine. With the reclassification of cannabis — where there is a 
‘presumption not to arrest’ reasonably discreet adult users of cannabis — there has thus 
been a complete reversal of the assessment of the relative dangers of these two drugs in 
the 1960s. It is worth adding, perhaps, that Paul McCartney and Mick Jagger were both 
eventually convicted of cannabis offences, for which they received small fines. Today, Sir 
Paul McCartney and Sir Michael Jagger have received knighthoods.
(17) Advisory Council on the Misuse of Drugs (1978) – Report on a review of the classification of controlled 
drugs and of penalties under schedules 2 and 4 of the Misuse of Drugs Act 1971, 15 December 1978. 
This proposal also called for the law to be recast to remove the sanction of imprisonment on statutory 
conviction for possession of cannabis.
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Chapter 5
Cannabis’s role in drawing 
attention to ‘the drugs problem’ 
in Sweden
Keywords: cannabis – jazz musicians – media coverage – moral panic – Sweden
Setting the context
In many aspects of government the ‘Swedish model’ is held up as a paradigm. Sweden 
is often cited as proof that a distributionist welfare state can co-exist with a strong 
market economy. Although Sweden is not immune to social problems, the country’s 
9 million inhabitants are able to boast an impressive record within EU countries on 
many health indicators.
So how does Sweden look in terms of cannabis and illicit drugs? Sweden promotes 
a vision of a ‘drug-free society’ at policy level. It recently appointed a National Drug 
Policy Coordinator to espouse what it terms a ‘restrictive and humane strategy’, and in 
September 2006 its drug policy was singled out for praise from the UNODC in a report 
which concluded that the country’s vision of a drug-free society ‘has not been found to 
be obsolete or misdirected’ (UNODC, 2006).
Cannabis prevalence rose in Sweden in the early 2000s, particularly among youths, 
and was reported as ‘very worrying’ in a Swedish government report (Ramström, 2004). 
Reported last month prevalence among young people rose from 1.3 % in 2000 (16- to 
34-year-olds) to reach 5.3 % in 2004 (18- to 34-year-olds) and dropping to 4.8 % in 
2005 (16- to 34-year-olds) (EMCDDA, 2006). Sweden has also observed a general 
increase in the tested potency of cannabis, and anxiety has been expressed about 
increases in treatment admissions. In 2007, the Swedish Rikskriminalpolisen published a 
report that suggested that the cannabis market is larger than previously thought: 25–30 
tonnes per year, with around 140 cannabis smuggling networks operating. Nonetheless, 
at 2.9 %, cannabis prevalence among young people in Sweden (15- to 24-year-olds) 
remains the third lowest in EMCDDA reporting countries, after Greece and Lithuania.
Cannabis’s role in drawing attention to ‘the drugs problem’ in Sweden
52
This chapter studies cannabis’s cultural role in what sociologists term a moral panic 
about drug use in Sweden. It examines the evolution of drug use from almost a non-
issue to a highly debated cultural construct. Its extracts from contemporary media reports 
with a salacious tone suggest that Europe was no stranger to the much-ridiculed ‘reefer 
madness’ campaigns of 1930s America. 
It is interesting to note how responses to drug use evolved to embrace a moral and 
welfare-related approach as opposed to a medicine- or psychotherapy-based focus. 
While in Sweden the vision of a drug-free society has been able to gain political 
legitimacy, in many other countries more pragmatic approaches have been adopted. 
Today, decades after the reports quoted in this chapter, stories about drug use — 
particularly among youths, celebrities, musicians, criminals and clubbers — still retain a 
hold over the public imagination.
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Cannabis’s role in drawing 
attention to ‘the drugs problem’ 
in Sweden
Börje Olsson
World illicit drug consumption has increased substantially since the beginning of the 
1990s. The annual number of users of all illicit drugs (1) in 2007 was estimated at 
about 200 million people. For cannabis, the corresponding number is 158.8 million, 
compared with 24.9 million for amphetamines, 15.6 million for opiates, 14.3 million for 
cocaine and 8.6 million for ecstasy (UNODC, 2007). 
Even if cannabis is by far the most frequently and widely used drug, the bulk of 
problems related to illicit drug use is linked to other substances, such as heroin and 
cocaine. In this respect, cannabis use is a subordinate issue, but in present and past 
policy controversies cannabis plays, and has played, a central role. Why is this so? This 
chapter focuses on the role of cannabis in the ‘cultural construction’ of the modern drug 
problem in Sweden. It aims to discuss cannabis’s central role, and to provide tentative 
answers.
The modern idea of ‘a drug problem’ developed fairly simultaneously in many Western 
societies in the late 1960s. It was characterised by an increased prevalence in groups 
not previously associated with drug use, and as a particular phenomenon that was 
distinct from previous, medical drug use. While historically cannabis experienced some 
pharmaceutical usage, it largely disappeared from legal medical practice in Western 
Europe before the Second World War (see Fankhauser, this monograph). A number of 
factors contributed to drugs being viewed as a problem: (i) recreational cannabis use as 
an intoxicant among ‘exclusive’ or ‘deviant’ groups as jazz musicians and other artists; 
(ii) claims that cannabis caused crime, mental illness and in severe cases even death; 
and (iii) the fact that synthetic preparations considered more effective than cannabis 
were invented, for example barbiturates and painkillers such as aspirin (Russo, 1998; 
Mack and Joy, 2000; Grotenhermen, 2002). Compared to many other substances 
which today are common on the illicit drug market — for example morphine and other 
opiates — cannabis was fairly easily ruled out from legal medical practice. Yet these 
medicinal substances continued to experience extensive, often highly praised use in 
(1) The number of people who have consumed an illicit drug at least once in the 12 month period 
preceding the assessment.
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regular medicine and as long as the users were seen as patients in need of treatment, 
drug use as a social problem was not an issue (Olsson, 1994; see also Fankhauser, this 
monograph).
Cannabis use played an extraordinarily important role in the process where drug use 
developed into a social problem in modern societies. This might seem odd considering 
its relatively mild effects and limited harms vis-à-vis opiates. As will be discussed, this 
paradox can be explained. In fact, it is doubtful whether our views on drugs and the 
policies developed upon them would have looked the same if cannabis had not existed. 
This general question will be discussed by taking its point of departure at the time of the 
Second World War and in one specific country, Sweden.
Though a prerequisite, the mere existence of drugs is not sufficient to create a drug 
problem. But to understand the roots of the ‘modern’ drug problem in Sweden, it is 
nevertheless a good starting point to turn to the introduction of amphetamines as 
pharmaceutical preparations towards the end of the 1930s. They were introduced 
for medical purposes and, as usual, the new medicament was praised as efficient, 
without side-effects and suitable for a variety of problems, such as narcolepsy, epilepsy, 
depression, psychosis, fatigue, excessive weight and obesity (Goldberg, 1944). 
Amphetamines or similar drugs that stimulate the central nervous system rapidly became 
popular and their use spread to a significant proportion of the Swedish population. It 
has been estimated that in 1942–3 there were about 200 000 users of amphetamines 
in the country, corresponding to 3 % of the adult population (a proportion that exceeds 
today’s amphetamine prevalence by 5 to 10 times). Even if the majority were occasional 
users, nearly 10 000 used them as frequently as between once a week to several times a 
day, and many in the latter group did so in extremely high dosages (Goldberg, 1968). 
Despite this, there were no signs of constructing drug use as a social problem. On the 
contrary, the privilege to formulate drugs as a problem was still solidly contained within 
the medical field. When drug use was perceived as a problem, it was as an individual 
disease suitable for the family doctor to treat (Olsson, 1994).
Multiple Swedish government investigations during the 1950s concluded that drug 
use offered little cause for alarm. Conclusions were drawn that there was appreciable 
prevalence in amphetamine (3%, Goldberg, 1968) and opiate use, although these 
were predominantly used by well-adjusted citizens for medical or therapeutic purposes 
(Medicinalstyrelsen, 1956). Moreover, incidences of opiate addiction could be best 
treated by a family doctor (Olsson, 1994). Although there was some acknowledgement 
of the threat of amphetamines, heroin (Bejerot, 1969) and cannabis, particularly to 
young users, reports on ‘societal risks’ — for example those associated with intravenous 
heroin use — drew predominantly on case studies outside Sweden. Furthermore, 
attempts to link problem drug use to subcultural groups by the Liberal Party MP 
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Rimmerfors were met with scepticism (Rimmerfors, 1954, 1958). In short, drug problems 
were generally perceived as alien to Swedish society. Swedes were using drugs for 
medicinal, not mind-altering, effects.
However, towards the end of the 1950s discussions appeared in which drug use as a 
social problem started to be identified and defined. The reasons behind this had little 
to do with the extensive oral use of amphetamines or morphine among well-integrated 
persons. What the public discourse started to pay attention to were three other 
phenomena: (i) drug use among musicians and artists; (ii) the link between these groups 
and youths; and (iii) a few years later drug addiction among marginalised groups. 
The first two received the most attention in the media. Amphetamines and cannabis 
use among musicians and other artists were perhaps the most frequently highlighted 
in the press. Limited use of morphine was also reported. Half a century after these 
reports and descriptions were published in newspapers, it is evident that one of the 
most distinguishing features in them was a strong tone of moral condemnation. This is 
true not only for drug use and drug users but also for the kind of lifestyle these artists 
represented. The following article illustrates this.
A lot has been written about the historical roots and developments of American jazz music. 
Unfortunately, the historical writing has been blind to the dark sides of jazz music and 
only focused on its charming, exciting and positive aspects (…) but the rush, stress and the 
increased competition between top musicians and, not least, unscrupulous managers have 
provided musicians and artists with an illusory substance that overcomes fatigue, increases the 
performance capacity at the same time as it turns them into slaves under the most dangerous 
vice that exists, drug addiction. (…) Youths talented for the profession as musicians worship 
the American stars as they were gods, and they try to imitate them at any prize. They make 
contacts at frequent guest performances and young Swedes get enthusiastic descriptions of 
how improvisation and other forms of liberation is amplified simply by smoking one joint of 
marihuana.
 (Aftonbladet, 11 April 1954: author’s translation)
The article highlights several aspects of the drug problem that were important in forming 
the general perceptions of drug use/misuse/addiction. In absolute numbers, the groups 
referred to involved only a few persons frequenting certain clubs and bars in the ‘Old 
Town’ of Stockholm, while the much larger group of persons using amphetamines were 
hardly given any attention. The quotation also indicates one of the main reasons why 
anxiety about drugs was soon to escalate, namely the clear link that was established 
between this exclusive group of American musicians and young Swedes. The anxiety 
was further increased through repetitive descriptions in other articles that appeared 
concerning promiscuous young girls and drugs.
It is well known to social workers that the mean age among female prostitutes in Stockholm is 
constantly decreasing. The influx of 16 to 20 year old girls is presently big. It involves teenage 
girls who have a history of being regular frequenters of obscure dance halls where they have 
established contacts with mediocre artists who have provided them with drugs.
(Aftonbladet, 7 November 1954: author’s translation)
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From 1954 onwards, the link between drug use and youth in media becomes more and 
more evident. Also, well-adjusted young people are described in the context of drugs 
and drug use, making it possible for any parent to identify with the narratives presented.
Daily, dozens of teenagers hang out at cafés. It is schoolchildren, often from well-off families, 
who without further ado skip school and homework, who drift about in gangs, who pretend 
they are Bohemians, poets, and drug users. Among the most advanced groups of youth 
in Stockholm, it has come into fashion to smoke hashish or marijuana or to get high on 
Phenedrine and sleeping-pills.
(Arbetaren, 24 February 1954: author’s translation)
Certain important features that have become central to how the Swedish drug problem 
later was conceived and defined were thus already present in 1954. Among the most 
important were the dominant perception of drugs as something alien to Swedish 
culture (2) and drugs as a serious threat to young people. At the same time, less 
attention was paid to the medically initiated use of drugs among somewhat older, 
ordinary citizens, and the fact that amphetamine use was already spreading among 
older criminals was not yet noticed. In other words, the portrayal of cannabis as a threat 
was both pronounced and distinct, but in reality did not yet live up to the legend. Even 
if jazz musicians, certain other groups of artists and a number of young people in their 
circles were given a prominent place in media narratives of drug use, their numbers 
were still very limited and an overwhelming majority of Swedes never had any contacts 
with drug users.
A simultaneous development took place which eventually would develop into the 
factual core issue in the Swedish drug problem: amphetamine use — in particular, 
amphetamines used intravenously — among established criminals. Due to reasons which 
are beyond the scope of this chapter, this unique form of drug use became extremely 
widespread in criminal circles. To some extent this process started already during the 
early 1950s, but it was not until the end of the decade and during the early 1960s 
that this pattern, peculiar to Sweden, really took off. As increased amphetamine use 
among criminals became evident, the controls of these substances also were made more 
stringent. Amongst other developments, by 1960 all amphetamine-like substances were 
included in the national list where narcotic drugs were classified. The legal channels 
to obtain access to these drugs were successively blocked, which led to an increasing 
number of drug crimes as the number of misusers and addicts continued to increase. 
This triggered a series of control measures such as, for instance, the setting up of a 
specific drug prosecutor and a police drug squad, together with a successive sharpening 
of drug legislation. At the same time, the legal consumption of narcotic drugs dropped 
to a fraction of its previous levels (Olsson, 1994).
(2) Drugs as an alien element in Swedish society and culture has later been analysed by Tham (1995).
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To summarise, taken together these three phenomena had a great impact on how 
the definition of the ‘modern’ drug problem developed and which drug policy was to 
be implemented. A crucial factor was that drug use (outside legal medical use) was 
something novel and unknown to Swedish society and culture, and to which frightening 
properties were attributed through references to intravenous heroin addiction in other 
countries. The image of drugs as a serious threat increased significantly due to the links 
made to ordinary youths running the risk to be drawn into the slavery of addiction. 
Also, and in sharp contrast to earlier images of the more familiar and legal medical use 
of drugs, clear links were outlined between drug use at the one hand and criminality 
and marginalisation at the other, as a result of the actual, visible and widespread 
amphetamine use among criminals.
As far as cannabis is concerned, thus far we can draw a tentative conclusion. Seen 
in isolation the actual prevalence of the substance played only a limited role in how 
basic perceptions and definitions of the drug problem originally were formulated in 
Sweden. Cannabis instead played an important role in adding strong moral and legal 
‘spin’ to Swedish drug policy. It was portrayed as strange, unknown, alien, exotic and 
frightening and, in contrast to, for instance, opiates, there was hardly any lingering 
‘normal’ medical use of cannabis after the Second World War. This concept of deviance 
was strengthened by the fact that people had almost solely to rely on illegal channels 
to obtain cannabis. Furthermore, the mind-altering effects of cannabis were unfamiliar 
to the ‘normalised’ intoxication culture in Sweden, that is to get drunk on alcohol. 
Empirical definitions of the substance in the medical field were held back by the absence 
of reporting of negative effects of cannabis in the medical literature. Such a ‘knowledge 
vacuum’ enabled moralists to step in and approach cannabis in alarmist terms. So 
public interest was weighted towards moral, legal and social aspects of cannabis use 
and the threat to young people that cannabis was seen to constitute. This weighting had 
a great impact on the process where not only cannabis, but drugs in general, grew to 
become a disproportionate public problem that required a response at the policy level.
By 1965 the situation around drugs had matured to the extent that all necessary 
prerequisites were at hand for the government to delineate what was to become a 
fundamental aspect of Swedish drug policy. A government commission was appointed 
to conduct the first comprehensive investigation into the drug situation in Sweden. 
The commission worked for four years and published four thick volumes (3) in which, 
apart from the articulation of negative moral perceptions, priority was given to the 
legal and social aspects of drug use. Control, prevention and treatment were from the 
beginning the main pillars in the model which later became one of the most restrictive 
in Europe. It is interesting to note that the legal and social aspects were not only 
dominant in the two first pillars, but also in the third, treatment. In contrast to many 
(3) SOU 1967, 25; SOU 1967, 41; SOU 1969, 52; SOU 1969, 53.
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other countries, the Swedish drug treatment system was built outside the medical sphere 
and to a large extent based on principles that do not constitute medical treatment. 
The overall responsibility for providing drug treatment was placed upon the social 
welfare system and many of the specific treatment methods utilised had strong moral 
and social components. Apart from a small experiment with methadone treatment, all 
treatment activities were drug-free and aimed at total abstinence from drugs. The role 
of medical authorities was limited to handling complications related to drug use and 
to providing detoxification before the patients were transferred to long-term treatment 
provided by the social welfare system, which was preferred to institutional treatment. A 
distinctive feature of Swedish drug treatment was that, at least during its first 15 years, 
drug use was perceived as a symptom of severe social and psychological problems 
and that treatment, therefore, should focus more on what caused the symptom than 
on the symptom itself. Both laymen and non-experts were given an important role in 
treatment, reflected by the very strong influence of treatment institutions run by NGOs 
(Socialstyrelsen, 1973).
A striking example, which serves to illustrate the strong legal, moral and social 
dimensions of drug policy, is the development of an influential form of institutional 
drug treatment model for youths in Sweden, which has become known as the ‘Hassela 
pedagogic’ (named after the village where the first institution was set up in 1969). This 
model — where one of the foundations is ‘medlevarskap’ (living together), meaning that 
clients and staff live together round the clock — put young addicts for a considerable 
period of time in a permanent and stable group of adults to work and study. Such firm 
fostering is a key concept in the model: adolescents are strictly reminded of ‘forgotten 
basics’ such as good friendship, solidarity with the group and respect for work. The 
‘Hassela pedagogic’ goes against the grain of the concept of therapy in the sense that 
treatment is explicitly rejected and the focus is instead on education and fostering pupils 
(the term used instead of clients or patients) into decent, well-integrated and hard-
working citizens (Tilander, 1991). It should also be noted that the majority of young 
addicts in this form of institution are treated compulsorily as a result of a legal decision 
(Bergmark et al., 1989).
This particular form of treatment had a significant impact on treatment models and 
methods for adults when they were designed and it is one of many examples of the 
strong legal, moral and social dimensions of Swedish drug policy. As has been shown, 
this architecture was rapidly constructed once drug use was recognised as a public 
problem and already before the advent of the 1970s, the foundation was laid for a 
policy that has remained unaltered if we consider the basic perceptions of drug use. 
It is true that drug policy became gradually more restrictive over the years and that 
numerous repressive measures were introduced, but this cannot be seen as a redefinition 
of the perceptions, but rather as a quantitative change where more weight was placed 
on the control side of drug policy (Lenke and Olsson, 2002).
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Some of the conclusions, at least tentatively drawn in this chapter, contradict popular 
understandings of how drug use developed in Sweden and how the drug problem was 
formulated. Maybe the most popular belief is that the Swedish drug problem took off 
when different youth cultural trends (hippies, flower power, etc.) spread around the 
world towards the end of the 1960s (see Abrams, this monograph). In these cultures 
drugs, and especially cannabis, played an important role. A closer look at the Swedish 
situation shows that drug use related to these types of youth cultures was hardly a new 
drug epidemic. Certainly, cannabis use among young people became more common 
from about 1965–7, but the prevalence figures which were reached were still modest 
and restricted to limited circles, in particular the major cities. Furthermore, for a vast 
majority of young people drug use was confined to trying cannabis once only or 
experimenting with the substance a few times (SOU, 1969: 53). Prevalence peaked only 
a few years later, after which a rapid decrease occurred (CAN, 2003). Later analysis 
shows that most of those who experimented with drugs in a more serious way, almost 
exclusively cannabis, only did so for a short period of time, after which they returned 
to a ‘normal’ life without drugs (Solarz, 1990). Those making up the group of problem 
drug users in Sweden were recruited through completely different channels, where the 
common denominator was the marginal position which preceded their drug use (Bejerot, 
1965, 1969; Olsson, 1994).
The Swedish hippie era, if it is possible to talk about such an era at all, and the radical 
youth movement around 1968 were important to conceptions of the drug problem. 
However, they added little in terms of originating or redefining ‘the drug problem’. 
The hippie era simply allowed media and other actors to revitalise the public discourse 
on youth and drugs that had already started some 10 years earlier but which, as with 
most discourses, had stagnated. In particular, two dominant aspects of the discourse 
in the mid-1950s were revived around 1968: firstly, the idea of youth oppositionism 
or rebellion, which was attributed to both the youth movements of the mid-1950s and 
those of the end of the 1960s; secondly, the idea of danger, in terms of the grave 
risks that were associated with drug use, with no exception made for cannabis. Since 
cannabis prevalence in the hippie era surpassed by far that in the 1950s, the effect was 
to ‘upscale’ the problem with little change to its key qualitative features. Again, we see 
portrayals of drug addicts as persons without will power who have become slaves to 
a lethal vice compelled to act as chemically driven ‘crime machines’ (Winsløw, 1984). 
Again, we see the factual domestic situation where amphetamine use rapidly spread to 
become an integral part of an established criminal sub-culture. 
In short, the main effect of the ‘drug wave’ towards the end of the 60s in Sweden was 
to revive dormant anxieties of an impending social catastrophe and at the same time 
provide fertile soil for a drug policy with strong moral, legal and social dimensions.
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Setting the context
This chapter examines cannabis use in the 10 Member States which joined the European 
Union in May 2004. It attempts to identify patterns in a cluster, and aims to increase our 
understanding of cultural, social and economic issues which are deeply embedded in 
cannabis use patterns and social responses.
More time will be needed to grasp the full impact of how drug use is affected by such 
a root-and-branch political shift as EU membership — if indeed any generalisations 
can be made in what remain, even after EU membership, very diverse countries. Will 
cannabis use patterns in EU Member States converge or continue to differ? To what 
extent does changing affordability, or the geographical proximity to supply routes, 
affect cannabis consumption? Will new EU members also experience the shift to 
herbal cannabis cultivation, as witnessed in a number of EU countries? Can country 
peculiarities, such as the high prevalence of cannabis in the Czech Republic, be 
easily explained? After EU membership, how does drug use interact with other social, 
economic and health indicators?
This chapter offers some thoughts, impressions and observations on early experiences. 
These experiences invite further validation and consideration as the drugs data for these 
countries mature. Moreover, since this article was written the European Union has further 
grown: two new Member States, Bulgaria and Romania, joined in January 2007. Drug 
use in two candidate countries, Turkey and Croatia, has also begun to be monitored 
directly by the EMCDDA. As the Centre is increasingly sought to comment on drug use 
among its new members and near-neighbours, this chapter emphasises the value of 
expert local insights: the voices behind the statistics.
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Introduction
The 2004 enlargement of the European Union (EU) covered 10 countries of very 
different size, population and culture, spreading from the Baltic to the Mediterranean. 
Considering existing commonalities and differences, three broad groups may be 
distinguished: the Baltic States (Estonia, Latvia and Lithuania); the Central European 
countries (Czech Republic, Hungary, Poland, Slovenia and Slovakia) and the 
Mediterranean islands (Cyprus and Malta). The number of their inhabitants ranges from 
just over 400 000 in Malta to over 38 million in Poland. Altogether, close to 80 million 
people live in the new members of the EU, sometimes referred to as the EU-10.
Significant differences exist in economic development and wealth among the EU-10. 
Gross national product (GNP) per capita adjusted for purchasing power varies from well 
below EUR 8 000 in the Baltic states to over EUR 15 000 in Cyprus, Malta and Slovenia. 
The new EU Member States are also very different in terms of political history. For about 
a half of the last century the Baltic states were part of the Soviet Union, and Poland, 
the Czech Republic and Slovakia, as well as Hungary, belonged to the bloc of socialist 
countries bound militarily and economically to the Soviet Union. Slovenia was part of 
socialist Yugoslavia, while Cyprus and Malta experienced market economies and more 
pluralistic political systems after rejecting the colonial power of the United Kingdom 
about 50 years ago. Eight out of 10 new EU members have been affected, then, by 
root-and-branch social change in the last 20 years.
Introduction of multi-party political systems and reinforcement of the market economy 
have resulted in more personal freedom and economic growth in recent years. On the 
other hand, a sense of everyday security has deteriorated. According to the participants 
of the project, security deteriorated the most, followed by housing security. Cannabis 
has been an illicit drug of choice for relatively large segments of young people in 
Western Europe. After the fall of the Iron Curtain cannabis use has rapidly increased in 
prevalence in Central and Eastern Europe as well, both in terms of physical presence 
and as a symbol of affiliation to the Western youth cultures.
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This chapter is co-authored by individuals from 10 countries. In the first stage of its 
preparation, representatives of each country produced a detailed inventory of available 
cannabis data in standardised format. The inventories served as background material 
that was used extensively during a two-day workshop with the aim to write a first draft 
of the chapter. The participants, divided into three groups which focused respectively 
on epidemiology, social perception and social responses, outlined three sections of 
the chapter which were then elaborated by three individuals: Airi-Alina Allaste (social 
perception), Zsolt Demetrovics (social response) and Danica Klempova (epidemiology). 
Finally, the chapter was combined and edited by Jacek Moskalewicz and Janusz 
Sierosławski. Support and encouragement was offered by Linda Montanari and Sharon 
Rödner Sznitman.
Epidemiology
History of cannabis in the region
Origins and industrial use of cannabis in the new EU Member 
States
Cannabis sativa was thought to be brought to Southern Europe by Scythians in the 
7th century bc. After that it gradually spread to other parts of Europe (Booth, 2004; 
Encyklopédia Slovenska, 1979). During feudalism, it was grown in central Europe, 
including the present territories of the Czech Republic, Hungary, Poland, Slovenia, 
Slovakia and possibly also other new EU Member States (e.g. Cyprus), usually in 
small-scale production by farmers, who processed it to make fabric, ropes and oils. 
The appearance of cheaper materials led to the replacement of hemp and decline of its 
cultivation. After the year 1945 the small-scale production of hemp almost disappeared. 
The industrial cultivation of hemp was, however, still present in some countries in the 
1980s. Main products made from it included fabrics for clothes, ropes, sheets, bags, 
cords for tyres, upholstering materials, oil used to make lacquers and varnishes, soap, 
materials for the food industry, animal foods, medications, materials for the construction 
industry, cellulose, etc. The contents of THC in the hemp grown for industrial purposes 
was low — about 1 %. At the end of the 1980s, growing and cultivation of cannabis 
was entirely stopped or heavily reduced due to stricter controls imposed by international 
conventions.
History of use of cannabis for its psychoactive properties
In Cyprus, cannabis as a psychoactive substance had culturally determined roots: both 
from Turkish culture present on the island, where cannabis resin used to be smoked 
in water pipes, and via Cyprus’s central location in historical Eastern Mediterranean 
cannabis trading routes (Egypt, Greece, Lebanon, Syria, Turkey). In Slovenia, the use of 
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cannabis for its psychoactive and hallucinogenic attributes is also believed to have been 
known to its inhabitants for centuries.
In Malta documented evidence of cannabis dates back to the early 1980s. During this 
time herbal cannabis was grown locally, mainly during the summer months. Between 
1985 and 1990 an increase in trade between other countries resulted in an increase in 
the importation of cannabis oil, which is quite rare today, and Lebanese and Moroccan 
cannabis resin. The latter remains the most common type of imported resin in Malta.
In the Czech Republic, Hungary, Poland, Slovakia and Slovenia anecdotal evidence 
exists about cannabis use during the revolt of the ‘hippie generation’ from the late 
1960s on, although prevalence was rather low. This can partly be explained due to 
low THC content in domestic cannabis and low availability and relatively high prices 
of cannabis sourced abroad. In Slovenia, with its warmer climate, cannabis use was 
supported from home growing during the 1980s. In that period, often referred to by the 
users as a golden age, cannabis supply was based on principles of reciprocity, barter 
and gifts, and not based on a criminal black market (Flaker, 2002).
In Estonia, Latvia and Lithuania, cannabis for psychoactive purposes is anecdotally 
reported to have been brought by soldiers serving their compulsory military service in 
Central Asian republics in the 1970s and 1980s. Herbal cannabis known as ‘anasha’ 
was consumed and brought home to some extent, especially by young soldiers (Kärdi, 
1993: 54–61, 58–63).
However, the history of the use of cannabis for its psychoactive properties in the 10 
new EU Member States is only documented anecdotally, and historical sources in most 
of the countries are scarce. With the exception of Cyprus, and perhaps Malta and 
Slovenia, before the 1990s the psychoactive properties of cannabis went either generally 
unrecognised or its use was very rare.
Contemporary prevalence of cannabis use
European School Project on Alcohol and Drugs
The most consistent data source for country comparison of cannabis use among 
teenagers is probably the European School Project on Alcohol and Drugs (ESPAD, see 
Hibell, this monograph). This survey took place in all of the 10 new EU Member States 
in the years 1995, 1999 and 2003 (Hibell et al., 1997, 2000, 2004).
Figure 1 shows trends in lifetime prevalence of cannabis use among 15- to 16-year-
olds, according to the ESPAD survey in the 10 new EU Member States, while Figure 2 
presents differences between lifetime, last year and last month prevalence, as recorded 
in 2003 (Hibell et al., 2004).
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Figure 1: Lifetime prevalence of cannabis use among 15- to 16-year-olds (ESPAD, 1995, 
1999, 2003)
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The reported lifetime prevalence of cannabis use among 15- to 16-year-old ESPAD 
respondents increased in the years 1995–2003 in all new EU member countries except 
Cyprus, where it remained approximately stable at a relatively low level (2–5 %). The 
increase in the years 1999–2003 was smaller in most countries than in 1995–1999. 
Among the 10 countries, a medium level of lifetime experience with cannabis can be 
found in the Baltic countries (Estonia, Latvia and Lithuania) and in Hungary, Malta and 
Figure 2: Lifetime, last-year and last-month prevalence of cannabis use among 15- to 
16-year-olds (ESPAD, 2003)
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Poland (10–18 %). The highest lifetime cannabis use prevalence is reported in the Czech 
Republic (44 %), Slovakia (27 %) and Slovenia (28 %).
Last year and last month prevalence of cannabis use among 15- and 16-year-olds 
show similar time trends. Last year prevalence is lower than, yet mostly close to, 
lifetime prevalence in this age group. Last month prevalence, as an indicator of regular 
cannabis use, is much lower. In the three countries with the highest prevalence, regular 
use ranges from 18 % in the Czech Republic through 14 % in Slovenia to 10 % in 
Slovakia. The range of the remaining seven countries is narrower and it varies from 2 % 
in Cyprus to 8 % in Poland. As a rule, prevalence of cannabis use during last month 
constitutes about 50 % of the last year prevalence, while last year prevalence is 15–40 % 
lower than lifetime cannabis experience. In effect, the wide gap among countries with 
regard to lifetime use tends to narrow with increasing frequency of use (Figure 3).
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Figure 3: Inter-country variation in lifetime, last-year and last-month prevalence of cannabis 
use among 15- to 16-year-olds (ESPAD, 2003)
The three syringes above show inter-country ranges in lifetime, last year and last month 
prevalence of cannabis use. Each cylinder represents two quartiles of respondents 
spread either side of the median and, finally, a horizontal pusher indicates a median 
value of prevalence among all countries. The declining values of all three indicators 
confirm that the cultural gap in cannabis use tends to close with growing frequency of 
use.
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General population surveys
The general population surveys provide a picture of cannabis use among the young 
population (15–34), which is slightly different from the ESPAD results (see Figures 4 
and 5). In Latvia, general population prevalence is similar to ESPAD survey results. In 
Lithuania, Slovakia and Hungary, the ESPAD results show similar values for lifetime 
prevalence, but indicate higher last year and last month prevalence. In the Czech 
Republic, Estonia, Malta and Poland, cannabis use among 15- to 16-year-olds surveyed 
by ESPAD is markedly higher than in the general population. Cyprus is the only country 
where general population data indicate higher prevalence than ESPAD data. There is a 
sharp contrast between figures for 15- to 16-year-olds — ranging from 1 to 5 % — and 
those for young adults aged 15–34 — ranging from 13 to 25 %. Data from Cyprus also 
show smaller gaps between lifetime experience and last year and last month use.
General population surveys across all 10 countries confirm that cannabis use is not only 
a matter of teenager behaviour, but is also prevalent among young adults up until their 
early 30s. Similarly to ESPAD, general population surveys show that while cannabis has 
been tried by a substantial proportion of young people, regular cannabis use is still only 
represented by small percentages of young adults.
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Figure 4: General population survey results from 2001 or 2002 about the prevalence of 
cannabis use among the young population (15- to 34-year-olds)
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Figure 5: General population survey results from 2003 or 2004 about the prevalence of 
cannabis use among the young population (15- to 34-year-olds)
Differentiation in cannabis use
Gender
Although in all countries cannabis use is higher among males than females, the size of 
the gap between the genders differs. Among 15- to 16-year-olds in 2003 there were 
five males to one female using cannabis in Cyprus, and two males to one female using 
cannabis in Latvia, Lithuania and Poland. The ratio ranged between 1:3 and 1:4 in 
Estonia, Hungary, Malta and Slovakia, and it was very small, at just below parity, in 
the Czech Republic (1:1) and Slovenia (1:1) (Hibell et al., 2004). It is worthwhile noting 
that a trend towards a more narrow gender gap was reported in most of the countries 
between 1995 and 2003.
Urban versus rural areas
All of the countries which explored the difference between rural and urban areas found 
a higher prevalence of cannabis use in the larger cities, for example Estonia, Lithuania, 
Poland or Slovakia (see Figures 6 and 7). In some countries, this difference between 
urban and rural areas is levelling off (e.g. in Poland) while in others (e.g. Slovakia) it 
remains stable.
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Other socio-economic factors
Data from the ESPAD survey in most countries revealed a clear association between 
cannabis use and truancy, sibling substance use and parents not knowing where the 
student spends Saturday night. A slightly weaker, yet still significant, association in most 
countries was living in a non-intact family structure. The association is unclear or non-
existent in the cases of parents’ education and the economic situation of the family in 
which the respondent lives (Hibell et al., 2004).
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Figure 6: Lifetime prevalence of cannabis use (%) by level of urbanisation in Lithuania 
among 15- to 64-year-olds
Figure 7: Lifetime cannabis use (%) among 17- to 18-year-olds in the capital of Poland, 
Warsaw, compared with national data
Source: General population survey 2004.
Source: ESPAD.
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In Estonia, analysis of the available data also revealed higher cannabis use among the 
Russian-speaking part of the population. This discrepancy, which has slowly tended to 
narrow, can be attributed to a number of factors. First of all, Russian-speaking schools 
are mostly located in the cities where drug use is more widespread. Secondly, the 
Russian-speaking population lives in the north-western part of Estonia, which suffers 
from a higher level of social exclusion, including high unemployment and criminality, as 
well as alcohol and drug use (Allaste and Lagerspetz, 2005: 267–285) (Figure 8).
Patterns of cannabis use
Description of the patterns of use
In all new EU Member States, cannabis is found in all forms with various levels of 
THC concentrations: herbal cannabis and cannabis resin, both imported as well as 
grown indoors or outdoors. The general pattern of smoking cannabis herb or cannabis 
resin dominates, with herb dominating in some countries and resin in others. In those 
countries where the traditional consumption mode was the water pipe, this is fading and 
hardly exists among youngsters.
In most countries cannabis use has become more or less normalised among youths. 
This does not mean that all young people use cannabis, but that the drug is fairly 
available and the majority of youths are ‘drug-wise’ and tolerate cannabis use among 
others, even if they themselves do not use the substance (Parker et al., 1998). According 
to qualitative data, cannabis use does not increase the social status of the user, nor 
does it benefit from aggressive marketing. Cannabis has emerged simply as a part 
of the culture of young people, who want to have fun with their friends (Fatyga and 
Sierosławski, 1999).
Figure 8: The difference in lifetime prevalence of cannabis use according to ESPAD surveys 
1995, 1999 and 2003 by working language at school in Estonia
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Polydrug use
Users of cannabis usually have a higher probability to have experienced other drugs, 
in particular stimulants and hallucinogens (e.g. Zimmerman et al., 2005; Milani et al., 
2005; Butler and Montgomery, 2004). This relationship also appears to hold true for 
the new EU Member States. According to secondary analysis of ESPAD data, last year 
prevalence of marijuana use in new EU members highly correlated (P < 0.05) with the 
prevalence of the use of ecstasy and any illicit drug other than marijuana and hashish 
(P= 0.722 and 0.691 respectively).
According to Slovenian qualitative research (Kvaternik, 2004), young people in the age 
group 15–25 (pupils and students) usually engage in more risky behaviour than their 
older peers while using drugs. They consume more drugs (polydrug use) and larger 
quantities in any one occasion. Although being reasonably informed, it seems that in 
practice they do not seriously consider potential health risks.
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Figure 9: Last-year prevalence of other drugs use among last year cannabis users (Poland 
2002, general population, aged 16- to 34-years old)
Users of ‘harder’ drugs are more likely to have used cannabis too. Practically all 
ecstasy users use cannabis to recover from a night of exposure to ecstasy and noise 
(Demetrovics, 2001; Moskalewicz et al., 2004). On the other hand, the majority of 
cannabis consumers do not use other drugs, as documented by the Polish survey data. 
As can be seen from the graph, under one-third of cannabis users combine cannabis 
with other drugs, mostly with stimulants and hallucinogens, while 65 % of them use only 
cannabis. It must be stressed that the vast majority of cannabis users never use opiates 
(Figure 9).
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The role of social networks
According to ESPAD, in all of the 10 countries except Lithuania, the illicit drug first used, 
usually cannabis, is typically obtained from a friend, or shared in a group (ESPAD, 
2003). Polish qualitative research has revealed that the pressure to use cannabis when 
peers are using is not perceived to be strong by young people. They argue that they are 
free not to use when they choose not to (Fatyga and Sierosławski, 1999).
Availability of the drug
Subjective availability
Availability of cannabis can be indirectly inferred from the data on perceived availability, 
police seizures data and also prices of the drug on the street as they indicate economic 
accessibility of drugs if related to incomes.
A few conclusions can be drawn from Figure 10. First, cannabis seems to be fairly easily 
available for a substantial proportion of students in all countries under review — from 
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Figure 10: Perceived availability of cannabis among 15- to 16-year-olds: percentage of 
students who perceive cannabis as ‘very easy’ and ‘fairly easy’ to obtain
Source: ESPAD 1995, 1999, 2003.
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more than 10 % in Cyprus to close to 60 % in the Czech Republic. Second, perceived 
cannabis availability has increased in all countries, and no saturation effect has been 
recorded. In other words, countries that reported high availability already 10 years 
ago tend to see it growing as fast as remaining countries. Third, it is evident that large 
differences still exist among the new EU members. Four groups of countries emerge, 
the first being high availability countries, including the Czech Republic, Slovenia and 
Slovakia, where subjective availability is around 50 % and over. These countries are 
followed by Poland, where the indicator approaches 40 %. Then, remaining countries 
report availability of approximately 20 %. Finally, Cyprus reports the lowest availability, 
where only 12 % of students consider cannabis easily available.
Economic accessibility
For decades, centrally planned economies in Eastern Europe were economically relatively 
self-contained. The economic systems included the non-convertibility of their currencies. 
In effect salaries, although adequate in terms of purchasing power, were extremely 
low when exchanged to any convertible currency, varying between USD 20 and USD 
50 per month. On the one hand, smuggled cannabis was practically unaffordable for 
young people, and, on the other hand, Central and Eastern European markets were of 
little interest for illicit suppliers. The transition to a market economy brought with it the 
convertibility of national currencies and a rapid increase of nominal incomes calculated 
in hard currencies. More than a decade after this transition, prices per gram of cannabis 
in the EU-10 have become relatively stable and are close to prices in the EU-15, ranging 
from EUR 3.5 in Slovenia to EUR 17 in Latvia.
There are substantial variations in prices in relation to purchasing power, too. The 
average monthly income in the Baltic States equates to the value of 30–50 g of cannabis, 
in the Central European countries to 100–150 g. In Cyprus, Malta and Slovenia, where 
the currencies have been convertible for decades, an average monthly income could buy 
200–400 g of marijuana.
Figure 11 shows that herbal cannabis prevalence increases with average purchasing 
power. This is particularly the case for former socialist countries, where national 
currencies became suddenly convertible at the beginning of the 1990s, and where 
purchasing power for imported goods increased manifold almost overnight. The 
outliers of this linear relationship are countries with very high (Czech Republic) or very 
low (Cyprus and Malta) cannabis use. Cyprus and Malta represent relatively affluent 
societies with a longer history of a market economy, where cannabis has been relatively 
affordable for decades. The third outlier — the Czech Republic — has the highest 
prevalence of cannabis use worldwide. Its high position on the plot may partially be 
attributed to its relative wealth. However, all three outliers confirm that socio-cultural 
factors in drug consumption are more important than affordability alone.
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Social representations of cannabis in new EU 
countries
General perception of the drug problem
Officially, the new EU countries do not make distinctions between cannabis and other 
drugs, and the general public supports such grouping of illicit drugs. In most countries, 
the media tends to sensationalise drug use (Paksi, 2000: 70–86). This means that 
overdose cases, seizures and other drug-related crimes are overexposed compared with 
other major social questions. Cannabis, if discussed at all, is primarily mentioned as a 
gateway drug, and the normative idea that smoking cannabis leads to use of harder 
drugs is expressed from time to time in most of the countries. As is common in many 
countries, problem drug users are often stigmatised. A common presentation of drug 
users that is propagated through the media is the image of drug addicts as dirty asocial 
human wrecks with frantic eyes. However, according to public opinion surveys from 
Poland and Estonia, people tend to perceive drug addicts as ill people rather than as 
criminals (Laidmäe and Allaste, 2004: 118–143).
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Figure 11: Herbal cannabis buying power of an average monthly salary
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Perception of cannabis by the younger generation
Whereas the older generations tend to perceive all drugs as equally dangerous, younger 
generations tend to consider cannabis less harmful than other drugs in all the new EU 
countries. The generation gaps emerge with rapid social and cultural change and ‘the 
young quickly acquire “new strategies of action” for coping with life in unsettled times’ 
(Misztal, 2003: 85). Illicit drugs were introduced to the Baltic market only during the 
last decade, and to the Central European markets only a little earlier. This created a 
situation where the younger generations, who are experimenting with drugs, know more 
about the topic and are also much more tolerant than the older generations.
According to the ESPAD study, social condemnation of experimenting with cannabis 
is decreasing in Central Europe, and the most tolerant attitude towards this issue is 
displayed by school teenagers in the Czech Republic and Poland.
Although cannabis use has become ordinary, especially in the countries of Central 
Europe, it has also sometimes acquired a symbolic meaning of rebellion, at least in 
some youth cultures. Nevertheless, this rebellion is not a total negation of the society’s 
value system, as was evident in the 1960s. Today, young people consider cannabis 
prohibition hypocritical within the context of the growing availability of alcohol. They 
either question the right of the state to impose the ban or demand that liberal economic 
policies applied to legal drugs should be extended to cannabis.
Images of cannabis in the arts and the media
Cannabis is not used extensively in the established visual arts, but the portrayal of 
cannabis with clearly positive connotations can often be seen in graffiti in most of the 
countries. Cannabis symbols are used in souvenirs, T-shirts, earrings, scarves, bracelets, 
cough drops, etc., and images of cannabis leaves can sometimes be found in book 
designs. However, these are niche products that can be bought from alternative shops 
or markets in most of the countries, and are found more commonly only in the Czech 
Republic.
Positive connotations of cannabis are much more often expressed in local popular 
and hip-hop music. In Poland, the vocalist Lora Szafran sings about the society which 
prohibits cannabis use but encourages youngsters to drink alcohol: ‘The society is telling 
you that you better drink and smoke (tobacco) but grass is peace while alcohol — 
madness.’ In the Czech Republic, the columnist of the magazine Reflex, Ji rˇí Doležal, has 
been a strong voice in cannabis advocacy (1).
(1) Seth Fiegerman, Ji rˇí Doležal: ‘Still looking for change’, The Prague Post, 18 April 2007.
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Popular culture stresses the positive features of cannabis in contrast to other drugs: 
‘Weed unites people’, ‘Marihuana heals, other drugs — never use them’. Marijuana is 
strongly associated with rasta culture and hip-hop music, and the respective attitudes 
are openly expressed in the songs. Hip-hop has become a popular part of youth culture, 
and those who claim to belong to the sub-culture often call themselves: ‘The Society of 
Hash and Scun’, ‘League of Blunters’ or ‘bluntoholics’. All of these play on slang for 
cannabis. Cannabis use combined with alcohol seems to have become an integral part 
of their lifestyles, as well as its symbol (Demetrovics, 1998, 2001, 2005; Tossman et al., 
2001).
Social response
Supply reduction
Legislation and policy
Drug legislation in all new EU members has evolved for several decades in an 
unexpected way. Twenty years ago drug legislation was restrictive and repressive in the 
Baltic States, as elsewhere in the Soviet Union. Restrictive laws prevailed in Cyprus and 
Malta, too. However, in Czechoslovakia, Hungary, Poland and Yugoslavia the penal 
sanctions were not that severe and possession of drugs was not penalised at all. In the 
1990s when a number of ‘old’ EU countries tended to liberalise their drug policies, 
countries of Central Europe introduced more repressive legislation, which generally did 
not make any distinction between cannabis and other drugs.
Currently, the new EU countries have stricter drug laws compared with the majority of 
pre-2004 Member States. Nevertheless, in terms of the most repressive legal control 
(prison sentences for drug use), only Cyprus among the 10 new EU Member States 
imposes prison sentences for drug use, vis-à-vis four existing Member States (Greece, 
France, Finland and Sweden). In addition to Cyprus, the Baltic countries deem drug use 
to be an administrative offence.
Possession of small amounts of drugs for personal use is criminalised in all of the new 
EU Member States, although differences exist between legislative penalties and actual 
sentencing practice at the judicial level. Nevertheless, in the Czech Republic, in the case 
of small quantities for personal use, and in the absence of aggravating circumstances, 
the law foresees ‘administrative’ sanctions only (EMCDDA, 2005). In the Baltic States 
(Estonia, Latvia and Lithuania), possession of a small amount of any drug is considered 
a ‘non-criminal offence’. The difference with regard to the Czech Republic is that in 
Estonia, Latvia and Lithuania a ‘non-criminal offence’ may be punished by deprivation 
of liberty for up to 30, 15 and 45 days respectively. In Slovenia, possession for personal 
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use is punished by a monetary fine or 5–30 days of arrest. In the remaining new 
EU Member States any kind of possession for personal use is considered a criminal 
offence, making sentences involving imprisonment possible (EMCDDA, 2005). However, 
possibilities to avoid imprisonment are available in some countries through diversion 
or referrals (entering treatment as an alternative of the legal process or imprisonment 
or suspension of a prison sentence). In other countries the application of the law seems 
to be more lenient than would be possible if the text of the law were taken literally. 
In Hungary, for example, two years of imprisonment is envisaged for possession of a 
small amount of cannabis for personal use only, but until the time of writing no-one has 
been sentenced to such a term of imprisonment. Differentiation between possession for 
personal use and trafficking exists in all 10 countries, while a differentiation between 
small and substantial quantities is defined in a number of ways. In some countries there 
is no exact definition, but the differentiation is based on whether the cannabis was for 
personal use or for dealing (Table 1).
Law enforcement
Among the new members, two groups of countries can be distinguished in terms of law 
enforcement (that is, the extent to which police and other law enforcement agencies 
implement a law). In the first group — Malta and Slovakia — any drug-related crime is 
subject to a high level of police activity, which means that the level of law enforcement 
is the same in the case of personal use as in the case of trafficking. In all other 
countries — with the exception of Estonia, for which data were not available — a more 
Table 2: Absolute number of seizures (all drugs and cannabis alone) and 
number of seizures per 100 000 inhabitants in 2004
Country Number of drug 
seizures (all)
Number of 
cannabis seizures
Number of drug 
seizures (all) 
per 100 000 
inhabitants
Number of 
cannabis 
seizures per 
100 000 
inhabitants
Czech Republic 907 572 8.9 5.6
Estonia (1) 940 270 69.6 20.0
Cyprus n/a n/a n/a n/a
Latvia n/a 316 n/a 13.6
Lithuania 1 552 265 45.0 7.7
Hungary 2 751 1 791 27.2 17.7
Malta 308 113 77.0 28.3
Poland (1) 543 305 1.4 0.8
Slovenia (2) 4 777 3 421 243.2 174.2
Slovakia 1 538 913 28.6 17.0
(1) Data from 2002.
(2) Data from 2003.
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differentiated picture can be identified. In these countries use and possession of a small 
quantity of cannabis for personal use is enforced at a low or medium level, while the 
focus of the police and other agencies is on trafficking or possession of substantial 
quantities of drugs.
Other, more objective data show that the most seizures (both cannabis and other drugs) 
occurred in Slovenia (4 777 seizures for any drugs in 2003; 3 801 in 2004) followed 
by Hungary (2 952 in 2003; 2 751 in 2004), Slovakia (1 532 in 2003; 1 538 in 2004), 
Lithuania (1 029 in 2003; 1 552 in 2004), Estonia (1 060 in 2003) and the Czech 
Republic (979 in 2003; 907 in 2004). When drug seizures are calculated per 100 000 
inhabitants, the highest rate of seizures is found in the smallest countries — Estonia, 
Malta and Slovenia — while the lowest is found in the Czech Republic and Poland. Only 
Hungary diverges from this rule, particularly with regard to cannabis, which has three 
times more seizures than the Czech Republic, yet a comparable number of inhabitants 
(Table 2).
However, there are large differences in what percentage of these numbers are cannabis 
seizures. For example, in Slovenia in the past four years, 70–90 % of all seizures were 
of cannabis. In the Czech Republic, Hungary, Poland and Slovakia this proportion 
varied between 40 and 70 %. Lower shares of cannabis seizures can be found in 
Lithuania (12–17 %), Estonia (26–29 %) and Malta (33–43 %). Figure 12 suggests that 
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Figure 12: Proportion of cannabis seizures among all drug seizures
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the proportion of law enforcement efforts devoted to cannabis is converging in the 10 
countries. In those with the highest ‘cannabis oversight’ (Hungary and Slovenia), the 
cannabis share in their seizures has declined while in the remaining countries this share 
has tended to rise (Figure 12).
Data are available only from Hungary and Malta about the type of cannabis seizures, 
but these two countries are worth comparing as they represent substantially different 
profiles. In Malta the highest percentage of cannabis seizures is registered for cannabis 
resin (70 % to well over 90 %), while in Hungary herbal cannabis represents 93 % of all 
cannabis seizures. This comparison may reflect either a great distinction in consumption 
patterns or a large difference in the focus of control (Figure 13).
A substantial proportion of those who are arrested for petty drug offences — drug 
possession or use but not trafficking — is arrested because of cannabis. The highest 
percentage can be found in Slovenia, where four out of five arrests are related to 
cannabis. In the three other countries where data are available, this share varies from 
30 % to 60 %.
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Demand reduction
Prevention
Prevention campaigns in all 10 countries are dominated by school-based universal 
prevention programmes, and these naturally integrate cannabis-related issues. However, 
programmes do not specifically discuss this drug, and no specific emphasis is placed 
upon cannabis (Paksi and Demetrovics, 2002).
Treatment response
Among the 10 countries, Hungary has the highest prevalence of cannabis users in 
treatment (see Figures 15 and 16), estimated at 45 cannabis clients in treatment per 
100 000 inhabitants (2004). Hungary is followed by Malta (32 per 100 000 in 2003), 
Estonia (15 per 100 000 in 2003) and the Czech Republic (14 per 100 000 in 2004). In 
all remaining countries there are 10 or fewer cannabis clients per 100 000. As is also 
evident in the pre-2004 EU Member States (see Montanari et al., this monograph), all 
of the new EU states have experienced a substantial increase in cannabis admissions 
to treatment in the past 10 years. This increase is, however, proportionately higher in 
Hungary than in the other countries. The reason behind this may be attributed to the 
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proportionately high possibility of referrals (choosing treatment as an alternative to 
the legal process) rather than a greater need for treatment in Hungary. In 2004, for 
example, more than half of the clients entered treatment in the frame of referrals, and 
not on the basis of experiencing physical or mental problems which requires professional 
help.
Slovakia: outpatient treatment services
In relation to the graphs above, it must, however, be noted that the increase in demand 
for treatment is a complicated issue and not fully explained in the literature. Trends 
which indicate an increase in cannabis admissions may reflect: growing numbers of 
problem cannabis users who look for help with their medical problems; an increase in 
specialised services which may attract more clients; and more restrictive legislation and 
enforcement which forces cannabis users to seek an alternative to prosecution in the less 
repressive medical sector (see Simon, this monograph).
Public debate
Political debate
Officially, there is no distinction between soft and hard drugs in any of the new 
Member States. Nevertheless, there are some differences in perception of cannabis at 
the official level. In the Czech Republic, the National Drug Commission has initiated 
amendments in the legislation in order to distinguish between soft and hard drugs. In 
Hungary, the distinction between soft and hard drugs and decriminalisation of cannabis 
use are supported by the representatives of the Hungarian Liberal Party. In Poland, 
representatives of left-wing political parties also favour depenalisation of cannabis. In 
2004, a member of the parliament from the then governing Democratic Left Alliance 
officially issued a statement on the legalisation of drugs, especially cannabis, which 
was widely quoted by the media. Two years ago, the agenda of a local left-wing party 
in Slovakia included decriminalisation of cannabis. By contrast, in the Baltic States and 
Malta, no officials have publicly expressed their support for the decriminalisation of 
cannabis.
The topic of legalisation of cannabis use has received much attention from the public 
in recent years. Much of this discussion has been driven by the liberalisation of drug 
policies and decriminalisation of cannabis in parts of Western Europe. In Estonia this 
Western liberalism is strongly opposed by the authorities. The Minister of Social Affairs 
stated publicly in a newspaper that use of cannabis is illegal and will remain illegal. In 
other countries, particularly in Slovenia, a co-author suggests that politicians may be 
waiting for EU directives or an external initiative in order to deal with this matter.
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To summarise, opposing political forces tend to gain political leverage from the drugs 
question in general, and cannabis in particular. Their motives include generating 
support either among young voters who defend decriminalisation or legalisation, or 
among conservative elements of society who demand more repressive policies. This 
political context is counterproductive to a technical discussion on how to achieve a more 
rational consensus on cannabis policy.
Cannabis activist groups
In Central and Eastern Europe there are active groups advocating drug law reform 
in terms of depenalisation or decriminalisation of cannabis. In Hungary, one of the 
leading professional drug reform organisations is the Hungarian Civil Liberties Union 
(HCLU), which advocates the human rights of other vulnerable populations as well. The 
Hemp Seed Association (Kendermag Egyesület), a local users’ group, actively speaks in 
favour of the legalisation of cannabis. Each year the Hemp Seed Association organises 
a demonstration as part of the Million Marijuana March (an annual, worldwide 
protest campaign for the legalisation of cannabis) in Budapest. It also initiated a civil 
disobedience movement in March 2005. Participants of this movement appeared at the 
National Police Headquarters, blaming themselves for violating drug laws in order to 
raise awareness of the criminalisation of drug users. In the Czech Republic, there are 
also rather professional organisations fighting for the rights of cannabis users, and there 
is also a ‘Cannabis Ombudsman’ whose mission is to help people who have problems 
with the law. In Poland, the Kanaba.info Association is a union of Polish drug users and 
other people alarmed by the present repressive drug policies. In 2003, they participated 
in ENCOD’s ‘Spread the Seeds’ campaign and coordinated a public demonstration 
in Warsaw. In Slovakia, the non-governmental organisation (NGO) ‘Free Choice’ was 
established, as a response to the repressive legislative situation in February 2004. Its 
goal is to ‘invoke discussion about cannabis and its legalisation and demythologise 
the plant that has been used for hundreds of years as food, a cure, for industry or 
pleasure’. In Slovenia, the Konoplja.org project campaigns for cannabis users to be 
given a political voice, together with the depenalisation of cannabis and the introduction 
of alternative sentences or admonitions. Every year, the Million Marijuana March is 
organised in Ljubljana and Maribor, where users can freely smoke cannabis (trafficking 
is forbidden) and point out that changes are necessary. In the Baltic States, Cyprus and 
Malta, activist groups exist, but are more covert and far less active and professional than 
in the above-mentioned countries. In the Baltic States, their main forum is the Internet, 
where they present articles and reports related to cannabis and its effects. There are 
also discussion forums and other information (legislation, pictures, smokers’ stories, 
instructions on how to grow cannabis at home, extracts from legal acts, etc.).
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Discussion
Eight out of the ten new EU Members States have undergone recent transformations 
from a centrally planned economy to a market economy, and from a single-party 
system to a pluralist political system. This shift has ushered in not only positive social 
developments but also a variety of problems which are measurable by ‘objective’ 
statistics and are often magnified in the public perception (Leifman, Edgren Henrichson, 
1999). Drug problems, despite their high media exposure, are considered less important 
compared with other burning social issues such as unemployment, poverty and even 
alcoholism. Nevertheless, a rapid increase in drug use is recorded by relevant statistics 
(Moskalewicz and Swia˛tkiewicz, 2005).
Based on current data it is difficult to fully explore determinates of cannabis use in the 
new EU Member States and, therefore, some of the explanations offered in this chapter 
are hypothetical and need more research. The data do, however, point towards broad 
trends and crucial and intriguing issues, which should be monitored and researched 
more closely.
Cannabis is a widely used illicit drug in the 10 new EU Member States, particularly 
among teenagers and young adults. Its prevalence used to be somewhat lower than in 
the EU-15, but a rising tide of cannabis use in the years 1995–2004 has meant that the 
new EU Member States are reaching approximately the same prevalence rates as the 
rest of Europe (EMCDDA, 2004).
The sudden rise in cannabis use in all the new countries — except for Cyprus and 
Malta — has accompanied root-and-branch social change, which could have increased 
demand for psychoactive substances. Significant influences have been imported from the 
pre-2004 Member States, where cannabis use was more widespread and normalised 
than it used to be in the new Member States before the 1990s. Intensive transmission 
of Western European consumption patterns has affected drug use patterns in general, 
including cannabis. Young men and boys seem to be more open to the new patterns, 
particularly in the more religious societies (Cyprus, Lithuania, Malta, Poland) where 
the gender ratios in prevalence of cannabis use range from 2:1 to 4:1. In other, more 
secular cultures, such as the Czech Republic, this ratio is 1:1. The gender gap tends 
to narrow in practically all countries that have a tradition of female emancipation. As 
in other parts of the world, Westernisation first affects capital cities and larger urban 
centres. This is reflected by the dynamic geographic spread of cannabis in the countries, 
which has spread fast from large cities to smaller towns and then to the countryside.
This Westernisation hypothesis is supported by the fact that new EU countries with the 
highest cannabis prevalence — the Czech Republic, Slovenia and Slovakia, and to 
a lesser extent Hungary and Poland — are also those which are closest to pre-2004 
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Member States. The process of cultural homogenisation of Europe seems to be most 
advanced among younger generations, which are more willing to adopt new cultural 
patterns, including cannabis use. The image of cannabis has a very positive connotation 
in the context of rasta and hip-hop culture, both of which are international youth 
cultures. Cannabis is also popularised by movies, music and souvenirs. The force 
exerted by these influences seems to be higher in Central Europe, especially when 
comparing the Czech Republic with the Baltic States, Cyprus and Malta.
The low prevalence of cannabis use in Cyprus and Malta may also have its roots 
in culture. Unlike in the remaining continental countries, where cannabis has been 
integrated into teenage culture, particularly in large cities, cannabis for young Cypriots 
may be associated with traditional hashish waterpipes smoked by middle-aged and 
elderly men, and therefore have a much less attractive cultural appeal. In Malta, being 
a smaller country where social stigmas may be felt to a greater extent, open views about 
cannabis use may be more restricted.
Increasing cannabis consumption can be explained by its growing availability, which 
is confirmed by subjective opinions collected by the ESPAD study in all countries. The 
availability hypothesis has been backed up by data from international and national 
control agencies that focus on the supply side of the drug market. Nevertheless, our 
study suggests that the availability increase is a phenomenon present in all countries, 
including those where consumption has tended to level off, such as Cyprus, Malta and 
Slovenia. Moreover, it is difficult to explain large gender gaps in cannabis consumption 
recorded in a number of countries, despite its similar availability for boys and girls (see 
Hibell and Andersson, this monograph).
Cannabis prevalence cannot be explained by its affordability. There is no linear 
relationship between the economic situation of the country and its level of cannabis use. 
However, experiences in the new EU members suggest that the income-price elasticity of 
cannabis demand is much higher in those countries whose currencies recently became 
convertible and where incomes expressed in terms of convertible currencies tended to 
grow fast. In more stable economies, cannabis price elasticity is much lower.
Public discussion tends to demonise drugs, to place cannabis on a par with other illicit 
drugs, and generally to portray drug use as something dangerous. Illicit drug use in 
society is also generally stereotyped (Young, 1971: 182), and despite idiosyncrasies 
among the 10 countries, common features include the high social visibility of the drug 
problem and the negative image of drug addicts in general. Since the Eastern European 
countries undergoing transition still suffer from many unsolved social problems, drugs 
have been attributed the role of the ‘good enemy’ (Christie and Bruun, 1986); that 
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is, drugs are seen as a straightforward political target, rather than attempts to resolve 
urgent matters such as the problems of disadvantaged groups, inequality in the 
employment market and undeveloped regional policy. However, especially regarding 
cannabis, it is possible to make distinctions between regions. In the Central European 
countries (Czech Republic, Hungary, Poland, Slovenia and Slovakia), cannabis has a 
higher social visibility than in the other countries, where the social perception of drug 
use is focused mainly on problem drug use. Nonetheless, since illicit drug use is a 
relatively new phenomenon in all of these countries, the older generations tend to have 
naive and homogenous views of drugs and drug users. Perhaps reflecting such concerns, 
the majority of new EU countries have recently introduced legislation that is more 
restrictive than under previous regimes.
Rapid political change in 8 out of the 10 new EU member countries and increasing 
integration with the EU has had a serious impact on drug policy. All these countries 
have become more open and more vulnerable to external pressures, particularly from 
the most powerful allies, such as the USA, which has attempted to exert its influence 
through relevant UN agencies and by targeting professionals as well as policymakers 
and politicians. Nordic countries, too, have tended to export their restrictive drug 
policies, especially across the Baltic Sea. On the other hand, pre-2004 EU members 
must also have felt the impact of enlargement in this area. Existing European divisions in 
drug policy may be reinforced by the new Member States, which are more likely to join 
coalitions of more restrictive countries.
The social response to cannabis is overwhelmingly dominated by individually oriented 
approaches, that is, law enforcement and treatment. From incomplete data it can be 
estimated that the number of cannabis users dealt with by law enforcement agencies is 
much higher than those in medical treatment. This results from increasingly repressive 
legislation which applies penalties even for possession of small amounts for personal 
use, which in fact implies penalisation of use. In some countries presence of cannabis 
in body fluids may legally be interpreted as possession. Such legislation implies that 
referrals to medical treatment, where present, are used as much as a social control 
as a psychosocial care method. In most countries cannabis-specific treatment is not 
widely available, and cannabis dependence is accepted as a phenomenon, which is not 
considered as requiring specific treatment centres and methods. Treatment of cannabis 
clients is integrated in general drug treatment settings which focus on opiate-dependent 
individuals. Thus, the growing share of cannabis users in medical treatment probably 
reflects referrals from the criminal justice system rather than impressive advances in 
treatment methods.
Enlargement 2005: cannabis in the new EU Member States
92
Bibliography
Allaste, A. A., Lagerspetz, M. (2005), ‘Drugs and double-think in marginalised community’, Critical 
Criminology 13: 267–285.
Booth, M. (2004), Cannabis: a history, St. Martin’s Press, New York.
Butler, G. K., Montgomery, A. M. (2004), ‘Impulsivity, risk taking and recreational ecstasy (MDMA) 
use’, Drug Alcohol Dependence 76: 55-62.
Christie, N., Bruun, K. (1986), Hyvä vihollinen. Huumausainepolitiikka Pohjolassa (Good enemy: Drug 
policy in Nordic Countries), Weilin and Göös, Espoo.
Demetrovics, Zs. (1998), ‘Drugs and disco in Budapest: smoking, alcohol consumption and drug-
using behaviour among youths in the clubbing subculture’ (in English), Regional Resource Centre, 
Budapest.
Demetrovics, Zs. (2001), ‘Droghasználat Magyarország táncos szórakozóhelyein’ (Drug use in 
Hungarian clubbing subculture), L’Harmattan Kiadó, Budapest.
Demetrovics, Zs. (2005), ‘The characteristics of psychostimulant use in the Hungarian party scene’, 
Abstracts of The Inaugural European Association of Addiction Therapy Conference Budapest, 6–8 
July 2005, 13.
EMCDDA (2004), Annual report: the state of the drugs situation in Europe, European Monitoring 
Centre for Drugs and Drug Addiction, Lisbon.
EMCDDA (2005), Annual report 2005, European Monitoring Centre for Drugs and Drug Addiction, 
Lisbon.
EMCDDA (2006), ‘Web page: ‘Possession of cannabis for personal use’, European Monitoring 
Centre for Drugs and Drug Addiction, Lisbon  
http://eldd.emcdda.europa.eu/index.cfm?fuseaction=public.Content&nnodeid=5769
Encyklopédia Slovenska [Encyclopedia of Slovakia], part III (1979), VEDA, SAV, Bratislava, 156.
Fatyga, B. and Sierosławski, J. (1999), ‘Uczniowie i nauczyciele o stylach z˙ycia i narkotykach’, Raport 
z badan´ jakos´ciowych, Instytut Spraw Publicznych, Warsaw.
Flaker, V. (2002), ‘Heroin use in Slovenia: social consequence or social vehicle’, European Addiction 
Research 8: 170–176.
Hibell, B., Andersson, B. (2008), ‘Patterns of cannabis use among students in Europe’, this 
monograph.
Hibell, B., Andersson, B., Bjarnasson, T., Kokkevi, A., Morgan, M., Narusk, A. (1997), The 1995 
ESPAD report: alcohol and other drug use among students in 26 European countries, The European 
School Survey Project on Alcohol and Other Drugs, CAN, Stockholm.
Hibell, B., Andersson, B., Ahlström, S., Balakireva, O., Bjarnasson, T., Kokkevi, A., Morgan, M. 
(2000), The 1999 ESPAD report: alcohol and other drug use among students in 30 European 
countries, The European School Survey Project on Alcohol and Other Drugs, CAN, Stockholm.
Hibell, B., Andersson, B., Bjarnasson T., Ahlström S., Balakireva O., Kokkevi A., Morgan M. (2004), 
The 2003 ESPAD report: alcohol and other drug use among students in 35 European countries, The 
European School Survey Project on Alcohol and Other Drugs, CAN, Stockholm.
Kärdi, V. (1993), ‘Marihuaana ja hashishi tarvitajatest Eestis’ [About marijuana and hashish users in 
Estonia], Vikerkaar 8 (5): 54–61 and 8 (6): 58–63.
Kvaternik, J. I. (2004), ‘Drugs as an element of political relations: human rights on the example of the 
subculture of drug users’, University of Ljubljana, Faculty for Social Studies, Ljubljana.
Laidmäe, I., Allaste, A. A. (2004), ‘Tervis’ (Health), in Hansson, L. (ed.) Valikud ja võimalused: argielu 
Eestis aastatel 1993–2003 [Choices and opportunities in everyday life in Estonia 1993–2003], 
Pedagooglise Ülikooli Kirjastus, Tallinn, 118–143.
Leifman, H., Edgren Henrichson, N. (1999), ‘Statistics on alcohol, drugs and crime in the Baltic Sea region: 
NAD Change, Helsinki’, European Addiction Research 8: 170–176.
Chapter 6
93
Milani, R. M., Parrott, A. C., Schifano, F., Turner, J. J. (2005), ‘Pattern of cannabis use in ecstasy 
polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic 
symptoms’, Human Psychopharmacology 20: 246–263.
Misztal, B. (2003), Theories of Social Remembering, Open University Press, Philadelphia.
Moskalewicz, J., Swia˛tkiewicz, G. (2005), ‘Naduz˙ywanie substancji psychoaktywnych na tle innych 
problemów społecznych w Polsce (Drug abuse in Poland against other social problems)’, in 
Pia˛tkowski, W., Brodniak, W. A. (eds) (2005) Zdrowie i choroba. Perspektywa socjologiczna 
(Heath and illness: a sociological perspective), Wyz˙sza Szkoła Społeczno-Gospodarcza, Tyczyn, 
203–216.
Moskalewicz, J., Swia˛tkiewicz, G., Da˛browska, K. (2004), ‘Ecstasy use in Warsaw: do cultural norms 
prevent harm?’, in Decorte, T., Korf, D. J. (eds), European studies on drugs and drug policy, VUB 
Press, Brussels, 179–193.
Mravcˇík, V., Korcˇišová, B., Lejcˇková, P., Miovská, L., Škrdlantová, E., Petroš, O., Radimecký, J., 
Sklenár´, V., Gajdošíková, H., Vopravil, J. (2004), Annual Report of the Czech Republic — drug 
situation 2003, Office of the Government of the Czech Republic, Prague.
Mravcˇík, V., Korcˇišová, B., Lejcˇková, P., Miovská, L., Škrdlantová, E., Petroš, O., Sklenár´, V., Vopravil, 
J. (2005), Annual report of the Czech Republic — 2004 drug situation, Office of the Government 
of the Czech Republic, Prague.
Paksi, B. (2000), ‘A szintetikus szerek képe a magyarországi sajtóban (Presentation of drugs in the 
Hungarian media)’, in Demetrovics, Zs. (ed.), Diszkódrogok, drogfogyasztók, szubkultúrák (The 
World of Synthetic Drugs. Disco drugs, drug users, subculture), Animula, Budapest.
Paksi, B. and Demetrovics, Zs. (2002), A drogprevenciós gyakorlat megismerése. (Evaluation of school 
prevention programmes), L’Harmattan, Budapest.
Parker, H., Aldridge, J., Measham, F. (1998), Illegal leisure: the normalisation of adolescent 
recreational drug use, Routledge, London.
Tossman, P., Boldt, S., Tensil, M-D. (2001), ‘The use of drugs within the techno party scene in 
European metropolitan cities’, European Addiction Research 7: 2–23.
Young, Y. (1971), The drugtakers: the social meaning of drug use, Paladin, London.
Zimmermann, P., Wittchen, H. U., Waszak, F., Nocon, A., Hofler, M., Lieb, R. (2005), ‘Pathways into 
ecstasy use: the role of prior cannabis use and ecstasy availability’, Drug Alcohol Dependence 
79: 331–341.

Policies, 
legislation 
and control 
strategies
PART II
97
Chapter 7
Cannabis control in Europe
Keywords: cannabis – decriminalisation – drug policy – Europe – legislation  
– international law – UN convention
Setting the context
The history of cannabis has been the subject of numerous books in recent years (see 
Fankhauser, this monograph). One of the many historical perspectives that have been 
explored is cannabis’s social, political and legislative history. This chapter provides 
a brief history of controls on cannabis, and analyses a series of recent government 
enquiries that have informed legislative reform, particularly in Europe.
Opinions are divided in this area. Liberalisers and cannabis advocacy groups — the 
key Internet publishers of information on the issue — continue to claim cannabis is a 
recently controlled substance and ‘natural product’, and have espoused a number of 
theories to explain its prohibition (1). Yet the historical picture is more complex. Use 
of cannabis as a psychoactive drug has stirred controversy for centuries. And finding 
the most appropriate control system has interested professionals, politicians and 
governments from the beginning.
Today, international drugs conventions recommend signatories to designate, under 
national legislation, the most stringent control over cannabis. However, some countries 
have used the granted discretion to move away from such recommendations. A cross-
(1) Among others, theories include: diplomatic dealmaking (with Turkey and Egypt) during the 1925 
amendment to the International Opium Convention; timber interests curbing hemp industry growth 
in the USA (particularly involving a marijuana scare campaign by media, controlled by William 
Randolph Hurst); synthetic fibre interests curbing hemp industry growth (in particular Du Pont); 
inter-agency conflict between the FBI and FBN in the USA (with Harry J. Anslinger cast as arch-
prohibitionist); cannabis control as a result of institutionalised racism (stigmatising cannabis as a 
drug of choice of specific racial groups, especially in the USA); and strong international focus on 
stringency by the United Nations (INCB and UNODC).
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reading of governmental enquiries shows that, while cannabis is considered a potentially 
dangerous substance, its dangers, in comparison with other controlled substances, may 
have been overstated and alternative forms of sanctions, such as civil sanctions, fines or 
compulsory health assessments, have been recommended in place of criminal penalties.
European countries’ laws or prosecution policies seem to be broadly in accord with 
these government enquiries. Nonetheless, more liberal positions have attracted some 
concerns, expressed in particular at UN level, on the grounds that leniency on cannabis 
can endanger the overall international effort against drugs. Accordingly, the latest 
developments in some countries seem to tip the balance back towards a new attention 
on restrictive measures.
Further reading
BBC Timeline (2005), ‘The use of cannabis’ 
http://news.bbc.co.uk/2/hi/programmes/panorama/4079668.stm
Böllinger, L., Stöver, H., Fietzek, L. (eds) (2002), Drogenpraxis, Drogenrecht, Drogenpolitik: Ein 
Leitfaden für Drogenbenutzer, Eltern, Drogenberater, Ärzte und Juristen, FHS Frankfurt.
EMCDDA (2001, updated 2006), ELDD: possession of cannabis for personal use, available at http://
eldd.emcdda.europa.eu/index.cfm?nNodeID=5769
EMCDDA (2005), Thematic papers — illicit drug use in the EU: legislative approaches  
www.emcdda.europa.eu/index.cfm?nnodeid=7082
Hall, W., Pacula, R. (2003), Cannabis use and dependence: public health and public policy, 
Cambridge University Press, Cambridge.
Inglis, B. (1975), The forbidden game: a social history of drugs, Hodder and Stoughton, London.
Mills, J. (2003), Cannabis Britannica: empire, trade and prohibition 1800–1928, Oxford University 
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See also the list of governmental reviews (Table 1) in this chapter and the grey literature list in the 
Appendix to Volume 1 of this monograph (p. 300).
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Cannabis control in Europe
Danilo Ballotta, Henri Bergeron and 
Brendan Hughes
Introduction
The use of cannabis as a psychoactive substance has always been a subject of 
controversy. International drugs conventions recommend signatories to designate, 
under national legislation, the most stringent control over cannabis, but some countries 
have used the granted discretion to move away from such recommendations. Indeed, 
finding the most appropriate control system has interested professionals, politicians 
and governments since the beginning. A cross-reading of governmental enquiries 
shows that, while cannabis is considered a potentially dangerous substance, its 
dangers in comparison with other controlled substances might have been overstated, 
and alternative forms of sanctions, such as civil sanctions, fines or compulsory health 
assessments, have been recommended in place of criminal penalties. European 
countries’ laws or prosecution policies seem to be broadly in accord with such enquiries, 
but these positions have attracted some concerns, expressed in particular at UN level, 
on the grounds that such a ‘lenient approach to cannabis’ can endanger the overall 
international effort against drugs. Accordingly, the latest developments in some countries 
seem to tip the balance towards a new attention on cannabis through restrictive 
measures.
Cannabis: a substance under continuous control
Origins of control
Cannabis has been used for a variety of purposes for thousands of years. Yet in Europe, 
consumption remained mostly limited to experimentation by small elites or to those 
having contact with specific countries, in particular North Africa and India (Booth, 2003). 
There is significant evidence to suggest that cannabis has always been a controversial or 
troubled substance, and was placed under some sort of restriction almost as soon as its 
psychoactive effects were discovered.
In 2000 bc in India, religious authorities used cannabis in holy rituals and it is likely 
that only priests had access to it (Booth, 2003). In the Muslim world in medieval times 
there existed an ambivalent attitude towards the use of cannabis (Hamarneh, 1957). 
Hashish, furthermore, had derogatory associations with Sufism and as a precipitator of 
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madness (Booth, 2003). Key critics of cannabis include the theologian Ibn Taymiyyah, 
the judge Ibn Ganim and historian Al Magrii. Much-cited examples of controls include 
the prohibition in 1265 of cannabis in Damascus by King al-Zahir Baybars (Hamarneh, 
1957), and the destruction of cannabis plants and prohibition of cannabis use in 
1378 by the Ottoman emir of Egypt, Soudoun Sheikouni (Rosenthal, 1971; Caballero 
and Bisiou, 2000; Arana and Márquez, 2006). In Europe in 1484 Pope Innocent VIII 
associated the use of hashish with witchcraft in the bull Summis Desiderantes (Booth, 
2003). Such examples, though anecdotal, illustrate that controversy surrounding 
cannabis use is not a new phenomenon.
Some precursors of controls relating to cannabis can be found in Europe’s colonial 
period, though outside the continent itself. Following Napoleon’s invasion of Egypt in 
1798, in 1800 he prohibited his soldiers to smoke or drink the extracts of the plant, 
imposing a penalty of imprisonment of three months, thus implementing perhaps the 
first ‘penal law’ on cannabis. A law in South Africa in the 1870s, that was tightened in 
1887, prohibited the use and possession of dagga (cannabis) by Indian immigrants, 
largely in response to a perception that its use by them was dangerous for white rule 
(Booth, 2003). In India, prohibition of cannabis was mooted in 1838, 1871, 1877 and, 
most famously, rejected following an extensive 3000-page report by the Indian Hemp 
Drugs Commission in 1894. Nonetheless, despite rejections of a blanket ban, various 
Indian cities and states issued quotas, tax regimes or restrictions on cannabis (Booth, 
2003).
While familiarity with cannabis products in the pharmaceutical sphere was widespread 
in the early 20th century (Lewin, 1924; Fankhauser, this monograph), within Western 
Europe there is little evidence of significant cannabis prevalence and criminal 
prosecutions until after the Second World War. Cannabis control is best viewed in the 
context of national and international initiatives in the area of drug control during the 
late 19th and early 20th centuries — in particular, relating to opiates, together with 
increased supervision of pharmaceutical products in general. Controls in Europe focused 
on regulating pharmaceutical use of cannabis. For example, in Germany, the first legal 
act on cannabis was in a Pharmacy Ordinance of 1872 when the sale of Indian hemp 
was limited to pharmacies (this ordinance was still valid in 1920) (see Fankhauser, this 
monograph).
However, in Greece and near-neighbour countries such as Turkey and Egypt, cannabis 
prevalence was higher and attracted strong legal responses. Hashish possession was 
made a capital offence in Egypt in 1868, with a tax on cannabis imposed in 1874, 
although exemptions for non-Egyptians and enforcement issues led to them being 
ineffectual (Booth, 2003). In Turkey a nationwide campaign to confiscate and destroy 
cannabis was begun by the Sultan in 1877, and an import ban imposed in 1879; 
in 1884 cultivation of cannabis became a criminal offence (Abel, 1980). In Greece 
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cultivation, importation, and usage of cannabis was banned in 1890, based on concern 
for hashish use among the poor. Nonetheless, Greece was a significant exporter of 
hashish to Turkey and Egypt into the 1920s (Abel, 1980).
Prior to the First World War, international agreements on narcotic substances increased 
the mechanisms of control on opium and related substances. For opiates, the Opium 
Commission in Shanghai in 1909 contributed to a framework agreement on opium 
control at the First International Opium Conference in the Hague in 1911–1912. 
While the Hague conference concentrated on opium, at this conference Italy lobbied 
for an international ban on cannabis, largely based on hashishism in its protectorates 
Tripolitania and Cyrenaica (obtained from Turkey during a war in 1911). In the USA, a 
number of states also prohibited non-medical use of cannabis: California (1915), Texas 
(1919) and Louisiana (1924). A parallel development was legal restriction on alcohol 
use: a ban in Finland (1919) and the USA (1920), and a rationing system in Sweden 
(from 1914). In Switzerland cannabis was outlawed in 1924.
The key driver of international cannabis prohibition in the early 20th century was an 
amendment to the International Opium Convention (1925), which was extended beyond 
opiates to embrace cannabis. The convention prohibited the export of cannabis resin 
to countries that prohibited its use (Bayer and Ghodse, 1999). The process behind the 
inclusion of cannabis in the convention has been both heavily discussed (e.g. Lowes, 
1966) and roundly criticised (e.g. Kendell, 2003; Holzer, 2004). There is consensus that 
the cannabis subcommittee advising the Second League of Nations Opium Conference 
succumbed to strong Egyptian demands for a ban on cannabis and that delegates were 
certainly given little time to conduct due diligence on materials (Booth, 2003; Kendell, 
2003; Holzer, 2004).
Following the approval of the 1925 International Opium Convention, European 
countries gradually outlawed cannabis use and possession (e.g. the UK’s Dangerous 
Drugs Act, 1928; Germany’s second Opium Law, 1929). Nonetheless, the first 
substantial wave of convictions for cannabis offences did not occur until the 1960s. 
Official crime reports in the 1960s and 1970s did not differentiate cannabis convictions 
from those for other illicit drugs, yet studies suggest that there were very few cases other 
than cannabis. Böllinger suggests that the bulk of the less than thousand ‘narcotics 
cases’ (police registrations) before 1960 in Germany related to the ‘stem of old 
morphinists’ (Böllinger et al., 2002). In Canada the first known seizure of marijuana 
did not occur until 1932, but widespread enforcement is reported much later, with a 
total of 261 convictions for drug offences in 1960 (the majority, however, for heroin 
offences). In the Netherlands, in the first half of the 20th century, no problems or social 
controversy are reported on cannabis, but the opium law was revised in 1953 to include 
cannabis and comply with international treaties. Thus, some authors (e.g. Fischer et al., 
1998) have argued that prohibition was introduced mainly in response to international 
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obligations — in a broader diplomatic context — than to answer to an urgent problem 
at national level between law and enforcement (or necessity of it), as ‘the solution 
without the problem’ (2).
International law
The United Nations Single Convention on Narcotic Drugs (1961) elevated the control on 
narcotic substances and on cannabis to a global level. Under the system introduced in 
1961 (mainly imported from previous treaties), cannabis is to be considered as one of 
the most dangerous existing drugs (3).
This section discusses the texts of the UN Convention. While this approach may appear 
legalistic to the non-specialist reader, a thorough understanding of the legal status of 
cannabis under international law is vital for understanding the ‘room for manoeuvre’(4) 
given to different countries on the issue.
Cannabis, cannabis resin and extracts and tincture of cannabis are listed in Schedule 
I of the 1961 Convention among substances whose properties might give rise to 
dependence and which present a serious risk of abuse, which are subject to all control 
measures envisaged by the Convention (5). Cannabis and cannabis resin are again 
listed in Schedule IV of the 1961 Convention, which comprises 15 substances already 
listed in Schedule I that are considered particularly dangerous by virtue of their harmful 
characteristics, risks of abuse and extremely limited therapeutic value. Among these 
15 substances, we find heroin and cannabis but not cocaine, which is (only) listed in 
Schedule I.
(2) Giffen et al. (1991) affirm that ‘unlike other narcotic drugs brought under federal control up to the 
1920s, marijuana was added to the Schedule I in 1925, before it came to be defined as a social 
problem in Canada. Why this was so remains a mystery’.
(3) Article 2.5(a) of the 1961 Convention introduces the concept of dangerousness for substances 
included in schedule IV.
(4) ‘Room for manoeuvre’ was the title of a report commissioned by the British charity Drugscope, 
with a focus on the UN conventions and potential changes to UK drugs possession laws (Dorn and 
Jamieson, 2000).
(5) There are four schedules under the 1961 Single Convention on Narcotic Drugs: Schedule I — those 
substances which are, inter alia, having, or convertible into substances having a liability to abuse 
comparable to that of cannabis, cannabis resin or cocaine; Schedule II — having addiction-producing 
or addiction-sustaining properties not greater than those of codeine but at least as great as those of 
dextropropoxyphene; Schedule III — preparations which are intended for legitimate medical use, and 
which the WHO considers not liable to abuse and cannot produce ill effects, and the drug therein is 
not readily recoverable; and Schedule IV — substances that are particularly liable to abuse and to 
produce ill effects, and such liability is not offset by substantial therapeutic advantages not possessed 
by substances other than drugs in Schedule IV.
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As specified by the 2001 INCB Annual Report, ‘to be included in Schedule IV, a drug 
has to be considered particularly liable to abuse and to produce ill effects, and such 
liability should not be offset by substantial therapeutic advantages’. In the view of 
the delegations present at the Plenipotentiary Conference that prepared the 1961 
Convention, cannabis certainly presented such characteristics (though cocaine, for 
example, did not). THC, the main psychoactive ingredient of cannabis, is also listed by 
the 1971 Convention on Psychotropic Substances, in the first of four schedules, its use 
being prohibited except for scientific and very limited medical purposes (Article 7a) (6).
This composite classification reflects the concern about the abuse of cannabis and 
the desire of the convention promoters to advise countries to design, under national 
legislation, the most stringent control on cannabis (7). Indeed, this double classification 
(Schedule I plus Schedule IV, 1961 Convention) allows signatory countries to adopt any 
special measures of control regarded as necessary, including prohibition of use, due 
to the ‘particularly dangerous properties’ of the drugs listed in Schedule IV. However, 
a country shall adopt any special measures of control if considered necessary having 
regarded the particularly dangerous properties of drugs in Schedule IV (8). The non-
obligation of this norm, in fact a condition for its implementation, is confirmed by the 
UN Commentary on the 1961 Convention, which restates that a party is ‘obliged to 
apply special measures only if it believes them to be necessary’ (9).
(6) There are four schedules under the 1971 UN Convention on Psychotropic Substances: Schedule I — 
substances whose liability to abuse constitutes an especially serious risk to public health and which 
have a very limited, if any, therapeutic usefulness; Schedule II — substances whose liability to abuse 
constitutes a substantial risk to public health and which have little to moderate therapeutic usefulness; 
Schedule III — substances whose liability to abuse constitutes a substantial risk to public health and 
which have moderate to great therapeutic usefulness; and Schedule IV — substances whose liability 
to abuse constitutes a smaller but still significant risk to public health and which have a therapeutic 
usefulness from little to great.
(7) The UN documents of the years preceding the signatures of the 1961 and 1971 Conventions 
confirm a particular concern towards cannabis. In 1959 countries were requested ‘to increase their 
efforts to suppress the illicit cultivation of cannabis’ (CND Decision 14 December (XIV) April/May 
1959). In 1968 they were recommended to ‘increase their efforts to eradicate the abuse of and 
illicit traffic in cannabis’ or to ‘promote research and advance additional medical and sociological 
information regarding cannabis, and effectively deal with publicity which advocates legalisation or 
tolerance of the non-medical use of cannabis as a harmless drug (Economic and Social Council E/
RES/1968/1291(XLIV), 1520th Plenary Meeting, 23 May 1968, on the abuse of cannabis and the 
continuing need for strict control). An extract from E/RES/1959/730(XXVIII)E 1088th Plenary Meeting, 
30 July 1959, reads as follows: ‘Recalling that the third draft of the Single Convention on Narcotic 
Drugs contains an express provision for the prohibition of the medical use of cannabis drugs except 
in certain systems of indigenous medicine’. An extract from Economic and Social Council Resolution 
IV(XII) on the question of cannabis, April/May 1957, ‘Requests all Governments to abolish, except for 
medical (Ayurvedic, Unani and Tibbi systems) and scientific purposes, the legal consumption of all 
substances having a cannabis base within a reasonable period where it has not been done so far’.
(8) Article 2.5(a), 1961 Convention.
(9) UN Commentary on the 1961 Single Convention (p. 65).
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It seems, therefore, that the 1961 Convention suggests to apply the most stringent 
control system to cannabis, yet leaves countries some flexibility in their interpretation 
of the necessity of such control. According to this classification, use and possession of 
cannabis should not be allowed except for authorised medical or scientific purposes 
(Articles 4c, 33, 36, 1961 Convention). Countries are requested to prevent its misuse 
(Article 28, 1961 Convention) and take all practicable measures for the prevention of its 
abuse (article 38, 1961 Convention). They should also not permit its possession (Article 
33, 1961 Convention) and if they decide to do so, they are entitled to make possession 
of cannabis a punishable offence (Article 36, 1961 Convention), and are mandated to 
make possession for the purpose of trafficking an offence of criminal nature (Article 3, 
paragraph 1(a)(iii), 1988 Convention). Possession for personal consumption may also 
be criminalised (Article 3 paragraph 2, 1988 Convention).
This system of provisions leaves no doubt about the severity requested towards cannabis 
and it is evident that signatory countries cannot allow non-medical use of cannabis, such 
as in a hypothetical legalisation regime, without renouncing the UN Conventions. They 
must set measures to discourage, prevent or — if considered necessary — prohibit and 
punish personal use of cannabis (10).
All this is, however, largely based on the acceptance of the Conventions by the 
signatory countries. This means that countries must judge the opportunity and necessity 
of applying the convention norms. Conventions are, in fact, not self-executing and in 
the transposition of the international dictate into national law, countries are allowed 
discretion, while applying the principle of good faith in interpreting international 
agreements. This is visible throughout in the presence of safeguard clauses in the text 
of the Conventions: subject to constitutional limitations (Article 36.1, 1961 Convention); 
subject to basic concepts of national legal systems (Article 3, paragraph 2, 1988 
Convention); the Parties shall as far as possible (Article 26, paragraph 2, 1961 
Convention); these measures are necessary or desirable (Article 22 and Article 30, 
paragraphs 2 and 4, 1961 Convention). Nevertheless, states should interpret treaties 
in good faith and in the light of their object and purpose, according to Article 31 of the 
1969 Vienna Convention on the Law of Treaties.
A constant quest for evidence
By 1970, 64 states had ratified the Single Convention on Narcotic Drugs and with it the 
control system required for cannabis. Nevertheless, the fact that cannabis was treated 
no differently, even more strictly, than other substances that were perceived to be more 
dangerous provoked uncertainty within governments and parliaments.
(10) An expression that, according to the country considered, might mean use of cannabis or possession 
of small quantities of cannabis for personal use or both.
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There is evidence to suggest that disagreements embraced the question of the 
international classification(s) of cannabis from its beginning. Already, during the 
Plenipotentiary Conference, which drafted the 1961 Convention, controversies arose 
around the question of whether the prohibition of drugs in Schedule IV should be 
mandatory or only recommended. More recently, some authors see the insistence of 
certain countries to place cannabis under the strictest control regime in the convention 
as the main reason for such classification (Canadian Senate Report on Cannabis, 
2002). Others go so far as to use the words ‘arbitrariness’ when addressing cannabis 
classification (Caballero and Bisiou, 2000).
Evidently, the question of the classification of cannabis or of its derivatives is 
controversial and has arisen from time to time (11). In 2003 the WHO Expert 
Committee on Drug Dependence (12), following a Critical Review (13), recommended the 
rescheduling of dronabinol (THC, the main active principle of cannabis), to Schedule 
IV of the 1971 Convention (14). This would mean that the active principle of cannabis 
would be moved from a schedule where substances have very limited, if any, therapeutic 
usefulness and their abuse constitutes an especially serious risk to public health, to a 
schedule where substances have some therapeutic usefulness with a smaller (but still 
significant) risk to public health due to their liability of abuse. If implemented, this would 
probably have important consequences on the overall classification of cannabis and on 
its control requirements worldwide, but no further procedural steps have been taken. 
(11) ARF/WHO Scientific Meeting on Adverse Health and Behavioural Consequences of Cannabis Use, 
WHO and the Addiction Research Foundation of Ontario, 1981; Cannabis: a health perspective 
and research agenda, Division of Mental Health and Prevention of Substance Abuse, World Health 
Organisation, 1997.
(12) The WHO Expert Committee has the task of carrying out medical and scientific evaluations of 
the abuse liability of dependence-producing drugs falling within the terms of the 1961 Single 
Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances. It then makes 
recommendations to the United Nations Commission on Narcotic Drugs on the control measures, 
if any, that it considers appropriate. The Expert Committee’s reports are published by WHO in the 
Technical Report Series.
(13) A Critical Review is an assessment process in which the Expert Committee, on the basis of (1) 
a notification from a Party to the 1961 or the 1971 Convention concerning the scheduling of a 
substance; (2) an explicit request from the UN Commission on Narcotic Drugs to review a substance; 
(3) a pre-review of a substance which has resulted in a recommendation for critical review; (4) 
information sent to the attention of the WHO that a substance of especially serious risk to public 
health and society, and of no recognised therapeutic use by any Member State, is clandestinely 
manufactured, with analysis of the substance according to its similarity to known substances and 
effects on the central nervous system, dependence potential, actual abuse and/or evidence of 
likelihood of abuse, therapeutic usefulness, and providing recommendations for scheduling or non-
scheduling.
(14) The WHO Expert Committee report recommend that ‘all stereochemical variants of delta-9-
tetrahydrocannabinol be moved to Schedule IV of the 1971 Convention’, and that this is ‘to avoid 
placing different stereochemical variants of the same substance under different control systems’. 
We have, in fact, to remind that in 1990 the WHO Expert Committee proposed the rescheduling of 
dronabinol, a stereochemical variant of delta-9-tetrahydrocannabinol, to Schedule II of the 1971 
Convention.
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In response to the WHO, the INCB expressed its concern in its 2003 report about this 
possible rescheduling of THC. In March 2006 the WHO Expert Committee on Drug 
Dependence concluded that dronabinol (THC) constitutes a substantial risk to public 
health, but the risk is different from that of cannabis, and it has moderate therapeutic 
usefulness. As a result, it recommended that dronabinol and its stereoisomers should 
be rescheduled from Schedule II to Schedule III of the 1971 Convention (WHO, 2006). 
At the 50th UN Commission on Narcotic Drugs in March 2007, members agreed 
to postpone any decision on dronabinol until more conclusive evidence is available, 
although firm opposition to the rescheduling was expressed by some delegates.
At the level of national authorities, evaluations of cannabis have been carried out on 
a regular cycle. The first ‘official’ enquiries date back to the late 19th and early 20th 
centuries, for example the Indian Hemp Drugs Commission in 1894, the Panama Canal 
Zone Report in 1925 and the La Guardia Report in 1944. The frequency of publication 
of such enquiries, however, picked up from 1969 onwards and has led to a proliferation 
of ‘official’ enquiries in the 1990s and 2000s. Despite their differences in scope, 
methods and conclusions, the recommendations of these, and older enquiries, reveal 
interesting common patterns. Three have been isolated for simplicity: (1) cannabis is not 
a harmless substance; (2) its dangers, in comparison with other controlled substances, 
have been overstated; and (3) civil sanctions, fines, or compulsory health assessments 
should be established in place of criminal penalties for personal use offences (Table 1).
Conclusion of reviews 1: cannabis is not a harmless substance
Cannabis is a substance that poses some kind of threats to health for which certain 
control would be justified. The UK Wootton Report in 1968 affirms that the ‘adverse 
effects that cannabis consumption, even in small amounts, may produce in some people, 
should not be dismissed as insignificant’ (15). These words were echoed more than 30 
years later by the UK Report of the Advisory Committee on Drug Dependence, which 
stated in 2002 that its use ‘unquestionably poses risks both to individual health and 
to society’ (UK Home Office, 2002). This view is also mirrored by other enquiries. For 
example, the inquiry for the Prime Minister of Jamaica in 2001, affirming that ‘it is 
accepted that cannabis is not entirely safe, even where it is still used for traditional 
religious rituals, such as in Jamaica’, and that ‘despite its proven folk medicinal 
qualities, its use can be injurious to health’ (National Commission on Ganja, 2001). The 
general attitude is that cannabis and its derivatives should be maintained as controlled 
drugs (UK House of Lords, 1998), as governments are responsible for restricting the 
availability of harmful substances, in particular to prevent the exposure of young people 
(Canada, 1970; Australia, 1994; New Zealand,1998).
(15) UK Home Office (1969): cover letter to the Wootton Report sent to the Home Secretary by Chairman 
Mr Edward Waine, 1 November 1968. See also Abrams, this monograph.
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Conclusion of reviews 2: the dangers have been overstated
The identification of cannabis as a potentially dangerous psychoactive substance did 
not, however, prevent a substantial number of these enquiries to explore the issue of 
whether current legislation reflected the real dangers posed by cannabis. Already in 
1944, the La Guardia Committee Report on Marihuana concluded that ‘the practice of 
smoking marihuana does not lead to addiction in the medical sense of the word’ and 
that ‘the use of marihuana does not lead to morphine or heroin or cocaine addiction’ 
(Zimmer and Morgan, 1997). In 1968 the Wootton Report stated that ‘the dangers 
of cannabis use as commonly accepted in the past and the risk of progression to 
opiates have been overstated’ and ‘cannabis is less harmful than other substances 
(amphetamines, barbiturates, codeine-like compounds)’. A similar conclusion was 
Table 1: Summary of governmental reviews on cannabis control
Title of report Country Year
Cannabis: Report by the Advisory Committee on Drugs 
Dependence (‘The Wootton Report’)
United Kingdom 1969
Le Dain Report Canada 1970
Baan and Hulsman Commissions The Netherlands 1970, 1971
Report of the Expert Group on the Effects of Cannabis 
Use
United Kingdom, Home 
Office Advisory Council 
on the Misuse of Drugs
1982
Legislative options for cannabis use in Australia, 
Monograph No. 26 
Australia 1994
Inquiry into the Mental Health Effects of Cannabis, 
Report of the Health Committee, AJHR, I.6A 
New Zealand 1998
House of Lords Science and Technology Select 
Committee, Ninth Report, Cannabis: the scientific and 
medical evidence, HL 151 1997–98
United Kingdom 1998
Swiss Federal Commission for Drug Issues, Cannabis 
Report
Switzerland 1999
A Report of the National Commission on Ganja to Rt 
Hon. P. J. Patterson, QC, MP, Prime Minister of Jamaica
Jamaica 2001
The Senate Special Committee on Illegal Drugs, 
Cannabis: our position for a Canadian public policy
Canada 2002
Report by the Advisory Committee on Drug Dependence, 
Home Office, The Classification of Cannabis under the 
Misuse of Drugs Act 1971
United Kingdom 2002
Rapport de la Commission d’enquête du Sénat français 
sur la politique nationale de lutte contre les drogues 
illicites, No. 321
France 2003
Report by the Advisory Council on the Misuse of Drugs, 
Home Office, Further consideration of the classification 
of cannabis under the Misuse of Drugs Act 1971
United Kingdom 2005
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arrived at 34 years later in 2002 when the Advisory Committee on Drug Dependence 
proposed the reclassification of cannabis from Class B to Class C (enforced by law in 
2004 and confirmed in 2005). These views were reiterated by other enquiries, such as 
the Baan Committee in the Netherlands, which affirmed in 1971 that ‘cannabis use does 
not lead directly to other drug use’ (16) or by the US National Commission on Marihuana 
and Drug Abuse, which in 1973 stated that ‘the existing social and legal policy is out 
of proportion to the individual and social harm engendered by the use of the drug 
[cannabis]’ (17). The Canadian Le Dain Commission saw ‘the UN Single Convention of 
1961 as responsible’ for such a situation which ‘might have reinforced the erroneous 
impression that cannabis is to be assimilated to the opiate narcotics’. The same 
commission, however, suggested that the UN Convention did ‘not prevent domestic 
legislation from correcting this impression’ (18).
Conclusion of reviews 3: personal use offences do not require 
criminal sanctions
Endorsing these interpretations, a number of enquiries proposed that criminal sanctions 
should be withdrawn from private use and/or possession for such use, to create instead 
a criminal exemption scheme or to impose fines, to decriminalise personal use or just 
to impose compulsory health assessment. These conclusions were largely based on the 
belief that criminalising the users of small quantities of cannabis could engender far 
more harm than good to the society as a whole (e.g. Jamaica, 2001), and that such 
alternative measures would remove the criminal stigma and the threat of incarceration 
from a widespread behaviour (possession for personal use) which does not warrant 
such treatment (US National Commission on Marihuana and Drug Abuse, 1973). The 
Canadian Senate in 1970 argued that ‘the criminal law should not be used for the 
enforcement of morality without regard to potential for harm’. Three years later, the 
US National Commission on Marihuana and Drug Abuse stated that ‘Relieving the law 
enforcement community of the responsibility for enforcing a law of questionable utility, 
and one which they cannot fully enforce, would allow concentration on drug trafficking 
and crimes against persons and property’. The French Senate in 2003 recommended 
to impose a fine in case of a first offence of drug use (all drugs), and to create an 
obligation for health or social measures. In 2002 the UK Advisory Committee on Drug 
Dependence proposed a reclassification of cannabis in the list of controlled substances. 
The UK government, which endorsed the recommendations to move cannabis from 
(16) In Cohen, P. (1994), The case of the two Dutch drug policy commissions. An exercise in harm 
reduction 1968–1976. Paper presented at the 5th International Conference on the Reduction of Drug 
Related Harm, 7–11 March 1994, Addiction Research Foundation, Toronto. Revised in 1996.
(17) Marihuana: a signal of misunderstanding. The official report of the National Commission on 
Marihuana and Drug Abuse, Raymond P. Shafer, Chairman (1973), 211.
(18) Le Dain, G. et al., Cannabis: report of the Commission of inquiry into the non-medical use of drugs. 
Ottawa: Government of Canada in Report of the Senate Special Committee on Illegal Drugs, 
‘Cannabis: our position for a Canadian public policy’, September 2002, Volume II, 278.
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Class B to Class C, pointed out that reclassification does not mean that cannabis is 
legalised or decriminalised, and that possession for personal use still carries a maximum 
sentence of two years in prison. Yet, following reclassification in the UK, it is unlikely 
that adults caught in possession of cannabis will be arrested, the usual outcome being 
a warning and confiscation of the drug. Nonetheless, some instances may lead to arrest 
and possible caution or prosecution, including repeat offending, smoking in a public 
place, instances where public order is threatened and possession of cannabis in the 
vicinity of premises used by children.
A few enquiries went even further, recommending the regulation of cannabis 
consumption and sale. The Senate Special Committee on Illegal Drugs in Canada 
recommended in 2002 that the government amend the Canadian legislation in order 
to create a criminal exemption scheme that would allow ‘for obtaining licences as well 
as for producing and selling cannabis’. The Senate also asked, as a consequence of 
this legislative modification, for an amnesty to be declared for any person convicted of 
possession of cannabis under current or past legislation (19). Illegal trafficking and export 
would still attract criminal penalties. In Switzerland, in 1999, the Federal Commission 
for Drug Issues recommended the removal of the prohibition of consumption and 
possession of cannabis, and the possibility for cannabis to be purchased lawfully. 
According to the Federal Commission, clear provisions for the protection of the young 
and the prevention of all the potential adverse consequences of legalisation ought to be 
included in the new system. The commission suggested that if the government accepted 
this model, Switzerland should renounce the Single Convention of 1961 given that these 
provisions were not compatible with international drug control agreements. In Australia, 
in 1994, the study undertaken by the government, Legislative options for cannabis use in 
Australia, concluded, more ambiguously, however, that ‘cannabis law reform is required’ 
and that the reform should be one ‘within the broad categories of prohibition with civil 
penalties, partial prohibition and relatively free but regulated availability’.
The value of these inquiries — while in many cases limited in the strict scientific point 
of view — lies in their political significance. The overall picture suggests that cannabis 
consumption potentially poses risks both to individual health and to society, and on this 
basis some sort of legal control seems justified. At the same time, it is acknowledged 
that the dangers of cannabis have in some cases been overstated, that there has been 
a lack of separation between cannabis and other more dangerous substances and that 
its consumption does not necessarily lead to crime or other drug use. Alternative forms 
of criminal sanctions, such as civil sanctions, fines or compulsory health assessments, 
have been suggested. In a few cases, enquiries have included in their suggested options 
the regulation of cannabis consumption and sale, while drawing attention to the political 
impracticability of the option.
(19) Report of the Senate Special Committee on Illegal Drugs, ‘Cannabis: our position for a Canadian 
public policy’, September 2002, Volume III, recommendations nos. 6 and 7, p. 618.
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European Union countries
Classification of cannabis
As far as the classification of cannabis at national level is concerned, the variety of 
laws and procedures within the EU reflect both the severe requirements as suggested by 
the UN Conventions and the ‘room for manoeuvre’ at Member State level. Legislation 
may be organised into a ‘pyramid’: on the bottom tier are those legal systems where 
cannabis is fundamentally considered as different from other drugs; at the top are those 
in which cannabis is treated on a par with all other drugs, but where prosecutorial 
instructions or even judicial discretion in practice apply a distinction between substances, 
usually based on criteria regarding the nature of the substance. Four general groups of 
countries can be identified in which cannabis is classified and controlled differently from 
other drugs, being thus subject to a different prosecutorial approach. These approaches 
are as follows: classification by law; exemption to the law; exception by guidelines; or 
exception due to judicial discretion.
Firstly, in certain countries, lists established in or directly linked to the laws are used 
to determine different legal degrees of severity in control and prosecution of offences. 
Cannabis is included in those lists that do not request the maximum legal response. 
For example, in Cyprus, the Netherlands and the United Kingdom, the respective laws 
classify cannabis in lists where the level of severity demanded in response to offences is 
not as strict as for substances included in other lists. Strikingly, no other substance listed 
in Schedule IV of the 1961 Convention has received this treatment.
Secondly, the law may consider drugs to be equally classified but provide specific 
exemptions for the prosecution of cannabis offences. In countries such as Ireland, 
Belgium and Luxembourg, cannabis is either legally classified amongst those substances 
presenting a serious risk of abuse, no medical value and subject to all control measures, 
or it is included in the general list of controlled substances which do not distinguish 
between such substances based on health risks. However, the national laws or penal 
codes introduce specific distinctions for cannabis possession that can render prosecution 
or sentencing for cannabis more lenient than for other drugs. In Greece, cannabis is 
classified on an equal footing to other drugs but production or cultivation of cannabis 
is legally distinguished from production or cultivation of other drugs for personal 
use. In Spain, classification of drugs is analogous to the UN Schedules, but there is 
a distinct lower penalty range for trafficking in drugs that are not considered as ‘very 
dangerous substances’, and jurisprudence shows this to be interpreted as cannabis. 
Less specifically, in Poland, while cannabis is classified in a way similar to the UN 
Conventions, the laws establish the category of a ‘minor’ drug possession offence, which 
may take into account the substance nature when determining if the offence qualifies as 
‘minor’. In practice, this may be attributed to first time personal use of cannabis.
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A third variant is visible in those countries in which cannabis is legally classified in the 
most stringent lists and the law or penal code does not provide for any exemptions. 
However, prosecutorial guidelines or judicial precedent indicate that a distinction should 
be made based on the nature of the substance when prosecuting. In Denmark a State 
Prosecutor directive and in Germany a Constitutional Court decision request less severe 
measures for possession of cannabis for personal use.
In a separate group of countries (e.g. Czech Republic, Estonia), cannabis is not classified 
differently from other drugs and the law does not differentiate among substances, that 
is, drug offences attract the same penalty regardless of the substances involved. In 
this group there are no prosecutorial guidelines in favour of a less severe approach 
to cannabis. Nonetheless, the nature of the substance is one of the criteria (together 
with the quantity, previous criminal records, and other circumstances) considered by 
prosecutorial or judicial discretion when deciding to reduce the charges or not prosecute 
an offender. Cannabis may be included in this category as a ‘less dangerous’ drug.
The evidence available thus implies that, although international policy suggests that 
cannabis ought to be classified as one of the most dangerous substances to which the 
most severe controls apply, this is not often transposed as such across the different 
European national criminal justice systems. Nevertheless, the different interpretations of 
international conventions can be visible ‘de jure’ or ‘de facto’. They can be managed 
either by legal classification, or by specific mention in the law or penal code, or by 
prosecutorial guidelines, or by the discretionary powers proper to each judicial system. 
The choices between ‘de jure’ or ‘de facto’ options might reflect different political 
attitudes towards cannabis.
Personal use of cannabis (20)
Based on laws passed in parliament, ministerial directives or prosecutorial guidelines, 
a variegated picture emerges of the overall legal attitude towards personal use of 
cannabis. Nonetheless, despite the different legal approaches towards cannabis, a 
common trend can be seen in the development of alternative measures to criminal 
prosecution for cases of use and possession of small quantities of cannabis for personal 
use without aggravating circumstances. Fines, cautions, probation, exemption from 
punishment and counselling are favoured by most European justice systems. The 
EMCDDA maintains a table enabling comparison of legislation regarding cannabis 
offences on its website (21).
(20) ‘Personal use’ here applies to offences for simple use or possession exclusively for personal 
consumption, and where other finalities are excluded (although legal definitions vary, these usually 
involve small quantities and absence of aggravating circumstances).
(21) See eldd.emcdda.europa.eu/index.cfm?nNodeID=5769
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In the European countries considered for this chapter, personal use of cannabis attracts 
administrative sanctions (22) or alternatives to custodial sanctions in 16 countries. 
This suggests that in many European countries considered, personal use of cannabis 
is an offence that attracts sanctions such as fines and deprivation of certain rights, 
for example suspension of driving licence, or other measures such as cautioning, 
discontinuance or suspension of proceedings or, if needed, referral to treatment, but 
does not lead to imprisonment. Indeed, drug policies in many European countries seem 
to concur that criminal action against non-problematic use/possession of cannabis 
should receive the lowest prosecutorial priority (23).
Cannabis legislation: between global consistency 
and national leniency
In recent years cannabis or general drugs laws have been substantially modified in 
a number of European countries. In Portugal, drug use was decriminalised in 2000. 
In Luxembourg in 2001 penalties for cannabis use and possession passed from 
imprisonment to fines. In Belgium in 2003, following a similar approach, legislation 
was introduced that would attract a police registration and fine for the first two cannabis 
use prosecutions, although police registration was annulled by the ruling of the Belgian 
Court of Arbitration in 2004. The United Kingdom reclassified cannabis from a Class B 
to Class C drug in 2004. These are in line with the conclusions of the inquiries described 
above. The cannabis issue has been strongly debated in recent years in France, 
Switzerland, Italy and the Netherlands, fuelled by a number of legislative proposals. 
Some debate has embraced the legal status of cannabis used for therapeutic purposes. 
For example, in the Netherlands a project to supply cannabis to patients was established 
from 2003, with an Office of Medicinal Cannabis strongly regulating supply. However, 
demand has proven lower than expected (1 000–1 500 patients, or around one-tenth of 
predicted demand), although the policy was renewed for a 5-year period in November 
2007.
Modification — or proposed modification of cannabis laws — have often been 
accompanied by heated debate in the media. The political sensitivity of moving away 
from strict control has caused governmental apprehension, and concern has also been 
manifested at the international level. The UN control system has taken a position on 
cannabis in several instances: the INCB has repeatedly raised objections to the way 
some EU countries deal with cannabis offences, in particular where personal use is 
(22) ‘Administrative sanctions’ applies to sanctions not including imprisonment, such as fines or other 
non-criminal measures.
(23) EMCDDA (2002) Prosecution of drug users in Europe, p. 69, and Rand Europe (2003), Cannabis 
policy, implementation and outcome.
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concerned. The Netherlands has often been criticised by the INCB for its ‘coffee shop’ 
policy, and also Luxembourg, Portugal and the United Kingdom have been the object of 
scrutiny for their new laws on cannabis, allegedly because of their non-alignment with 
international drug control treaties (24). This message was again made clear in a chapter 
on ‘the new [high potency] cannabis’ in the UNODC’s 2006 World Drugs Report, which 
stated that ‘It is essential (…) that consensus be regained, and that what is truly a global 
issue is again approached with consistency on a global level. After all, it is for precisely 
this that the multilateral drug control system was designed.’
Such calls for awareness on the presumed cannabis leniency and the danger that such a 
‘soft line’ on cannabis could provoke have not fallen on deaf ears. Without suggesting a 
direct link, some acknowledgement may be detected in the 2004 EU Council Resolution 
on cannabis, and increased scrutiny of cannabis in some EU countries. In Denmark, 
where since the 1970s people caught for possession of cannabis (for personal use) were 
just warned, a new directive of 2004 advises prosecutors that a fine should now be the 
norm. In the Netherlands, the government adopted an action plan to reduce the use 
of cannabis. In Italy, a country where since 1993 cannabis was officially considered to 
be different from other drugs, a 2006 law eliminated this difference on the assumption 
that all drugs are dangerous. In France, in 2005, a new campaign was launched on 
the risks of cannabis for young people after the government turned down the possibility 
of substituting penal sanctions with administrative fines for cannabis consumption, 
adducing that such a modification could have been interpreted as recognition of the 
‘weak dangerousness’ of cannabis and could lead to an increase in consumption (25).
To conclude, there is sufficient evidence to confirm that the legal approach to personal 
use of cannabis is far from homogeneous across the European countries. Nevertheless, 
avoiding imprisonment seems to be the trend for personal use offences, which can be 
applied more or less openly, through the law or through prosecution powers. However, 
there are some efforts to limit this trend. A rise in concern is visible at international 
and national level. An alleged increase of THC content (see King, this monograph) and 
increased demand for treatment with cannabis being the primary drug have contributed 
to this concern. The UN system openly condemns ‘lenient policies’ and recent policy 
shifts in some Member States suggest a renewed attention towards cannabis. Overall, 
it is interesting to note that while drug policies which appeared in the 1990s and early 
2000s suggested a non-criminal approach to personal use of cannabis, more recent 
policies seem to tip the balance back towards more restrictive measures.
(24) See International Narcotics Control Board (INCB) Reports 1999, 2001 and 2002.
(25) Plan gouvernemental de lutte contre les drogues illicites, le tabac et l’alcool 2004–2008. Available at: 
www.drogues.gouv.fr
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Chapter 8
In thinking about cannabis 
policy, what can be learned from 
alcohol and tobacco?
Keywords: alcohol – cannabis – economics – environmental strategy – polydrug 
consumption – prohibition – regulation – taxation – tobacco
Setting the context
Cannabis is just one of many psychoactive substances used in Europe for recreational 
and therapeutic purposes. Research into the topic has never really ignored this real-
life polydrug use. Most joints contain tobacco. A cannabis session often includes the 
consumption of alcoholic drinks. These are givens. Nonetheless, only recently have 
professionals working in the area of cannabis control genuinely begun to look at the 
‘cross-substance’ effects of legislation targeted at other, legal, substances such as 
alcohol and tobacco.
This is not to say that there has been a revolutionary shift towards examining the 
interrelationships of polydrug consumption. The epidemiological regime — which splits 
drug taking along neat substance-specific lines (cannabis, ecstasy, cocaine, etc.) — 
remains in place. Rather, there has been a shift in national drug strategies — at least 
in Europe — to erode the substance-specific approach which traditionally segregated 
activity on licit psychoactive substances from activity on illicit drugs (1). Politically, it is 
no longer taboo to compare legal and illegal substances. The recent advent of smoking 
bans in Europe represents a golden opportunity to measure the knock-on effects on 
consumption of other substances. Moreover, evidence on the effects of decriminalisation 
of cannabis (that is, lower penalties for personal possession) in many European countries 
during the early 2000s is now filtering into the policy literature.
This chapter does not retread the well-worn track of comparative drug harm indexes and 
the relative harms of cannabis and society’s chosen licit drugs. Instead, it examines the 
(1) EMCDDA Annual Report 2006, selected issue: ‘European drug policies: extended beyond illicit 
drugs?’.
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ways in which the market for licit substances has been subject to government control, 
together with brief commentary on the merits of these interventions. The ‘elephant in 
the room’ has been dutifully ignored. There are no ‘what-if’ scenarios on how market 
controls could be transposed to cannabis in a post-legalisation environment. A postscript 
to this chapter provides a range of sources for further reading on the topic of mooted 
cannabis regulation. However, for the time being, any such options would require a 
huge shift in the political balance, which currently appears to be, if anything, more 
tipped in the favour of increased controls on cannabis rather than liberalisation (see 
Ballota et al., this monograph).
Further reading on the regulation of alcohol and 
tobacco
Alcohol
Anderson, P., Baumberg, B. (2006), Alcohol in Europe, Institute of Alcohol Studies, London  
ec.europa.eu/health-eu/news_alcoholineurope_en.htm
Gerritsen, H. (2000), The control of fuddle and flash: a sociological history of the regulation of alcohol 
and opiates, Brill Academic Publishers, Leiden.
Walton, S. (2003), Out of it: a cultural history of intoxication, Random House, New York.
Tobacco
European Commission (2007), Green paper — towards a Europe free from tobacco smoke: policy 
options at EU level, Health & Consumer Protection Directorate-General.
Kopp, P., Fenoglio, P. (2000), ‘Le coût social des drogues licites (alcool et tabac)’, in Observatoire 
Français des Drogues et Toxicomanies 22.
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In thinking about cannabis 
policy, what can be learned from 
alcohol and tobacco?(2)
Robin Room
If caffeine and other such banalised psychoactive substances are left out of 
consideration, almost everywhere in Europe today cannabis is one of the ‘big three’ of 
psychoactive substances, along with alcohol and tobacco. Although the international 
drug control system applies continuing pressure against it, cannabis has taken on a 
semi-legal status in many parts of Europe, at least at the level of the user.
This raises the question, what can be learned from the extensive literatures on alcohol 
and tobacco policy which might be useful in thinking about cannabis policy? The 
question is obviously applicable in a situation where cannabis has a legal or semi-legal 
status. It also has some applicability where cannabis has a clearly illegal status. Total 
prohibition was once fairly common in both the tobacco (Austin, 1978) and alcohol 
fields, in the case of alcohol applying less than a century ago in many parts of Europe 
— Norway, Finland, Iceland, the Russian Empire and then the early Soviet Union. 
Studies of what happened during alcohol prohibition, and also of what happened with 
legalisation, are of interest in thinking about cannabis policy.
Taking into account the alcohol and tobacco experience is particularly important 
because the field of empirical studies of cannabis policy is so little developed. A 
landmark in this field is the sustained effort by MacCoun and Reuter (2001) to assemble 
the evidence on the likely results of illicit drug legalisation in the USA. A byproduct of 
this study, however, was an underlining of how weak the evidence base is in this area. 
A recent review of ‘the contribution of economics to an evidence-based drugs policy’ 
(MacDonald, 2004) found agreement that illicit drug use showed some responsiveness 
to price, but that ‘there is not yet a consensus on the possible range of price elasticities 
for certain drugs’. Evidence on the effects of depenalisation of marijuana still depends 
on a rather small range of studies (Single, 1989; MacCoun and Reuter, 2001; Donnelly 
et al., 2000), in some cases of paradoxical instances where the reach of the criminal law 
actually widened (Single et al., 2000).
(2) This paper draws in part on Room (2005).
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Traditions of studying the impact of alcohol and 
tobacco policies
Alcohol policy impact studies
There is a very substantial literature on the effects of alcohol control policy changes on 
drinking amounts, patterns and problems. Data used in these analyses has primarily 
been of two types: social and health statistics, such as alcohol sales data, police statistics 
and mortality and hospital discharge data; and before-and-after surveys, mostly cross-
sectional but in a few cases longitudinal. Some studies have included control sites, 
and one or two notable studies have included a random assignment to intervention or 
control condition (e.g. Norström and Skog, 2003).
Alcohol policy impact studies have primarily been carried out in a limited range of 
countries, generally excluding both the developing world (Room et al., 2002) and 
Southern European wine cultures. Even between somewhat similar societies, there are 
substantial variations in the research emphasis on particular topics (Room, 2004).
There is an imperfect fit between what those involved in liquor licensing decisions 
may want to know and what is available in the literature on alcohol controls. This gap 
between the content of alcohol control legislation and the research literature has been 
documented in the USA (Wagenaar and Toomey, 2000), but exists also elsewhere — 
particularly in countries where the tradition of alcohol policy impact studies has not 
been strong. The studies are sometimes done because a change was controversial in a 
particular jurisdiction, and funding an evaluation was a way of defusing the controversy. 
Other studies have been opportunistic, where a researcher seizes the chance to do a 
‘natural experiment’ study (‘natural’ here means that the researcher did not have a 
voice in the circumstances of the change, so that the study’s design is often constrained). 
Often studies have made use of available data, such as per-capita consumption data 
or mortality registers. Since research is usually a national government responsibility, its 
topical focus is not necessarily attuned to the concerns of local jurisdictions.
Nevertheless, the growth of the literature evaluating the effects of alcohol controls has 
been a substantial achievement involving a number of national traditions, and lessons 
from it can be applied, with suitable caution, across jurisdictions, and drawn on in 
thinking about cannabis policy. Reviews are now available (e.g. Babor et al., 2003; 
Room et al., 2002) which summarise the findings and implications of the literature. A 
new step forward, as part of the WHO-CHOICE programme (‘Choosing interventions 
which are cost effective’, available at: www3.who.int/whosis/menu.cfm?path=evidenc
e,cea&language=english), has been the estimation of the relative cost-effectiveness of 
different strategies and combinations of strategies to prevent alcohol-related problems 
(Chisholm et al., 2004), in terms of dollars per saved DALY (disability-adjusted life 
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year). Table 1 shows some of the results from these analyses for the ‘Europe-A’ WHO 
subregion, which is roughly coextensive with the European Union. Since evidence was 
lacking for any effectiveness of mass media persuasion of school-based education, these 
strategies were excluded from the analysis as having no apparent cost-effectiveness. In 
terms of cost-effectiveness per DALY saved in developed European countries, then, the 
policies tested ranked as follows (most cost-effective first): taxes (even without counting 
the revenues from taxes); advertising ban; closing times (specifically, Saturday closing for 
off-sales); random traffic breath tests; screening and brief medical advice; and (with no 
cost-effectiveness) mass media persuasion and school education.
Tobacco policy impact studies
There is also a substantial literature of tobacco policy impact studies. As for alcohol, 
there are several synthetic reviews of the literature (e.g. Jha and Chaloupka, 1999; 
Rabin and Sugarman, 2001). Whereas the alcohol policy impact literature aims 
primarily at assessing the impact of specific interventions, the equivalent tobacco 
literature is often aimed at assessing the impact of anti-smoking policy packages as a 
whole (e.g. Siegel and Biener, 1997; Pierce et al., 1998). This partly reflects the reality 
that policy changes in the tobacco area have often involved the simultaneous application 
of multiple strategies. It also reflects the different circumstances of the substances in the 
countries where the main policy impact studies have been done. For alcohol the status 
quo ante has often been a detailed system of controls on availability and on places 
and times of use, with the literature often studying what happens when one or more 
of the controls is removed or relaxed. For tobacco the status quo ante has been very 
little control on availability, and the literature is primarily studying the effect of initiating 
measures such as anti-smoking persuasion campaigns, controls on places of use and 
on age of purchase, and raised prices, which have been increasingly put forward as a 
coordinated package.
Table 1: Comparative cost-effectiveness of alcohol interventions in ‘Europe-A’ 
(Chisholm et al., 2004)
DALYs saved/million 
population
Average cost-effectiveness 
ratio ($/DALY)
Brief medical advice 1 889 2 351
Tax: current + 50 % 1 764 258
Tax: current + 25 % 1 576 289
Tax: current 1 365 333
Advertising ban 459 594
Saturday closing for off-sales 251 1 087
Random traffic breath tests 247 2 467
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Comparing the alcohol policy and tobacco control literatures, one can find clear 
differences in emphasis. Taxes loom even larger as a strategy for tobacco than they 
do for alcohol (see Chaloupka et al., 2001). Although a much greater proportion of 
the total harms from alcohol than from tobacco are to others, the aim of reducing 
harm from ‘second-hand smoke’ has proved politically potent for tobacco control in a 
way that has only been true for drink-driving in alcohol policy. Accordingly, a strong 
emphasis in the tobacco literature has been put on environmental prohibitions — bans 
on smoking at work and in public places — which are already, to a considerable 
degree, taken for granted with respect to alcohol. 
In this connection, Hauge (1999) has argued that the modern emphasis on health 
harm to the drinker has been a policy mistake in the alcohol field. The two policy 
impact literatures have also reached substantially different conclusions about the effects 
of counter-advertising campaigns. This probably primarily reflects the differences in 
the aims and content of the campaigns, as well as differences in the social politics of 
the substances. The anti-smoking campaigns which have proved effective (Pechman 
and Reibling, 2000; Sly et al., 2001, 2002; Wakefield et al., 2003) have often 
involved frontal attacks financed by governmental agencies on the bona fides of the 
tobacco industry. This is an unusual enough occurrence in a capitalist society to have 
impressed teenagers, at least in the short run — although the campaigns have often 
proved politically unsustainable in the longer run (Givel and Glantz, 2000). Also, 
more available in the nicotine field, though underutilised, has been the option of harm 
reduction through changing the mode of use of the psychoactive substance (Shiffman et 
al., 1997).
As for alcohol, the WHO-CHOICE programme has calculated estimated cost-
effectiveness ration for specific interventions, and for combinations of interventions 
(Shibuya et al., 2003). Results for ‘Europe-A’ are shown in Table 2. Again, the cost-
effectiveness calculations exclude the government revenue gained from the tax from 
the calculations. A comparison of the results suggests that somewhat more conservative 
assumptions were used in the alcohol calculations than in the tobacco calculations.
Instead of impact studies: ‘expert knowledge’
As will be apparent from the discussion above, there is great variability in the availability 
of published evidence on the effects of policies governing the availability and use of 
psychoactive substances, both licit and illicit. It should be noted, however, that the lack 
of a formal academic literature does not mean a lack of practical knowledge of the 
effects of policies. As Valverde (2003) has documented for the alcohol control system 
in Ontario, those staffing regulatory systems typically build up a job-based stock of 
knowledge, often mixing ‘facts’ and values, which guide their everyday actions. On 
the other hand, there is ample experience from medicine and other professions with 
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such practice knowledge that its conclusions about effects are often mistaken, when 
subjected to the harsh test of well-designed outcome and impact studies. It would 
be advantageous, with respect to cannabis policy, and for that matter policy on all 
psychoactive substances, to move to an ‘evidence-based’ standard of policymaking. This 
requires a substantial investment in developing the evidence on which the policymaking 
can be based.
Some specific lessons from alcohol and tobacco 
policy research
Does consumption necessarily go up after legalisation?
The answer to this question seems to be, ‘it depends’. The total alcohol consumption 
does not seem to have changed much after the legalisation of alcohol at the end of US 
Prohibition (Gerstein, 1981). But this was in a circumstance of economic depression, and 
with quite stringent alcohol control regimes replacing prohibition in many US states. As 
MacCoun and Reuter (2001 pp. 356–366) conclude, in the US context, depenalisation 
of use seems not to increase cannabis use, but outright legalisation probably would. 
However, the circumstances of legalisation would certainly affect this, and stringent 
regulatory control of cannabis would be likely to hold consumption down (see below).
What regulatory alternatives are there to prohibition?
The history of control of alcohol and other psychoactive substances is full of examples of 
different regulatory regimes, and the effects of some of them have been evaluated. One 
part of such a system is the regulation of the market in the substance, including retail 
sales.
Table 2: Comparative cost-effectiveness of tobacco interventions in ‘Europe-A’ 
(Shibuya et al., 2003)
Total DALYs saved 
(millions/year)
Average cost-
effectiveness ratio 
($/DALY)
Doubling the highest tax 6.9 13
Highest regional tax rate (75 %) 4.8 18
Global average tax rate (44 %) 2.0 44
Enforced bans on smoking in indoor public space 0.8 358
Counter-advertising campaigns 0.7 337
Nicotine replacement 0.7 2 164
Comprehensive advertising ban 0.6 189
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One option for such regulation is a kind of prescription or permit system, issuing licences 
to individuals to purchase cannabis. This could be a system organised with physicians 
and pharmacists as the gatekeepers, like prescription systems for psychoactive 
medications. Such a system, with a mental health screening component, might be 
adopted if there is a major policy concern about cannabis precipitating schizophrenia. 
But it seems more likely that a more bureaucratised system, as for driver’s licences, 
would be adopted. Sweden’s ‘Bratt system’ for alcohol in the decades before 1955 had 
a version of such individualised controls (Frånberg, 1987).
A second option is a rationing system, which allots a maximum purchase amount to the 
purchaser in a particular time period. The Swedish Bratt system included a rationing 
system, and there are also some more recent examples of alcohol rationing (Schechter, 
1986).
A third option is a government monopoly system, where the state monopolises one or 
more levels of the production, distribution and sale of the substance. Such monopoly 
systems presently exist for alcohol in 18 US states and all Canadian provinces (though 
only a few of the states and nine of the provinces have monopoly stores at the retail 
level), as well as in all Nordic countries, except Denmark. There have been state 
monopoly systems for cannabis in India, and monopoly systems for opiates were 
a feature in the Asian territories of the empires of the first half of the 20th century 
(Brook and Wakabayashi, 2000). The medicinal cannabis office set up by the Dutch 
government may be seen as a similar monopoly. There is a recent Canadian proposal 
for government shops to take over the sale of tobacco (Callard et al., 2005), and 
there have also been proposals in Canada and in the US northwest for cannabis to be 
legalised for sale in government alcohol stores.
The fourth option is a licensing system, where private commercial enterprises are 
licensed to sell the product, with the licence conditional on the seller abiding by the 
rules of a regulatory system. Such a system is common for alcoholic beverages, as an 
alternative to a government monopoly. A licensing system is used in the Netherlands to 
regulate the ‘coffee shops’ that allow non-criminalised retail purchase of cannabis (see 
Korf, this monograph). Specific licensing systems for retail tobacco sales have become 
common, for instance, in the USA in recent years (www.healthpolicycoach.org/doc.
asp?id=3147).
Is a rationing system effective?
There is good evidence that rationing systems for alcohol hold down the levels of 
problems from alcohol, whether in terms of violence (Schechter, 1986) or long-term 
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health consequences (Norström, 1987). When the Swedish system of individualised 
rationing was abolished in 1955, for instance, the rate of liver cirrhosis mortality 
jumped by one-third in the following year, reflecting the removal of a constraint on the 
consumption of heavy drinkers (Norström, 1987).
Is a government monopoly system effective?
It has been shown that government monopoly of retail sales can be quite effective in 
holding down retail sales of alcoholic beverages (Her et al., 1999). The effects are partly 
through associated characteristics which have been shown to be effective in holding 
down sales: limitation of the number of sales outlets, and limitation of hours and days 
of sale. Government management of the system also results in more professionalised 
employees, less likely, for instance, to sell to those who are under legal age. And it 
removes the private profit motive, which tends to drive consumption upwards, not only 
in terms of sales promotion but also in terms of political influence from private actors to 
loosen restrictions in availability (Room, 2001).
Do taxes on psychoactive substances affect the amount of 
consumption?
As already indicated in Table 2, the answer to this from both the tobacco and the 
alcohol literature is an emphatic ‘yes’.
Can regulatory policies affect the potency of the psychoactive 
substance used?
The answer to this question is clearly ‘yes’. At least a dozen US states, for instance, ban 
Everclear spirits, a product that is 95 % pure ethanol. The legal availability of lesser-
strength alcoholic beverages (including regular-strength spirits) means that there is no 
substantial black market for Everclear.
Prior to 1915, spirits were the main form of alcohol consumed in all Nordic countries. 
By the 1980s, the main form was beer (wine has now replaced beer in Sweden as the 
most used form in terms of alcohol content). The changeover from spirits to beer was 
accomplished very quickly in Denmark by a swingeing tax on spirits imposed during the 
First World War (Bruun et al., 1975). In other Nordic countries the change was more 
gradual, accomplished partly by differential taxation and partly by making low- and 
middle-strength beer more widely available than other alcoholic beverages.
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Whether a more potent form of the psychoactive substance is more harmful than a 
less potent form is an apparently easy question to answer for alcohol, in the sense that 
most of the harm from drinking alcohol comes from the psychoactive ingredient itself. 
Nevertheless, it can be questioned how much effect the Nordic political effort to channel 
consumption toward beer and wine and away from spirits had on alcohol-related 
problems. The political intent was to moderate drinking customs along with the change 
in beverage, but there is little evidence that this happened. At least in the short run, the 
‘trouble per litre’ of alcohol did not decline when beer was made much more available 
in Finland in 1969, and consumption rose by about 50 % (Mäkelä et al., 1981).
For tobacco, as for cannabis, the issue of whether greater potency is more harmful is 
obviously more complicated, since much of the harm results not from the psychoactive 
ingredient but from what accompanies it, particularly in smoked form (tars, carbon 
monoxide). Thus, low-nicotine, high-tar tobacco cigarettes are likely to cause more 
health harm than high-nicotine cigarettes, since the smoker will get more tar and carbon 
monoxide in the course of reaching the same level of nicotine. Analogously, it should 
not be assumed that a higher THC content will be more harmful.
Interacting with the issue of potency is the issue of mode of ingestion. It is likely that 
there is less risk to health from eating or vapourising marijuana than from smoking 
it. However, for licit as well as illicit psychoactive substances, there is relatively little 
systematic knowledge on the effects in a population of measures designed to favour one 
mode of ingestion over another. Often policies are made on the basis of vague fears 
rather than systematic knowledge. For instance, the Swedish form of snuff, known as 
snus, is banned for sale in the European Union, other than in Sweden, on the grounds 
that it is a health hazard. There are good public health arguments for promoting the 
use of snus as a much less harmful alternative to smoking cigarettes, although these 
arguments are also disputed (Gilljam and Rosaria Galanti, 2003). But at present the 
European legal system considers that it must make decisions on whether snus should 
remain banned on the basis of suppositions.
Snus is much less deadly than smoked tobacco ... [But] one cannot conclude with certainty 
whether offering snus on the market would principally have the effect of encouraging smokers 
to stop smoking (a ‘substitution effect’) or of facilitating, on the contrary, the path towards 
consumption of tobacco (a ‘passage-way effect’) ... The insufficiency of data and the scientific 
uncertainty [is about] the supposed behaviour of the public. The question which poses itself is 
that of knowing if, in these circumstances, the ban on snus can be considered as a protective 
measure efficacious for public health.
(Geelhoed, 2004; translated from French version)
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Can regulatory policies affect the location and circumstances of 
use?
Again, the answer to this is clearly positive. One result of prohibitory policies is to push 
consumption into private or semi-private places. The Dutch coffee shop model of limited 
cannabis availability in designated places may be seen as holding down the public 
nuisance from cannabis smoking (see Korf, this monograph).
Again, however, the issue of which locations of use are more harmful has turned out 
to be complicated in the alcohol field. Drinking in streets and parks is usually seen as 
increasing the nuisance for others (Törronen, 2003), but the perception has varied at 
different times on whether drinking in a tavern or restaurant is more or less harmful than 
drinking at home. On the one hand, control laws in US states at repeal of prohibition 
often forbid sale of ‘liquor by the drink’, since at that time the ‘old-time saloon’ was 
defined as the seat of most alcohol problems. But when ‘liquor by the drink’ was 
finally allowed in North Carolina, no effect on alcohol-related harm statistics could be 
detected (Blose and Holder, 1987). On the other hand, Finnish authorities in the 1970s 
presumed that drinking in a bar or restaurant would be more restrained than drinking 
at home. But in fact, Partanen (1975) found that the empirical results in Helsinki were 
the opposite: ‘people do not drink any more at home than in a restaurant, but they do it 
in a more leisurely manner, which seems to lead to a lower degree of intoxication’. The 
issue of the harm associated with specific circumstances of use should be treated as an 
empirical question rather than a matter of ‘expert knowledge’.
What about the impact of the European single market and of trade 
agreements and disputes?
The prohibition on cannabis sales under the international drug control regime is 
presumably primarily responsible for the fact that there have been so far no challenges 
to any legislation that discriminates, for instance, between cannabis grown in the country 
and imported cannabis. Such challenges have been a regular occurrence for both 
tobacco and alcohol, and both the single market mechanisms of the European Union 
and the trade agreements administered by the World Trade Organisation have created 
substantial difficulties for alcohol and tobacco control regimes (e.g., Room and West, 
1998; Taylor et al., 2000). The new Framework Convention on Tobacco Control may 
help to remedy this situation, but the issue of whether it overrides trade agreements 
is not settled (Room, 2006). It would thus be wise for any move to legalise cannabis, 
however restrictive the regulations, to take into account the need to exempt hazardous 
substances from coverage under trade agreements and disputes.
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Conclusion
Although the literatures have their limits, studies of the impact of tobacco and alcohol 
policies are much more numerous and cover a broader territory than the equivalent 
studies for cannabis. In the absence of formal studies, estimation of the impact of laws 
and policies remains a matter for ‘expert knowledge’, although it is clear from the 
alcohol and tobacco fields, as well as from medical and other research, that expert 
knowledge based only on general principles or practical experience is often wrong. Any 
government that is serious about making laws and policy that have specific intended 
effects needs to build funding into any policy initiative for a scientific evaluation of its 
actual effects, both intended and otherwise.
The alcohol and tobacco research findings suggest some general conclusions about 
the relative strength of different prevention and policy strategies. As with cannabis, it is 
difficult to show lasting effects from public information campaigns and school education 
on tobacco and alcohol. On the other hand, laws which channel rather than forbid 
use — for instance, laws against drink-driving — have been shown to be effective. 
In general, the findings in both the alcohol and the tobacco literatures underline 
the power of regulatory approaches, including taxation, in limiting the harm from 
psychoactive substances. Such regulations are more easily and effectively applied where 
there is a legal market, since in that case there are licensed actors in the market who 
have something to lose by having their licences suspended or taken away. From this 
perspective, the state ties one hand behind its back with a prohibition regime, since its 
ability to control the market is greatly restricted.
On the other hand, it must be acknowledged that Europe has serious health and social 
problems from both tobacco and alcohol. In both areas, the European Union is now 
taking some steps to assist national and local governments in reducing the levels of 
problems. But a clear difficulty in this effort, both at EU and national levels, is the 
entrenched political power of vested economic interests in maintaining the size of the 
alcohol and tobacco markets. Any shift towards regulatory regimes for cannabis would 
be wise to take account of this, and to build into cannabis policies insulation from the 
potential influence of market forces and interests.
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Editorial postscript
This chapter focuses deliberately on experiences with regulating alcohol and tobacco. It 
does not include crystal gazing for regulation of legalised cannabis. In the production of 
the monograph, some reviewers felt that some more information on specific regulatory 
controls on cannabis was required. The chapter, however, remains useful in drawing 
attention to the many ‘unknowns’ faced when regulating psychoactive substances. For 
illicit drugs in general, economic analysis of market size is relatively immature, relies 
on broad assumptions and triangulation of diverse datasets (seizures, prevalence, retail 
prices, arrests, potency, etc.), and usually implies a large margin for error. So significant 
preparatory work would need to be done before regulatory models could be seriously 
considered for cannabis. At this point, it is premature to discuss topics such as product 
certification and licensing, feasibility studies, econometric analysis, market sizing, 
regulatory standards, fiscal forecasting, seasonality, etc. with any degree of certainty. 
While some exploratory work has been done on market sizing in the EU, estimates to 
date remain problematic. In particular, regulation would need to respond to findings 
that home-grown self-supply and informal supply ‘among friends’ make up a substantial 
amount of the market in EU countries (see Legget and Pietschmann, this monograph) 
(Table 3).
In terms of further reading on economic controls of cannabis in a (hypothetical) 
regulated market, the subject has recently experienced a revival in interest. This is true 
both of economic and statistical journals, as well as in the usual drugs and public health 
journals. As a basic introduction, the difficulties of drug market sizing formed the subject 
of a chapter in the UNODC’s World Drug Report 2005 (UNODC, 2005). Specific 
studies on cannabis are generally based on patterns that follow the decriminalisation 
of cannabis use. Specific studies include those in Australia (Clements and Zhao, 2005), 
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British Columbia (Easton, 2004) and Massachusetts (Miron, 2003). In Europe, while a 
regulated cannabis market is frequently a subject of lobbyists’ pamphlets (e.g. Holtzer, 
2004; Atha, 2004), policy-oriented study has either been restricted to domestic market 
profiling (Bramley-Harker, 2001; Pudney, 2004) or has favoured the broad-brush 
analysis of illicit drugs in general (Clark, 2003; Bretteville-Jensen, 2006). A recent study 
in France (Ben Lakhdar, 2007) provides a useful exploration of how the French cannabis 
market is structured, in terms of volume and values. Such quantitative study is rare in 
Europe, yet would contribute greatly to our understanding of the economics of cannabis.
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An open front door: the coffee 
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Setting the context
A European monograph on cannabis would not be complete without a chapter on Dutch 
‘coffee shops’. ‘Coffee shop’ in the Dutch context is a euphemism for cafés where, since 
1976, the sale and consumption of cannabis has been tolerated.
This chapter provides a number of surprising insights on the coffee shop phenomenon, 
from the leading Dutch authority on the subject. The Netherlands has relatively low 
prevalence of cannabis use (see Monshouwer et al., this monograph), despite the 
proximity of retail outlets. The 737 coffee shops (2004) are also found in a small 
number of towns, and their numbers have dwindled as municipalities have sought to 
tighten their licensing. The chapter also describes a number of features of coffee shops: 
the AHOJ-G operating restrictions, under which coffee shops operate; the challenges in 
enforcement of ensuring a limited supply of 500 g on the premises (1); the ‘back door 
problem’ and controlling links with wider trafficking and crime. Indeed, beyond such 
retail outlets, the Netherlands is a wholesale hub in the trafficking of Moroccan cannabis 
resin across northern Europe (see Gamella, this monograph).
Coffee shops are controversial, both within the Netherlands and in the international 
context. This chapter remains focused on the domestic situation in the Netherlands: 
coffee shops and their impact on Dutch drug use patterns. However, coffee shops also 
(1) This problem has become known as ‘the back door’ problem in the Netherlands. A recent case 
in the town of Terneuzen highlights the problem. A police check of the coffee shop Checkpoint in 
June 2007 found over 5 kg of cannabis on the premises and over 90 kg in a nearby warehouse 
(www.hvzeeland.nl/nieuws.php?id=5542).
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Table 1: Dutch coffee shops at a glance
Number 
of coffee 
shops in the 
Netherlands
Coffee shop 
density (in the 
103 localities 
with coffee 
shops present)
Number 
of people 
employed at 
coffee shops
Estimated size 
of domestic 
cannabis 
market
Estimated 
size of non-
domestic 
cannabis 
market
Average 
estimated 
revenue 
per coffee 
shop from 
cannabis 
sales
737 (2004) One coffee 
shop per 
28 715 
inhabitants. 
Highest density: 
Amsterdam 
(one coffee 
shop per 2 969 
inhabitants)
3 400 EUR 211–283 
million (32–43 
tonnes)
EUR 43–88 
million 
(6.6–13.3 
tonnes)
EUR 280 000– 
380 000
Sources: Bieleman et al. (2005), Bieleman and Snippe (2006).
(2) This was one of the broad conclusions of the Cannabis zonder coffee shop report.
play an interesting role in cross-border supply: annual sales volumes to non-Dutch 
buyers are estimated at 6.6 to 13.3 tonnes (Bieleman and Snippe, 2006). Cross-border 
drugs tourism has led to considerable and repeated criticism of the Dutch coffee shop 
policy, particularly among neighbouring countries. A counter argument of note is that 
cannabis prevalence among young people in the Netherlands is lower than many of its 
neighbouring countries, and that most cannabis consumed in these countries will not 
have been purchased at Dutch coffee shops (Table 1).
Perhaps most significantly, Dutch coffee shops play a symbolic role as a paradigm of 
liberal cannabis policies. In addition to their common appearance in academic studies 
of drug policy, they have become associated in popular culture with the liberal attitudes 
of the Netherlands. The coffee shops themselves do little to prevent such notoriety, 
and play a role in cannabis advocacy and the seed distribution businesses operating 
from the Netherlands. So, although in the Netherlands discussions in recent years have 
focused on the inevitability of supply — i.e. underground dealers will supply the demand 
which is currently served by coffee shops (2) — Dutch drug policy is likely to remain a 
controversial subject.
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An open front door: the coffee 
shop phenomenon in the 
Netherlands
Dirk Korf
Introduction
Although cannabis is still an illicit drug in the Netherlands, herbal cannabis and 
cannabis resin are openly sold in so-called ‘coffee shops’. In general, coffee shops are 
café-like places, although some function more as a store where one can buy, but not 
use cannabis. In this paper we first describe the process of decriminalisation of cannabis 
and the evolution of coffee shops in the Netherlands. Then we discuss long-term trends 
in cannabis use in the Netherlands, both among the general population and among 
students at secondary schools, followed by exploring some problems regarding the 
causal relationship between coffee shops and trends in cannabis use in the Netherlands. 
Next, we examine the role of coffee shops relative to other cannabis sellers at retail 
level. Finally, we discuss recent developments regarding the supply of coffee shops.
From underground market to coffee shops
The Netherlands was one of the first countries where cannabis became the object of 
statutory regulation. The import and export of cannabis was introduced into the Opium 
Act in 1928. Possession, manufacture and sale became criminal offences in 1953. 
Statutory decriminalisation of cannabis took place in 1976. De facto decriminalisation, 
however, set in somewhat earlier.
With regard to the cannabis retail market in the Netherlands, four phases can be 
distinguished.
Phase 1
During the first stage, the 1960s and early 1970s, the Dutch cannabis retail market 
was a predominantly underground market. Cannabis was bought and consumed in a 
subcultural environment, which became known as a youth counterculture.
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Phase 2
The second stage was ushered in when Dutch authorities began to tolerate so-called 
‘house dealers’ in youth centres. Experiments with this approach were formalised 
through statutory decriminalisation in the revised Opium Act of 1976. This law 
distinguishes between two types of drugs: on the one hand, hemp products (Schedule 
II drugs), and on the other hand, drugs that represent an ‘unacceptable’ risk (Schedule 
I drugs, such as heroin and cocaine). The law also differentiates on the basis of the 
nature of the offence. For example, drug use is not an offence, possession of up to 30 
grams of cannabis is a petty offence or misdemeanour, while possession of more than 
30 grams is a criminal offence.
Official national Guidelines for Investigation and Prosecution came into force in 1979. 
These guidelines are founded on the expediency principle, a discretionary principle in 
Dutch penal law which allows authorities to refrain from prosecution without first asking 
permission of the courts. Basically, the expediency principle can be applied in two ways. 
The first favours prosecution: prosecution is a default response, but is waived if there 
are good reasons to do so (‘prosecution, unless ...’). This case-directed approach was 
common in the Netherlands until the end of the 1960s.
The second approach applies the expediency principle differently: prosecution takes 
place only if it is expedient and serves the public interest (‘no prosection, unless ...’). 
Society-wide prosecution of cannabis offences was believed not to serve the public 
interest: it would stigmatise many young people and socially isolate them from society. 
According to the 1979 national guidelines, the retail sale of cannabis to consumers 
would be tolerated, provided the house dealer met the so-called AHOJ-G criteria. These 
criteria are:
no overt advertising (•	 affichering);
no hard drugs;•	
no nuisance (•	 overlast);
no underage clientele (•	 jongeren); and
no large quantities (•	 grote hoeveelheden).
Small-scale dealing of cannabis thus remained an offence from a legal viewpoint, but 
under certain conditions would not be prosecuted. It should be acknowledged that this 
legal tolerance was initiated before the Opium Act was revised in 1976, and became 
more visible after 1979 with the entry into force of the national guidelines and AHOJ-G 
criteria. So by the end of the 1970s, the house dealer had become a formidable 
competitor to the street dealer.
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Phase 3
In the third stage, cannabis resin and herbal cannabis were sold predominantly in 
café-like places, which have become known as ‘coffee shops’. Although the government 
never intended this development, through case law it was decided that coffee shops 
were to be tolerated according to the same criteria as house dealers. During the 1980s 
coffee shops captured an increasingly large share of the Dutch retail cannabis market 
(Jansen, 1991).
Phase 4
The fourth stage began in the mid-1990s, when legislative onus was placed on curbing 
the number of coffee shops. Since then, the number of coffee shops has steeply declined 
from about 1 500 to 813 in 2000 and further to 737 in 2004 (Bieleman and Goeree, 
2000; Bieleman et al., 2005). Moreover, in 1996 local communities received the 
opportunity to decide whether or not they would allow coffee shops in their municipality. 
To date, 77 % of the 483 communities have decided not to allow coffee shops at all. 
Consequently, they can close down coffee shops even if they do not violate the AHOJ-G 
criteria. In addition, the minimum age for visitors was increased from 16 to 18 years.
So, coffee shops are not distributed evenly over the country. Over half (52 %) of all 
coffee shops are located in the five largest communities (> 200 000 inhabitants), while 
only 1 % can be found in communities with less than 20 000 inhabitants. Although only 
5 % of the national population lives in Amsterdam, the city is the home of one-third of 
all coffee shops in the country.
Trends in cannabis use
From an analysis of available data on the prevalence of cannabis use between the 
late 1960s and the late 1990s, we concluded that there was little room to doubt that 
cannabis use in the Netherlands spread rapidly around 1970 (Korf et al., 2002). Most 
probably, cannabis use among youths in the Netherlands evolved in two waves, with a 
first peak around 1970, a low during the late 1970s and early 1980s, and a second 
peak in the mid- to late-1990s.
Prior to the Second World War, cannabis use in the Netherlands had hardly been 
heard of, and this did not change much in subsequent years. The 1950s witnessed the 
introduction of cannabis in the Netherlands, when herbal cannabis was used by small 
groups of jazz musicians and other artists who had learned to use it while abroad, as 
well as foreign seamen and Germany-based US military personnel, in particular in 
Amsterdam (Cohen, 1975; de Kort and Korf, 1992).
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In the course of the 1960s, cannabis use in the Netherlands rapidly gained popularity. 
An increasing number of adolescents began smoking it, but not until the end of the 
decade did a cannabis smokers’ subculture emerge. Cannabis spread significantly in 
the wake of the hippie movement, and smoking cannabis at the national monument 
in Dam Square or in the Vondelpark in Amsterdam became a staple of a burgeoning 
international youth sub-culture (Leuw, 1973).
The first indication of the rapid growth in the popularity of cannabis towards the end 
of the 1960s can be found in school surveys. In 1969 as many as 9 % of the students 
in the final form at secondary school reported having used cannabis at least once. Two 
years later this percentage had doubled to 18 %. Yet rates did not continue to rise in 
subsequent years. In 1973, lifetime prevalence was again put at 18 % (see Korf, 1995). 
It was more than a decade before the next national school survey was carried out, in 
1984. This survey yielded a much lower lifetime prevalence of cannabis use (5 %). To a 
considerable degree, however, the lower rate can be explained by inconsistencies in the 
samples. If comparable age groups are examined, the difference between 1973 and 
1984 rates is much smaller: 18 % ever use of cannabis for students with a mean age of 
17.5 years in 1973; 12 % for students 17 years and older in 1984 (Plomp et al., 1990).
Unfortunately, these school surveys did not address nationally representative samples. 
Since 1988 nationally representative surveys have been conducted on the extent to which 
secondary school students aged 12 and older have experience with alcohol, tobacco, 
drugs and gambling. From 1988 to 1996, cannabis rates among students rose, but 
stabilised in the late 1990s, followed by a drop (Monshouwer et al., 2004). (Figure 1).
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Figure 1: Cannabis use among secondary school pupils, aged 12 years (1988–2003)
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General population surveys are another indicator of trends in cannabis use. Between 
1970 and 1991 six national household surveys have been conducted in the Netherlands 
(see Korf, 1995). They reveal a growing percentage of people that report having used 
cannabis at least once in their lives: from 2–3 % in 1970, to 6–10 % during the 1980s 
and to 12 % in 1991. In 1997, a new series of general population studies was initiated, 
using large representative samples of people aged 12 years and over. In addition to 
figures on lifetime use of — amongst others — cannabis, this National Prevalence Study 
also includes data on current use (Abraham et al., 1999). According to the 1997 data, 
the vast majority have never tried cannabis and only one in six respondents have ever 
used cannabis (15.6 %). One in 40 respondents (2.5 %) used cannabis in the month prior 
to the interview (current use). The second National Prevalence Study, conducted in 2001, 
revealed a lifetime prevalence rate of 17 % and 3 % for last month use (Abraham et al., 
2002). A different age group (15–64 years) was studied in the third National Prevalence 
Study (2005/2006). Between 1997 and 2005–2006, trend analysis showed: a decrease 
in last year prevalence in the age group 15–24 years; an increase in lifetime, last year 
and last month prevalence among the age group 25–44 years; and an increase in last 
month prevalence in the age group 45–64 years (Rodenburg et al., 2007).
Cannabis use is not distributed evenly across the Netherlands. Cannabis use is more 
prevalent in urban than in rural areas. Amsterdam tops the list with respect to ever use 
and current use. Such an uneven geographical spread of cannabis use is not only typical 
for the Netherlands, but can also be found in other countries (Partanen and Metso, 
1999). Since 1987, five surveys have been conducted among the general population of 
Amsterdam aged 12 years and over, applying a similar methodology as in the National 
Prevalence Study. Prevalence rates increased (Abraham et al., 2003). To a large extent, 
this increase reflects a generation effect. This generation effect also helps to explain why 
rates for ever use increase much more strongly than those for current use (Figure 2). The 
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Figure 2: Trend in cannabis use, general population, Amsterdam, 12+ years (1987–2001)
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majority of the adult ever users in Amsterdam have stopped using cannabis. While many 
young ever users are currently taking cannabis, few older ones continue to do so. The 
mean age of cannabis use in Amsterdam remained stable at around 20 years. For the 
age cohort of 25–29 years, lifetime use first increased in the 1990s and then stabilised, 
while current use remained quite stable during the period (Figure 3).
Decriminalisation and cannabis use
During the transition from the first to the second phase in Dutch cannabis policy, the 
many underground selling points became consolidated into a more limited number 
of formalised sales outlets that were publicly accessible yet shielded from public view. 
During the third phase, availability increased markedly in numerous coffee shops. More 
recently, availability may have decreased because of the declining number of coffee 
shops. It is striking that the trend in cannabis use among youth in the Netherlands 
parallels our four stages in the availability of cannabis. The number of adolescent 
cannabis users peaked when cannabis was distributed through an underground market 
during the late 1960s and early 1970s, when the drug was available through many 
small-scale retailers (street dealers, in homes and bars). Adolescent use then decreased 
as house dealers superseded the underground market during the 1970s. It increased 
again in the 1980s after coffee shops took over the sale of cannabis. And it stabilised 
or slightly decreased at the end of the 1990s, when the number of coffee shops was 
reduced.
Rising or falling cannabis consumption need not be the unequivocal result of 
decriminalisation or criminalisation. In order to study the possible link between 
decriminalisation and the evolution of Dutch cannabis use, first we need to analyse the 
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Figure 3: Trend in cannabis use, general population, Amsterdam, 25–29 years 
(1987–2001)
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prevailing rates of cannabis use both before and after decriminalisation. Moreover, 
longitudinal trends in cannabis use in the Netherlands can only properly be ascribed to 
decriminalisation when it is made plausible that they are causally related.
In line with MacCoun and Reuter (1997), reasoning by analogy might be helpful in 
getting closer to an understanding of the nature of the link between decriminalisation 
and cannabis prevalence rates in the Netherlands. How do the Dutch trends in the 
cannabis case compare to those in other Western nations? Such a question is not easy 
to answer, mainly because there are few countries where cannabis consumption has 
been consistently and systematically recorded over the years.
The USA has a relatively long tradition of surveys on drug use and the American figures 
consistently appear to be higher than those in the Netherlands (Plomp et al., 1990; 
NDM, 2006). Clearly the USA, as the prototype of a prohibitionist approach towards 
cannabis, reports higher cannabis consumption than the Netherlands, the prototype 
of anti-prohibitionism. Marijuana use among youth in the USA also evolved in waves, 
with a peak during the late 1970s, a decline in the 1980s, a rise in the 1990s and 
then stabilisation. Harrison (1997) concludes that such a wave-like development can 
be understood as a verification of Musto’s more general model on trends in drug use 
(Musto, 1987). In addition, structural factors such as the post-Second World War baby 
boom and drug education (affecting health risk perception) might help to explain the 
development in marijuana use in the USA (Harrison, 1997). Other European countries 
have also reported a wave-like trend in cannabis use (Kraus, 1997). For example, 
cannabis use spread rapidly in (West) Germany toward the end of the 1960s, followed 
by stabilisation and decline in the early 1970s and then an increase in the 1980s 
(Reuband, 1992; Kraus, 1997). The rising use of cannabis in Germany continued in the 
1990s (Kraus and Bauernfeind, 1998; Kraus et al., 1998).
Cannabis use in some other countries with a prohibitionist approach towards cannabis 
— Sweden in particular — is substantially lower than in the Netherlands. Although this 
has been used as supporting evidence that prohibition deters use, the argument does 
not hold when seen in relation to data from other prohibitionist countries, for example, 
the USA, and elsewhere in Europe. From the available data from general population 
surveys in 10 Member States of the EU (which are not absolutely comparable), the 
EMCDDA concluded that the level of cannabis use varies strongly within the EU 
(EMCDDA, Annual Report 2001); from 9.7 % in Finland to 25 % in the UK (England 
and Wales). The Netherlands is placed somewhere in the middle (and this would 
most probably be lower if its level of urbanisation were taken into account). From a 
comparison of data from general population surveys in Germany (Kraus et al., 1998) 
and the UK (Ramsay and Partridge, 1999), we concluded that adolescents and young 
adults in these countries have showed a similar trend to that in the Netherlands: 
increasing cannabis use from the late 1980s onwards (Korf et al., 2002).
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So, trends in cannabis use in the Netherlands appeared to run along similar lines to 
those in other European countries, and Dutch figures on cannabis use between the 
late 1960s and the late 1990s were not out of line with those from countries that did 
not decriminalise cannabis. Over time, prevalence of cannabis use shows a wave-like 
trend in many countries, including the Netherlands. This supports Reuband’s earlier 
conclusion that cannabis use trends evolve relatively independently from drug policy, 
and that countries with a ‘liberal’ cannabis policy do not have higher or lower rates than 
countries with a more repressive policy (Reuband, 1995).
From the data discussed so far, it appears unlikely that decriminalisation of cannabis 
causes an increase in cannabis use. However, before we draw such a final conclusion, 
we need to address three issues. First, we have compared Dutch prevalence data with 
those from countries that did not officially decriminalise cannabis. However, the actual 
enforcement of cannabis offences may be less strict than the law suggests. Second, 
at the level of the ‘dependent variable’, the question is ‘what is the most appropriate 
indicator for cannabis use?’ Third, we must take into account the accessibility of coffee 
shops: as mentioned, there is a minimum age for visiting coffee shops.
How do drug laws relate to the actual enforcement of cannabis offences? The 
Netherlands has separate schedules for cannabis and other illicit drugs. The use of 
cannabis is not illegal, and penalties for trafficking are higher than for possession. 
In this respect, the Dutch drug law is not unique. There are other EU countries with 
differential drug laws (two or more schedules), where cannabis use is not illegal, and 
where the drug law sets higher penalties for trafficking than possession (see Ballotta 
et al., this monograph; Korf, 1995; Leroy, 1992). Most EU countries have penalties 
for cannabis possession, ranging from a fine to incarceration (EMCDDA ELDD, 2001). 
According to Kilmer (2002), in practice most arrests for cannabis possession in EU 
Member States appear to only lead to a fine, while few data are available on the levels 
of these fines and about what happens when they are not paid. So Kilmer examined 
actual cannabis law activities within a number of Western countries, by comparing police 
capacity, enforcement of and punishment for cannabis possession laws. He concluded 
that the probability of cannabis users being arrested for cannabis possession is generally 
between 2 and 3 %. Probability of arrest was fairly similar (2–3 %) in EU countries with 
relatively low cannabis prevalence rates (e.g. Sweden: arrest rate, 2.4 % in 1997) and 
those with higher rates (e.g. United Kingdom: arrest rate, 2.1 % in 1996 and 2.9 % in 
1998). Consequently, formal criminalisation of cannabis possession rarely leads to 
actual criminalisation in practice. So it appears plausible that current cannabis laws in 
EU Member States, as well as other Western countries, have little deterrent effect on 
cannabis use.
It is not uncommon to discuss the effects of decriminalisation of cannabis in the 
Netherlands on the basis of data from school surveys. The analysis by MacCoun and 
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Reuter (1997) was largely based on data from school surveys, and we included such 
figures in our analysis earlier in this chapter as well. Unfortunately, this is not without 
problems. In 1996 the minimum age for coffee shop visitors was raised from 16 to 18 
years. Consequently, minors are not allowed to buy and use cannabis in coffee shops, 
which means that prevalence rates of cannabis use among youth below the age of 18 
cannot be defined as valid indicators in the analysis of the effects of decriminalisation.
In a secondary analysis of national school survey data from 1992, 1996 and 1999 we 
looked at how the use of cannabis evolved amongst adolescents (Korf et al., 2001). We 
faced two difficulties. First, school populations are constantly changing, partly due to an 
ongoing rise in percentages of ethnic minority students. Second, samples do not always 
precisely reflect school populations. Statistical bias can be corrected to an extent by 
weighting, but that still does not ensure full representativeness. Both the real changes in 
the student population and the sampling errors could potentially damage the reliability 
of the cannabis use statistics. We allowed for this as much as possible by performing 
logistic regression analysis. This enabled us to detect any changes in the use of cannabis 
that were not due to differential background characteristics (gender, ethnicity, school 
type and urbanisation) in the samples. Analysis revealed a break in the previous upward 
trend in current cannabis use among 16–17-year-olds after the raising of the age limit 
for coffee shops in 1996. Cannabis use stabilised between 1996 and 1999. In addition, 
the analysis indicated a shift in supply from coffee shops to other sources. Current 
16–17-year-old cannabis users among the students in 1999 bought their cannabis less 
often in coffee shops (25.7 %) than those from 1996 (45.2 %). Logistic regression led to 
the same conclusion: the 1999 students showed a greater likelihood of buying cannabis 
outside coffee shops (an odds ratio of 0.76).
These figures are a strong indication that the higher age limit at coffee shops has indeed 
resulted in a reduction of cannabis sales to adolescents in coffee shops, in favour of 
more informal supply through friends (from 47.6 % in 1996 to 66.5 % in 1999). These 
figures are somewhat problematic as what has been reported as buying in a coffee 
shop could also mean that the respondents had someone else buy the drug there. 
Nevertheless, the data strongly suggest that raising the minimum age for coffee shops 
had an effect on buying behaviour. According to the 2003 national school survey, 
most current cannabis users among students aged 18 years buy their cannabis also or 
exclusively in coffee shops, substantially more often than younger users (Monshouwer et 
al., 2004). It is tempting to interpret the nationwide stabilisation in adolescent cannabis 
use as a result of raising the age limit. Adolescents are now more likely to obtain 
cannabis from friends and acquaintances instead of from coffee shops. Thus, at the user 
level we see an apparent displacement of the cannabis market (Korf et al., 2001).
In conclusion, trends in the lifetime prevalence of cannabis use in the Netherlands 
developed in parallel to changes in cannabis policy. Alongside the rapid growth in 
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the number of coffee shops, we observed a significant increase in prevalence rates. 
However, this does not automatically support the conclusion that decriminalisation has 
led to an increase in cannabis consumption. First of all, lifetime prevalence is often not 
an adequate indicator since it largely reflects a ‘generation effect’. Current (last month) 
use seems to be a better indicator, although from the perspective of harm reduction it 
might be argued that ‘problem use’ is an even better one. Unfortunately, there is no 
standardised indicator for problematic cannabis use.
Reasoning by analogy through cross-national comparison partly leads to conclusions 
other than MacCoun and Reuter’s (1997). In particular, their conclusion that commercial 
access — through coffee shops — is associated with growth in cannabis use has to be 
questioned. Their study largely focused on data from the USA and Nordic countries 
(Denmark and Norway). Within a Western European context, prevalence rates in 
the Nordic countries are generally rather low, with the exception of Denmark, which 
combines relatively high lifetime figures with low current use. Comparison with other 
EU countries shows striking similarities with Dutch figures on current cannabis use. 
In addition, neighbour countries, as well as the USA, report similar trends in current 
cannabis use over time. Cannabis use in neighbour countries also shows a wave-like 
development, so it seems implausible that the trends in cannabis use in the Netherlands 
were causally related to Dutch cannabis policy. It seems more likely that the parallel 
development of cannabis use with stages in the decriminalisation process in the 
Netherlands was accidental, and that trends in cannabis use were predominantly 
affected by other factors that were not unique to the Netherlands.
Most probably, these factors relate to general youth trends that make cannabis more 
or less fashionable and acceptable. We were able to include more recent figures on 
cannabis than MacCoun and Reuter, and these data show that cannabis use stabilised 
among Dutch youth in the late 1990s. At first glance, this seems to be a result of raising 
the minimum age for access to coffee shops from 16 to 18 years. However, informal 
networks of friends appear to have quickly taken over the role of coffee shops as retail 
suppliers of cannabis. Most probably, the role of such informal networks is similar 
to those in other European countries. This leads to the conclusion that regulating the 
cannabis market through law enforcement has only a marginal, if any, effect on the 
level of cannabis consumption.
The restricted role of coffee shops
As has been mentioned, most communities in the Netherlands do not have coffee 
shops at all, in particular smaller towns and villages. In 2003–2004 we conducted a 
study on the ‘non-tolerated’ sale of cannabis in the Netherlands (Korf et al., 2004). By 
non-tolerated cannabis dealers, we meant the ones outside the officially tolerated coffee 
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shops. The study focused on the retail trade and not on the coffee shop suppliers (the 
back door) or the middle and higher levels of the cannabis market.
The study was conducted in 10 municipalities with more than 40 000 inhabitants, that 
were geographically spread throughout the country and different as regards their size 
and coffee shop density (number of coffee shops per 10 000 residents). Eight of the 
municipalities had one or more coffee shops and the other two did not have any official 
coffee shop at all. Local experts were interviewed in all 10 communities, a survey 
was made among approximately 800 current cannabis users (not recruited in coffee 
shops) in seven communities and an ethnographic field study was conducted in five 
communities.
In all the municipalities we studied, there was a non-tolerated cannabis market at the 
retail level. We distinguished two main categories: fixed and mobile sale points. The 
fixed non-tolerated sales points can be divided into home dealers and under-the-counter 
dealers primarily at clubs or pubs. The mobile non-tolerated sales points can be divided 
into home delivery after cannabis is ordered by telephone (mobile phone dealers) and 
street sales in the street and at spots where people hang out (street dealers). In addition, 
there are home growers, who can be either fixed or mobile dealers.
We found that, whether or not municipalities have coffee shops, the non-tolerated sale 
of cannabis is widespread. At the retail level, the non-tolerated cannabis market was 
very similar in all the municipalities in the study, and the same sales patterns were found 
in virtually all municipalities. In the municipalities with officially tolerated coffee shops, 
an estimate of approximately 70 % of the local cannabis sales went directly through the 
coffee shops. The higher the coffee shop density, the greater their percentage of the 
local sales. In municipalities with no coffee shops or a low coffee shop density, users 
most frequently bought cannabis somewhere else, as well as in a coffee shop.
There are various reasons why non-tolerated cannabis dealers also operate in 
municipalities with coffee shops. The major reasons are the geographic distribution 
of the coffee shops, their opening hours and the minimum age they adhere to. In 
particular, it is the mobile phone dealers and home dealers who take advantage of 
the geographic gaps in the cannabis market and are mainly active in districts where 
coffee shops are rare or non-existent. Additionally, coffee shops are not open 24 hours 
a day and the non-tolerated dealers explicitly take advantage of this by being easy to 
reach customers at times when the coffee shops are closed. For minors, the minimum 
age at coffee shops is an important reason to have cannabis resin or herbal cannabis 
delivered, or to buy it on the street or from a home dealer. In addition, non-tolerated 
dealers can serve as an attractive alternative for coffee shops because users can buy 
larger quantities of cannabis, and sometimes the cannabis is sold more cheaply.
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The ‘back door’ of coffee shops: diverging policy 
options
Originally, most cannabis used in the Netherlands was cannabis resin, and until the 
mid-1980s most cannabis was imported. Due to strong improvement in cultivation 
techniques, domestically grown herbal cannabis became more and more popular. 
In the early 1990s approximately 50 % of the cannabis used in the Netherlands was 
domestically grown (Boekhoorn et al., 1995). In the second half of the 1990s, the 
popularity of domestically cultivated herbal cannabis further increased. According 
to a study among experienced cannabis users by Cohen and Sas (1998), about half 
preferred herbal cannabis, mostly ‘nederwiet’, one-quarter preferred cannabis resin and 
another quarter had no preference. In 2001, from a survey among coffee shop visitors 
in Amsterdam, it was concluded that two-thirds preferred herbal cannabis to cannabis 
resin (Korf et al., 2002).
Today, herbal cannabis is the product sold most often in coffee shops. Mostly this 
is so-called ‘nederwiet’, or home-grown herbal cannabis. In practice, this kind of 
herbal cannabis is grown indoors and only a small proportion is imported herb grown 
outdoors. Most cannabis resin is imported, predominantly from Morocco (see Gamella, 
this monograph) and only a very small proportion of the resin sold in coffee shops stems 
from indoor cultivation in the Netherlands.
The THC content of cannabis as sold in coffee shops in the Netherlands has been 
systematically monitored by the Trimbos Institute since 1999. It might be debated to 
what extent these figures are correct as there is dispute among researchers over what 
is the most appropriate method to measure THC concentrations (King et al., 2005), 
and perhaps the Dutch method generates relatively high concentrations. Nevertheless, 
while consistently applying the same laboratory techniques, the monitoring system is an 
adequate instrument to analyse trends in purity over time. THC concentrations in sold 
‘nederwiet’ more than doubled between 1999–2000 and 2003–2004, from an average 
of 8.6 % to 20.4 %. In 2004–2005 the average concentration dropped to 17.7 %, and 
17.5 % in 2005–2006, which was comparable to 2002–2003. Imported hashish showed 
an increase in THC concentration from 11–12 % in the first two years to 17–18 % in 
2002, and then remained stable. THC concentrations in imported herbal cannabis 
remained quite stable at around 6 % (Pijlman et al., 2005; Niesink et al., 2006).
The supply of coffee shops is commonly known in the Netherlands as ‘the back door’, 
even though in reality both suppliers and customers use the same door to enter the 
coffee shop. While the sale of cannabis to consumers is tolerated in coffee shops, the 
supply remains illegal and is subject to law enforcement. Although a maximum of 
500 grams ‘in stock’ is tolerated, coffee shops can still be prosecuted for sourcing the 
cannabis into their locality. Moreover, cultivation of five plants or more per person is 
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illegal. Police and the judicial authorities have increased their actions against herbal 
cannabis growers. Between 2000 and 2003, the number of cases brought to the public 
prosecutor for cannabis offences increased by more than 40 % (from 4 324 to 6 156). A 
growing number of cannabis plantations have been raided and in both 2005 and 2006 
approximately 6 000 herbal cannabis cultivation sites were dismantled, and about 2.5 
million plants confiscated and destroyed per year (Wouters et al., 2007).
When the Dutch authorities decided to decriminalise cannabis and to tolerate the retail 
sale of cannabis to consumers, they did not, and probably could not, envision that this 
would lead to the coffee shop phenomenon. The strong growth of the number of coffee 
shops — that were never intended to exist — meant that the authorities were confronted 
with a new problem. In order to cap this growth, the national government decided 
to give local communities legal instruments to regulate the number of coffee shops, 
including the option to not allow coffee shops at all. Regarding the supply side of the 
cannabis market, enforcement has focused on large-scale dealers. Interestingly, herbal 
cannabis has taken over from the once-dominant resin. While cannabis resin typically 
was, and still is, imported, herbal cannabis is today mostly domestically cultivated. 
Consequently, a shift in law enforcement can be perceived from controlling import 
to controlling cultivation within the country itself (Decorte and Boekhout van Solinge, 
2006).
While finalising this paper, two options for regulating the supply of coffee shops have 
been debated in the Netherlands. On the one hand, at a national level the Ministry of 
Justice of the previous government was a strong advocate of persistent repression of 
the illegal cultivation of cannabis in the Netherlands. On the other hand, a growing 
number of communities with coffee shops, as well as a majority in the Dutch parliament, 
have pleaded to take a further step towards decriminalisation by regulating the back 
door problem. From their perspective, the fight against international traffickers should 
be continued and intensified, while supply for the national market should become 
less profitable for criminals by allowing the cultivation of herbal cannabis under strict 
conditions for coffee shops only. Just before Christmas 2005, the Ministry of Justice 
gave up its resistance and declared to no longer block an experiment with regulated 
cultivation of herbal cannabis. With the new national government, installed early in 
2007, the future of the supply of coffee shops is an open question.
Recent developments
In 2007, the national guideline that coffee shops are not allowed to sell alcohol has 
finally been implemented in Amsterdam. As a result, most of the approximately 40 
coffee shops in Amsterdam that were also serving alcohol, have decided to stop selling 
cannabis and consequently lost their coffee shop licence.
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Also, there is a trend to be more strict on allowing coffee shops in the proximity of 
schools. The city council of Rotterdam has been the first to decide to close down 
approximately 27 of a total of 62 coffee shops, mostly in the inner city. It is to be 
expected that coffee shop owners will continue to protest in the courts against this 
decision, in particular because the city of Rotterdam has declared that the coffee shops 
to be closed will neither receive any financial compensation, nor be given a licence for a 
coffee shop elsewhere in Rotterdam.
As part of the plans of the national government to ban tobacco smoking from 
restaurants and cafes in 2008, a vivid discussion continues on the question of whether 
coffee shops should become totally smoke-free, be allowed to have a separate smoking 
facility, or will be exempt from the general anti-smoking policy.
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Chapter 10
Cannabis policy: tightening the 
ties in Denmark
Keywords: cannabis – crackdown – enforcement – Christiania – Copenhagen  
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Setting the context
Several chapters in this monograph have touched on the link between cannabis culture 
and social movements of the 1960s and 1970s. One of the remnants of this period is 
the alternative district of Christiania in Copenhagen, Denmark, recently described by 
Time-Life magazine as ‘Europe’s last commune’.
One of the features of Christiania was an open cannabis market known as Pusher Street. 
This chapter describes the events preceding and following the closure of Pusher Street 
in March 2004. The clashes between police and residents described here were more 
recently echoed in a series of incidents in May 2007, which again brought Christiania 
into the international limelight.
So how does Denmark look in terms of cannabis (1)? It has the highest reported lifetime 
prevalence of cannabis in the EU, at 31.3 % of the adult population (EMCDDA, 2005) 
and although recent use is also relatively high, with 20 % of 16- to 24-year-olds reported 
to have used cannabis in the last month (EMCDDA Danish Focal Point, 2004), it is not 
exceptionally high.
This chapter is written from a liberal perspective. Its arguments serve to illustrate the 
resistance law enforcement can face in any attempt to break from established tolerance. 
The chapter documents the considerable efforts made to close down a long-established 
drug market. These efforts were ultimately successful, although the author’s view 
(1) General information and analysis about the Danish drugs situation is compiled each year 
by the EMCDDA’s national focal point in its national report and country situation summary. 
See www.emcdda.europa.eu/index.cfm?nNodeID=435
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suggests that they may have been heavy-handed and not delivered the benefits intended 
in reducing cannabis use.
Others might take a different perspective. It could equally be argued that the authorities 
had demonstrated that public drug dealing was an unacceptable behaviour which would 
not be tolerated and that firm action could be effective. The extent to which longer term 
use of cannabis is influenced by police action is more difficult to assess. This debate 
is still ongoing and will not be resolved here. Nonetheless, enforcement clampdowns 
can be seen as a visible declaration that use of a drug is not socially condoned. Such 
‘denormalisation’ may have an impact in the longer term on the attitudes of young 
people to drug-taking.
Ongoing reporting of cannabis use in Denmark will tell us how current Danish drug 
strategy is affecting cannabis use and drug prevalence in general. This chapter makes 
interesting reading as it details the concerted efforts made to close down Pusher Street. 
Developments in Copenhagen underline the conclusion drawn by Ballotta et al. earlier. 
Although public perception is that attitudes to cannabis are becoming more liberal in 
Europe, there are plenty of examples where a tougher approach is observable.
Further reading
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ties in Denmark
Vibeke Asmussen
General background
Christiania
The self-declared free state of Christiania was set up by activists in 1971. It occupies 
34 hectares of military property in central Copenhagen. In 2004, Christiania had a 
population estimated at between 850 and 1 000 out of a population of over 500 000 in 
central Copenhagen. An eviction ruling from 1976 has never been enforced, enabling 
Christiania to develop over 30 years as a centre for alternative culture, crafts and art. 
As a rare survivor of hippie utopian culture — Time magazine recently called it ‘Europe’s 
last commune’ (2) — it has long played a role as great divider in Danish politics, 
simultaneously lauded by the left and damned by the right. Current developments in the 
late 2000s suggest that the free state’s days may be numbered: negotiations between 
Christiania and the government on its future status have been going on for the past 
three years (Asmussen, 2007).
Pusher Street
Parallel to its free state ideals, Christiania developed a lucrative criminal sideline, 
Pusher Street, which its website calls a ‘multi-million business’(3) for drugs. In 2004, the 
cannabis market included about 40 street stalls, attracting both a domestic clientele and 
cross-border drugs tourists, particularly from Sweden. Clients could openly buy drugs to 
take away, or could smoke ‘in situ’ in the street or in Christiania’s bars and cafés.
Although ‘hard drug’ sales were voluntarily banned from 1980, a 6 May 2003 report 
on Christiania by the Minister of Justice and the Minister of Defence documented links 
with organised crime and biker gangs. It also reported a ‘spillover’ effect of hard drugs 
being sold on the periphery of Christiania, if not actually within it (4) (EMCDDA Reitox 
Danish Focal Point Report, 2004). Regular police drugs seizures — not to mention the 
contested estimate of 20 kg per day, discussed below — suggest a high revenue business 
(2) Christopher Thompson, ‘Europe’s last commune braces for battle’, Time magazine, 23 July 2007. 
Available at: www.time.com/time/world/article/0,8599,1637000,00.html
(3) www.christiania.org, accessed February 2007.
(4) On 24 April 2005 a shootout among cannabis gangs left one dead and three injured.
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with efficient logistics, where daily deliveries were made to the point-of-sale. Moreover, 
experience with arrests of dealers over two decades revealed Pusher Street’s resilience to 
controls: points-of-sale were restaffed and replenished within hours of police action. The 
May 2003 report concluded that extraordinarily high police resources, most likely for a 
sustained duration, were needed.
While for many years Pusher Street was effectively a no-go area for uniformed police 
patrol routines, surveillance and arrests in the area intensified throughout the early 
2000s as the Ministry of Justice and the Copenhagen Metropolitan Police Force sought 
to ‘normalise’ conditions for drug dealers in line with the rest of the city (EMCDDA 
Danish Focal Point, 2004). Increased policing of Christiania was accompanied by the 
nationwide tightening in 2004 of legislative controls over cannabis in Denmark, aimed 
at curbing both dealing and personal possession of cannabis (EMCDDA ELDD, 2006).
The culmination of police actions in Pusher Street was the March 2004 operation to 
‘close’ the market and arrest its dealers. This chapter describes the nature of the police 
action in March 2004, together with the judicial process and convictions that followed 
it, as reported in the Danish press (5). It also discusses the political background to the 
government’s official policy on drugs, launched in 2003, The Fight against Drugs.
Danish drug policy 2001–2005: legal tightening
In the course of the 2000s, Denmark has experienced a tightening in drug policy — and 
cannabis policy in particular — from a liberal to a relatively repressive regime.
2001’s Law Prohibiting Visitors to Designated Places (popularly called ‘the Hash-
Club Law’) was proposed as a response to a moral panic about youths frequenting 
underground ‘hash clubs’ (6) (Asmussen and Moesby-Johansen, 2004). The new law 
enabled police to clamp down on hash clubs, and has since been reinterpreted in 2005 
to make it even easier to close down hash clubs. The number of offences that the police 
needed in order to close a hash club was reduced from 10–15 to 3–5.
2004’s Law on Euphoria-inducing Substances was revised to criminalise possession 
of cannabis. While possession of less than 10 grams of cannabis was not prosecuted 
(5) Descriptions of the arrests, trials and sentences are based on a corpus of newspaper articles published 
between March 2004 and July 2005 in three Danish newspapers: Jyllands-Posten, Berlingske Tidende 
and Politiken. A second source of information — a description of the sentences handed out — is 
taken from the Copenhagen City Court’s website (www.domstol.dk/). For a detailed description of 
the closure of Pusher Street, see Asmussen, 2007.
(6) Hash clubs are illicit speakeasies at private addresses where cannabis can be bought. The hash club 
law states that an apartment’s inhabitant can be forbidden to receive visitors if he or she is known 
‘to practice a systematically illegal business which can disturb and endanger his neighbours’.
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before the revision, it is now punished with the minimum of a fine. It is thus illegal 
to possess any amount of drugs, cannabis included, in Denmark. At the same time, 
another part of the Law on Euphoria-inducing Substances was revised. Penalties were 
increased from a fine to a prison term ‘if drug dealing is performed with children and 
young people under the age of 18 years’ at discos, clubs or music festivals.
Also in 2004, prison sentences for drug crimes were raised during revisions to The 
Prison Law. The maximum prison sentences for drug crimes were raised from 6 to 10 
years, for serious drug crimes (trafficking and dealing) from 10 to 16 years, with even 
sentences of up to 24 years for particularly serious drug crimes (Storgaard, 2005).
The swing towards repression is not an entirely new phenomenon (7). Storgaard (2005) 
argues that drugs policy — about different control policies for users versus dealers, ‘soft’ 
drugs versus ‘hard’ drugs, etc. — has been a permanent parliamentary battlefield in 
Denmark over the last 30 years, with the liberal-conservative and the centre-left wing, 
headed by the Social Democratic Party, in opposing camps (Storgaard, 2005). The 
centre-left’s position dominated Danish drug policy until 2001. For example, from 1969 
to 2004 possession of up to 10 grams of cannabis for personal use was not prosecuted, 
and onus was placed on combating hard drugs and organised crime, with a blind eye 
being turned towards small-scale cannabis sales (Grytnes, 2003).
Since the liberal-conservative government came into power in 2001, its self-styled 
‘zero-tolerance’ policy has been to tighten the legal control of drug crimes and to raise 
the penalties for drug offences, while also increasing access to treatment, particularly 
in prisons. Moreover, its action plan, The Fight against Drugs, explicitly removes the 
distinction between seller and buyer, stating that the drug policy targets both supply and 
demand side, drug dealers and drug users (Danish Government, 2003). The action plan 
also prioritises actions that protect youths from drug misuse.
Party political divides should also be placed in the context of growing responsiveness 
to media ‘hot button’ issues, with drugs suffering both negative connotations on one 
hand and a stranglehold on headlines on the other (Christie and Bruun, 1985). Thus, 
the first new legal instrument, the Hash Club Law, was as much the work of the former 
social democratic government as of the new liberal-conservative government. Moreover, 
at the same time that laws were tightened, liberalising proposals by the centre-left 
opposition — respectively to decriminalise cannabis on almost the same terms as the 
Netherlands, to implement safe injection rooms, and to implement heroin trials — were 
all overturned, suggesting a general hostile climate towards liberalisation.
(7) On the Danish drug policy combating hard drugs in the 1990s and the effects it had on hard drug 
users see, for example Frantszen (2003) and Laursen and Jepsen (2002).
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So what does this legal tightening mean in practice? First, the former differentiation 
between users and dealers, ‘soft’ drugs and ‘hard’ drugs is no longer the heart of 
Danish drug policy. Use of any drug is perceived as drug misuse, and in particular, 
use of cannabis is now criminalised. This effectively brings the appreciable numbers of 
cannabis consumers in Denmark within reach of prosecution (EMCDDA Danish Focal 
Point, 2005; Storgaard, 2005).
Another aspect of these changes is the concern for young people. On the one hand, 
adolescent drug users have been criminalised by the legislation covering possession of 
cannabis for personal use. On the other hand, they are protected by the revision of drug 
dealing to young people and the closure of illicit dealing premises under the Hash Club 
Law (Asmussen and Moesby-Johansen, 2004).
Finally, sentences for drug crimes have been raised and can be compared to sentences 
for manslaughter and homicide. The former focus in Danish drug policy on organised 
crime is now also widened and includes ‘zero tolerance’ towards all kinds of dealers. 
It is this last change which provided the leverage to police to tackle the long-standing 
quandary of Pusher Street.
The Pusher Street raid: 50 cannabis dealers and security guards 
arrested
The date 16 March 2004 represents a milestone in Danish drug policy. At 5 am police 
action to close down Pusher Street began. Bulldozers and several hundred armed police 
officers entered Christiania and removed the small wooden, zinc-roofed stalls where 
cannabis was sold (Asmussen, 2007). Simultaneously, over 50 cannabis dealers and 
security guards were arrested in different locations in Copenhagen and remanded in 
custody. Major police actions had occurred in Christiania before, as Laursen (1996) 
and the EMCDDA Danish Focal Point (2005) point out, but this was the first time that 
a police action was planned so thoroughly with the aim to actually close down Pusher 
Street. This was also the first time so many dealers (and security guards) were arrested 
simultaneously.
Surveillance of Pusher Street was carried out by police between October 2003 
and March 2004, involving videotaping of Pusher Street and the tapping of radio 
communication and phone calls. Tapped phone calls and radio communications were 
especially important in enabling the police to charge people for being members of, 
or employed by, a private security force that warned the dealers and customers about 
police activity. This security force was dubbed Christiania’s Intelligence Service by the 
police, and it represented a key argument for the police, the judges, and prosecutors 
in categorising Pusher Street as ‘well organised’. The police claimed the security force 
was regimented into six posts in different parts of Christiania from where guards could 
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warn dealers if the police were approaching. Police argued that the guards worked in 
shifts from these posts and communicated via radio and cell phones, substantiating 
claims with both tapped phone calls and radio communications between the guards 
and with a duty roster found in one of the managers’ houses. The duty roster consisted 
of initials of the guards, their phone numbers and a list of day and evening shifts. The 
police also worked as undercover agents, buying cannabis at the stalls in Pusher Street. 
Swedish and Norwegian policemen were used together with the Danish police. Using 
undercover police as a method of investigation is exceptional in Danish police work 
and requires court permission. With the videotapes and the undercover police work the 
police systematically registered the dealers that operated from the different stalls. It was 
on the basis of the videotapes and the undercover police work that the police estimated 
that about 3.6 tonnes of cannabis was sold in Pusher Street during the six months of 
surveillance. The amount was, however, disputed by the defence lawyers as well as by 
the defendants, and the judges later found these calculations too uncertain.
The pre-trial detention
The dealers and security guards arrested on 16 March were remanded in custody in 
solitary confinement by the City Court of Copenhagen. The pre-trial detention was 
prolonged multiple times on the grounds that the police needed time to investigate and 
prepare the trials. A few were released after two months, but about 40 of the defendants 
spent three months in solitary confinement, the legal upper limit for solitary confinement 
in Denmark. At the same time, the pre-trial procedures were held behind closed doors 
on account of police investigations. In July several of the dealers were discharged, but 
during the summer and autumn of 2004 the City Court continued to prolong pre-trial 
detention, three to four weeks at a time, with the security guards in particular having 
their custody prolonged. Five months after 16 March, 36 defendants were still in 
custody. On several occasions when a defendant was discharged by the City Court the 
prosecutor immediately appealed to the High Court, who on all occasions decided to 
confirm the prolonged pre-trial detentions. The defence attorneys protested each time 
the City Court prolonged the pre-trial detentions, and called into question the closed 
doors at the pre-trial procedures.
Since the court meetings were held behind closed doors the detailed arguments behind 
the prolongations were kept secret from the public. The only reason given was that the 
defendants could jeopardise the police investigations as well as the presumed risk that 
the defendants would take up their criminal activities again, that is, dealing cannabis, 
and this risk was considered especially high since they were ‘well organised’.
In the beginning of September one of the defence lawyers received permission from 
the Danish Board of Appeal Permission to try one of the cases with the long pre-trial 
detentions in the Supreme Court. In late November the Supreme Court confirmed 
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the decision made by the High Court that the defendants should continue to be in 
custody. The reason given was, again, that the cannabis sale had been extensive and 
well organised, which was reason enough to keep them in custody. Therefore, in late 
November 2004, 36 of the initial 50 defendants were still in custody. They had at 
that time been in custody for almost nine months. Media reports mentioned two of the 
defendants in custody that were affected by illness. One suffered from claustrophobia, 
the other had gained 23 kg, and as a consequence suffered repeatedly from thrombosis 
in his legs. These cases were reported in the news because their defence lawyer 
complained about the defendants being in custody while suffering different forms 
of illnesses. The City Court in Copenhagen discharged the two defendants, but the 
prosecutor appealed to the High Court. Here, one was discharged, the other one who 
suffered from claustrophobia was moved to a larger cell and maintained in custody.
The charges
The defendants were charged as dealers or as security guards. The dealers were 
charged with extensive cannabis dealing from stalls in Pusher Street and for having sold 
between 25 and 150 kg of cannabis in the period the police held Pusher Street under 
surveillance. The amount that each individual dealer was charged with was based on 
calculations made from the surveillance and the undercover police work. The dealers 
were ‘and could only be’ charged for the amount of cannabis they had sold themselves, 
that is, for specific dealing. Thirty of the defendants were charged as dealers, and some 
were facing up to three-and-a-half years of imprisonment.
The security guards did not sell cannabis themselves but secured that all the dealers 
could run their business, and were therefore charged for complicity. The police 
calculated that 20 kg of cannabis was sold every day in Pusher Street and multiplied this 
by the days the police monitored Pusher Street, resulting in total sales of several tonnes 
of cannabis. Since the guards worked on a structured duty roster in day and evening 
shifts, they could be charged collectively, and thus faced up to four years’ imprisonment.
This was the first time in Denmark that persons were charged collectively for drug 
crimes. The police claimed that the security force during the preceding years had 
developed from individual persons warning cannabis dealers with whistles if the police 
were in the neighbourhood, to a structured force with duty rosters, managers organising 
the shifts, and payment by the dealers, thus making guarding a lucrative business. The 
defendants themselves, however, described themselves as a kind of ‘buffer’ between the 
police and the dealers in Christiania, ensuring that any trouble accompanying police 
presence in Christiania did not escalate. They also claimed that they ensured hard 
drugs or biker gang members did not appear in Christiania. This was highlighted by 
the defence lawyers, who also denied the existence of a formal Christiania Intelligence 
Service.
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The trials and sentences
At the end of August 2004 the first trial began. Two dealers — a stallkeeper and a 
helper — were charged with having sold 114 and 30 kg of cannabis respectively. 
However, the sentences that the two dealers received in December only convicted them 
for selling 25 and 10 kg of cannabis respectively, with accompanying prison sentences of 
one-and-a-half years and one year. The method of calculation that the police had used 
was accepted by the judges, but only in part: they accepted what was to be seen on 
the videotapes and the testimonies from the undercover policemen, but in general the 
means of calculating what was sold from the stalls in the whole period was deemed too 
uncertain. After this first trial, 10 of the defendants that were charged with having sold 
less than 40 kg of cannabis were released from custody by the City Court on the account 
that the sentence would no longer be equivalent with the pre-trial detention.
Throughout December 2004 and January 2005 the rest of the dealers were convicted. 
However, it was not until the end of May 2005 that the last trial ended. The dealers were 
all convicted for having sold less cannabis than they were charged with. They received 
sentences of between 30 days and 2 years and 6 months. In total, the convicted dealers 
got 35 years of imprisonment. Only one defendant was found not guilty.
The joint trial against the security guards began in May 2005. Seventeen persons 
were charged for being security guards in the Christiania Intelligence Service and 
three were charged for being managers of the service. The latter organised the shifts, 
supervised the security guards and collected money from the cannabis dealers. All the 
defendants pleaded not guilty to the charges. Based on tapped phone calls and radio 
communication between the guards and the three managers, the City Court found 
all guards, but only two of the three managers guilty. The two managers received a 
two-and-a-half years prison sentence each. The security guards got a sentence between 
one and two-and-a-half years, depending on how long they had been employed in the 
security force. In total, the 19 defendants received 34 years of imprisonment.
Concluding remarks
This report of the arrested dealers and security guards illustrates how the Danish 
government’s ‘zero-tolerance’ drugs policy is implemented in practice. The closure of 
Pusher Street was clearly a ‘show of strength’, as seen in the Ministry of Justice and 
Ministry of Defence report submitted in 2003, detailed planning by police, the use of 
undercover agents, the simultaneous arrest of so many dealers and security guards, the 
involvement of detectives from Norway and Sweden, etc. Also unusual was the use of the 
upper level of solitary confinement (three months), as well as of extremely long pre-trial 
detentions (up to 10 months) for what in effect was retail street dealing rather than 
wholesale trafficking of drugs.
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In terms of police success, the convictions could be viewed as a mixed bag. Many 
of the dealer defendants were discharged after sentence for time served in pre-trial 
custody, with none being convicted of selling the full volume of cannabis claimed by 
police. Conversely, the collective charging of the security guards resulted in all but 
one being found guilty as charged. This latter result highlights the extension of Danish 
drug legislation beyond dealers towards those aiding and abetting drug sales, and the 
lowering of the threshold for what is considered ‘organised’ and ‘well organised’ drug 
crime.
One can question the rationale behind the sudden departure from the ‘blind eye’ that 
was turned to cannabis dealing for about 30 years in Pusher Street. Nothing indicates 
that cannabis dealing had changed or increased in years preceding before the closure 
of Pusher Street. Moreover, when denying the existence of the Christiania Intelligence 
Service the defence lawyers pointed to the self-regulation within Christiania with 
regard to hard drugs, even the cooperation of individuals as mediators during any 
confrontations between police and dealers. The clampdown must therefore be viewed 
as a political and ‘moral’ change in attitude rather than a change in cannabis dealing 
practice.
The most important question is, what effect did closing Pusher Street have? Not much, 
it seems. Cannabis dealing is still carried out in Christiania, according to the police 
as well as personal observation. However, cannabis dealing no longer occurs in 
public from small stalls in Pusher Street, but more discreetly from person to person. In 
Copenhagen in general there is also just as much cannabis circulating, both according 
to the police and the Municipality of Copenhagen. However, the market has dispersed 
into many different and new areas, with some anxiety that cannabis is now even more 
easily available to young people (Asmussen, 2007).
So, the recent change in Danish drug policy seems to follow what scholars on drug 
policy like Kilmer (2002) and Korf (2002) in general argue: drug policy, whether 
repressive or liberal, does not influence either a decrease or an increase of cannabis 
use. The closure of Pusher Street is more an example of how a government pursues a 
‘zero tolerance’ policy rather than a serious attempt to solve drug problems. Seen in the 
context of the gradual dismantling of the Christiania commune, it can also be viewed as 
a moral rejection of laissez-faire.
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Chapter 11
Cannabis: a harm reduction 
perspective
Keywords: cannabis – education – harm reduction – information – vaporisers
Setting the context
‘Harm reduction’ means many things to many people. A useful and concise definition 
is provided by the UN’s Glossary of Terms on Demand Reduction (1), which mentions 
‘policies or programmes that focus on reducing the harm resulting from the use of 
alcohol or other drugs, both to the individual and larger community (...) without 
necessarily requiring abstinence’. The definition clarifies that harm reduction may 
‘precede subsequent efforts to achieve total abstinence’ and ‘is neutral regarding the 
wisdom or morality of continued drug use and should not be synonymous with moves to 
legalize, decriminalize or promote drug use’.
With regard to cannabis, harm reduction is more difficult to define than, say, 
programmes to reduce needle injuries, hepatitis and HIV transmission among 
heroin users. One problem is that harm reduction for cannabis is often a bottom-up 
phenomenon that is delivered via unofficial rather than governmental or central sources, 
for example, cannabis magazines, websites and headshops. Harm reduction is also 
transferred via word of mouth. Long before a user comes into contact with a drugs 
professional, information will be delivered by dealers, fellow cannabis users, peers and 
siblings.
Among the more formal harm reduction programmes, there is considerable overlap 
across harm reduction, prevention and early treatment interventions. For example, 
low threshold interventions such as drugs helplines, the Jellinek self-screening test 
and French cannabisetconduite.fr campaign (see Burkhart, and Beck and Legleye, 
(1) UNDCCP (2000), Demand reduction: a glossary of terms, UNODCCP, Vienna. Available at: 
www.unodc.org/pdf/report_2000-11-30_1.pdf
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this monograph) could be loosely defined as harm reduction initiatives. Although the 
nature of harm reduction programmes varies greatly across the EU, many programmes 
borrow from the fields of alcohol and tobacco. Actions include advice on safer modes 
of administration (e.g. on the use of vaporisers, on rolling safer joints, on less risky 
modes of inhaling); skills to prevent confrontation with those who disapprove of use; 
encouraging users to moderate their use; discouraging mixing cannabis with other 
drugs; drug driving prevention and controls; reducing third-party exposure to second-
hand smoke; education about spotting signs of problematic use; and self-screening for 
problematic use.
First and foremost, harm reduction centres on helping users to make informed 
decisions with information that is understandable, accurate and non-judgemental. 
For example, a recent initiative, the Evidence-based Electronic Library for Drugs and 
Addiction (EELDA) (2), attempts to filter the huge body of scientific literature on cannabis, 
cocaine and ecstasy into a more accessible format using relatively simple language. It 
includes discussion of the risks of cannabis use as it relates to medical conditions (while 
pregnant, if epileptic, if suffering from liver, lung or heart problems) and to specific use 
settings (at work, when driving).
This chapter focuses on specific work on harm reduction at the HIT project in the United 
Kingdom. Its discussion of the need to communicate effectively, to empathise with 
cannabis users and to understand the motivations for using cannabis will be relevant to 
drugs practitioners everywhere.
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cannabis and THC’, Journal of Cannabis Therapeutics 1 (3).
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Cannabis: a harm reduction 
perspective
Andrew Bennett
Harm reduction forms a part of many European countries’ response to licit and illicit 
drug use: drinkers are advised to consume alcohol at safe levels; heroin users receive 
substitute drugs such as methadone; and drug injectors are encouraged to use clean 
injecting equipment.
Defining harm reduction
There is not a generally accepted definition of harm reduction. Historically, the main 
stimulus to the development of harm reduction policies and programmes was the 
identification of the role of injecting drug use and the sharing of needles and syringes 
in the transmission of HIV (Hunt, 2003). This led to the introduction of a range of 
practical initiatives such as needle and exchange schemes, low threshold services and 
programmes offering safer injecting advice. Thus, harm reduction strategies were seen 
as concerned with providing services to drug users at the individual level intending 
to reduce risk or rates of harm (e.g. needle exchange), while also aiming to reduce 
harm to others, e.g. preventing HIV among the wider community; and reducing public 
nuisance connected to drug taking.
Harm reduction definitions often do not describe whose harm should take priority: the 
user, the family or the wider community, and what type of harm it refers to — health, 
social, economic. Harm reduction also posits that individuals are able to make rational 
decisions about their behaviour. Once informed about the risks associated with drug use 
and how to avoid them, drug users are expected to be able to act on this information 
(Rhodes, 2002). While some commentators have seen abstinence as an ideal goal, most 
harm reduction strategies do not require abstinence.
Swift et al. (2004) provide practical criteria for assessing whether a policy or programme 
practises harm reduction that encompasses some of the above key points. Their central 
defining characteristic of harm reduction is the reduction of harm as a primary goal 
rather than the reduction of use per se. It must include strategies for those that continue 
to use as well as those aimed at reduction of use or abstinence. There should also be 
some attempt to evaluate whether these strategies will result in a net reduction in drug-
related harm.
Cannabis: a harm reduction perspective
174
While harm reduction is often associated with schemes to reduce the harms of opioid 
use, strategies have also addressed other substances, in particular tobacco and alcohol. 
These include alcohol campaigns promoting sensible drinking and discouraging drink 
driving, training bar staff and door staff in avoiding incidents of drunkenness, and 
public space smoking bans to reduce people’s exposure to second-hand smoke. While 
experience and practical measures are still limited, harm reduction may also have a role 
to play in helping with cannabis-related problems.
Health-related harm reduction and cannabis
Information, education and communication
Citizens in the EU will have varying degrees of access to a range of materials and media 
designed to impart knowledge about cannabis. However, drug related information, 
education and communication is an area of practice that is widespread yet seriously 
under-researched. In his review of harm reduction research, Hunt concludes that the 
existing evidence says very little about what sort of approaches work; for whom; to what 
extent; and whether they are cost-effective (Hunt, 2003).
In the United Kingdom, a small number of government-funded but independent 
organisations, such as DrugScope, HIT and Lifeline, produce and distribute booklets, 
leaflets and posters; host websites; and run multi-component campaigns that focus 
specifically on cannabis or include cannabis amongst other drug communications. 
Schools have a mandatory responsibility to educate young people about drugs, 
including cannabis. While guidance exists regarding school-based education and 
drug communication, the nature and extent of both activities can vary enormously. 
Increasingly, much health information is disseminated through non-official channels. 
Cannabis users, activists, ‘headshops’ and seed suppliers inform and educate about 
cannabis. Increasingly, websites and other multimedia publications offer information on 
the health effects of cannabis (3).
Information, education and communication approaches are not necessarily strategies of 
harm reduction.
Producing information materials that aim to reduce harm rather than prevent use per 
se is challenging, especially when the target audience is young people. Politicians, 
the media, parents and others can easily misconstrue a resource as condoning or 
(3) While web resources on cannabis vary greatly, some sites offer strong harm reduction materials, 
for example www.seedsman.com/en/health/cannabis-and-health and http://en.eelda.org/index.
aspx?o=5809
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encouraging drug use. Below is an extract from HIT’s The Stuff on Cannabis booklet, 
which is aimed at young people aged 14 and above. The objective of the booklet 
(in its entirety and not just the extract) is to provide accurate, acceptable and useful 
information about cannabis for young people. The goal of the resource is to reduce 
harm.
To avoid the dangers of cannabis:
Don’t use it. But if people do use cannabis the advice is ...
Don’t take too much or use too often. Don’t smoke every day.
Be aware that some types are very strong and could make you feel bad.
Remember it is still illegal and you could get into trouble with the law.
Don’t smoke it with tobacco.
Avoid using it when you feel really down. It will probably make you feel worse.
Don’t operate machinery or drive whilst stoned.
Avoid sexual situations you may later regret. If you have sex, use condoms.
Don’t take other drugs at the same time, particularly alcohol. Mixing drugs can be dangerous.
If you are trying to cut down or stop, avoid people using it and places where they go.
© 2005 HIT UK Ltd
Consumption methods and techniques
The potential long-term harmful consequences of cannabis use are strongly related 
with the consumption method, that is respiratory risks associated with smoking the drug 
without, or simultaneously with, tobacco. A UK House of Lords Cannabis Report (1998) 
proposed the following hierarchy of risk:
Smoking a cannabis and tobacco joint is the most risky way of using the drug because the tars 
and toxins (plus the cigarette paper) is inhaled. Smoking a cannabis only joint enables the user 
to avoid inhaling tobacco. If cannabis is smoked in a pipe, no papers are burnt and inhaled 
and a proportion of tars and toxins may remain in the pipe. Water pipes or bongs may have 
advantages since the smoke will be inhaled at a cooler temperature and some tars may 
remain suspended in the water. Vaporisers are designed to heat cannabis to a point where the 
THC will be released without the plant combusting. Finally, the respiratory risks of cannabis 
smoking would be completely eliminated if users adopted oral methods of use.
Although research shows that cannabis may be a risk factor for the development of 
respiratory-related diseases (see Witton, this monograph), cannabis smoking is not 
thought to have a major public health impact on respiratory risks, including cancer, 
because most cannabis users stop their use in their 20s, few smoke more than a few 
joints in each session and the number of people who use in a chronic way is currently 
relatively small (Hall and MacPhee, 2002).
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Nonetheless, recent information of the comparative pulmonary risks of cannabis 
smoking vis-à-vis cannabis smoking has improved, and suggests that cannabis has 
a similar effect on airflow obstruction to the lungs of two-and-a-half to five cigarettes 
(Aldington et al., 2007). Moreover, the low overall impact of cannabis smoking assumes 
that existing low-intensity patterns of use, together with a tendency for users to quit 
in their 20s, will continue. If more people smoked cannabis more frequently and for 
longer periods of their lives, the public health impact associated with respiratory-related 
diseases would be greater. It is also important to consider that cannabis consumption 
affects public health in other ways, for example its contribution to mental health 
problems and the consequences to users of a criminal conviction.
A number of cannabis resources provide information about specific techniques and tips 
that may reduce potential harm linked to airflow obstruction and inhalation of toxins. 
The rationale for such advice by necessity is often based on ‘common sense’ rather than 
research evidence. Below is an extract from HIT’s cannabis booklet, which is aimed at 
cannabis users aged 16 and above.
You should:
Avoid holding the smoke in your lungs – you won’t get any more stoned and this just makes 
more tar and other dangerous chemicals stick to your lungs.
Avoid inhaling too deeply – sucking on a bong or buckets may cool the smoke, but it forces it 
deeper into your lungs, so you breathe in more tar.
Clean weed properly – the bulk of THC is in the sticky tops and flowers, so you should take 
out the stem, leaves and other bits.
Avoid using a cigarette filter for a roach – filters may reduce the amount of THC you smoke. 
As a result you inhale more deeply which may increase the amount of tar you breathe. Avoid 
using anything printed (printers’ ink gives off dangerous fumes when heated). A piece of plain 
card, loosely rolled up for a roach, allows the smoke to flow easily.
Avoid using too many papers — three-skinners are big enough and you will inhale less burnt 
paper.
Avoid using plastic bottles, rubber hoses, PVC, aluminium or foil to smoke cannabis — these 
all give off toxic fumes when hot (you run fewer health risks with a pipe made from glass, steal 
or brass.
Clean bongs and pipes properly after use – germs can hang around long enough to infect you 
and your friends.
Warning: Just because you like to get high, it doesn’t mean everyone does. Show some respect 
and don’t smoke around others, particularly children, who may be affected by you sparking 
up.
© 1999–2005 HIT UK Ltd
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Assessing the evidence that one mode of consumption is safer than 
another
In theory, the risk of damage to the respiratory system could be reduced if users 
adopted consumption methods and techniques that reduced the inhalation of cannabis 
(and tobacco) and related tars and toxins. The evidence for proposing that one mode of 
consumption is safer than another is, however, limited.
Laboratory studies suggested vaporisers provided the safest delivery of cannabis when 
compared with unfiltered and filtered joints and waterpipes (Gieringer, 1996; 2001). 
Vaporisers heat cannabis to temperatures between 180°C and 200°C and above, 
enabling the release of THC and other cannabinoids as a fine mist while reducing 
the toxic byproducts of smoked cannabis. While vaporisers are becoming increasingly 
available for cannabis smokers, a need for a safe delivery mode for therapeutic 
cannabis products have also prompted interest in this technology.
Perhaps surprisingly, the unfiltered joint ‘performed better’ than the waterpipes, that is, 
the ratio of THC to tar was less in an unfiltered joint compared with the waterpipes. The 
performance of the filtered joint was similar to the waterpipe, that is, the filter reduces 
the amount of THC, thus leading to the user inhaling more vigorously, resulting in 
increasing the amount of tars. The two vaporisers performed better than the unfiltered 
joint. A follow-up study by Gieringer (2001) confirmed that vaporisers offer the best 
prospects for reducing the harm from cannabis smoke. However, the researchers stress 
caution with these findings. They point out that the findings in the laboratory may not be 
reflected in humans, for example, the potency of cannabis used may be different than 
street cannabis.
Further research has been done on vaporisers as a delivery method. A laboratory study 
found that a vaporisation device provided an efficient and reproducible mode of delivery 
of THC (Hazekamp et al., 2006). A further pilot human laboratory study comparing a 
vaporiser to smoked cannabis found that the vaporiser was as effective as delivering 
THC but with little or no increase in carbon monoxide levels, a marker for toxins that 
may be generated by smoking (Abrams et al., 2007). Further suggestive evidence for 
the value of vaporisers emerged from a large Internet survey, which found that the 
use of vaporisers was associated with fewer respiratory symptoms than other modes of 
delivery used by respondents, although the self-selecting nature of the sample and the 
self-report basis of the data limits the generalisability of the study’s findings (Earleywine 
and Barnwell, 2007).
This may have important health implications if, as is reported in Australia, users believe 
waterpipes are ‘safer’ because the water cools the smoke and dissolves some tar 
(Hall and Solowij, 1998). The study raised concerns about waterpipes not necessarily 
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protecting users from dangerous tars since they filter out more psychoactive THC than 
they do tars, thereby requiring users to smoke more to get the desired effect. The 
research raises doubts about the likelihood of an improved high by using waterpipes 
because some of the THC is lost in the water. However, as Gieringer (1996) and Iversen 
(2000) recognise, this ‘loss’ may be compensated by simply using more cannabis and 
holding the fumes in the lungs for longer periods.
Some studies also highlight the possibility that increased cannabis potency may have 
a potentially protective effect, since the concentration of tars relative to THC will be 
reduced. If this is the case, it would suggest a contradictory perspective to that which is 
most commonly highlighted in scientific and popular debate regarding increased THC 
potency, namely that potency increase causes increased adverse health effects (Hall and 
Swift, 2000; see also King, this monograph).
Will cannabis users adopt safer ways of administration?
The consumption modes significantly associated with respiratory risks — cannabis and 
tobacco joint or cannabis joint — are the most frequently used in Europe. Conversely, 
only a minority of cannabis users choose to vaporise or swallow the drug as their main 
method of use, even though they offer a means to avoid respiratory risks. Hence, it is 
important to pose the question: will users adopt safer ways of administration?
Smoking is an effective way of delivering drugs to the brain and the rapid delivery of 
the drug to the brain by smoking seems to be an important factor in determining the 
subjective experience of the ‘high’ (Iversen, 2000). The effects are felt almost instantly 
and it is relatively easy to control or titrate the dose, for example if the cannabis is 
stronger than anticipated, the user will know this within a matter of seconds. By contrast, 
taking cannabis by the mouth is less reliable in delivering a consistent dose of the drug. 
Most of the drug when swallowed will be processed in the liver before general circulation 
takes it to the brain. The peak levels of the drug, and thus the ‘high’, will occur 1–4 
hours after taking the drug (Stafford, 1992; see also Corrigan, this monograph).
However, the behaviours and consequences of cannabis consumption are not just 
determined by the drug and its method of use. Individual beliefs, expectations and 
reasons for using, as well as the social environment in which it is used, are also 
important. Surprisingly, there is a limited amount of research that explores the social 
context, use preferences and roles of cannabis use. Research that did explore the 
functions and pathways of young adult drug takers in Salford in the United Kingdom 
illustrates that different modes of cannabis consumption produce different effects.
I don’t really take buckets (4) cos they don’t really agree with me, the rush is too fast. It hits me 
too quick. I like to get it gradually. I’ll have a bong cos it don’t hit you as fast. Spliffs are just 
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brilliant because you get everything out of it, you get all the feeling. Buckets you don’t cos it 
just hits you and then it’s gone. Bongs hit you slow but it don’t last long.
20-year-old unemployed female, as quoted in Henderson (1995).
In a Mixmag (2002) (5) article a ‘willing guinea pig examines the merits of spliffs, bongs 
and cakes’. In response to the question ‘how long till you’re battered?’ the guinea pig 
answers ‘two minutes’ (spliff), ‘little under a minute’ (bong) and ‘two hours’ (cake). In 
response to the question, ‘how long do you feel caned for?’ the subject answers ‘two 
hours’ (spliff), ‘no idea ... in the morning I realise it had lasted six hours’ (bong) and 
‘fucking ages. I’m useless for eight hours’ (cakes).
Bell et al.’s (1998) research focuses on the role of friendship groups as a means of 
initial contact with cannabis, and learning about its use in the context of transitions to 
adulthood. He argues that understanding the social context of cannabis use involves 
examining their explanations for cannabis use, the methods of use, the physical location 
and the time they take it, and the social group it occurs within. Examples are provided of 
young people experimenting with a range of methods of using cannabis, and different 
ways of getting a ‘hit’, sometimes with unintended consequences, as one interviewee 
explains:
I was cookin’ it and that, yeah, an’ I didnae get to ma bed til aboot 4 am, ken and I didnae 
feel quite right ken, I woke up in the morning and I was still the same.(6)
Research conducted by Bennett (2002) explored the reasons why people use cannabis 
in the way they do and discussed the public health implications of the findings. It was 
concluded that a range of factors negate against the adoption of safer consumption 
methods. Cannabis, when inhaled in the form of a joint or spliff, is controllable in 
terms of the severity and length of the effect when compared with using bongs and 
vaporisers or eating the drug. Preparing and sharing joints is routine and a social 
activity. Alternative methods of smoking, including bongs and vaporisers, involve using 
other paraphernalia that may be inconvenient to use and expensive to buy. Further 
research that examines the different nuances and complexities of cannabis use, including 
consumption methods and techniques, is needed.
(4) ‘Buckets’ is a way of smoking cannabis in the UK. Usually, the cannabis smoke is captured in a plastic 
bottle with the bottom cut off. The plastic bottle is then pushed down into water (often in a bucket), 
thus causing the cannabis smoke to be released very quickly through the top of the bottle in relatively 
large amounts. The smoke is then inhaled.
(5) Mixmag is a UK dance magazine. The phrase ‘how long till you’re battered?’ means, how long 
before you feel the effect of the cannabis; and ‘how long do you feel caned for?’ means, how long 
do the effects last.
(6) The extract is in the local dialect. The word ‘cookin’ refers to preparing cannabis in food; and ‘ken’ 
should read ‘know what I mean’.
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Cannabis and tobacco: double trouble?
It has been estimated that 70 % of cannabis users in the United Kingdom smoke with 
tobacco (Atha and Blandchard, 1997). Two qualitative studies in Scotland with 15- to 
19-year-olds have identified three links between cannabis and tobacco (Amos et al., 
2004) (7). These are:
Cannabis is linked to starting tobacco consumption — ‘I hadn’t smoked at all, but •	
... I got into that (hash) and then that made me get addicted to tobacco.’
Cannabis can reinforce tobacco consumption — ‘if you’ve no’ got any hash, you •	
just smoke your fags.’
Cannabis can make giving-up tobacco more difficult – ‘I’ve tried to stop smoking •	
but ... you cannae go without a fag ... you need it for your hash.’
Recognising the cannabis-tobacco link, Health Scotland published a booklet for young 
people titled Fags ‘n’ Hash: the essential guide to cutting down the risks of using tobacco 
and cannabis. In some parts of the United Kingdom, the National Health Service 
tobacco smoking cessation services are incorporating cannabis within their interventions 
with adults. Faced with the difficulties in promoting safer cannabis use, secondary 
prevention and treatment approaches aimed at controlling, cutting down or stopping 
consumption could also be seen as a plausible harm reduction technique.
A number of countries have recently developed and implemented interventions designed 
to enable heavy, frequent users to reduce or stop their cannabis use. In the UK the 
government in 2004 launched the Know Cannabis campaign to enable users to cut 
down or stop their cannabis consumption. The multi-component campaign included 
leaflets, posters, A Guide to Cutting Down or Stopping Cannabis and a self-help 
website (8). In the Netherlands a self-help website has been in existence for a number 
of years (9). These interventions use cognitive behavioural approaches, and include: 
assessment of the benefits and costs of cannabis; planning and preparing for change; 
setting targets; identifying high-risk situations; dealing with withdrawal; and relapse 
prevention.
The above types of secondary prevention or treatment approaches should form a part 
of a comprehensive approach to reducing cannabis-related harm. Harm reduction 
establishes a hierarchy of goals, with the more immediate and realistic ones to be 
achieved as first steps toward reduced risks or, if appropriate, abstinence. Cannabis 
users need to be aware and have the option of accessing a range of appropriate 
interventions.
(7) ‘Hash’ is cannabis and ‘fags’ are cigarettes.
(8) See www.knowcannabis.org.uk
(9) See www.jellinek.nl/zelfhulp/cannabis
Chapter 11
181
Conclusion
Cannabis is the most widely used drug in Europe and many users seemingly enjoy their 
use of the drug without it leading to any significant negative social or health effects. 
However, it is not a harm-free drug. Heavy, frequent use is associated with increased 
susceptibility to respiratory disorders, dependency, precipitation or exacerbation of 
mental health problems in vulnerable people, and cognitive impairment. Some young 
people, especially those that use heavily and frequently, may be particularly vulnerable 
to mental health problems. Furthermore, a criminal record as a consequence of 
cannabis can also cause problems.
Harm reduction frameworks provide a useful way to appraise and respond to cannabis-
related problems. However, there is a lack of information about the design and delivery 
of harm reduction interventions, and a greater lack of evidence of successful application. 
Many EU countries are beginning to recognise the healthcare needs of cannabis users. 
There is a need for the development of accessible interventions for cannabis-related 
problems including accurate, credible and targeted information; and secondary 
prevention for young people and adults who want to cut down or stop their cannabis 
consumption.
Unfortunately, the most common method of using cannabis — smoking — is also the 
most risky mode of administration. While some cannabis consumption methods and 
techniques, such as vaporiser use, may protect health to an extent, the evidence base is 
limited. Social, cultural and economic obstacles, and preferences by users themselves 
indicate that such modes of administration may not be widely adopted.
Cannabis and harm reduction has been considered in various ways in this chapter. 
Critical to the success of any intervention is the need to recognise that many people 
experience cannabis as enjoyable and trouble free, whilst accepting that some people 
require help to reduce or stop. Another vital aspect is to realise that non-official sources 
of information — cannabis-using peers, advocacy groups, headshops and websites — 
often play a role in educating cannabis users, and there is a need to engage such actors 
in delivering accurate harm reduction messages.
Thanks to Mark Bellis, Annemarie Carr, Neil Hunt, Simon Lenton and John Witton.
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Setting the context
Sizing markets for illicit products is always difficult. The most basic challenge is that the 
standard yardsticks common for legal markets cannot be used. Analysis and forecasts 
are simply not available for illicit goods, and economists working on the issue are faced 
with a lack of standard sources such as investor reports, tax declarations and fiscal 
yields, obligatory bourse filings, performance indicators, customs duties, wholesale and 
retail reports and the trade press.
So drug market analysts must instead make do with a piecemeal substitute, triangulating 
information obtained from various channels: enforcement (police reports, crime 
statistics, customs seizures data), healthcare (drugs epidemiology, treatment indicators) 
and a more nebulous literature base produced by drugs workers and charities, think 
tanks, academics and policymakers, and journalists. While in some cases, statistics are 
produced on a standard, usually annual cycle (United Nations Office on Drugs and 
Crime (UNODC), EMCDDA, World Customs Organisation, Interpol), more often than 
not analysis is ad hoc and restricted in scope, for example national, regional or single-
theme studies.
UNODC is the primary provider of research into the machinations of the global illicit 
drugs market. In this chapter, UNODC authors reveal that, for cannabis, estimating 
supply is even more difficult than for other drugs, such as heroin and cocaine. For 
example, while satellite data have recently been used to estimate areas of cultivation in 
a report on Morocco, there is strong variation in crop yields and the cost of expanding 
such scrutiny on a global level is prohibitive. Another difficulty is that supply is moving 
closer to the consumer. As indoor cultivation, self-supply and locally grown herbal 
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cannabis become more common, the likelihood of seizures providing a complete picture 
of the market decreases. Beyond this, there is also considerable variation in how herbal 
cannabis and cannabis resin seizures are reported, a fact further impacted by the 
relatively low standardisation of information on the product itself (e.g. resin or herb, 
potency and estimated dose consumed by users).
Nonetheless, this chapter points out that indicators suggest that worldwide cannabis 
cultivation increased throughout the 1990s until 2004, in keeping with growing 
demand, both at the global level and in Europe. Only in 2005 was a reduction 
reported. For herbal cannabis, North America remains the largest market and is largely 
self-contained. For cannabis resin, Europe remains the largest consumer market, 
predominantly supplied by Morocco (see also Gamella and Jiménez Rodrigo, this 
monograph), even though Morocco’s importance as a source country for cannabis is 
declining. Despite some progress made in recent years, there can be no doubt that 
more research and better official record-keeping are required to provide more precise 
estimates on the total amount of cannabis grown and consumed globally. And while 
work is taking place — some European countries are modelling consumption patterns 
for intensive cannabis use (EMCDDA, 2007) — this chapter offers practical suggestions 
for improving our knowledge of the market.
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Global cannabis cultivation and 
trafficking
Ted Leggett and Thomas Pietschmann
Abstract
Though cannabis is, by far, the most widely used illegal drug worldwide, consumed by 
some 3.8 % of the population aged 15–64 in 2005–2006, little scientific information 
is available on the actual extent of its cultivation and its yields. Information collected 
by UNODC indicates that it is produced in (at least) 172 countries across the globe. 
UNODC’s best estimates, based on Member States’ estimates and some indirect 
measurement techniques, suggest that some 42 000 tonnes of cannabis herb and 6 600 
tonnes of cannabis resin were produced at the global level in 2005, slightly down from 
the peak in 2004, though still significantly more than in the early 1990s. This pattern is 
in line with global cannabis herb and resin seizures and global cannabis consumption 
estimates. The largest cannabis herb seizures have been reported from North America 
(Mexico, followed by the USA), followed by Africa and South America. The largest 
cannabis resin seizures have been reported from Western Europe (notably Spain), 
followed by countries of South-West Asia (Pakistan, Iran and Afghanistan) and North 
Africa (Morocco). Production of cannabis resin in Morocco, the world’s largest cannabis 
resin producer and main supplier of it to Europe, has been declining since 2004, while 
production in Afghanistan is increasing. The chapter also makes a number of proposals 
on key areas where more research is needed.
Strong increases in global cannabis cultivation have been reported over the last four 
decades, largely related to rising demand in North America, Europe and Australia. 
Increased production occurred first in the traditional cannabis-producing countries and, 
more recently, in the developed countries that provide the most lucrative consumer 
base. Only in 2005 were the first signs of a decline in global cannabis production seen, 
following years of continuous increases in the 1990s and in the early 2000s.
It remains difficult to establish how much cannabis is produced globally. Unlike other 
drug crops, cannabis is a plant that can be grown in virtually every inhabited region 
of the world, and can be cultivated with little maintenance in small plots, or even 
indoors. UNODC regularly collects, mainly using its Annual Reports Questionnaire 
(ARQ), estimates from UN Member States on the areas under cannabis cultivation 
and estimated yields. But reliability of these figures is significantly lower than the 
corresponding estimates for heroin or cocaine, which are typically made using satellite 
photos and scientific yield assessments.
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Heroin and cocaine production estimates are facilitated by the fact that production of 
opium and of coca leaf is nowadays geographically concentrated in just a few areas. 
A global assessment of cannabis cultivation, in contrast, would have to be truly global, 
and would be both extremely difficult and expensive. An idea of the costs involved can 
be derived from UNODC’s work in this area. UNODC has conducted studies of the 
extent of cannabis cultivation in Central Asia in the late 1990s and, in collaboration 
with the government of Morocco, of the primary cannabis-producing areas of that 
country in 2003, 2004 and 2005. The latter studies employed the use of remote 
sensing technology as well as ground survey data. Conducting such comprehensive 
surveys in countries the size of Morocco would probably cost between USD 200 000 
and USD 300 000 per country. While Morocco actually covers a large part of the survey 
costs, many other countries would not be in a position to do so, which would leave the 
costs with the international community.
Even if the precise number of hectares dedicated to cannabis cultivation worldwide 
could be determined with the help of remote sensing technology, estimates of crop 
yields would still be a challenge. Although cannabis can be grown in most countries, its 
productivity is directly linked to growing conditions, and cannabis is a highly adaptable 
plant. Depending on the cultivar and the environment in which it grows, cannabis can 
vary in appearance from a small weed to a substantial bush to a five-metre tree (Clarke, 
1981).
Yield estimates provided by Member States to UNODC ranged from as low as 5 kg per 
hectare for wild cannabis to 17 500 kg per hectare for countries that reported a high 
proportion of hydroponically grown cannabis. The median cannabis yield was 730 kg 
per hectare, and the unweighted average yield was 2 070 kg per hectare (UNODC, 
2007). Moreover, cannabis can be ‘adulterated’ considerably by the inclusion of inert 
(or relatively inert) plant material. All of this makes coming up with an estimate of yield 
per plant or per unit area (square metre or hectare) a difficult exercise. Yield estimates 
must also take into consideration whether the plants in question were intended to be 
used for cannabis herb or resin production. Cannabis can be consumed with little 
processing after harvesting. As a result, users can feasibly cultivate their own supply, and 
production is highly decentralised. While substantial international trafficking of cannabis 
does occur, it is unclear what share of the total market this comprises. It appears that 
many countries can satisfy much of domestic demand with locally produced cannabis 
(see Korf, this monograph), and this trend appears to be growing in many important 
markets.
The matter is complicated further by the fact that cannabis comprises two distinct drug 
products, cannabis herb and cannabis resin. Over the period 2000–2005, 82 % of 
the cannabis end-product seizures concerned cannabis herb and 18 % cannabis resin 
(UNODC, ARQ). Herbal cannabis comes in various grades, including a product made 
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up of only the unfertilised buds of the female plant, known as sinsemilla. There are also 
various grades of hashish, based on amount of impurities contained in the final product. 
In addition, it is possible to produce ‘cannabis oil’, although this form of the drug is not 
widespread: 0.02 % of global seizures of cannabis end-products over the 2000–2005 
period, and only 0.01 % in 2005.
While herbal cannabis is consumed throughout the world, the largest market for 
cannabis herb is in North America, where 63 % of global seizures occurred in 2005, 
followed by Africa (18 % in 2005). Europe accounted for just 2 % of global cannabis herb 
seizures in 2005, down from 4 % in 2000 (UNODC, ARQ). Changes in law enforcement 
priorities among some European countries may also have played a role here.
Western Europe is the largest market for cannabis resin, responsible for more than 
70 % of global seizures in 2005. UNODC estimates that around 70 % of this hashish 
was produced in Morocco in 2006, down from some 80 % in previous years (UNODC, 
2007). In 2003, France reported that 82 % of the cannabis resin found on its market in 
2002 originated in Morocco. Similar estimates were made for Belgium (80 %), Sweden 
(85 %), and the Czech Republic (70 %). Spain, Italy, Denmark, Finland and Ireland 
reported that almost all of the cannabis resin originated in Morocco (UNODC, 2006). By 
2005–2006, most European countries reported a decline of the importance of Moroccan 
cannabis resin. Based on individual drug seizure data provided by the World Customs 
Organisation (WCO) to UNODC cannabis from Morocco accounted for, in weight terms, 
74 % of total cannabis resin seizures made in Western Europe in 2006, down from 82 % 
in 2004. In terms of number of seizure cases, the proportion of Moroccan cannabis fell 
to 67 % by 2006, according to WCO data. All of this reflects an underlying decline of 
cannabis resin production in Morocco in recent years.
While UNODC relies primarily on official government figures for its global estimates, 
these estimates are not available for all cannabis-producing countries in the world. 
Only a few countries have scientifically valid estimates based on remote sensing 
technology or based on ground surveys. Most countries provide estimates based on 
some extrapolations from their cannabis eradication activities. Where official figures for 
cannabis herb production are not available, UNODC bases its estimates on demand 
data, also taking police intelligence into account. Law enforcement information is 
often available with regard to a country’s position as a cannabis production, transit or 
export country. For countries that are neither importing nor exporting countries, it can 
be assumed that domestic demand is covered by domestic production. For cannabis 
importing countries, there are usually rough estimates available on the share of 
imported cannabis. Similarly, for cannabis exporting countries there are rough estimates 
available on the proportion of cannabis produced for local production and for export. 
Based on such information and estimates on the size of the local cannabis market, likely 
orders of magnitude of domestic cannabis production can be established.
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This approach, of course, is not without difficulties. Survey data on cannabis use are 
also not available for all countries. In such cases, the sub-regional prevalence rates 
are used as a proxy. Even where available, many important questions may remain 
unanswered, particularly with regard to the quantities of cannabis consumed per user. 
Where these figures are available, the reliability of such consumption estimates can still 
be questioned. Even for experienced users, estimating total consumption can be difficult: 
cannabis is often smoked communally, with many consuming less than a whole ‘unit’ in 
a single session of use. Use levels also vary based on drug availability and potency.
Despite these difficulties, available data show some general trend patterns. Most 
available indicators suggest that cannabis production, after having fallen in the late 
1980s (mainly due to large-scale eradications in Latin America), rose again in the 
1990s and continued rising in the new millennium until 2004 before falling back 
in 2005. Similarly, the volumes of cannabis seized by customs and the police have 
been increasing from the early 1990s until 2004 at the global level before declining 
strongly in 2005. Drug use surveys also show that global demand increased until 2004 
before declining in 2005. An estimated 159 million people, or 3.8 % of the population 
age 15–64, used cannabis at least once in the 12 months prior to the survey(s) in 
2005–2006, down from 162 million people in 2004. This figure for 2005–2006 
is, however, still some 10 % higher than for the late 1990s (144 million people in 
1997–1998) (UNODC, 2007). Despite the decline in 2005, consumption estimates and 
expert opinions solicited from UN Member States suggest that cannabis use has been 
growing faster than the use of cocaine or opiates over the last decade (UNODC, 2007).
To keep up with growing demand, either more land area would have been needed 
for the crop, or technological innovation would have been required to make cannabis 
production more efficient. Both factors seem to have played a role in increasing 
supply over the last decade. In fact, in addition to some expansion in the area under 
cultivation, great strides have been made in improving cannabis plot productivity, 
particularly indoors in developed countries.
Cannabis herb production
As argued above, the unique properties of the cannabis plant have led to its widespread 
and diffuse cultivation. Over the 1995–2005 period, 82 countries provided UNODC 
with cannabis production estimates. For comparison, only 46 countries provided 
estimates for opium-poppy cultivation, and only five provided estimates for coca-leaf 
production (DELTA, 2007). But the fact that a country did not provide an estimate does 
not mean that no cultivation exists, as some countries simply lack the capacity to come 
up with estimates. However, there are also some other ways of identifying cannabis-
producing countries.
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UN Member States — as part of the ARQ — are asked to identify the source(s) of the 
cannabis consumed in their countries. While this anecdotal evidence is basically opinion 
data, it is often based on considerable experience in the field, and its value should not 
be underestimated. On this basis, 134 producer countries could be identified as likely 
cannabis producers (UNODC, 2007). A third list of producer countries can be generated 
by singling out those that report the seizure of whole cannabis plants. It is extremely 
inefficient to transport whole plants internationally, as only certain parts are useable as 
a drug. Thus, when a whole plant is seized, it is very likely that it was locally produced. 
Seizures of whole cannabis plants were reported in 146 countries during the 1995–2005 
period. Combining these three lists results in the identification of 172 countries and 
territories where cannabis is produced, out of 197 countries reporting (87 %) (UNODC, 
2007).
Of course, evidence of some cultivation does not mean the practice is large in scale. 
Many of these 172 countries seem to produce primarily to satisfy local demand, but 
there are a number of countries that produce for mass export.
For example, Paraguay produces much of the cannabis consumed in its neighbouring 
countries, and European production hubs include Albania and the Netherlands. Other 
significant exporters include:
in Africa: Nigeria, South Africa, Malawi, Lesotho and Swaziland;•	
in the Americas: Mexico, Canada, Jamaica and Columbia;•	
in Central Asia: Kazakhstan and Kyrgyzstan;•	
in the Middle East: Egypt and Lebanon;•	
in South Asia: India; and•	
in South-East Asia: Cambodia, Thailand and the Philippines.•	
Quantifying this production is another matter. As discussed above, estimating the 
volume of global cannabis production is extremely difficult. The 2004 World Drug Report 
(WDR) provided an estimate of about 32 000 tonnes of cannabis herb production at the 
global level for 2001–2002. The 2005 WDR estimated global cannabis herb production 
to have amounted to 42 100 tonnes in 2003. Since the methods used in arriving at 
these two calculations were not identical, this should not be interpreted as a dramatic 
increase in just two years. Excluding demand-based production estimates, introduced for 
the first time in the 2005 WDR, the global estimate would have still increased to around 
35 000 tonnes for 2004. Applying the revised methodology, as developed for the 2005 
WDR, the 2006 WDR saw a further increase from 42 100 to 45 000 tonnes in 2004. The 
upward trend, however, did not continue for the subsequent year. Without any further 
change in methodology, the 2007 WDR saw a decline to 42 000 tonnes in 2005 — the 
first decline in several years — mainly due to declines reported from North America and 
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Africa, while production continued to rise in many other parts of the world. Despite this 
decline, production is still higher than a decade ago (Figure 1).
There are also other indications suggesting that global cannabis production has been 
increasing over the last decade before falling in 2005. Estimates of the number of 
cannabis consumers globally (based on survey data) and information on the quantities 
of cannabis seized globally by law enforcement have shown increases until 2004 and a 
decline in 2005. Where prevalence data and seizure data are available, such as in the 
USA, a strong correlation between the two datasets was identified in the past, suggesting 
that cannabis seizure statistics, in general, do reflect consumption trends rather well. The 
same is true, if looked at from a global perspective, for cultivation and production trends 
(UNODCCP, 1999) (Figure 2).
In terms of distribution, estimates made available to the UNODC suggest that the 
Americas account for some 47 % of global cannabis herb production. About half of this, 
or close to 10 000 tonnes, is produced in North America. The second-largest producer 
is Africa, accounting for some 25 % of global production. Asian countries account for 
about 22 % of global cannabis production. Most of the cannabis in Asia is produced in 
South-West Asia and the Middle East. Production in Europe, estimated at less than 2 300 
tonnes, accounts for 5 % of global cannabis herb production.
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Figure 1: Estimates of global cannabis herb production
Sources: UNODC annual reports questionnaire data, other government reports and UNODC estimates.
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As mentioned above, all of these must be considered as tentative estimates. For 
instance, for the USA, one of the best studied countries in the world, estimates based on 
cannabis eradication data ranged from 5 600 tonnes to 16 700 tonnes (Drug Availability 
Steering Committee, 2002) in 2000/2001 while demand-based estimates suggested 
production figures of around 1 000 tonnes (ONDCP, 2000). Eradication-based 
production estimates for 2006 ranged from 5 650 to 9 420 tonnes, with a mid-range 
estimate of some 7 530 tonnes. Estimates of net production (after eradication) ranged 
from 2 830 to 6 590 tonnes with a mid-range estimate of 4 710 tonnes for the USA in 
2006 (US Department of Justice, 2007) (Figure 3).
There has been some debate as to whether potency has increased in recent decades. 
This debate is complicated by the fact that comparable potency data are available for 
only a small number of countries throughout the world. A review of the potency evidence 
in Europe was undertaken by EMCDDA in 2004 (see King, this monograph). It remained 
sceptical about overall increases in Europe. Unfortunately, this analysis conflated herbal 
and resin markets.
In fact, the potency of cannabis resin — which is mainly imported into Europe from 
Morocco — seems to have remained stable. However, there is strong evidence that 
herbal cannabis, which appears to be growing in popularity in a number of European 
countries, is becoming more potent, largely due to the increasing availability of indoor-
produced sinsemilla, a trend seen both in Europe and in other developed countries. 
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Figure 2: Global cannabis herb seizures
Source: UNODC annual reports questionnaire data.
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For example, Dutch sinsemilla, which accounts for the bulk of the cannabis market in 
the Netherlands, doubled in potency in just five years, from about 9 % in 1999/2000 
to about 18 % in 2004–2005 (Niesink et al., 2005). In Germany, the European country 
with the largest sample base, no distinction is made between sinsemilla and commercial 
cannabis. Despite this, aggregate herbal potency has doubled in less than a decade. In 
1996, samples averaged about 5 %, rising to about 11 % in 2004. (Bundeskriminalamt, 
2005). In the United Kingdom, sinsemilla potency doubled between 1995 and 2002, 
from about 6 to about 12 % (King et al., 2004). In the other two countries for which 
comparable data are available, the USA and Canada, cannabis potency is also 
increasing (Second Technical Conference on Drug Control Research, 2004). In the USA, 
the Cannabis Potency Monitoring Project found an increase in the average potency of 
cannabis from less than 2 % in 1980 to around 4 % in the late 1980s, around 5 % in 
the late 1990s and 8.5 % in 2006 (1). This total included an average sinsemilla potency 
of over 14 % in each year since 2002, up from 8 % in the mid-1980s (University of 
Mississippi, 2007) (Figure 4).
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Figure 3: Distribution of cannabis herb production, 2005 (42 000 tonnes)
(1) The proportions were calculated based on 59 369 cannabis herb samples, 1 225 cannabis resin 
samples and 443 cannabis oil samples analysed by forensic laboratories in the USA over the 
1975–2006 period. Two-thirds of the 2006 samples were obtained from law enforcement seizures 
and purchases, and the remaining were from domestic eradications. The law enforcement seizures 
were obtained from 45 different states across the USA (University of Mississippi, 2007).
Source: UNODC annual reports questionnaire data, other government reports and UNODC estimates.
Chapter 12
197
Increases in potency may be also linked to a growing share of the herbal cannabis 
market in developed countries being produced domestically, with a declining share 
being the relatively low-potency product traditionally imported from developing 
countries. In the United Kingdom, it is estimated that as much as half the cannabis 
consumed is domestically grown, and this share has been on the increase in recent 
years (Hough et al., 2003). In Iceland, ‘domestically cultivated marijuana has become 
increasingly competitive with imported marijuana, and current estimates indicate it 
makes up anywhere from 10 to 50 percent of the total cannabis market’ (INCB, 2005). 
Again, this trend appears to be occurring in a number of other developed countries as 
well. In 1986, it was estimated that one-sixth of cannabis consumed in the USA was 
produced within the country (President’s Commission on Organized Crime, 1986), 
whereas more recent estimates are closer to a third (Williamson, 2005), and it would 
appear that this trend is continuing (National Drug Intelligence Center, 2005 and 2007). 
In Canada in 1985, only 10 % of the cannabis consumed was produced domestically 
(Stamler et al., 1985), but by 2002 it was estimated that ‘well over half’ was Canadian 
grown (RCMP, 2002).
In most developed countries, an increase in the share of domestic production means 
an increase in the share of indoor production, and thus an increase in sinsemilla in the 
Figure 4: USA — average cannabis potency, 1980–2006
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Source: University of Mississippi, 2007.
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market (2). Unfortunately, time-series data on the share of the herbal cannabis market 
commanded by sinsemilla in Europe are scant. In discussing the results of their surveys 
of regular cannabis users, Atha et al. concluded that ‘skunk’ (sinsemilla) was the only 
type of herbal cannabis to improve its market share in the United Kingdom between 
1994 and 1997, up just under 10 % (Atha, 2002). Sinsemilla is now said to comprise 
about half of the United Kingdom and Irish herbal markets (King et al., 2004). Outside 
Europe, the share of eradicated cannabis cultivation operations that are located indoors 
in the USA has increased in recent years, from 2 % indoor in 1985 (DEA, 2005) to 
more than 6 % in 2005 (National Drug Intelligence Center, 2006). According to the US 
National Drug Threat Assessment 2005, the prevalence of sinsemilla is continuing to 
grow in the USA (National Drug Threat Intelligence Center, 2005). In Canada between 
1997 and 2000, some 78 % of cannabis production operations detected in British 
Columbia, which produced over 40 % of the detected cultivation operations in Canada, 
were indoors. The number of detected indoor operations tripled during the same time 
period (Plecas et al., 2002). On a national level, a slightly lower share of all operations 
detected were indoors (RCMP, 2002). In New Zealand, the number of national survey 
respondents who had ever used ‘skunk’ increased from 10 % in 1998 to 14 % in 2001 
(Wilkins et al., 2002). After many years of winning market share from both imports and 
a remarkable outdoor industry, hydroponic production is now also the most commonly 
detected method of cultivating cannabis in Australia (Australian Crime Commission, 
2004, reconfirmed in Australian Crime Commission, 2007).
Cultivation for personal use is also a significant source of supply in many areas, and 
in many developed countries this is likely to mean indoor cultivation. In the United 
Kingdom, one study found that 63 % of a sample of regular users reported having 
grown the drug at some point in their lives, growing an average of 24 plants. The 
authors estimated that 30 % of the cannabis used by regular users in the UK was home-
grown in 1997 (Atha et al., 1999). In Spain, legal constraints on carrying — but not 
consuming — cannabis have led to an increase in production for personal consumption 
since 1992 (Gamella and Jimenez Rodrigo, 2004). Cultivation for personal use is also 
common outside Europe, in Oceania, for example. In New Zealand, a household survey 
found that 10 % of all current users grew at least some of their own supply (Wilkins et 
al., 2002). The share of people cultivating for personal use is much higher among those 
who use the drug frequently. A survey of regular users in Australia found that two-thirds 
of respondents grew some cannabis for their own use, and nearly half grew all or most 
of the cannabis they used (Reilly et al., 1998).
(2) The terminology in this area can be confusing. While it is possible to produce seeded cannabis 
indoors, most indoor operations of any scale produce sinsemilla, and as do nearly all hydroponic 
operations. And while there is extensive outdoors production inside consumer countries like the USA, 
in many developed countries there is a substantial overlap between domestically produced cannabis 
and indoor-produced cannabis, due to poor climate and the presence of law enforcement, as well 
as a desire to enhance yield and potency through available technology. The term ‘skunk’ is also used 
for high potency strains of cannabis in parts of Europe and Oceania, a reference to an early ‘Indica/
Sativa’ cultivar that forms the basis of many modern breeds.
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Cannabis resin production
Global cannabis resin production estimates are derived from estimates of hashish 
production in key producing countries, seizure information and intelligence information 
about the importance of various markets. Another approach has been to estimate 
cannabis resin production backwards from estimated cannabis herb production, 
applying the global distribution of cannabis resin to cannabis herb seizures. The two 
approaches give a range of the likely cannabis resin production from 3 800 to 9 500 
tonnes for 2005, and a mid-point estimate of around 6 600 tonnes. Previous year’s 
estimates, based on the same methodology, resulted in a range from 4 200 to 10 700 
tonnes with a mid-point estimate of some 7 500 tonnes. These results reflect falling 
cannabis resin production in the world’s largest hashish producing country, Morocco. 
The declines in Morocco were, however, partially offset by rising levels of cannabis resin 
production in other parts of the world, notably Afghanistan. As a side-product of the 
annual village surveys undertaken as part of UNODC’s Afghanistan Opium Survey, data 
on the area of cannabis cultivation are also collected. These surveys found that the area 
under cannabis (resin) cultivation in Afghanistan rose from some 30 000 hectares in 
2004 to 50 000 hectares in 2005–2006 and 70 000 hectares in 2007 (UNODC, 2007, 
and UNODC, Afghanistan 2007) (Figure 5).
Attempts to break down global cannabis resin production in 2002–2003 suggested that 
more than 40 % of the global cannabis resin supply is being produced in northern Africa 
and more than a quarter in the Near East and Middle East. These two regions thus 
Figure 5: Global cannabis resin production
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Sources: UNODC estimates based on UNODC and government of Morocco cannabis surveys 2003, 
2004 and 2005 and UNODC annual reports questionnaire data.
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accounted for more than two-thirds of global cannabis resin production. Central Asia 
and South Asia accounted for less than 10 % each; South-East Europe for some 5 % and 
the Caribbean for some 3 % of global production (UNODC, 2005).
When UN Member States were asked about the source of cannabis resin in their 
countries, Morocco was also the most often cited country (27 % of all mentions over the 
period 2003–2005 period), followed by Pakistan and Afghanistan. Other important 
source countries identified are Nepal and India, the Commonwealth of Independent 
States (CIS) countries, notably Kazakhstan and Kyrgyzstan, the Netherlands and Albania 
in Europe, Jamaica and Paraguay in Latin America, as well as the Lebanon and Egypt in 
the Near East. If compared with a similar exercise done previously, data suggest that the 
importance of Morocco is declining: 31 % of all mentions over the 1999–2003 period 
versus 20 % in 2005 (UNODC, 2007) (Figure 6).
Morocco remains, nonetheless, the world’s most significant cannabis resin exporter. 
In recent years, about 80 % of cannabis resin seized in Western Europe originated in 
Morocco. By 2005–2006, it is estimated that this proportion declined to around 70 %. 
Since resin is the primary form of cannabis consumed in most of Europe, an analysis of 
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Figure 6: Main source countries of cannabis resin, 2003–2005 (based on information from 
61 countries)
Note: the percentages reflect the number of times a country was identified — by other countries — as a 
major source country for cannabis resin, expressed as a proportion of all such mentions. Source: 
UNODC annual reports questionnaire data, other government reports and UNODC estimates.
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cannabis production for the European market must focus on Morocco (see Gamella and 
Jiménez Rodrigo, this monograph).
UNODC and the government of Morocco conducted comprehensive cannabis resin 
surveys of the country in 2003, 2004 and 2005. The resulting estimates are based on 
the analysis of satellite photos (SPOT 5 and IKONOS) (3) covering the whole of the Rif 
area of northern Morocco, and subsequent ground truthing. The 2003 survey placed 
total resin production at about 3 070 tonnes, cultivated on 134 000 hectares of land in 
the Rif region (equivalent to 10 % of the total land or 27 % of the agricultural area in 
the five provinces (4) investigated) by some 96 600 families, providing income for some 
800 000 people in the region. This was significantly higher than the previously estimated 
80 000–85 000 hectares for the late 1990s by the EU (US Department of State, 2000) or 
the 44 500 hectares estimated by the Moroccan authorities in 1995 (5).
The 2004 survey showed a 10 % decline in the land dedicated to cannabis cultivation 
(120 500 hectares) compared with a year earlier, with production falling to 2 760 tonnes 
(UNODC, 2004) (6). This decline was mainly due to lower levels of cannabis cultivation 
in the provinces of Taounate (–43 %) and Al Hoceima (–54 %), an indirect consequence 
of the earthquake in early 2004, which led to increased ‘interest’ and assistance by the 
authorities. Most cannabis was produced in the province of Chefchaouen (50 % in 2003, 
62 % in 2004) (Figure 7).
The 2005 survey showed a further strong decline (–40 %) in the area dedicated to 
cannabis cultivation in Morocco to 72 500 hectares. Cannabis resin production declined 
to 1 066 tonnes. The area under cultivation was, thus, also lower than the levels in 
the late 1990s. Declines were reported from most provinces, including Chefchaouen 
(–46 %). The largest areas under cannabis cultivation continued to be in the province of 
Chefchaouen (56 % of total), followed by Taounate (17 %) and Al Hoceima (16 %).
The overall area dedicated to cannabis cultivation in Morocco in 2005 was less than 
the area found in a previous UNODC cannabis survey in Kazakhstan (330 000 hectares 
in 1998–1999; though most of this was ‘wild cannabis’) (UNODCCP, 1999) and less 
than opium-poppy cultivation in Afghanistan in 2005 (104 000 hectares) but more than 
opium-poppy cultivation in Myanmar (32 800 hectares) or Laos (1 800 hectares). It was 
(3) The survey was based on the analysis of 16 SPOT5 (multi-spectral, 10 m resolution) and 13 IKONOS 
(panchromatic, 1 m resolution). 
(4) The five provinces were Al Hoceima, Chefchaouen, Larache, Taunate and Tétouan.
(5) It should be noted, though, that all cultivation estimates prior to 2003 have not fulfilled strict scientific 
criteria and must thus be treated with caution.
(6) Some of the decline appears to have been a consequence of an earthquake, resulting in increased 
attention being given by the national authorities and the international community to the region 
concerned.
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also less than the area under coca cultivation in Colombia (860 000 hectares), but 
more than the area under coca cultivation in Peru (48 200 hectares) or Bolivia (25 400 
hectares) in 2005 (UNODC, 2007).
The yield estimates for 2004 were based on a scientific study, conducted on 30 plots 
across the five provinces. The yield on rain-fed land was found to amount to 750 kg/ha; 
the yield on irrigated land was, on average, 1 270 kg/ha in 2004. The rain-fed area 
amounted to 106 100 hectares; the irrigated area was 14 500 hectares. The overall yield 
of herbal material amounted, thus, to 813 kg/ha. Total production of cannabis material 
was estimated at 98 000 tonnes. Out of this cannabis material the farmers produced 
1 019 tonnes of first-quality resin, 921 tonnes of second-quality resin and 823 tonnes 
of third-quality resin, that is, in total some 2 760 tonnes of cannabis resin. This was 
equivalent to 2.8 % of all cannabis material (UNODC Morocco, 2007).
A subsequent yield survey, conducted in 2005, based on data from 87 plots across 
the cannabis producing provinces, found overall lower results. While average 
cannabis production on irrigated land increased to 1 821 kg/ha, due to an increasing 
concentration of cannabis production in more fertile areas of the Rif region, cannabis 
production on non-irrigated land declined, due to a drought, to just 459 kg/ha. Given 
the distribution between irrigated and non-irrigated land in the Rif area (14 750 hectares 
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Figure 7: Area under cannabis cultivation in Morocco, 1986–2005
Sources: UNODC, Maroc — Enquête sur le cannabis 2005, January 2007; UNODC, Maroc — Enquête 
sur le cannabis 2004, May 2005; UNODC annual reports questionnaire data; United 
States Department of State, Bureau for International Narcotics and Law Enforcement Affairs, 
International narcotics control strategy report, March 2000.
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irrigated; 57 728 hectares non-irrigated), the overall average yield amounted to 735 
kg/ha, yielding 53 300 tonnes of raw cannabis. The conversion ratio from dried raw 
material to cannabis resin — based on the analysis from 87 plots — fell to 2 kg of 
cannabis resin per 100 kg of cannabis raw material in 2005, down from 2.8 kg in 
2004. Total cannabis resin production thus amounted to 1 066 tonnes in 2005, down 
from 2 760 tonnes a year earlier (UNODC Morocco, 2007).
In parallel to the decline in production, cannabis farm gate prices doubled, from 25 Dh/
kg in 2004 to 50 Dh/kg in 2005 (i.e. from EUR 2.3/kg to EUR 4.5/kg); cannabis resin 
farm gate prices almost tripled, from 1 400 Dh/kg in 2004 to 4 000 Dh/kg in 2005 (i.e. 
from EUR 127/kg to EUR 363/kg) (UNODC Morocco, 2007). No such price changes 
were, however, reported from European countries in 2005 (UNODC Morocco, 2007).
The income for the farmers from the production of cannabis resin was around EUR 260 
million in 2004, equivalent to 0.7 % of GDP. In 2005, high prices led to an increase 
to EUR 325 million. The amount of money earned with this Moroccan cannabis resin 
in Western Europe (deducting seizures made in Morocco and in Western Europe) was 
estimated at around EUR 10.8 billion in 2004. As cannabis resin prices were not 
reported to have increased significantly in European countries in 2005, the value of the 
smaller amounts of cannabis exported from Morocco and sold on European markets is 
estimated to have declined to some EUR 4.6 billion in 2005 (UNODC Morocco, 2007).
The analysis of the THC content, done by the Laboratoire de Recherches et d’Analyses 
Techniques et Scientifiques, MARATES, based on samples from the 30 plots in 2004, 
revealed that the dry cannabis leaf had, on average, a THC content of 1.2 %; the dried 
flowering tops had a THC content of on average 2.7 % (confidence interval 2.1–3.4 %) 
and the cannabis resin had on average a THC content of 8.3 % (confidence interval 
7.1–9.4 %) with a THC content of the samples analysed from 5.5 to 11.3 % (UNODC 
Morocco, 2005).
Trafficking
Survey data from a number of countries suggest that much of the cannabis consumed 
is not ‘trafficked’ in the traditional sense of the word, but rather grown on a small scale 
and distributed within social networks. As discussed above, cultivation for personal use 
is widespread in many countries. In the United Kingdom, Atha et al. note that ‘most 
home grown (cannabis) is not sold’ and they estimate that 30 % of the cannabis used 
by regular users in the UK was home-grown in 1997 (Atha et al., 1999). If this is 
correct, a significant share of the cannabis used in the UK at that time was produced 
and distributed free within the country. A second study concurs, ‘domestic production is 
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on the increase and as much as half of the cannabis consumed in England and Wales 
may be grown here. Some cultivation is on a commercial basis, but much is on a small 
scale, for personal use or use by friends’ (Hough et al., 2003). As this second study 
suggests, what these small growers do not use or give away, they often sell within their 
social circle. According to survey data from the United States National Survey on Drug 
Use and Health, most (78 %) of those who say they bought the drug in the last year say 
they bought it from ‘a friend’. Similar figures were found in an international comparative 
study of cannabis users in Bremen (80 %) and San Francisco (95 %) (Borchers-Tempel 
and Kolte, 2002) (7). The 2006 National Survey on Drug Use and Health revealed that 
53 % of the persons who used cannabis in the last year at least once, obtained it most 
recently for free (i.e. they shared someone else’s cannabis); 42.8 % bought it; 1.19 % 
traded something for it; and 0.9 % grew it themselves (SAMHSA, 2007). Distribution 
along social lines thus undercuts many of the negative effects associated with drug 
markets dominated by organised crime, but it also facilitates access to the cannabis 
market.
In terms of volume, cannabis remains the most extensively trafficked drug worldwide. 
Expressed in drug units (doses), 70 % of all drug units seized in 2003 concerned 
(7) This study also included users in Amsterdam, most of whom bought their cannabis from a coffee 
shop.
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Figure 8: Global cannabis seizures, 1985–2005
Source: UNODC, annual reports questionnaire data/DELTA.
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cannabis (DELTA, 2005). By 2005, this proportion declined, however, to 59 %, followed 
by cocaine (24 %), opiates (12 %) and amphetamines (4 %) (UNODC, 2007). In contrast 
to other drugs, most of the cannabis-related trafficking arrests — in most countries — 
are accounted for by nationals of the respective country (DELTA, 2007).
Cannabis end-product seizures showed a small downward trend in the late 1980s, 
strong increases in the 1990s and in the first years of the new millennium, but declined 
by 31 % in 2005 to around the levels reported in 2002. Cannabis herb seizures 
amounted to 4 644 tonnes, cannabis resin to 1 302 tonnes and cannabis oil to 0.7 
tonnes in 2005. Cannabis herb seizures thus accounted for 78 % of all cannabis end-
product seizures in 2005. In addition, 32 million cannabis plants and more than 600 
tonnes of cannabis plant material were seized worldwide in 2005. This corresponded to 
a decline of close to 70 % compared with 2003 (DELTA, 2007) (Figure 8).
Following years of increase in the 1980s, the 1990s and the first years of the new 
millennium, cannabis seizures declined by 18 % in Europe in 2005. While cannabis 
herb is the predominant type of cannabis product found globally, cannabis resin is 
the predominant form of cannabis seized in Europe, accounting for almost 90 % of all 
cannabis end-product seizures in 2005. Most of these seizures have been made by the 
Spanish authorities (Figure 9).
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Figure 9: Cannabis seizures in Europe, 1985–2005
Source: UNODC, annual reports questionnaire data/DELTA.
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The global market for cannabis herb in 2003 was estimated at production level to 
amount to some EUR 8 billion, at the wholesale level to some EUR 28 billion and at the 
retail level to some EUR 107 billion. The global market for cannabis resin was estimated 
at the production level to amount to some EUR 0.6 billion, at the wholesale level to 
some EUR 10 billion and at the retail level to some EUR 27 billion in 2003. In value 
terms, the cannabis market accounted for 44 % of the global drug market (EUR 304 
billion) while in terms of the number of drug users (161 million) about 80 % of all drug 
users (200 million) were estimated to consume cannabis (UNODC, 2005). Though no 
new estimates are available, one could assume that the global cannabis market in 2005 
was of similar magnitude.
Trafficking in cannabis herb
More cannabis herb is seized, in a wider range of locations, than any other drug in 
the world. Out of 182 countries and territories reporting seizures to UNODC over the 
2003–2005 period, 165 reported seizures of cannabis herb, more than for heroin (150), 
cocaine (150), cannabis resin (119), amphetamines (96) or ecstasy (97). Cannabis herb 
seizures declined, however, by 35 % in 2005 to the levels reported in 2000, but were still 
92 % higher than in 1990 (DELTA, 2007) (Figure 10).
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Figure 10: Cannabis herb seizures — regional breakdown, 1985–2005
Source: UNODC, annual reports questionnaire data/DELTA.
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In 2005, 63 % of global cannabis herb seizures occurred in North America, followed 
by Africa (18 %) and South America (‘non-NAFTA’) (11 %). The remainder took place in 
Asia (5 %), Europe (2 %) and the Oceania region (0.1 %). This distribution of seizures, 
with most cannabis herb seizures being reported from North America followed by Africa 
and South America, has been consistent for most years since 1994. The proportion of 
seizures made in North America rose from 32 % in 1990 to 63 % in 2005 reflecting 
stronger efforts to fight cannabis trafficking, while the proportion of seizures made in 
South America declined over the same period from 46 % to 11 % as cannabis production 
increasingly shifted to North America, where cannabis with a higher THC content is 
being produced. The proportion of seizures made in Africa increased from 16 % of 
global cannabis herb seizures in 1990 to a peak of 41 % in 2004 (DELTA, 2007), in 
line with reports of ever larger areas under cannabis cultivation. In 2005, however, 
the proportion fell back to 18 % as eradication efforts were intensified in a number of 
countries. This decline in cannabis herb production may not be sustainable, however 
(UNODC, 2007).
The world’s largest cannabis herb seizures in 2005 were made by the law enforcement 
agencies of Mexico (1 781 tonnes or 38 % of the total), followed by those of the USA 
(1 112 tonnes, or 24 % of the total). These two countries have led the world in cannabis 
seizures since 1994 (except for the year 2000, when the USA ranked fifth). The next 
largest seizures in 2005 were reported by South Africa (6 % of total), followed by 
Brazil, Tanzania, India, Colombia and Nigeria (3 % each). The largest seizures among 
European countries were shown by the Russian Federation (rank 15), followed by the UK 
(rank 18) (DELTA, 2007).
The share of Europe in global cannabis herb seizures increased from 1 % in 1985 
to 13 % in 1994 as consumption increased, before falling gradually back to 2 % of 
global seizures by 2005. In 2005, cannabis herb seizures declined in Europe by 40 % 
compared with a year earlier, thus exceeding the global decline in that year (–35 %). 
Declines were also reported from Africa, North America and the Oceania region, while 
seizures increased in Asia and in South America (DELTA, 2007). The decline of cannabis 
herb seizures in Europe seems to reflect primarily changes in law enforcement priorities 
in a number of European countries. In addition, the decline may have been due to a 
decline in cannabis herb imports into Europe, as supply is increasingly shifting towards 
domestic sources. The fall in seizures does not appear to be due to any significant 
decline in consumption. Lifetime usage among 15- to 16-year-olds in Europe increased 
by more than 80 % between 1995 and 2003 (UNODC, 2005) and cannabis use also 
increased among the general population over the last decade. In recent years, cannabis 
use seems to have reached a plateau in several European countries and started falling 
in others. However, these declines have been far less important than the reported 
declines in seizures (UNODC, 2007).
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Trafficking in cannabis resin
Global cannabis resin seizures declined in 2005 by 11 % compared with a year earlier, 
dropping to 1 302 tonnes, below the levels reported in 2003. Resin seizures declined 
at a rate above average in Europe (–15 %), reflecting falling levels of cannabis resin 
production in Morocco (DELTA, 2007).
Out of global cannabis resin seizures, Europe accounted for 922 tonnes, of which 916 
tonnes (70 % of the total) was seized in West and Central Europe, 18 % in the Near and 
Middle East/South-West Asia and 8 % in North Africa. The largest seizures worldwide 
were reported by Spain (670 tonnes, or 51 % of the total), followed by Pakistan (94 
tonnes, or 7 %), Morocco (92 tonnes, or 7 %). Significant amounts were also seized by 
the authorities in Iran (69 tonnes, or 5 %) and Afghanistan (42 tonnes, or 3 %) (DELTA, 
2007). The largest seizures in Europe, after Spain, were reported by France (6 % of total 
in 2005), the UK (5 %), Portugal (2 %) and Italy (2 %) (Figure 11).
The main destination of cannabis resin is West and Central Europe. About 70 % of the 
cannabis resin destined for the West and Central European market in 2005–2006 is 
estimated to have originated in Morocco, down from around 80 % a few years earlier 
(UNODC, 2007). Much of the cannabis resin transits Spain and the Netherlands before 
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Figure 11: Cannabis resin seizures — regional breakdown, 1985–2005
Source: UNODC, annual reports questionnaire data/DELTA.
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being shipped to other countries (see Gamella and Jiménez Rodrigo, this monograph). 
Most of the remainder of the resin supply originates in Afghanistan/Pakistan (e.g. 59 % 
in Greece, 30 % in Turkey, 30 % in the Czech Republic, 14 % in Belgium, less than 10 % 
in France and Italy), in Central Asia (mostly for the Russian Federation, other CIS states 
and some of the Baltic countries) or from within Europe (mainly Albania, supplying the 
markets of various Balkan countries and Greece) (DELTA, 2007).
The second-largest destination of cannabis resin is the Near and Middle East/South-West 
Asia region. This region is mainly supplied from cannabis resin produced in Afghanistan 
and Pakistan and, to a lesser degree, from cannabis resin originating in Lebanon. Some 
of the cannabis resin from Afghanistan/Pakistan is also being shipped to Canada and to 
countries in Eastern Africa.
North Africa makes up the third-largest market and is predominantly supplied by 
cannabis resin produced in Morocco. The importance of other markets is limited. Nepal 
is a source country for cannabis resin exports to India and to some other countries and 
Jamaica is a source country for cannabis resin exports to some other countries in the 
Americas.
More research required
Generating sound estimates of global cannabis production levels is likely to remain a 
slippery subject for many years to come, but there are several areas where data could 
be improved greatly:
There is a need for more scientific surveys on the areas under cannabis cultivation. •	
These should help to identify the areas under ‘wild cannabis’ and the areas where 
cannabis is cultivated, on irrigated and on rain-fed land. This may be expensive, 
but remote sensing technology is becoming more readily available and is being 
used in other areas of agriculture. Using a sampling approach, a growing number 
of countries should be in a position to undertake such surveys if control of cannabis 
cultivation is deemed a priority. Where satellite imagery is not available, UNODC 
has developed methods to identify illicit crops by means of a sampling approach 
and helicopter over-flights, as well as through ground surveys. The ‘know-how’ for 
such surveys is readily available in UNODC to be shared with Member States. The 
situation is more difficult when it comes to indoor cultivation which, in general, 
cannot be identified through the analysis of satellite photos or helicopter over-
flights. Nonetheless, more reliable estimates on the extent of outdoor cultivation of 
cannabis could form the basis for reasonably good estimates on the likely extent of 
such indoor cultivation activities, in combination with eradication data and forensic 
analyses of cannabis seizures.
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There is also a need for scientific yield data across a wide typology of cultivars and •	
cultivation styles. Feral or semi-cultivated strains found in Kazakhstan are likely to 
differ greatly in productivity when compared with intensively grown cannabis in 
Morocco, or informal plots in South Africa, or indoor operations in Canada. These 
figures will remain imprecise, but at the very least, a plausible range of values 
needs to be compiled.
Distinction between the various cannabis products is essential: a standardised •	
definition of sinsemilla would be useful to differentiate this drug from other herbal 
cannabis.
The quality of reported seizure data should be analysed. One possible source of •	
the discontinuity between supply- and demand-based production estimates could 
be inflated seizure data, based on either inaccurate plant-to-product conversion 
rates or the inclusion of bulk plant material not suitable for sale. Finally, there is 
a general danger of double counting once various law enforcement bodies are 
involved.
There remains a need to analyse, on a systematic basis, the THC content of •	
cannabis found on the market, and its development over time. Standards to 
undertake such analyses in an internationally comparable way would need to be 
developed. Forensic analysis could also help to identify the sources of the cannabis.
It would also be useful to have studies made of the distinction between the drug as •	
sold and the drug as used. Herbal cannabis users, including sinsemilla users, clean 
their product before consumption. This could help to explain some of the significant 
differences between supply and demand-side estimates.
On the demand side, more data are required on cannabis consumption (amounts 
consumed per cannabis user). While some data exist on the number of days of use 
amongst annual users, the data on volumes consumed remain dubious. Scientific 
study needs to be made of the standard dose for inexperienced users and the rate and 
extent to which tolerance develops. In addition to this, empirical observation of actual 
use patterns needs to be made across a wide range of cultural contexts. User surveys 
would benefit if they were to distinguish between herbal cannabis and cannabis resin 
consumption.
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Chapter 13
Monitoring cannabis availability 
in Europe: issues, trends and 
challenges
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Setting the context
In most of Europe, few would argue that cannabis is difficult to obtain for those who 
seek to use it. Nonetheless, when looking at issues of supply and demand, sellers 
and buyers, products and distribution, there are numerous pieces of the picture which 
need to be assembled to gain an insight into how policymakers may tackle the drug’s 
distribution. This chapter looks at the broader concept of availability of cannabis, a 
concept that goes beyond market analysis and embraces further issues such as price and 
the perceived ease of purchasing a drug.
Cannabis is the most frequently used illicit drug in the EU. Some commentators 
have suggested that the drug has become more readily available, yet the concept of 
availability is one that is both difficult to define and to measure. Nonetheless, it is 
possible to look at a number of indirect indicators that, when taken together, allow for 
the construction of a more general picture of cannabis availability in Europe.
In this chapter, data on drug seizures, prices, potencies and perceived availability 
among the general public are used to explore overall trends in the availability of 
cannabis products in Europe between 1998 and 2003. Analysis is presented for EU 
Member States and Norway.
Data analysis at this level is always challenging and a range of methodological issues 
and data limitations means that conclusions must be drawn with caution. In particular, 
the amount of missing data on some measures presents a serious problem for analysis. 
Despite these difficulties some clear trends do seem evident in some of the indicators. 
However, when taken together no coherent picture emerges, with some datasets 
supporting the assumption that cannabis availability has been increasing whilst other 
information suggests a more stable situation.
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Further reading
Cyclical sources of data on drug supply
EMCDDA, Annual reports and Statistical bulletin, European Monitoring Centre for Drugs and Drug 
Addiction, Lisbon (published annually in November).
UNODC, World drugs reports and Interactive seizure reports, United Nations Office on Drugs and 
Crime, Vienna.
World Customs Organisation, Customs and drugs reports (published annually in June).
General reading
Gouvis Roman, C., Ahn-Redding, Simon, R. (2007), Illicit drug policies, trafficking, and use the world 
over, Lexington Books, Lanham.
UNODC (1987), Recommended Methods for Testing Cannabis, United Nations Office on Drugs and 
Crime, Vienna.
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Monitoring cannabis availability 
in Europe: issues, trends and 
challenges
Chloé Carpentier, Meredith Meacham and Paul 
Griffiths
Towards a conceptual framework for exploring 
drug availability — approaches and data sources
The availability of illicit drugs is an important concept for drug policy, and reducing 
availability can be found as an explicit policy objective at both European and national 
levels (1).
Rationale
Policy interest in drug availability can be broadly characterised as focusing on two 
topics. The first topic is the relationship between availability and demand and rests 
upon an implicit assumption that changes in the availability of drugs will be associated 
in some way with levels of use. At EU level this has resulted in a fairly pragmatic 
monitoring strategy of collecting and analysing information that may allow changes over 
time in drug availability to be charted. Currently, as described below, EMCDDA activities 
in this area focus on improving the reliability and comparability of data sources to allow 
better monitoring of trends in availability at street level for the more prominent groups 
of drugs.
The second topic of interest is to understand what factors can have an impact on the 
availability of different drugs, in order to inform the development of interventions with 
the aim of addressing these factors. Answering this sort of question goes beyond simply 
monitoring and requires more complicated research or statistical modelling exercises.
(1) Drug availability appeared in the EU political debate in the mid- to late-1990s. One of the four initial 
aims of the UK 10-year (1998–2008) Drugs Strategy, ‘Tackling drugs to build a better Britain’ (UK 
Government, 1998), was ‘to stifle the availability of illegal drugs on our streets’. It was soon followed 
by a similar target (Target 4) at the EU level in the EU Drug Strategy 2000–2004 (European Council, 
1999), ‘to reduce substantially over five years the availability of illicit drugs’, while the EU Action 
Plan 2000–2004 (European Council, 2000) emphasised a monitoring approach of this issue in its 
call for the development of ‘indicators of availability of illicit drugs (including at street level) and drug 
seizures’ to be supported by the EMCDDA and Europol.
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Defining ‘availability’
From an operational perspective it is clear that defining availability is not simple: the 
word has been interpreted differently in different contexts. In a general sense, availability 
might be treated as synonymous with ‘access’, and in the drugs field the concept has 
sometimes been simply associated with ‘drug supply data’. For example, one report 
from the USA on cocaine availability produced various estimates based on a model 
derived principally from production and interdiction data (ONDCP, 2002).
Data from demand-side indicators have also been used to estimate drug availability, 
most simply in questionnaires that ask respondents to rate, in some way, the availability 
of drugs in their locality. Additionally, data on drug consumption or offers of drugs have 
also been used as indirect indicators. Currently, the developing consensus supports 
a conceptual framework for assessing drug availability that includes both supply and 
demand elements, though these elements have been made operational in a variety of 
ways and no common approach currently prevails.
Nonetheless, it does appear reasonable to consider drug availability as consisting of a 
synthesis of the following elements:
the amount of illicit drugs physically on the market (drugs produced and trafficked •	
but not seized — drug supply to the market);
the structure of drug flows and distribution (retail outlets, dealers, drug scenes); and•	
the relationships between drug users/non-drug users and this distribution structure •	
(access).
A further valuable analytical distinction is between global availability and street level 
availability. In the context of the EU, global availability might be defined as drug 
availability at the upper/wholesale level of the market, or at the trafficker’s level, as 
a result of the interaction between drug supply and drug control strategies at that 
level of the market. Street level availability might be defined as drug availability at the 
retail level of the market, or at the user’s level, as a result of the interaction of global 
availability, distribution processes and strategies, drug control strategies at retail market 
level and access of various groups of users/non-users to different illicit products. Except 
for data relating to seizures, a common link between global and street level availability, 
this paper will focus on the street level of availability.
Current indicators
The current EMCDDA approach has been to develop a set of indicators of drug 
availability, with particular focus on street level availability. As drug availability is an 
ill-defined concept, a multi-indicator approach has been adopted with the objective 
Chapter 13
219
of bringing together these different data sources into a more general measure of 
availability. Information is provided annually through the Reitox network of national 
focal points and covers areas including: drug prices at retail level, contents of drugs and 
potency, drug seizures and the perceived availability of drugs at street level.
Clearly, none of these information sources produce a simple or unproblematic reflection 
of the availability of drugs in Europe and any analysis must be made with caution. 
The corroboration of contextual and qualitative information is particularly important 
if erroneous inferences are to be avoided. Drug seizures, for example, are influenced 
by the level and efficiency of law enforcement activity (which vary both between and 
within countries over time) as well as the availability of drugs in a particular market. 
Despite this problem, seizure data do appear to be useful in looking at trafficking routes 
(UNODC, 2005) and in many cases it seems fair to make the assumption that drug 
seizures in a given country are at least somewhat correlated to the amount of drugs 
imported or smuggled into that country. It has even been assumed in international 
discourse that drug seizures represent a relatively stable proportion of the drug supply 
(often assumed to be about 10 %) and could therefore be considered as an indicator 
of drug availability on the national market. In the case of cannabis, seizures of plants 
have also been taken as an indicator of the extent of domestic cannabis cultivation or 
cultivation in neighbouring countries (Pietschmann, this monograph).
Similarly, both price and the potency of illicit drugs may have an impact on the 
perceived availability of illicit drugs and reflect important supply-side factors that affect 
access. This relationship is often not a simple one, but both price and potency can be 
considered as indirect indicators of drug availability. Drug prices may vary according to 
many factors including the level of the market or volume at which they are traded. Prices 
are also likely to reflect the basic laws of supply and demand. In this respect, lower 
prices would in theory seem to indicate a higher availability (or a greater supply), or, 
although it is perhaps less likely, reduced demand.
For a number of methodological and practical reasons, interpreting data on potency 
is a complicated task — and these difficulties are particularly apparent for cannabis 
(see below). However, this information is collected in some EU countries principally as 
a legal requirement for criminal prosecutions, but also, in some cases, as part of drug 
monitoring activities. Although establishing a direct link between potency and availability 
is difficult, changes in the overall potency of drugs, especially when prices are moving in 
an opposing direction, can be regarded as a useful indirect indicator of availability — 
albeit one to be interpreted carefully.
Finally, school and adult surveys sometimes include questions on the perceived 
availability of drugs in the communities from which the respondents are drawn. Although 
important methodological questions exist, such as the influence on such perceptions of 
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different kinds of exposure to drug use and the overall reliability of perceptions reported 
in drug surveys, this kind of data can also provide indirect yet complementary data on 
drug availability.
What do the available data tell us about cannabis 
availability in Europe?
Due to methodological issues and a simple absence of complete and detailed time-
series data, limitations are imposed on any attempt to answer this question. Despite 
this setback, it is possible to some extent to construct a general picture of the different 
indicators of cannabis availability in Europe. Taking the year 2003 as an example, 
below we describe the information available and explore to what extent a coherent 
picture of trends in cannabis availability can be established.
Seizures
The EMCDDA dataset on drug seizures dates back to 1985, and the data records 
both seizures and quantities of drugs seized. Data availability has varied as countries 
have improved their reporting capacity, but considerable work remains to be done on 
improving the comparability of measures used. These data relate to all seizures made 
over the course of a year by all law enforcement agencies (police, customs, national 
guard, etc.). Although generally rare, double-counting may occur within the data 
presented by some countries.
The implications of looking at quantities seized or numbers of seizures can be different. 
A major proportion of the number of overall seizures usually comprises small seizures 
made at the retail or street level of the market. Quantities seized may fluctuate from 
one year to another due to a few exceptionally large seizures of drugs made further up 
the distribution chain. For this reason the number of seizures is sometimes considered 
a better indicator of trends — although a count of the number of seizures is sometimes 
less available. A further complication for cannabis arises because of the different types 
of cannabis available in Europe. Only since 1995 has it been possible to begin to make 
a distinction between different types of cannabis products — that is, plants, herb and 
resin — and some countries are not able to do this. Therefore, the corresponding time 
series are sometimes incomplete, making the analysis of EU trends more difficult (2).
(2) Caution is required on the reporting of herbal and plant seizures, as practices might vary by country, 
possibly leading to the incorrect categorisation of one type of substance into either herbal or plant 
seizures.
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Seizures of cannabis plants
Cannabis grown within the EU is beginning to represent a significant part of the market. 
Data on seizures of cannabis plants from EU reporting countries and Norway in 2003 
amounted to 8 600 (3) seizures of about 1.6 million plants and 8.9 tonnes of the same 
material. The highest numbers of seizures were reported by the United Kingdom, 
followed by Hungary and Finland (4), while the largest quantities were recovered in the 
Netherlands, followed by Italy, Poland and the United Kingdom.
Not all countries can provide data for the period 1998–2003 but based upon the 
information available a decline was evident in the number of seizures of plants reported 
until 2001, followed by a subsequent increase. Since 1998, overall quantities seized 
have been increasing with peaks in 2000 and 2001, mainly due to exceptionally large 
seizures made by Italy in these years (1.3 and 3.2 million plants, respectively).
Seizures of cannabis resin
About 200 000 seizures (5) and 1 025 tonnes of cannabis resin seized were reported in 
the EU and Norway in 2003, with Spain accounting for the biggest share by far, both 
in terms of numbers and quantities seized, and reflecting the importance of the Iberian 
peninsula as an importation route for Moroccan-produced cannabis entering Europe 
(see Gamella et al., this monograph). France and the United Kingdom, which represent 
relatively large markets for cannabis, also stand out as countries seizing significant 
quantities of the drug. Both in terms of numbers and quantities, overall cannabis resin 
seizures increased during the period 1998–2003. However, in 2003, the number of 
seizures declined while quantities increased highly due to large amounts recovered in 
Spain.
Seizures of herbal cannabis
In the EU herbal cannabis is less commonly seized than resin — illustrated by the fact 
that in 2003 the total amount of herbal cannabis seized was 79 tonnes, or less than 
10 % of the amount of resin seized, with the United Kingdom recovering the largest 
quantities every year, followed by Italy. Numbers of seizures of herbal cannabis have 
been increasing overall since 1998, though they remained stable in 2003, as opposed 
to figures for quantities seized, which have been declining for most years.
(3) Reported by 17 countries (data not available for Denmark, France, Italy, Cyprus, Latvia, the 
Netherlands, Poland, Slovenia and Sweden).
(4) However, data on the number of seizures made were not available for countries seizing the largest 
quantities — Italy and the Netherlands.
(5) Reported by 19 countries (data not available for Denmark, France, Italy, Cyprus, Latvia, the 
Netherlands and Slovenia).
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In analysing seizure data a useful distinction can be made between police and customs 
seizures, based on the assumption that police seizures may better reflect retail level 
activity and that customs seizures are at a wholesale level and may include drugs in 
transit to third countries. Since 1995, data collection at the European level have included 
a request for a breakdown by seizing entity. This dataset requires further development 
as not all countries are currently able to provide this information nor is it possible at 
present for some countries to make a distinction between different cannabis products. 
Therefore, due to missing data, totals will represent an underestimate of the true 
situation.
Despite these limitations, data show that from 1998 to 2003 there was a general 
increase in the number of police seizures of cannabis (all material included) whilst the 
number of reported customs seizures remained relatively stable. Quantities of cannabis 
seized by both police and customs authorities increased during this period at about 
the same rate. For both seizing entities Spain was responsible for a major share of 
the quantity of drugs recovered. A gross calculation of the average sizes of cannabis 
seizures (6) over the period 1998–2003 shows that police seizures are usually smaller 
than customs ones, with size ratios up to 1:100 in Spain and the United Kingdom.
Retail prices
Data on retail prices of cannabis products come from a range of different sources, the 
comparability of which is often unclear. These sources include test purchases, interviews 
with arrested dealers/consumers, police intelligence and surveys of drug users. 
Sampling strategies used for calculating price estimates also vary considerably and in 
some countries the representativeness of these data is questionable. The EMCDDA is 
working with national experts to improve the comparability of data and methodological 
approaches of collecting price data at the street or retail levels. Although caution is 
required when drawing any firm conclusions from the currently available dataset, it is 
possible to obtain a general picture of overall trends.
Because prices vary by product type, efforts have been made to distinguish between 
different types of cannabis. The main breakdown by product type is made between 
herbal cannabis and cannabis resin. Whenever possible, a further distinction is made 
between different types of herbal cannabis, as the herbal cannabis market often contains 
a number of distinct products. In particular, high potency types of cannabis, such as 
some forms of domestically produced product, attract a premium price. However, it has 
only recently become possible to make this sort of distinction, and further analysis is 
hampered by a lack of data on the dynamics of the European cannabis market.
(6) Dividing quantities seized by numbers of seizures.
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Prices in 2003
Data for 2003 on the price of resin and herbal cannabis are available from 24 and 
21 European countries respectively. The ranges reported for minimum and maximum 
prices of cannabis resin and herb are relatively narrow compared with potency data 
(see below). Although considerable variation is seen between the cheapest and most 
expensive countries, considerable overlap also exists between many countries with 
respect to average prices reported. The average price of resin varied from EUR 1.4/g 
in Spain to EUR 21.5 in Norway, with about half of all countries reporting average 
prices in the range of EUR 5–11. Most countries reported a lower price for herbal 
cannabis than resin, again with a considerable range of EUR 1.1/g in Spain to EUR 12 
in Latvia, and most countries reporting average prices between EUR 5 and 8 per g. The 
importance of looking at sub-types of herbal cannabis was illustrated by the Netherlands 
and the United Kingdom, where analysts were able to provide a separate estimate for 
home-produced cannabis, the price of which was higher — on average EUR 6/g in the 
Netherlands and EUR 8.2/g in the United Kingdom.
Because cannabis prices may be higher in countries where other goods are more 
expensive or there is a higher standard of living, in order to attempt to explain 
differences in cannabis prices between countries, it is possible to look at correlations 
between a country’s average prices of cannabis products and the country’s demographic 
and socio-economic situation in the same year, as represented by two indices — the 
human development index (HDI) (7) and gross domestic product per capita in purchasing 
power parity (GDP per capita in PPS) (8). Analyses show that there is no clear correlation 
between such indicators and cannabis prices (by product) when considering all the 
reporting countries together. However, further distinction between groups of countries 
suggests that prices of both resin and herbal cannabis are positively correlated to both 
the HDI and GDP (per capita in PPS) in the countries from the EU-15 (9). In the new EU 
Member States, there is either a negative or non-existent correlation between prices of 
both cannabis products and the HDI and GDP (per capita in PPS). However, it should be 
noted that the negative correlations found in this group of countries were stronger for 
herbal cannabis than for resin (10).
(7) The Human Development Index is a composite index measuring the average achievements in a 
country in three basic dimensions of human development: a long and healthy life (measured by 
life expectancy at birth); knowledge (measured by the adult literacy rate and the combined gross 
enrolment ratio for primary, secondary and tertiary schools); and a decent standard of living 
(measured by GDP per capita in purchasing power parity (PPP) US dollars) (UNDP, 2005).
(8) Taking as a basis EU-25 = 100 (source: http://epp.eurostat.ec.europa.eu).
(9) The correlation coefficients in the EU-15 in 2003 were: 0.66 between resin price and HDI; 0.46 
between resin price and GDP (per capita in PPS (purchasing power standard)); 0.54 between herbal 
cannabis prices (type unspecified or imported) and HDI; and 0.59 between herbal cannabis prices 
(type unspecified or imported) and GDP (per capita in PPS).
(10) The correlation coefficients in the new Member States in 2003 were: –0.16 between resin price and 
HDI; –0.05 between resin price and GDP (per capita in PPS); –0.50 between herbal cannabis prices 
(type unspecified or imported) and HDI; and –0.34 between herbal cannabis prices (type unspecified 
or imported) and GDP (per capita in PPS).
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Though this analysis is tentative, it does suggest some relationship between cannabis 
prices and national demographic and socio-economic situations in the older EU Member 
States, where cannabis markets are relatively long established. The picture is less 
clear for the new Member States, where there are not only questions of data quality 
but also the possibility that markets in these countries are subject to strong change. 
Other indicators have suggested that cannabis use is increasing, though often from low 
initial levels, and that these cannabis markets should be considered relatively ‘young’ 
and far less established. Routes of cannabis trafficking might also explain some of the 
differences observed between EU countries in the retail level price of cannabis products 
— particularly by noting the proximity of Morocco for producing cannabis resin and the 
increasing importance of Albania for producing herbal cannabis. Countries that are 
closer to these producing regions are likely to experience lower transport costs during 
trafficking and, therefore, lower prices.
Long-term price trends
An analysis of long-term trends in prices is hampered by the fact that although a few 
countries have been reporting data on cannabis products since the mid-1990s or earlier, 
it takes several years for the dataset to grow sufficiently large enough to explore trends 
at a European level. It should also be noted that data from the new EU Member States 
have only been available since 2002. The EU mean (arithmetic mean) of average prices 
of cannabis resin (corrected for inflation (11)) in reporting countries slowly decreased 
in the period 1996–2003 (see Figure 1). A more detailed analysis of such prices in 
countries that have been reporting for four years or more shows that overall trends for 
1999–2003 (12) were either stable or declining in all countries, with the exception of 
France and Luxembourg, where a modest increase was noted.
Changes in the average prices of herbal cannabis are less clear than those of 
cannabis resin. Indeed, Figure 2 does not show a clear overall EU trend of such 
prices in reporting countries, except for a fall in 2003 in a majority of countries. Over 
1996–2003, however, the EU mean (13) of reported prices increased overall, with a 
peak in 2001 and a fall since then (14). In most of the countries reporting for at least 
four years, herbal cannabis prices have remained stable or have decreased (15), while 
an upward trend was reported by the Czech Republic, Latvia, Luxembourg and Portugal. 
The average price of locally produced herbal cannabis has been declining in recent 
years in both of the countries that are able to report on the price of these products 
separately (Netherlands, United Kingdom).
(11) Taking 1996 as a base year for the value of money in all countries.
(12) Taking 1999 as a base year for the value of money in all countries.
(13) Arithmetic mean.
(14) Taking 1996 as a base year for the value of money in all countries.
(15) Taking 1999 as a base year for the value of money in all countries.
Chapter 13
225
Figure 1: Average retail price of cannabis resin (EUR/g) — adjusted to inflation — in the EU 
Member States and Norway, 1996–2003
Notes: Prices are adjusted for inflation, taking 1996 (for all countries) as a base year. Belgium (1996, 
1997, 1999, 2000, 2003); Czech Republic (1998–2003); Germany (2002); Latvia (2001–2003); 
Norway (2002–2003); Poland (2002–2003); Slovakia (2002–2003); Slovenia (1996–2003): 
figures reported as averages are actually middle points between minimum and maximum prices. 
The Netherlands: 1999 data refer to 1999/2000; 2000 data refer to 2000/2001; 2001 data refer 
to 2001/2002; 2002 data refer to 2002/2003; 2003 data refer to 2003/2004. Spain: the price 
reported as average refers to quantities sold by gram. Hungary: the figure reported as average is 
actually the modal, or ‘typical’ price. Source: Reitox national focal points.
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Figure 2: Average retail price of herbal cannabis (EUR/g) — adjusted to inflation — in the 
EU Member States and Norway, 1996–2003
Notes: LP refers to ‘nederwiet’, usually locally produced cannabis herb. Prices were adjusted to inflation, 
taking 1996 (for all countries) as a base year. Hungary: the figure reported as average is actually 
the modal, or ‘typical’ price. The Netherlands: 1999 data refer to 1999/2000; 2000 data refer 
to 2000/2001; 2001 data refer to 2001/2002; 2002 data refer to 2002/2003; 2003 data refer 
to 2003/2004. United Kingdom: figures submitted as ‘nederwiet’ refer to ‘skunk’. Belgium (1996, 
1997, 1999, 2000, 2003); Czech Republic (1998–2003); Germany (2002); Latvia (2001–2003); 
Poland (2002–2003); Slovakia (2003); Slovenia (1996–2003): figures reported as averages are 
actually middle points between minimum and maximum prices. Source: Reitox national focal 
points.
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Time trends of the average price of both resin and herbal cannabis have also been 
reported by 15 EU Member States (16). Comparisons between prices of both products (17) 
show that over the period 1996–2003, the average price of resin was overall higher 
than that of herbal cannabis in all but two of the reporting countries, although this 
difference was not often strongly pronounced. Additionally, trends in the average price 
of both products by country are similar in all the reporting countries, except France, 
which reported an overall fall in herbal cannabis prices and an increase in average 
resin prices. Lastly, reported data show a possible convergence between average prices 
of cannabis resin and herb in many countries.
Potency
The potency of cannabis products is a topic considered in detail elsewhere in this 
monograph and so will only be briefly considered here. Potency of cannabis is usually 
defined as the tetrahydrocannabinol (THC) content by percentage. Both practical 
and methodological difficulties mean that data on cannabis potency must be viewed 
with some caution. For example, the number of samples analysed varies greatly 
between countries (from four to over 3 000 samples in the 2003 data submitted to the 
EMCDDA) and, thus, the representation of samples in a given user population may be 
questionable. Furthermore, there are analytical difficulties in the precise and accurate 
determination of the potency of cannabis products (EMCDDA, 2004) and considerable 
variations in both the practice of taking samples from cannabis cultivation sites for 
analysis and that of sampling parts of the material to be analysed (ENFSI, 2005). All of 
these reasons mean that there is a need to improve and standardise approaches in this 
area if the reliable monitoring of cannabis potency is to be achieved. As stated above, 
it is important to distinguish between different types of cannabis (resin and herbal 
cannabis) — especially when considering potency. Theoretically, a further distinction 
should be made whenever possible between imported herbal cannabis and home-
produced herbal cannabis, although in practice very few countries can systematically 
report data separately. For all types of cannabis the assessment of trends over time are 
hampered by a lack of historical data, with only a couple of countries reporting before 
1999.
(16) Belgium, Czech Republic, Germany, Ireland, Spain, France, Cyprus, Latvia, Lithuania, Luxembourg, 
Netherlands, Portugal, Slovenia, Sweden, United Kingdom.
(17) In each country, we have taken the first year of the series of data available (from 1996 onwards) as 
a basis for the value of money.
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Cannabis resin potency
Compared with prices, cannabis potency is reported by fewer countries but still shows 
considerable variation. Average potencies of cannabis resin in 2003 varied between 
less than 1 % and nearly 25 %, with a majority of countries reporting average potencies 
between 7 % and 15 %. The range of values upon which average potencies are 
calculated was very wide in some countries — raising questions about how meaningful 
the reported average values are for describing the cannabis market. An extreme 
example is in Slovakia, where there is a difference of 53 percentage points between 
the lowest and the highest potencies found. Out of the 16 countries reporting data 
on resin potency in 2003, eight report minimum values under 1 % while seven report 
maximum values over 25 % (three of which report maximum values of 40 % or over). 
Given that much of the cannabis resin consumed in Europe is produced in North 
Africa under similar conditions, these differences are difficult to explain (see Gamella, 
this monograph). Data available show an overall (moderate) increase in the average 
potency of cannabis resin since 1999, although there has been a decline in 2002 in a 
majority of reporting countries.
Herbal cannabis potency
The average reported potency of herbal cannabis in 2003 was generally lower than 
that of resin in all countries, with the exception of the United Kingdom. Reported values 
ranged from less than 1 % to nearly 14 %, with half of the countries (18) reporting 
estimates of between 4 % and 9 %. Locally produced herbal cannabis is now available 
in most EU countries, and when produced under intensive conditions it can be of high 
potency. Only the Netherlands was able to provide a separate estimate in 2003 for this 
type of product (20.3 % THC on average). It is hard to observe any overall clear trend 
for the EU in the potency of herbal cannabis in general over the last five years (see 
Figure 3). At a national level some countries reported a modest increase. Elsewhere, a 
relatively stable situation can be observed. Overall, the mean value (19) of the reported 
averages of herbal cannabis shows little variation over the period 1999–2003 (20). The 
reported potencies of locally produced herbal cannabis where these data are available 
show an increase in the Netherlands, and a relatively stable situation in the Czech 
Republic. In both countries the estimated potency of home-produced herbal cannabis 
exceeded that of cannabis resin from 2002.
(18) Seven out of a total of 14 countries reporting data on the average potency of herbal cannabis in 
2003.
(19) Arithmetic mean.
(20) It is actually slightly decreasing over 1999–2003, but variations in the mean can be explained by the 
fact that the number of countries reporting data has varied over the period, thus affecting the number 
of countries upon which the mean is calculated; indeed five countries reported data on the average 
potency of herbal cannabis of type unspecified or imported for 1999 and 14 for 2003. Indeed, the 
calculated means of the data from the nine countries reporting over 2001–2003 and of those from 
the seven countries reporting over 2000–2003 are both slightly increasing.
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Figure 3: Average potency of herbal cannabis, measured as percentage of THC content, in 
the EU Member States and Norway, 1996–2003
Notes: LP refers to ‘nederwiet’, usually locally produced cannabis herb. Czech Republic: figures reported 
as average are actually middle points between minimum and maximum potencies. Figures 
reported as ‘nederwiet’ refer to more potent cannabis herb, such as sinsemilla or ‘skunk’ (locally 
produced as well as imported). Figures reported as ‘other herb’ refer to cannabis herb of type 
other than ‘nederwiet’. Germany: figures reported as average are actually the median. The 
Netherlands: 1999 data refer to 1999/2000; 2000 data refer to 2000/2001; 2001 data refer to 
2001/2002; 2002 data refer to 2002/2003; 2003 data refer to 2003/2004. Portugal: data are 
based on users’ reports until 2001 and since 2002 on users/traffickers and traffickers’ reports. 
Portugal LP: although these are resin samples, given the high THC % found, it is suspected that 
they might be locally produced herbal cannabis. Source: Reitox national focal points.
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Similar trends in resin and herbal cannabis potency?
Data available from 12 countries allow a time trend comparison of the average potency 
of both resin and herbal cannabis. Although resin potency was estimated as higher in 
2003, this was not necessarily the case in previous years: only two countries reported 
resin as having a consistently higher potency than herbal cannabis. Overall trends 
are difficult to define. Data available show similar trends in resin and herbal cannabis 
potencies in France (customs data) (21), the Netherlands and Slovakia. In France both 
resin and herbal potencies showed a moderate increase from 1997–2002 and then a 
decrease in 2003. In the Netherlands and Slovakia, average potencies of all cannabis 
products have been increasing (1999–2003 in the Netherlands, 2001–2003 in 
Slovakia), although the increase for resin (and locally produced herb in the Netherlands) 
was much steeper. In the United Kingdom too, overall trends in the potency of resin 
and herb in the period 1998–2003 are similar, although the potency of resin increased 
steadily while the potency of herbal cannabis fluctuated greatly within the general 
upward trend. Austria (2001–2003) and Italy (1999–2003) (22) reported the opposite 
trend in resin and herbal cannabis potencies. In Austria, resin potency decreased 
from 2001 to 2002 then increased in 2003, while the potency of herbal cannabis 
increased and then decreased. In Italy, cannabis resin potency increased until 2002 then 
decreased, while the potency of herbal cannabis decreased then increased. Although 
these reports must be checked against data for future years, trends reported in 2003 
suggest a convergence between potencies of cannabis resin and herbal cannabis in 
some countries — Belgium, Italy, Latvia and the United Kingdom (23).
Perceived availability
In addition to market information, the availability of drugs has been a part of questions 
posed in surveys of both general and school populations. Surveys allow researchers to 
get information on the perception of availability and behaviours of the population in 
terms of reported use or non-use of illicit substances. Availability questions have been 
used in a number of surveys in Europe, though with no standardisation of approach. 
Thus, differences in formats, variables and answering modalities make comparisons 
and analysis difficult at the EU level. The EMCDDA is currently working with Member 
States to develop a new module on drug availability in the existing European Model 
Questionnaire (EMCDDA, 2002) for population surveys. Recently, guidelines have 
(21) This is also the case in France for the data from the police, but this source reports only data for 2002 
and 2003, which limits the analysis of time trends.
(22) As well as in Latvia and Norway, but these countries report only data for 2002 and 2003, which limits 
the analysis of time trends.
(23) In Germany, too, a convergence was reported, but only in 2001 and 2002 since 2003 data were 
not available.
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been developed to include questions on exposure (offers or propositions of drugs 
and opportunities to use drugs), perceived availability (subjective assessment of drug 
availability based on current individual circumstances) and access to drugs (how, where 
and from whom to get drugs in individuals’ current situations).
Currently, the only cross-European source able to provide standardised data on 
perceived availability is the ESPAD (2005) school survey series (European School Survey 
Project on Alcohol and Other Drugs) (see Hibell, this monograph). This is a repeated 
survey carried out among 15–16-year-old students in 26 to 35 European countries in 
1995, 1999 and 2003. The survey allows a comparison to be made on the perceived 
availability of cannabis across the EU Member States and Norway for the age group 
sampled. Results for 2003 show that getting ‘hashish or marijuana’ was reported to be 
‘fairly easy’ or ‘very easy’ by 40–60 % of the students in the Czech Republic, Denmark, 
Ireland, France, Italy, Slovenia, Slovakia and the United Kingdom; by 25–40 % in 
Poland, Portugal and Norway; and by 10–25 % in Estonia, Greece, Cyprus, Latvia, 
Lithuania, Hungary, Malta and Sweden. The percentage of those finding it fairly or very 
easy to get cannabis has been increasing overall since 1995 in the Czech Republic, 
Estonia, Italy, Lithuania, Hungary, Poland, Slovenia and Slovakia, and at a more 
moderate rate in Cyprus, Denmark, France (24), Latvia, Malta, Portugal, Finland, the 
United Kingdom and Norway, while the reported ease of getting cannabis decreases in 
Ireland, Greece (25) and Sweden.
These differences broadly reflect patterns found in consumption data in the EU Member 
States and Norway between aggregated data on perceived availability of cannabis and 
lifetime prevalence of cannabis use in this population — demonstrated by a strong 
linear correlation for the years 1995 (r = 0.91), 1999 (r = 0.81) and 2003 (r = 0.90). 
There is also a relatively strong correlation between changes in perceived availability of 
cannabis and changes in lifetime prevalence of cannabis use, between 1995 and 1999 
(r = 0.83) and between 1999 and 2003 (r = 0.62).
Discussion
Clearly, many methodological challenges exist regarding the interpretation of data on 
seizures in general (26), the analysis of data on price and potency, and understanding 
data on perceived availability in general and school populations. One of them, not 
(24) Based on 1999–2003 only.
(25) Based on 1999–2003 only.
(26) It is now widely acknowledged that, across countries, drug seizures do not represent the same 
proportion of the amount of drugs being smuggled into or circulating in a given country, especially 
as this may vary according to trafficking routes and location of production areas. We have assumed 
for this analysis that there is a somewhat positive relationship between cannabis seizures and its 
availability on the national market.
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Table 1: Comparative analysis of national cannabis trends (seizures, prices, potency, 
perceived availability) during the period 1998–2003  
Country Seizures Qty police Nb customs Qty customs Price Potency Perceived availability
Nb plant Qty plant Nb resin Qty resin Nb herbal Qty herbal Nb police Resin herbal Resin herbal 95–03 99–03
Belgium (+) + + (+) (+) + – =/– + + H
Czech Republic (+) (=) (=) (+) (+) + + + – + – (+ rec) (+ H) = LP =/+ +
Denmark (+) + –
Germany – – – + =(– rec) – =/+ =/+ – +
Estonia + + + = – + (+) (=) + +
Ireland = – – + + + + – – – =/– –/= =/+
Greece (=) (+/=) + (–/=) – (–) – = =/+ –
Spain (+) + (+/=) + (+) + + + + + = =
France (–) (–/=) k 
(=/+) p
(+) + (+) + – + + – +C (+P) = H/Cu 
(+/= H/Po)
+
Italy = = – +/= – + (–) H + =/+
Cyprus + (–) = – (–) (–) +/= +
Latvia = + (–) (+) H +
Lithuania (+) (+) + – (+) (+) (=) (+) – = + +
Luxembourg – +/= + + + + + – + + + +
Hungary (+) (+) (+) + (+) H
Malta (=) (+) + (+) (–) H + +
Netherlands + = – = = H
= LP
+ + IMP
+ LP
Austria + + – + + –(+ rec) (–)
Poland + + + + + + + + + (=) + +
Portugal + (+) = + + + = + + + +/= +/= + =/+ H
(– LP)
+ +
Slovenia (=) (+) (=) = (+/=) + (–) (=) – – + +
Slovakia + + = = + – (+) (–) (–/=) (=) + (+) H + +
Finland + + + =/+ + + – + (–/=) =(/+) (–) (–) H + =/–
Sweden (=) (=) + =/+ + + + + + – – – –/= –
United 
Kingdom
= –(+ rec) – –(+ rec) + + – + – –(+ rec) – – = + H +/= +
Norway + + = + +/= + = (–) H
Notes
Nb, number of seizures; Qty, quantity seized; PAV, perceived availability (‘fairly easy’ and ‘very easy’ to get cannabis).
Prices adjusted to inflation (taking as a basis the initial year of the series for each country).
+, increasing; –, decreasing; =, stable; +/=, slightly increasing; –/=, slightly decreasing; =/+, rather stable, although very 
slightly increasing; =/–, rather stable, although very slightly decreasing.
rec, recent change in the trend; LP, locally produced herbal cannabis; IMP, imported herbal cannabis; H, herbal cannabis of 
type unspecified; k, quantities in kg; p, quantities in number of plants.
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Table 1: Comparative analysis of national cannabis trends (seizures, prices, potency, 
perceived availability) during the period 1998–2003  
Country Seizures Qty police Nb customs Qty customs Price Potency Perceived availability
Nb plant Qty plant Nb resin Qty resin Nb herbal Qty herbal Nb police Resin herbal Resin herbal 95–03 99–03
Belgium (+) + + (+) (+) + – =/– + + H
Czech Republic (+) (=) (=) (+) (+) + + + – + – (+ rec) (+ H) = LP =/+ +
Denmark (+) + –
Germany – – – + =(– rec) – =/+ =/+ – +
Estonia + + + = – + (+) (=) + +
Ireland = – – + + + + – – – =/– –/= =/+
Greece (=) (+/=) + (–/=) – (–) – = =/+ –
Spain (+) + (+/=) + (+) + + + + + = =
France (–) (–/=) k 
(=/+) p
(+) + (+) + – + + – +C (+P) = H/Cu 
(+/= H/Po)
+
Italy = = – +/= – + (–) H + =/+
Cyprus + (–) = – (–) (–) +/= +
Latvia = + (–) (+) H +
Lithuania (+) (+) + – (+) (+) (=) (+) – = + +
Luxembourg – +/= + + + + + – + + + +
Hungary (+) (+) (+) + (+) H
Malta (=) (+) + (+) (–) H + +
Netherlands + = – = = H
= LP
+ + IMP
+ LP
Austria + + – + + –(+ rec) (–)
Poland + + + + + + + + + (=) + +
Portugal + (+) = + + + = + + + +/= +/= + =/+ H
(– LP)
+ +
Slovenia (=) (+) (=) = (+/=) + (–) (=) – – + +
Slovakia + + = = + – (+) (–) (–/=) (=) + (+) H + +
Finland + + + =/+ + + – + (–/=) =(/+) (–) (–) H + =/–
Sweden (=) (=) + =/+ + + + + + – – – –/= –
United 
Kingdom
= –(+ rec) – –(+ rec) + + – + – –(+ rec) – – = + H +/= +
Norway + + = + +/= + = (–) H
For potencies in France: Cu, customs data; Po, police data.
Between brackets (. . .): to be taken with great caution as series might be too incomplete (only two years available or two last 
years missing), numbers might be too small or there might be a dramatic change in the last year.
Blank: no (trend) data available, or high fluctuations showing no clear trend.
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yet mentioned, is that available data may indicate changes in different parts of the 
population. Indeed, changes in the perceived availability in one group of young people 
(which uses only a small proportion of all the cannabis consumed) may indicate 
something else than, for example, changes in seizures or potency. Yet, if analytical 
difficulties are put aside for a moment, a simple comparative analysis of the national 
trends in each of the indicators over 1998–2003 (27) can be constructed. This can be 
seen in Table 1 (pp. 232–233), which summarises the trends per indicator and per 
cannabis product that available data show.
Existing data point towards increasing availability of cannabis products in four countries. 
In Belgium, there seems to be a clear trend towards the increasing availability of both 
resin and herbal cannabis, based on an upward trend in seizure and potency data and 
a downward trend in cannabis prices. In the United Kingdom too, the availability of 
both products seems to be on the increase, although this is comparatively less clear-
cut as seizure and perceived availability data experienced shifts in trends. Data from 
France point towards an increasing availability of herbal cannabis, while it is less clear 
that this is also true for resin. In the Netherlands, the availability of locally produced 
herbal cannabis seems to be on the increase, while that of resin and (imported) 
herbal cannabis might be said to have remained comparatively stable, or have slightly 
increased, during this period.
In other countries the picture is less clear, or there is simply insufficient information 
available to judge. In Italy, Lithuania and Slovakia data point to a possible increase in 
the availability of resin, while in Spain, Portugal and Slovenia data seem to indicate an 
increase in the availability of both resin and herbal cannabis. In Ireland it is not clear 
whether data point to an increasing availability of both herb and resin (especially at 
retail level as quantities seized by customs are decreasing) or to a stable trend. And 
in Poland there is a possible increase in availability of cannabis in general (data do 
not allow for more specificity). It should be noted, however, that data may point to 
decreasing availability in Greece at the retail level, in particular for herbal cannabis, 
and in Germany, with respect to resin.
Conclusion
It is not our intention here to suggest that this simple analysis can be anything but 
exploratory. However, it is helpful in illustrating the difficulties in producing an 
operational research and analysis framework for the concept of availability, especially 
for a drug like cannabis. The first of these difficulties is the simple observation that 
(27) However, trends in perceived availability in school surveys have been included for both 1995–2003 
and 1999–2003, as considering only the latter trend means calculating a trend between only two 
measures, which is quite limited.
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availability is a very difficult concept to separate out from that of prevalence. Trying to 
decide this from available indicators risks asking chicken-or-egg type questions. For 
example, perceived availability can be seen as closely associated with levels of use, 
as can some seizure data. That said, there may still be a use for a general concept of 
availability that is not simply reducible to an indirect reflection of prevalence. Clearly, 
both conceptual and modelling work is required here if a more robust and useful 
conceptual framework for thinking about drug availability is to emerge.
A second general observation regards the need to improve both the availability and 
quality of data sources. In all the data sources discussed above, some progress has been 
made in moving towards common approaches, definitions and reporting standards. But 
in comparison to other areas of monitoring much remains to be done and at present 
any attempt at identifying trends is severely limited by the available time-series data. 
This is a particular problem for cannabis because there are particular methodological 
and practical problems to overcome in some of the areas of data collection, such as 
assessing potency or the amount of plant material seized. Additionally, at least three, 
and possibly more, major product types exist and trends in availability vary by each 
type and may be different in different countries. Trends in the availability of herbal 
imported cannabis, cannabis resin and cannabis grown with the EU may all be different 
and yet at the same time are all important in understanding the overall availability of 
the drug. Currently, data sources are simply not sufficiently developed to elaborate this 
complexity adequately. In conclusion, if cannabis has, as many believe, become a more 
available drug in Europe, it is difficult to show it convincingly using the available data. 
If the concept of availability is to remain a key target for drug policy then investment is 
required in improving the availability of data necessary to measure changes in this area, 
as is conceptual work to better understand and define the concept of availability itself.
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Setting the context
Perhaps spurred by rises in treatment admissions and increased knowledge about the 
health-related harms of cannabis, much has been claimed in the past few years about a 
change in the potency of cannabis.
There are patterns in recent media coverage of cannabis potency. High-potency herbal 
cannabis is often contrasted with a purported milder substance smoked in the 1960s 
and 1970s. European languages use evocative words to label high-strength, indoor-
grown cannabis —‘skunk’, ‘nederwiet’, ‘summum’. There is a tendency for coverage 
of high-potency cannabis to share newspaper pages with extreme cases of cannabis-
related psychosis, schizophrenia, treatment admissions or violent crime. Occasionally, 
high-potency herbal cannabis is linked to discussion of genetically modified crops, 
subverting identification of cannabis as a ‘natural’ drug.
There are historical precedents to such alarmism about cannabis potency. Higher 
strength has been attributed in the past to variants in cannabis products, notably Thai 
sticks in the 1970s. Authors often refer to an infamous response at a murder trial in 
1938 in Newark, New Jersey: when the pharmacologist James Munch was asked about 
what happened when he himself had tried cannabis, he replied ‘After two puffs on a 
marijuana cigarette, I was turned into a bat’. Such quotes reveal the difficulties we face 
when trying to discuss cannabis potency from an objective perspective.
This chapter, based broadly on the findings of a longer Insights publication produced by 
the EMCDDA in 2004, is refreshingly scientific and reassuring in tone. It suggests that 
overall recorded cannabis potency has not increased dramatically in Europe in recent 
years.
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This is not to say that cannabis potency is a non-issue, but rather that the data in this 
area are incomplete and far from conclusive. This chapter should be read with the 
caveat that potency data were — and remain — very limited and that some forms of 
cannabis now grown in Europe show relatively high potency. More research would be 
welcome, for example, on how exposure to high potency cannabis affects different user 
populations, particularly young people and vulnerable groups. In terms of long-term 
trends, very little is known about the strength of the cannabis smoked in the 1960s 
and 1970s. And what is striking is that there is considerable variation in the potency 
of cannabis recorded in Europe. While press coverage tends to concentrate on the 
strongest THC concentrations rather than average potency, what is constant is the wide 
range in recorded potency, with only moderate variation in average potency for all 
cannabis consumed.
One complicating factor is that there has been a recent shift in consumption away from 
imported cannabis resin to indoor-grown herbal cannabis. While few question that 
high potency herbal cannabis is increasingly available, particularly in northern Europe, 
there is a need to track the precise nature of this shift in the market from resin to herb. 
Are people receiving higher THC doses today than before? Are they smoking fewer 
joints per session? How are they consuming alcohol and tobacco in combination with 
high-potency cannabis? Are they smoking joints on more, or fewer days each month? 
How does a resin joint smoked in the early 2000s compare with a herbal joint smoked 
today? Can we profile typical consumers of high-potency cannabis, and are they more 
at risk of problems? Is the shift to herb affected by the drop in supply of Moroccan resin 
to Europe?
Potency is thus far more complex than the basic task of measuring seized samples 
of cannabis. More research in particular is needed on titration (the potency–dose 
relationship) and whether high-potency cannabis is necessarily linked to patterns of 
problematic use (see Beck and Legleye, Volume 2 of this monograph). While a recent 
study in the Netherlands provided some findings that high-potency cannabis sourced 
from Dutch coffee shops can lead to a higher THC concentration in the blood, it also 
suggested that a core risk group exists (young males aged 18–45, smoking cannabis 
regularly) which will ‘get as high as possible in one session’ (Mensinga et al., 2006). 
Such insights help policymakers to make joined-up decisions that go beyond issues of 
strength alone, addressing risky use patterns and behaviour over time.
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Abstract
The ∆9-tetrahydrocannabinol (THC) content (potency) of herbal cannabis and cannabis 
resin imported into Europe has remained stable for many years at around 2–8 %. Yet 
cannabis produced locally by intensive, indoor cultivation (sinsemilla) typically has 
twice as much THC. In some Western European countries, where cannabis resin is the 
most commonly consumed product and herbal cannabis continues to be imported, 
the weighted average potency is largely unaffected by these modern developments. 
However, elsewhere not only is herbal cannabis the dominant product, but that market 
is largely supplied by sinsemilla. Few countries in Europe have THC measurements 
stretching back more than five years, and the data are somewhat compromised by 
analytical difficulties, sampling strategies and the varying nature of cannabis and 
cannabis resin. Also lacking is any evidence to show that users of high-potency cannabis 
have higher blood THC levels. The widely publicised claims that cannabis is now 10 
or more times more potent than it was 10 or 20 years ago are not supported by the 
evidence from Europe.
Introduction
The potency of cannabis is defined as the concentration (%) of ∆ 9-tetrahydrocannabinol 
(THC), the major active principal of the cannabis plant. As a broad guide, cannabis and 
cannabis resin typically contain 2–8 % THC. However, as will be discussed later, certain 
products may contain appreciably more. Cannabis grown for fibre production (hemp) 
will normally contain less than 0.3 % THC. Although references will sometimes be found 
in the literature to ‘cannabis purity’, this term is ambiguous and could refer to whether 
or not the material has been adulterated. For example, in the publication Global Illicit 
Drug Trends (UNODC, 2003), ‘purity levels’ of herbal cannabis and cannabis resin are 
either clustered around 1 to 10 %, where they probably reflect the THC content, or they 
are much higher, typically above 50 %, suggesting some other measure of purity.
The chemical structure of THC is shown in Figure 1(a). It is one of a large number of 
related substances known as cannabinoids. Other major constituents of cannabis and 
cannabis resin are cannabinol (CBN; Figure 1(b)) and cannabidiol (CBD; Figure 1(c)). 
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It has been suggested that CBD can act as an antagonist of THC (Smith, 2005). This 
would be of some concern if, as THC levels increased, the CBD concentration stayed 
constant. However, as far as can be determined from the limited published analytical 
data, there is a positive correlation between the THC and CBD levels (King et al., 
2005a). Cannabis resin has higher relative levels of CBD than herbal cannabis, but the 
pharmacological significance of this is unclear.
A large fraction of the THC may be in the form of ∆9-tetrahydrocannabinolic acid 
(THCA). When cannabis is smoked, THCA is converted to THC, although other 
substances are also formed (Hazekamp, personal communication, 2004). The active 
isomer ∆8-THC is found in much smaller amounts. The highest levels of THC occur in the 
resinous material produced by glandular trichromes, mostly situated around the flowers 
of the female plant. Fertilisation and consequent seed production cause a reduction in 
the level of THC. Much lower amounts are present in the leaves and in male plants, 
while the stalk and clean seeds contain almost no THC.
Atmospheric exposure of THC causes oxidation to cannabinol (CBN; Figure 1(b)) and 
other substances. In cannabis resin, Martone and Della Casa (1990) showed that, even 
when stored in the dark, the half life of THC was often less than one year, and in some 
cases THC had disappeared almost completely within two years. In a block of resin, this 
could lead to variations in the THC concentration between the outside and the inside. 
The rate of THC decomposition in cannabis at room temperature was estimated as 
H3C
H3C O
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CH3
C5H11
H3C
H3C O
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Figure 1: The structures of three major cannabinoids (THC, CBN and CBD) 
Notes: (a) ∆9-tetrahydrocannabinol (THC); (b) cannabinol (CBN); (c) cannabidiol (CBD).
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17 % per annum by Ross and ElSohly (1997–1998). Since CBN is almost entirely absent 
from fresh cannabis, these authors suggest that the ratio CBN/THC could serve as a 
measure of the age of a sample. The relevance of this to questions of potency can be 
understood when it is realised that some imported products may have been harvested 
or manufactured many months before consumption or analysis. By contrast, local 
production will lead to a fresher product containing more THC.
During the past few years, some concern has been expressed that the potency of 
cannabis could be much greater than it was. It has been suggested that the THC 
concentration may have increased so much that the illicit drug now bears little 
resemblance to the cannabis that was used only 30 years ago. A widely publicised 
example of this is the statement by the so-called ‘drug czar’ in the USA (Walters, 
2002), published in the Washington Post, that ‘parents are often unaware that today’s 
marijuana is different from that of a generation ago, with potency levels 10 to 20 times 
stronger than the marijuana with which they were familiar’. In a similar vein, Henry 
(2004) commented on the apparent increase in association between cannabis and 
deaths recorded as accidents and suicides. He is quoted as saying, ‘until the early 
1990s, there was less than one per cent tetrahydrocannabinol in most cannabis. Now 
the most potent form, skunk, contains up to 30 per cent’. Most cannabis is smoked, 
and according to Ashton (House of Lords, 1998), ‘a typical “joint” today may contain 
60–150 milligrams or more of THC’.
Meanwhile, in some European countries the numbers of those entering specialised drug 
treatment centres, who are reported as having cannabis-related problems, have been 
rising (EMCDDA, 2004) and it has been suggested that high-potency cannabis may be 
a factor in this trend. High dose cannabis may also be a consideration in evaluating the 
impact of cannabis on the development of mental health problems such as psychosis, 
depression and schizophrenia (see, for example, Arseneault et al., 2004).
However, the potency question is not new. Nearly 20 years ago, Cohen (1986) noted 
that ‘material ten or more times potent than the product smoked ten years ago is being 
used, and the intoxicated state is more intense and lasts longer’. But Mikuriya and 
Aldrich (1988) pointed out that the cultivation of sinsemilla and its superiority to other 
forms of cannabis was well known to the British government in India in the 19th century. 
So what is the evidence that the potency of cannabis has increased in recent decades?
Changes in cannabis potency in Europe
The THC content of cannabis products is routinely determined in many European and 
other countries. Analyses are usually carried out in forensic science laboratories on 
behalf of law enforcement agencies, in some cases to provide evidence of cultivation/
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production. Some information on cannabis potency since 1998 can be found in the 
EMCDDA’s national reports (Standard Table 14). However, these data are rather limited, 
and no clear trends can be detected. In a recent study (King et al., 2004), much more 
data were collected, although information on potency trends over five years or more 
was only available from five countries and a number of methodological problems and 
information gaps existed. The participants in that survey were asked, by means of a 
questionnaire, to provide annual mean values of THC percentage in cannabis products, 
together with information on sample sizes, sampling strategies, method of analysis, 
the relative consumption of different cannabis products and other information. Despite 
the limitations, a fairly clear pattern emerged from the survey. Firstly, the potencies of 
resin and herbal cannabis that have been imported into Europe have shown little or 
no change, at least over the past 10 years or so. This is hardly surprising since these 
products have been made by traditional methods that have probably remained the same 
for generations (see Gamella and Jímenez, this monograph). A brief summary of those 
findings and a discussion of the implications has been provided by King et al. (2005b). 
Figure 2 shows the potency of cannabis resin over the period 1997–2003 in the original 
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Figure 2: Mean potencies of cannabis resin in seven European countries
Notes: UK, United Kingdom; NL, Netherlands; D, Germany; CZ, Czech Republic; P, Portugal; A, Austria; 
F, France.
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six countries reported by King et al. (2004) together with data subsequently received 
from France (OFDT, 2005).
The rapid rise in potency in the Netherlands after 1999 can be explained by the 
local production of cannabis resin. This material, known as nederhasj, is not only 
uncommon in the Netherlands, but is almost unknown elsewhere. When the data from 
the Netherlands are excluded from Figure 2, no overall trend is apparent in the overall 
mean potency. In the United Kingdom, THC measurements date back 30 years, and the 
annual mean potencies of cannabis resin as shown in Figure 2 are, if anything, slightly 
lower than those in the period 1975–1989 (Baker et al., 1980, 1981, 1982; Pitts et al., 
1990; Gough, 1991). Cannabis (hash) oil is uncommon in Europe, but its THC content 
has also shown no clear trend over many years (Baker et al., 1982; Gough, 1991; 
King, 2001).
What has changed throughout Europe and elsewhere is the appearance, from the early 
1990s, of herbal cannabis grown from selected seeds by intensive indoor methods. 
This material, best described as domestically produced ‘sinsemilla’ (from the Spanish, 
‘without seeds’), is also known as ‘skunk’, ‘buds’, ‘tops’ or ‘nederwiet’. Its hydroponic 
cultivation, with artificial control of ‘daylight’ length, propagation of female cuttings and 
prevention of fertilisation, certainly does produce cannabis with a greater potency; on 
average, it may be twice as high as imported herbal cannabis. Further information on 
the production of sinsemilla can be found in the reviews by Szendrei (1997–1998) and 
Bone and Waldron (1997–1998).
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Figure 3: Mean potencies of two types of herbal cannabis examined in the United 
Kingdom
Note: The total sample sizes were: sinsemilla = 938; imported herbal = 117. Source: Forensic Science 
Service.
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The THC content of herbal cannabis in the United Kingdom is shown in Figure 3. 
However, it must be recognised that it is not always possible for a forensic scientist 
to distinguish the two forms of herbal cannabis. To a large extent, the definition of 
material as sinsemilla must rely on other circumstances, such as the characteristics of 
the plantation or ‘grow room’. This information may not always be provided by law 
enforcement agencies and hence some confounding of the two forms may occur. This 
is illustrated in Figure 3 where the rise in the potency of imported herbal cannabis 
after 1998 could be an artefact. A similar, albeit modest, rise in the potency of herbal 
cannabis was also found in Germany (see Figure 4) although no distinction was 
made between traditional (i.e. imported) herbal cannabis and material produced by 
hydroponic methods. A small rise in the potency of herbal cannabis was reported by the 
Czech Republic, but no information was available on the sampling strategy or sample 
sizes. Further evidence that sinsemilla has a higher potency than imported cannabis 
can be seen in data produced by the Netherlands (Figure 5). Potency data for herbal 
cannabis in France are shown in Figure 6, and represent the overall annual mean 
values for both police and customs seizures (OFDT, 2005). No distinction was made 
between traditional imported herbal cannabis and sinsemilla, but in each year the mean 
potency of material examined by the police was close to the mean potency of customs 
cases. Furthermore, for both herbal cannabis and resin in France, there was little 
difference in the THC content, according to whether the samples had been seized by law 
enforcement agencies or the samples had been collected from users (Bello et al., 2005). 
As with the other countries for which trend data were supplied (Austria and Portugal), 
little evidence was found for an increase in the potency of imported herbal cannabis.
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Figure 4: Mean potencies of all herbal cannabis in Germany
Note: Figures against each point represent the number of measurements.
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The most recent data from the Netherlands (Pijlman et al., 2005) show that the THC 
content of cannabis products has increased even further than illustrated in Figure 5. 
However, these data need to be interpreted with caution since the Netherlands is 
anomalous for several reasons. Firstly, in all other countries in the EU the available 
THC data derive from the analysis of law enforcement seizures. In the Netherlands, 
the material examined has been purchased in coffee shops: establishments that are 
permitted to sell small amounts of cannabis (see Korf, this monograph). The samples 
purchased were generally of better quality material and may not have been necessarily 
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Figure 5: Mean potencies of two types of herbal cannabis in the Netherlands
6
1999 2000 2001 2002 2003
1
0
291
253
318
541 509
603
1998
Year
M
ea
n 
po
te
nc
y 
(%
)
2
3
4
5
7
8
Figure 6: Mean potencies of all herbal cannabis in France
Note: Figures against each point represent the number of measurements
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Figure 7: Frequency distributions of THC in herbal cannabis examined in the United 
Kingdom
representative of all cannabis products consumed. This may explain the finding that 
the cannabis resin purchased for analysis also had a much higher THC content than 
is seen elsewhere in Europe. Secondly, as noted elsewhere in this report, the relative 
consumption and origins of cannabis products available in the Netherlands is quite 
different to other countries.
There is little doubt that, on average, sinsemilla has a higher potency than imported 
herbal cannabis, but it is also clear that the two potency distributions overlap, as shown 
in Figure 7. Some samples of imported cannabis are, and always have been, of high 
potency. The increased THC content of herbal cannabis produced by indoor methods is 
a consequence of a number of influences. These include: genetic factors (selected seed 
varieties and cultivation of female plants); environmental factors (cultivation technique, 
‘pruning’ during harvesting, prevention of fertilisation and seed formation); and 
freshness (production sites are close to the consumer and storage degradation of THC is 
thereby reduced).
More recent data from the UK for 1999 to 2005 (Figure 8) show that the THC content of 
sinsemilla may have increased further, probably as a result of continual improvements 
in technique. Figure 8 also shows, for comparison, the frequency distribution of THC in 
cannabis resin. Whereas the shape of the distribution of THC in sinsemilla is reasonably 
symmetrical, the distributions of both imported herbal cannabis and cannabis resin are 
strongly skewed, with the most common values occurring at the lowest end of the scale.
The increases that have occurred with time in the potency of some types of cannabis 
must be put into the context of the relative consumption of the various products in 
Source: Forensic Science Service, 1996 to 1998.
Understanding cannabis potency and monitoring cannabis products in Europe
250
different countries. Table 1 sets out estimates of the relative proportion of each cannabis 
product on the domestic market in recent years. These estimates are shown for those 
countries where data were either available in the published literature, were supplied 
directly in response to a questionnaire in the EMCDDA study (King et al., 2004) or were 
derived indirectly from the relative number of samples examined in each case.
Using both potency data and a knowledge of the relative consumption of different 
products as shown in Table 1, it is possible to derive the weighted mean potency, that 
Table 1: Relative consumption (%) of cannabis products in European countries 
since 1999
Country Imported cannabis Cannabis resin Sinsemilla Domestic resin
Belgium 80 (1) 20 (2) – –
Czech Republic 90 (1) 10 (2) – –
Germany 40 (1) 60 (2) – –
Estonia 85 (1) 15 (2) – –
Ireland 5 90 5 –
Netherlands 3 29 67 1
Austria 70 (1) 30 (2) – –
Portugal 10 (1) 90 (2) – –
United Kingdom 15 70 15 –
(1) All herbal, imported or not.
(2) All resin, imported or not.
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Figure 8: Frequency distributions of THC in cannabis resin and sinsemilla examined in the 
United Kingdom
Source: Forensic Alliance, 1999–2005.
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is, the effective THC concentration as would be perceived by the average user. Figure 9 
shows the effective potency averaged over all cannabis products in several European 
countries.
Except for the Netherlands, where it is a dominant product, the limited market share 
experienced by sinsemilla in other countries suggests that, other aspects of behaviour 
being constant, users have not been exposed to significantly larger amounts of THC. 
Although not shown graphically here, UK data for the earlier period 1975 to 1989 
indicate that the effective potency in the UK has been around 6 % for the past 30 years. 
In Ireland, where resin is also the main product, the effective potency in 2000 was closer 
to 4 %.
If the effective potency of cannabis had shown an appreciable rise over the past 10 to 
20 years then it might be assumed that users would need to consume less cannabis on 
a weight basis. However, the content of reefer cigarettes (also known as joints or spliffs) 
examined in the UK over the past 20 years has been remarkably constant (Figure 10). 
Thus, the typical reefer contains 150–200 milligrams of cannabis or cannabis resin, 
equivalent to around 10 mg of THC (Humphreys and Joyce, 1982; Bal and Griffin, 
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Areas for improvement in analysis and 
interpretation
If a more accurate picture of potency trends is to be obtained then a number of areas 
require attention. Apart from a purely quantitative need to obtain more data, these 
improvements include the following.
Nomenclature of cannabis products
A particular need is the use of an agreed scheme for describing and naming imported 
herbal cannabis and sinsemilla. At present, a wide variety of terms are in use by 
authors, including ‘seeded cannabis’, ‘skunk’, ‘tops’, ‘buds’ and ‘nederwiet’. Even 
the term ‘imported’, usually implying a source such as the Caribbean, Africa or Asia, 
may not be ideal since, in some cases, sinsemilla may be imported from elsewhere in 
Europe. As noted earlier, confusion may still occur if the growing conditions of the plant 
material are uncertain, since visual examination of isolated plant material is not always 
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Figure 10: Mean herbal cannabis and cannabis resin content of reefer cigarettes examined 
in the United Kingdom over a 20-year period
Note: The sample size in each case is shown. Source: Forensic Science Service.
2001). Similar results were found in Ireland (Buchanan and O’Connell, 1998). The 
assertion by Ashton (House of Lords, 1998) that ‘a typical “joint” today may contain 
60–150 mg or more of THC’, suggests a potency of over 50 %.
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conclusive. Yet, the alternative possibilities for classification (THC content, size of seizure, 
type of cultivation, such as indoor or outdoor or level of sophistication) also seem 
unsuitable.
Relative consumption of cannabis products
In most countries, estimates of the relative consumption of different cannabis products 
are based largely on seizure data. Such data have limits and may not directly reflect the 
relative market share of different cannabis products or availability as experienced by 
drug users. One way forward would be to complement statistics from drug seizures with 
data from user surveys carried out at the retail level. This might also include information 
from seed suppliers and shops selling growing equipment/paraphernalia.
Proxy measures of potency
Few countries have published data on the herbal cannabis or cannabis resin content of 
reefers. This information would be useful as a proxy measure for potency as well as a 
means of tracking methods of consumption (i.e. use with or without tobacco). In Europe, 
information is collected routinely by the EMCDDA on drug prices at retail level. However, 
the quality and comparability of this information needs to be reviewed and standard 
methods for collection and reporting developed. Data from the Netherlands suggest a 
close relationship between potency and price (Trimbos Institute, 2002).
Extent of domestic production
It is important to have a better understanding of the extent of domestic cannabis 
production, the different types of production methods used, as well as the use of 
domestically produced cannabis products compared with imported products and how 
this varies within Europe and over time. Furthermore, home-produced cannabis may not 
always benefit from hydroponics or other sophisticated growing techniques.
Data presentation
When compiling data, many laboratories calculate simple mean values (often called 
averages: the sum of all values divided by the number of values). In a few cases, 
weighted means may be calculated. These take account of the fact that not all samples 
may be of equal size. Few authors consider whether the distribution of potency is 
normally distributed or if other measures of central tendency such as the median or 
mode would be better. Ideally, data collections should always indicate details about the 
sampling strategy, sample size, the mean, and where possible more detailed descriptive 
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statistical information (e.g. mode and median values, standard deviation and treatment 
of outliers).
Sampling
Sampling is probably the most important variable relating to the measured potency 
of cannabis. Cannabis, and to a lesser extent cannabis resin, is an extremely 
inhomogeneous material. As noted earlier, the THC content of different parts of 
the plant shows considerable variation. As well as the flowering tops of the female 
plant, where most of the THC is located, a sample may contain varying amounts of 
stalk, seeds and leaves, none of which contains much active drug. If potency is to be 
compared between different laboratories, or even within the same laboratory at different 
times, then a standard method of sample preparation is required.
Laboratory analysis
Assuming that the THC in cannabis and cannabis resin can be solvent-extracted with 
total, or at least a known, efficiency, then most laboratories use gas chromatography, 
often with flame-ionisation detection (Raharjo and Verpoorte, 2004) to determine 
THC concentration. This has the merit that the naturally occurring precursor (THCA) 
is decarboxylated to THC, just as occurs during smoking. Cannabinoids can also be 
determined by high-performance liquid chromatography, a method suited to profiling 
(‘chemical fingerprinting’) and the separate measurement of THCA. To measure the total 
THC content by HPLC, the sample must be heat treated before analysis (Lehmann and 
Brenneisen, 1995; Rustichelli et al., 1998; Kanter et al., 1979).
The major issue to arise in the analysis of THC concerns the accuracy (closeness to the 
‘true’ value) of the measurement process. Poortman van der Meer and Huizer (1999) 
claimed that in a series of proficiency tests, using standard solutions of THC, and 
organised in 1997 for 30–40 European laboratories, the relative standard deviation was 
about 29 %, whereas cocaine and amphetamine gave less than 5 % and 8 % respectively. 
This means that around one-third of results for THC were either more than 29 % above 
or more than 29 % below the mean value. It is clear that even worse precision could be 
expected if the measurement error caused by the sampling and extraction process were 
to be included.
As a reference standard, THC is usually only available from chemical suppliers in the 
form of an ethanolic solution and may be labelled, for example, as ‘approximately 
95 %’. Not only could confusion arise if analysts assume the concentration to be 100 %, 
but Poortman van der Meer and Huizer (1999), using the response of a flame-ionisation 
detector, found that one sample of a commercial THC solution had only 90 % of the 
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concentration of a different commercial solution. These authors recommended that THC 
quantification should be based on cannabinol or cannabidiol as the internal standard 
and a correction made for the expected detector response from the effective carbon 
number of the respective substances. They claimed that this method had been used 
in Germany for the past 10 years. It was also the method used by Maguire (2001) to 
study the cannabinoid content of (mostly fibre-type) cannabis in Ireland. However, as 
far as could be determined in the EMCDDA study (King et al., 2004), other European 
laboratories continue to prepare standard dilutions of stock THC solution to construct 
calibration curves.
To a large extent, and excluding the special situation of locally produced Dutch 
nederhasj, the cannabis resin consumed in Europe in recent years has originated mostly 
from North Africa, with smaller amounts coming from South-West Asia. Since resin is 
rarely adulterated, it could be argued that, in any given year, all laboratories have been 
measuring broadly similar material. Despite the variation of THC content in cannabis 
products discussed above, if those laboratories had made sufficient measurements, 
then the mean potency of cannabis resin in any year should be found to be similar 
for all countries. Inspection of Figure 2 shows that not only is there no time trend, but 
there is considerable variation in the reported THC levels, both against time in any one 
country and between countries at any one time. It is not obvious why there should be 
consistently less THC in cannabis resin in Portugal compared with cannabis resin in, for 
example, the Czech Republic or France. This finding raises questions about the accuracy 
of measurement of THC in different laboratories. In other words, if all analysts had used 
the same THC reference standard for instrumental calibration, then these differences 
might not have occurred.
Pharmacology
In Europe, cannabis is normally smoked often in a mixture with tobacco in a reefer 
cigarette, but some is smoked in a water pipe (a bong). By contrast, in the USA where 
little resin is consumed, cannabis is usually smoked alone. Furthermore, the sources of 
cannabis and cannabis resin consumed in North America are not the same as those in 
Europe. Nearly all studies on the smoking of cannabis and its relation to potency have 
been carried out in North America, and it is clear that this research may not translate 
well into the European situation. Thus Matthias et al. (1997) found some evidence that 
those who smoke more potent cannabis are less exposed to noxious smoke components 
than those who use less potent forms. But in Europe, or at least in Ireland and the 
United Kingdom, where a reefer cigarette typically contains only 150–200 milligrams 
of cannabis (Buchanan and O’Connell, 1998; Bal and Griffin, 2001; Humphreys and 
Joyce, 1982), much of the tar, carbon monoxide and other combustion products will 
derive from the concomitant tobacco.
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The concerns that have been expressed about a possible rise in cannabis potency 
often assume that users will necessarily consume more THC, but the evidence for this 
is equivocal. If the potency of cannabis products has shown a marked increase, then it 
might be expected that the typical user would need to consume less on a weight basis to 
achieve the desired effect. Given a choice, users preferred cigarettes with a higher THC 
content (Chait and Burke, 1994; Kelly et al., 1997). Ashton (1998) also argued that 
users would not titrate the dose of THC from cannabis in contrast to tobacco smokers. 
However, Heishman et al. (1989) found that those smoking cigarettes with a higher THC 
content tended to have a lower inhalation rate than control subjects. Yet little research 
has been conducted, particularly in Europe, to answer a crucial question: do those 
smoking high potency cannabis have higher blood levels of THC?
However, even if the strength of some forms of cannabis has increased, and even 
assuming that, as a consequence, users do have higher blood levels of THC, then 
it cannot be concluded that this will translate into a greater harm to the individual. 
Experience with alcohol suggests that the health consequences are not simply related 
to the alcohol concentration of what is consumed, but rather it is the total quantity of 
alcohol consumed that is important. As Hall et al. (2001) note, age of onset of use and 
frequency of use are likely to be more influential than changes in potency in determining 
consumption levels.
Medicinal cannabis
In any discussion about the health impact of high-potency cannabis, mention 
should also be made of cannabis used for medicinal purposes (see also Witton, this 
monograph). In the Netherlands, herbal cannabis is available as a prescription medicine 
(Office of Medicinal Cannabis, 2004). It is indicated for multiple sclerosis, certain types 
of pain and other neurological conditions. Patients are advised to consume the cannabis 
by means of a hot water infusion. However, Hazekamp (personal communication, 2004) 
has found that, even in boiling water, the conversion of THCA to THC can take some 
hours and other byproducts are formed. Remarkably, one of the forms of this medicinal 
product, known as ‘cannabis flos’, has a nominal THC content of 18 % and is locally 
produced by the same intensive indoor methods that are used for illicit cultivation. 
Not only is high-potency cannabis considered suitable as a medicinal product, but 
an assessment carried out by the Dutch Coordination Centre for the Assessment and 
Monitoring of New Drugs concluded that (illicit) higher-potency cannabis products 
did not pose any additional risk than those present for cannabis products as a whole, 
either to the individual, to society, to public order or criminality (W. Best, personal 
communication, 2004).
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Conclusion
The potency, that is, the THC concentration, of herbal cannabis produced by intensive 
indoor cultivation can average over 10 %, compared with an average of 5 % for both 
imported cannabis resin and cannabis grown by traditional methods. For all cannabis 
products there is a wide variation about average values and some users will inevitably 
have been exposed in almost random fashion to higher than normal THC levels in 
their careers. The evidence from Europe does not support the widespread claims that 
cannabis potency is now 10 or more times greater than it was in earlier periods. 
Although not part of this present review, experience from outside Europe (King et al., 
2004) comes to a similar conclusion.
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Chapter 15
Multinational export–import 
ventures: Moroccan hashish into 
Europe through Spain
Keywords: cannabis – cannabis resin – crime networks – criminology – Morocco 
– socio-economic analysis – trafficking
Setting the context
In recent decades, Morocco has emerged as the world’s largest producer and exporter 
of cannabis resin, or hashish. The Moroccan cannabis resin market is substantial: the 
country supplies over 70 % of the cannabis resin consumed in Europe, and half of 
global production (EMCDDA, 2006). Within Morocco itself, hashish is one of the key 
agricultural products of the provinces containing the Rif mountain range in northern 
Morocco, and an estimated 760 000 peasant farmers (2.5 % of the population) obtain 
their livelihoods from hashish. By 2003, Morocco’s cannabis resin production had 
reached 3 070 tonnes, with a retail market value estimated at over EUR 12 billion 
by the UNODC. Since then, cultivation has decreased substantially, due both to 
crop eradication efforts, political pressure placed on the Moroccan government and 
the damage wrought by a major drought in 2005. The most recent UN figures put 
production at around 1 070 tonnes, resulting in a retail market estimate of EUR 4.6 
billion.
The full picture of hashish trafficking is more complex. It is estimated that only about 
a tenth of the retail earnings are likely to end up in the pockets of Moroccan farmers, 
wholesalers and traffickers. The majority of profits are made lower down the supply 
chain once the resin has entered the EU. Most Moroccan hashish is exported through the 
Iberian peninsula, particularly Spain, a country that is today the crucial transit zone for 
Moroccan hashish sold in the European market. From Spain, cannabis resin is bounced 
through a complex network that unites producers, traffickers, dealers and consumers.
This chapter examines the export–import system of cannabis resin between Morocco and 
the EU through Spain. It combines a review of the literature on the Moroccan production 
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of hashish and a preliminary analysis of over 2 000 press reports using an event history 
analysis approach (Franzosi, 1995; Olzak, 1992). The result is data on 1 370 groups of 
importers and dealers apprehended during a 27-year period, and a first sketch of the 
structure of the multinational smuggling industry. The result is a typology of networks 
and groups who deal with hashish at different levels of a distribution pyramid, profiled 
according to the size of ‘project’ they manage. The chapter thus clarifies the importance 
of networks and hierarchies in illegal enterprises, the type of complex and impermanent 
structure that has received considerable attention in EU criminology literature (see Dorn 
et al., 2005).
A number of enforcement questions arise from this chapter. Given the strong decrease 
in Moroccan cannabis resin production, is supply moving elsewhere? A number of 
countries in northern Europe are reporting increasing use and domestic cultivation of 
cannabis herb (see Carpentier, this monograph), with an indirect effect on the potency 
of cannabis consumed (see King, this monograph). Recent press reports also suggest 
that Sub-Saharan Africa is stepping into a gap in the market: seizures of resin are 
increasing along the Saharan route via the North African coast, and countries such as 
Algeria, Libya, Niger and Mali have reported overall increases in seizures. However, 
given the fluctuation that characterises such seizure statistics, it is difficult to draw clear 
conclusions. Another question is whether Moroccan cannabis resin trafficking networks 
are diversifying into cocaine trafficking. This is a concern expressed by the Spanish and 
French authorities, together with Europol with some concern about cocaine seizures on 
the Cádiz coast, a traditional hashish route. Reported seizures of cocaine in Morocco 
have fluctuated greatly since 2000, peaking at 15.8 tonnes in 2002, yet with a wide 
range starting at 0.9 tonnes in 2000 to just over 4 tonnes in 2004 (UNODC, 2006).
Further reading
Dorn, N., Levi, M., King, L. (2005), Literature review on upper level drug trafficking, UK Home Office 
Online Report 22/05, London.
Europol (2005), European Union situation report on drug production and drug trafficking 2003–2004, 
Europol, The Hague.
UNODC (2007), ‘Invisible empire or invisible hand? Organized crime and transnational drug 
trafficking’, Chapter 2 in World Drugs Report 2007, United Nations Office on Drugs and Crime 
Control, Vienna.
UNODC and Kingdom of Morocco (2007), Enquête sur le cannabis 2005, United Nations Office on 
Drugs and Crime, Vienna.
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Multinational export–import 
ventures: Moroccan hashish into 
Europe through Spain (1)
Juan Francisco Gamella and Maria Luisa Jiménez 
Rodrigo
Introduction
The production of cannabis is a global phenomenon; 134 countries have been 
identified as source countries of this substance (UNODC, 2007). Two regions, however, 
concentrate the largest markets for cannabis products, and the largest accumulation of 
revenues: North America, where two-thirds of all cannabis products are sold, mainly 
in the form of marijuana, and Europe, the largest importer and consumer of resin or 
hashish (for more detail on the world cannabis market, see Legget and Pietschmann, 
this monograph).
(1) We want to thank Alicia Rodríguez Marcos for her help in collecting news clips, and Alexandra 
Bruehl, Aryelle Goins and Isabel Velez for their suggestions and corrections to previous versions of 
this paper.
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While the production of herbal cannabis is widely dispersed around the planet, including 
a growing number of European home-growers, the production of resin is centred in 
a few countries such as Morocco, Pakistan, Afghanistan, Lebanon and Nepal. Among 
them, Morocco has become the world’s largest producer and exporter, supplying over 
70 % of resin consumed in Europe (EMCDDA, 2007). Although statistics vary widely, 
in recent years Morocco’s hashish production has declined from 3 070 tonnes in 2003 
to 1 070 tonnes in 2005 (UNODC, 2007). Average retail prices for cannabis resin is 
reported in Europe at between EUR 2.30 and EUR 11.40 per gram, while cannabis 
resin seizures for 2003 in Spain and Portugal were reported at 809 tonnes, or just 
over a quarter of Moroccan production (EMCDDA, 2006). The UNODC’s estimate of 
the annual international market for Moroccan cannabis resin has seen a decline from 
EUR 10.8 billion in 2004 to EUR 4.6 billion in 2005.
Most Morocco-produced hashish is exported through Spain, a country that is today the 
crucial transit zone for Moroccan hashish sold on the European market (Figure 1). In 
2003, out of the 757 tonnes of Moroccan resin seized in the EU, 727 tonnes (over 90 %) 
were seized in Spanish territory or jurisdictional waters (UNODC, 2005). This binational 
industry has exploded in the last three decades from a traditional base of rural growers 
in the Ketama region, whose products were distributed from the late 1960s by hippie 
entrepreneurs. In the last decade, smuggling networks have begun to move faster and 
further, and to establish international connections with traffickers of other drugs, for 
instance with large cocaine exporters from South America, who are increasingly using 
the routes opened by the distribution of Moroccan hashish.
The 14 km of the Strait of Gibraltar, and the frontier around the Spanish enclaves of 
Ceuta and Melilla, make up one of the deepest socio-economic and cultural divides on 
the planet (2). Disparities in wealth, income, demographic structure, educational and 
labour opportunities are huge and stimulate a licit and illicit movement of persons that 
in many ways parallels the movements of drugs, money and manufactured products. 
This is a crucial frontier for the EU and its policies concerning development, immigration 
and drug control.
This chapter examines the export–import system of cannabis resin between Morocco 
and the EU through Spain. First, we will review what is known about the extent, location 
and organisation of cultivation and manufacture in northern Morocco. We will then 
explore the structure of the import industry using Spanish data. We will consider the 
type of organisations and networks that participate in this trade, their structure, and the 
tasks their members perform in their transactions. We will also examine the profile of 
(2) In 2004 the GNI per capita of Spain was 14 times that of Morocco; the GNI per capita of France 
was 20 times that of Morocco. By comparison, the US GNI per capita was six times that of Mexico, 
its southern neighbour (World Bank).
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workers and entrepreneurs in these groups, and the changes that seem to have occurred 
in recent decades. We will also present some observations about the permanence of 
the smuggling networks and organisations, their strategies to avoid detection, and the 
pricing tendencies in this market. This information may help to clarify the importance of 
networks and hierarchies in illegal enterprises (Morselli, 2001; Natarajan and Belanger, 
1998; Ruggiero and South, 1995; Reuter and Haaga, 1989; Adler, 1985; Reuter, 
1984), and the nature of the cannabis industry.
Data sources
We use a combination of primary and secondary data sources, including prior studies 
and reports published by international agencies, data from our ethnographic fieldwork 
in drug trading environments and our ongoing research and analysis of seizure cases 
published in the Spanish press from 1976 to 2003. In this period, thousands of illegal 
deals were prevented. The press reports on these failed transactions provide important 
insights on the structure of hashish distribution and the character of drug trafficking 
organisations. We have applied to this topic the methodology of event analysis as it has 
been developed by historians in their study of collective actions along a wide time span 
(see Franzosi, 1995; Olzak, 1992; Tilly et al., 1975).
Production and manufacture in Morocco
In the past 20 years, cannabis cultivation has spread in all directions from the traditional 
areas in the central Rif, where it has been present since the 15th century (OGD, 1996). 
However, recent crop eradication efforts, together with the effects of a drought in 
2005 have led to a strong decline in cultivation from 2004 until 2006. From the early 
1980s to the 2000s, the area devoted to cannabis seemed to have multiplied by 20, 
and doubled every three to five years. There is considerable agreement in the literature 
about this rising trend in the various estimations available, notwithstanding their 
disparities (see Labrousse and Romero, 2001). This constant growth occurred despite the 
well-publicised campaigns by the Moroccan government in the 1990s to eradicate drug 
trafficking (Ketterer, 2001).
Recently the UNODC has undertaken detailed surveys of cannabis cultivation with the 
cooperation of the Moroccan government (UNODC, 2004, 2005, 2006). These surveys 
provide the most accurate data on the extent, characteristics and value of cannabis 
production in the country today. Table 1 summarises their results.
Most kif, as cannabis is locally known, is grown in four northern provinces along the Rif 
mountain chain. One province alone, Chefchaouen, accounts for 56 % of cultivation, 
followed by Taounate (17 %), Al Hoceima (16 %) and Tetouan (11 %). A further province, 
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Larache, reported no significant cannabis cultivation following a crop eradication 
programme in the summer of 2005. In Chefchaouen a quarter of arable land was 
planted with cannabis in 2005, while in other provinces this share was between 3 % and 
10 %. Cannabis was grown in three out of four duars (villages), mostly in smallholdings. 
Nearly 90 000 families grew kif, obtaining about half their income from cannabis (Dh 
38 900 or EUR 3 600). About 760 000 peasants live from this illicit crop (UNODC, 2005) 
and other estimations are even larger (3). Kif has become a pillar of the economy.
A hectare planted with kif produces 2–8 tonnes of raw plant (2.3 tonnes on average) 
depending on soil conditions, irrigation, use of fertilisers, etc. The estimated resin 
production for 2005 was 1 066 tonnes. Productivity varies from year to year, often 
drastically. This is typical of dry farming conditions in the Mediterranean basin, due to 
great oscillations in rainfall. Part of the crop is locally consumed, mostly in the form of 
low-grade marijuana, which has been traditionally smoked in the region since the 16th 
century (OGD, 1996). Nevertheless, most of the production is exported to European 
markets in the form of resin or hashish. Programmes for substituting cannabis with 
alternative crops have failed so far, although significant progress was made from 
2004 until the time of publication in 2008. Kif is 12 to 46 times more profitable than 
traditional cereal crops, such as wheat and barley (Labrousse and Romero, 2001). In 
fact, some of the best plots, previously devoted to food crops, are now used to grow 
cannabis, and forest land has been cleared to plant kif.
Manufacturing: from kif to hashish
Farmers sell both raw cannabis plants, and powder (sandouk). According to UNODC, 
35.4 kg of raw cannabis are needed to make 1 kg of hashish. Extracting resin powder 
from plant material increases profits by about 13 % (4) (UNODC, 2005). Pascual Moreno 
offered different estimations. According to his fieldwork, extracting the resin dust from kif 
would increase profits by up to 66 % (5). However, the risks of being denounced to the 
police also increase (Labrousse and Romero, 2001). Thus, it seems that two out of three 
farmers sell raw plants to manufacturers and middlemen.
(3) Pascual Moreno, an agronomist, director of an EU substitution program in the Rif, has worked for 25 
years in the region. He estimated that over 200 000 smallholders cultivated cannabis in the Rif in the 
early 2000s, covering a total area of around 250 000 hectares and affecting from 1 to 1.5 million 
people (cited in Labrousse and Romero, 2001).
(4) The difference in price is from Dh 3 500 for 100 kg of raw cannabis to about Dh 3 950 for the 2.82 kg 
of resin obtained from them.
(5) According to Pascual Moreno, 100 kg of kif will get the farmer 5 200 Dh. The 3.5 kg of hashish that 
can be obtained from the 100 kg, Dh 8 750, a further profit of Dh 3 500 (Labrousse and Romero, 
2001).
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Hash oil is more concentrated and valuable than hashish itself, and is also easier 
to conceal and to transport. 10 kg of hashish is needed to produce 1 kg of oil. The 
techniques for hash oil production were introduced to Morocco in the 1960s following 
Lebanese and Pakistani methods, in what is claimed to be a dual initiative of both 
foreign and Ketami traffickers to address export demand and to increase the value of 
their products (Labrousse and Romero, 2001).
Farm prices and export prices
Cannabis offers a good source of income for small farmers in an underdeveloped 
region, even though the farmer only receives a small part of the retail price of hashish. 
According to UN data for 2003, farmers sell 1 kg of resin for Dh 1 400, or about 
EUR 130. In Spain, the same kilogram could be sold for EUR 2 725 at wholesale prices 
(UNODC, 2007) or around EUR 4 400 at retail prices (EMCDDA, 2006).
Export prices in Morocco vary considerably, depending on quality, amount purchased, 
place of acquisition, etc. If bought directly from the farmers, a gram of best quality 
hashish (sputnik, doble cero) could reach a price of EUR 0.45 to EUR 0.75 (6). Second- 
or third-rate hashish will get a third of that (Labrousse and Romero, 2001). In our 
own research we have found prices as low as EUR  0.10 per gram, or EUR 100 per kg 
for larger quantities. A common price of second-rate hashish would be EUR 0.50 per 
gram for those who smuggle up to 1 kg. In one field trip to Chefchaouen in 2001, for 
instance, we knew of three Spaniards who bought 500 g of second quality hashish at Dh 
8.5, about EUR 0.60, per gram. They felt cheated, because the sample they were shown 
in advance was of much better quality. However, they retailed most of the batch in Spain 
at about EUR 4.00 per gram, which paid for the costs of their trip, together with a small 
profit.
Comparing different sources, including our fieldwork, we estimate that export prices 
oscillate between EUR 0.10 and EUR 1.00 per gram of hashish. The total country 
earnings of the Moroccan hashish industry includes farmers’ revenues, exporters’ profits 
and remittances from Moroccan traders and dealers abroad. If about 2 200 tonnes of 
Moroccan hashish were successfully exported in 2003, earnings could be estimated in 
the range of EUR 1 billion to EUR 1.5 billion. In any case, earnings are multiplied by 
a factor of 8 to 10 when sold in Europe. Compared with the price paid by consumers, 
at about EUR 5.4 per gram of resin, the total turnover of the market for Moroccan 
cannabis could be estimated at EUR 12 billion. Yet most of this is generated in European 
markets and is invested in Europe.
(6) In 2001 we noted that in a café in Chefchaouen, a 10 g egg of good quality hashish retailed at 
around EUR 1.50 for foreign customers.
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The commodity chain of hashish: private and public actors
Smallholders in the Rif economy grow cannabis plants both in rain-fed and irrigated 
plots. They often hire labourers in summer months, mostly in August, to harvest the 
plant. Once harvested and dried, plant material is sold to middlemen who extract the 
sticky dust, especially from the tops of the female plants, press it into balls or blocks 
of hashish and often adulterate it. Intermediaries then stockpile large amounts of the 
product in central locations such as Tangier, Tetouan, Al Hoceima and Asilah and 
have the resin sent to Ceuta and Melilla or across the Strait of Gibraltar to Spain. From 
Spanish locations, the product is then distributed to all European countries directly, or 
to the Netherlands, which serves as a secondary distribution centre for northern Europe 
(Korf and Verbraeck, 1993; De Kort and Korf, 1992).
A pyramid-like structure may be at work, with middlemen buying kif or sandouk from 
peasants and producing blocks of hashish of different qualities, stockpiling them, and 
transporting them to storehouses (Labrousse and Romero, 2001).
Cannabis fields are visible from the roads, and there is no attempt to hide them. Every 
summer, busloads of workers arrive to work in the kif harvest and thousands of tonnes 
of plant product are moved, apparently within reach of police officers. Bribery may be 
widespread, and a local joke tells of traffickers who count distances by the number of 
bribes they have to pay (Labrousse and Romero, 2001; Ketterer, 2001).
Some cannabis resin networks use a legal business as a façade and have no difficulty 
recruiting from the young and unemployed in what is a poor region. Among the higher 
echelons, there is evidence that the hashish trade has become industrialised. The 
Observatoire Géopolitique des Drogues (OGD) notes that hashish exporters are involved 
in large Moroccan firms in agribusiness, fishing, transportation, and import–export 
operations. There is some speculation that this would mean a shift away from the 
Tangier cartels and toward the Casablanca cartels, which are more acceptable to the 
government because they do not contest state power in the same way (Ketterer, 2001).
Export practices serve to link expatriate Moroccans in different European countries 
with drug distributors in the target country. Drug money has changed the consumption 
patterns of the region. Ketterer recently described the scene:
Driving east from Tangier along the Mediterranean coast, the signs of drug power are 
obvious: heavily guarded villas with strangely stylised pagodas, frequent roadblocks with police 
looking for the next payoff and an endless supply of young men going about their workdays in 
the drug business.
(2001)
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Corruption of public officials is part of the operating routine of illegal businesses (Reuter, 
1984). In the case of the Moroccan cannabis resin trade, it is difficult to avoid the 
conclusion that involvement or interested acquiescence of law enforcement officials must 
be widespread, considering the level of cultivation, storage and export in place. Some 
scandals have revealed the involvement of powerful actors in the Moroccan political 
scene. For instance, in November 1995, data from a secret report of the OGD appeared 
in the French newspaper Le Monde, alleging public sector corruption had reached the 
highest political levels, including the royal entourage (7). The Moroccan government 
sued the newspaper. A backlash against the drug trade produced several notorious 
arrests and trials in the following months and years. These revealed the connections that 
operated in the hashish trade between public officials and entrepreneurs.
Two major drug traders had become leaders of networks in the north and had become 
a threat to state power. One of them, Yakhaoufi, was arrested in late 1995. His 
subsequent trial revealed a sophisticated and massive organisation with international 
scope. His own organisation transported hashish out of the central Rif, stockpiled it in 
Tetouan, shipped it to Spain by sea, then delivered it to wholesalers in Amsterdam. In 
addition to bank accounts in Morocco, Spain, Gibraltar and Canada, along with a yacht 
and 15 cars, Yakhloufi boasted of personal, commercial and political ties to the Castro 
regime in Cuba. These ties facilitated contacts with the Colombian cocaine cartels, which 
craved Morocco’s easily penetrable borders as distribution points into Europe. Yakhloufi 
was sentenced to 10 years in jail and died of an apparent heart attack in 1998. ‘He 
was too dangerous — he knew too much,’ said one Tangier street dealer of Yakhloufi’s 
death (Ketterer, 2001).
A second major figure in the cannabis resin trade in Morocco was H’midou Dib. He 
retains folk hero status in northern Morocco. A former fisherman, he constructed his 
own port in Sidi Kankouch on the coast north of Tangier, which was an embarkation 
point for a steady stream of speedboats. Dib constructed an enormous network of 
loyal foot soldiers and villagers eager to protect him. He supplied jobs, built mosques, 
delivered social services and kept the despised authorities at bay. Dib was also involved 
in complex real estate transactions in Tangier, money laundering operations and other 
elements of organised crime.
The Dib trial revealed other links between drug traffickers and government officials, 
including two advisors to former governors in the Tangier province, three civilian police 
colonels, the military police colonel in charge of coastal surveillance and three former 
chiefs of the Tangier urban judiciary and national security police services. Some of these 
officials were fired, arrested and tried, but it is clear that the cleansing campaign of the 
mid-1990s did little to curb the growth of the drug trade or its ties to official Morocco 
(Ketterer, 2001).
(7) See www.ifex.org/en/content/view/full/60123 for further details.
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Sociopolitical and ecological consequences
The cannabis industry has had powerful effects on the society of northern Morocco, the 
ecology of the region and its political relationships with the rest of the country. Cannabis 
plots have expanded so fast and so far into hillsides that they are causing soil erosion 
and the destruction of old forests (Bowcott, 2003; Labrousse and Romero, 2001). 
Moreover, they compete with the best land for traditional food products and now the 
region is dependent on food imports. On the other hand, the Rif has traditionally been 
an impoverished region, discriminated against in investment and infrastructure and 
driven by resentment towards the central government and the accumulation of wealth 
and power in the hands of a few. In the years after independence, people in the region 
revolted and were subjugated by military intervention that caused thousands of deaths 
(OGD, 1996).
Today, the economy of northern Morocco depends heavily on the kif trade and is 
becoming a society of smugglers, both of people and commodities into Europe, and 
manufactured goods into Morocco, with multiple links with Costa del Sol real estate 
business, Gibraltar offshore banks, and Ceuta and Melilla smuggling organisations. 
Furthermore, the drug trade affects the crime situation in the country. Some networks 
of drug traffickers are very often involved in other drug-related crimes and activities. 
Moreover, there are certain crime prevention-related phenomena inherent to the country 
and its traditions, namely child labour, some involvement of underage recruitment in 
liberation movements (mostly in the Western Sahara region), trafficking of human beings 
and smuggling of migrants (UNODC, 2003).
A young, growing and often restless population looks to the other side of the 
Mediterranean for jobs, money and a better future. As Ketterer (2001) observed, 
northern Morocco represents a challenge for the Moroccan state. The region has a 
potent mix of discontent, drugs, organised political opposition and religion. Morocco’s 
drug barons have steadily become a serious crime problem and security threat, and 
also major players in the domestic political system. Moreover, there is a growing 
evidence that violent Islamist cells have become involved in the hashish trade both in 
Morocco and in Spain. Tragically, several major terrorists acts have been funded with 
hashish money (Wilkinson, 2003). The two most important so far are the bombing in 
Casablanca in May 2003, which left 32 people dead; and the train bombings in Madrid 
in March 2004, that killed 192 people and injured over a thousand (8).
(8) See, among others, ‘La masacre financiada por el narcotráfico’ [The massacre funded by drug 
trafficking], El Mundo, 15 April 2004.
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The other side of the Strait: smuggling kif into 
Europe
Hundreds of tonnes of hashish are smuggled into Europe every year from the Rif. This is 
a multifaceted export–import industry which enriches thousands of people. Balls, blocks 
and packages of hashish and hashish oil are carried to Europe by speedboat, fishing 
boat, cargo ships, cars, vans, trucks, small aircraft, and individuals who carry the drug 
in their bags, their clothes or their bodies (9). Hashish is hidden beneath vegetables, fish, 
wood and any other commodities crossing the Strait. Lately, Moroccan hashish and Latin 
American cocaine have been smuggled together, and South American networks are 
using West African connections with bases in Morocco to smuggle cocaine into Europe.
In Spain most hashish is seized at sea or in coastal areas, including docks, harbours, 
beaches and local roads. The most common route of entry crosses the provinces 
of Cádiz and Malaga, bordering the Strait of Gibraltar. However, more and more 
quantities have been seized as far away as Catalonia in the east, and Galicia on the 
north-west Atlantic coast, as drug smugglers use both faster and larger boats. One of 
the reasons for this displacement of smuggling routes may be the stricter control of the 
Strait trying to curb illegal immigration.
The constant growth of the hashish trade
If enforcement agencies’ data on seizures are an indicator of this trade, and not of 
police resources or priorities, the evolution of cannabis seizures in Spain shows the 
substantial growth of this drug industry in the last 15 years. Spain has recorded a 
continuous rise in cannabis resin seizures since 1980, reaching over half a million 
kg a year by the 2000s (Figure 2). Spain alone seizes more hashish than the other 
26 countries of the European Union (plus Norway) together. The increase might 
partly reflect the increase or improvement of police resources. However, the rise 
in confiscations in Spain parallels the spread of cannabis crops in the Rif, with the 
moderate tail-off reported for 2005 reflecting the reduction in cultivation reported 
since 2004. It is thus plausible that the increase in confiscations in Spain is mostly due 
to growth in the hashish trade. By comparison, seizures in Morocco have fluctuated 
throughout the last decade (Table 2).
(9) The World Customs Organisation splits cannabis resin seizures as follows: vessel, 56 %; vehicle, 
42 %; air, 1 %; mail, 0.1 % (Pierre Bertrand, WCO RILO unit, meeting at the EMCDDA, 29 November 
2004).
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Demand/supply: prices in Spain and Europe
Retail prices for cannabis resin vary greatly within and between European countries 
(see Carpentier, this monograph), with average prices reported in Europe at between 
EUR 2.30 (Portugal) and EUR 12.50 per gram (Norway) (EMCDDA, 2006). Average 
prices of cannabis resin, corrected for inflation, fell over the period 1999–2004 in 
EMCDDA reporting countries except in Germany and Spain, where prices remained 
stable, and Luxembourg, where a slight increase occurred (EMCDDA, 2006). In Spain 
prices tend to increase as one moves north. In Seville or Granada, for instance, in 
2003 retail prices of hashish ranged from EUR 2 to EUR 5 per gram, while in Bilbao 
or Barcelona they commonly ranged from EUR 3.5 to EUR 7. The quality of Moroccan 
hashish seems to oscillate considerably, although its potency has remained in a 
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Figure 2: Seizures of cannabis resin in Spain (kg), 1981–2005
Table 2: Seizures of cannabis in Morocco (kg), 1995–2005
1995 1996 1997 1998 1999 2000
Herb 35 808 38 521 27 956 37 161 46 136 83 720
Resin 110 245 64 769 71 887 55 520 54 755 143 946
Total 146 053 103 290 99 843 92 681 100 891 227 666
2001 2002 2003 2004 2005
Herb 68 169 88 529 69 058 318 610 115 000
Resin 61 356 66 394 96 306 86 800 92 423
Total 129 525 154 923 165 364 405 410 207 423
Source: UNODC, 2007.
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range of 5–14 %, with little sign that it has increased in the last decade (see King, 
this monograph). If export prices range from EUR 0.15 to EUR 0.60, retail prices 
provide a margin of 16–80 times cost. This is an important price differential, and the 
main incentive for the international trade, but does not seem larger than other drug 
businesses (see Moore, 1977; Reuter, 1985; Reuter and Kleinman, 1986; Wagstaff, 
1989; Reuter et al., 1990).
Event analysis from a sample of newspaper articles
We have applied to this topic an event analysis methodology developed by historians for 
the study of collective actions such as strikes and social protests across a wide time span 
(see Olzak, 1989; Franzosi, 1995). In this methodology, events are commonly defined 
as non-routine, collective, and public acts. The first step in this method is to establish 
formal rules for coding information on collective events using records from archives, 
newspapers, historical documents, and police and magistrate records. This allows 
information on different aspects of a particular type of collective action to be measured 
and compared across social systems or across time periods, as data are collected in 
commensurate dimensions (Olzak, 1989).
Historians have observed that newspapers provide the most complete account of 
events for the widest sample of geographical or temporal units (Tilly et al., 1975) and, 
despite the limitations of the newspapers as a source of socio-historical data, they 
often constitute the only available source of information. ‘Exclusion of newspaper data 
would prevent research in fields where no alternative data are available’ (Franzosi, 
1987). This is especially apt in the case at hand. However, as Franzosi has noted, ‘the 
validity of newspaper information is questionable: newspapers differ widely in their 
reporting practices and news coverage’. ‘The values, routines, and conventions of 
news organisations constrain the amount and nature of coverage devoted to any story’ 
(Kielbowicz and Scherer, 1986). Nevertheless, in using mass media reports, the type of 
bias more likely to occur ‘consists more of silence and emphasis rather than outright 
false information’ (Franzosi, 1987). In the study of illegal enterprises it is evident ‘that no 
data source is without error, including officially collected statistics’, but ‘in the absence 
of systematic and comparative validation, there is no a priori reason to believe that data 
collected from newspaper would be less valid than other commonly used sources’.
The sample of events
We have reviewed over 2 000 news reports from the newspaper El País, concerning 
cannabis seizures from May 1976 to December 2003. They describe 1 370 failed 
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schemes or projects of smugglers or distributors. On average, these events represent 
40.2 % of all cannabis seized during this period in Spain, with a considerable variation 
from year to year (standard deviation: 21.7). In total, our sample includes reports 
of about one out of every three groups detained in Spain for hashish trafficking in 
this 27-year period. We chose El País for the quality and consistency of its reporting 
concerning social issues, and because it is the only newspaper that is edited throughout 
Spain with local editions in all major regions, and, more importantly, because it has 
indexed all of its issues published since its first edition in May 1976. We have attempted 
to check the selected cases found in El País against other news and police reports of 
the same events. Our analysis is still ongoing, and the results we present here are 
provisional and tentative.
The organisation of smuggling and distribution of hash into Spain
We can draw some preliminary conclusions from our sample of events. In Table 3 we 
present the number of episodes described in our sample by the amount of cannabis 
seized. In most cases the substance confiscated was hashish, although some herbal 
cannabis was also seized, in particular during the 1970s and in the last decade.
When examining the 1 370 operations we found that over 800 regional distributors 
and importers were involved. Almost all of those arrested with over 500 kg of hashish 
were smugglers or large-scale distributors. It is important to note that some of the 
Table 3: Number of seizures by amount seized, news events sample from El 
País (1976–2003) (n = 1 370)
Amount (kg) n % % accumulated
1 or less 86 6.3 6.3
2–9 76 5.5 11.8
10–49 156 11.4 23.2
50–99 94 6.9 30.1
100–499 331 24.2 54.2
500–999 197 14.4 68.6
1 000–4 999 363 26.5 95.1
5 000–9 999 37 2.7 97.8
10 000 or more 30 2.2 100.0
Total 1 370 100.0 100.0
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Nationalities of smugglers and traders
We were able to identify the nationality of people arrested in 757 cases. Over a third 
of all groups (38 %) were formed by Spaniards working with Spaniards (Table 4). 
Moroccans working with people of their nationality formed the second most frequent 
type (19 %), and groups of nationals from other European countries formed the third 
most common type. When people from different nationalities cooperated within range 
of Spanish police, the most frequent combination was that of Spanish and Moroccan 
nationals (8 % of all groups arrested). Spaniards working with other Europeans was 
also a common type of association, representing 5.5 % of all episodes in our sample 
(Table 5).
We observed a correlation between the size of the haul seized and the nationality of the 
members of the distribution groups. Furthermore, nationality was linked to the dominant 
task of the organisation. Almost all retailing is done by Spaniards working alone or 
in small groups of same-country nationals. Moroccan immigrants were commonly 
Table 4: Number of seizures larger than 1 000 kg by period, total news events 
from El País, Spain, 1976–2003 (n = 1 370)
Years n % % accumulated
1976–1979 5 1.2 1.2
1980–1984 10 2.3 3.5
1985–1989 27 6.3 9.8
1990–1994 120 27.9 37.7
1995–1999 122 28.4 66.0
2000–2003 146 34.0 100.0
Total 430 100.0
groups or individuals caught with smaller amounts, even those arrested with less than 
1 kg, were also smugglers. Large import operations of 1 000 kg or more became more 
frequent from 1990 onwards (Table 4). This is coherent with the growth of total seizures 
that surpassed 100 tonnes in 1990 and 1991. In the 2000s, the level of operations 
seems to have increased even more. We have found data on 430 groups that imported 
between 1 and 36 tonnes. On average, 3.4 tonnes were seized in these operations, 
although there is great variation in this sample (standard deviation: 4.5). On average, 
7.4 people were arrested by project or police raid (mean: 4.5). The size of these groups 
varied a great deal (standard deviation: 10.6). In one case, 97 people were arrested in 
several European countries in a connection with a wide transnational ring of smugglers, 
distributors and money launderers; in some cases only one person was arrested, for 
instance, the driver of the truck.
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found in small smuggling and wholesale operations involving less than 100 kg. French, 
British, Dutch and other Europeans were also important in smuggling these quantities, 
and sometimes they transported cannabis from Morocco. Often, however, for these 
quantities the traffickers sourced the cannabis from Spain before shipping it to France, 
the UK and the Netherlands. In large-scale smuggling, the role of foreigners tends to 
be proportional to the size of the cargo. Besides Spaniards, French, Dutch and British 
nationals were commonly involved in smuggling between 1 and 5 tonnes of resin. In the 
largest, multi-tonne schemes, the groups tended to be more complex and international, 
and some of the combinations are not reflected in Table 4. For instance, South 
Americans appeared to be progressively associated with Spaniards and Moroccans in 
smuggling operations of over 5 tonnes.
We were able to collect information on the nationality of members of 224 groups of 
importers dealing with one or more tonnes of cannabis resin. Most of these groups were 
composed of non-Spanish Europeans (40 %), followed by groups in which Spaniards 
cooperated with other Europeans (30 %). It is important to note that the data cover 
only people who were arrested in Spain and do not provide information on all the 
members of transnational drug-dealing organisations. Thus, it underestimates the level 
of international cooperation in cannabis trafficking to Europe.
Hashish trafficking and gender
In 280 cases the sex of traffickers was specified, and about 19 % were women. Women 
were especially active in the lower ranges of the hashish trade. Thus, in the groups 
dealing with 1 kg or less, a third were women working alone or in association with 
men. In the range of over 1 kg to 50 kg, 29 % of all arrestees were women, often 
dealing in same-sex teams. In the higher echelons of the trade, however — defined 
as those involving 500 kg or more — less than 5 % of arrestees were women, and they 
always worked in groups led by men. Mixed gender teams were present in all levels of 
the trade; 11 % of all groups were of mixed gender. We found two culturally defined 
feminine roles culturally sanctioned in the hashish trade — one was sanctioned by 
the derogatory labels of ‘culeras’ and ‘vagineras’, or mules who conceal the drug in 
their rectums (‘culo’, ‘ass’) and vaginas. The other involved middle-aged women with 
grown-up sons and daughters leading family networks in unstructured families and 
destitute neighbourhoods. Evidently, this is a male-dominated market and women often 
experience processes of exclusion and exploitation.
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Types of organisations and networks
We have found a variety of organisations and networks involved in smuggling and 
distributing cannabis resin into Europe via Spain. They vary in structure, strategy and 
main tasks. Case examples of the schemes and groups included in the newspaper 
corpus serve to illustrate key aspects of smuggling networks, such as their size, tactics, 
roles, tasks and permanence in the trade. These are crucial elements in the organisation 
of illegal enterprise (Haller, 1990; Dorn et al., 1992).
The smallest unit of smuggling and distribution
The smallest unit of smuggling and distribution is formed by individuals or by small 
groups of two or three people who carried the drug in their bags, clothes or within their 
stomachs, rectums or vaginas. They do not need much investment or organisation, and 
can repeat their schemes several times every month, or not at all. They are ‘freelancers’, 
in the typology proposed by Natarajan and Belanger (1998).
In the early 1980s, trips to the Spanish enclaves of Ceuta and Melilla in northern Africa 
or to Tangier or Tetouan to import small amounts of hashish, often within one’s own 
body, became a sort of rite of passage for many novices of the Spanish drug wave. 
In slang, the adventure was known as ‘bajar al moro’. A theatrical comedy and the 
subsequent film of this title were commercial successes. The film, somehow, reinforced 
the gendered hierarchies of the trade, as the protagonist had to lose her virginity to be 
able to make such a trip to a ‘Moorish’ country. What follows are several examples of 
this level of trafficking.
Case 1 A 60-year-old ‘mule’
In May 1985, a 60-year-old woman went to the emergency room at the hospital in 
Ciudad Real, a city in central Spain. She could not defecate the 96 10-g ‘eggs’ of 
hashish she had swallowed in Morocco. She had to undergo several surgical procedures 
to extract what had become a large pulp of hashish. She was later indicted for drug 
trafficking (El País, 1 May 1985). This case reflects the not infrequent involvement of 
older women in the hashish trade. They may transport drugs in order to pay for their 
family’s needs, sometimes with the help of male members of the family.
Case 2 Three Frenchmen who loved oil
Three young Frenchmen bought 80 g of hash oil in Tetouan. They sealed it in packages 
made with condoms, swallowed them, and crossed into Spain through Algeciras. In 
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Madrid, one of them felt very sick and his colleagues took him to the hospital. The 
police were called (El País, 10 April 1980).
Case 3 An individual multikilo importer
In September 1989, a 28-year-old Moroccan was arrested in Almeria’s harbour when 
getting off the Melilla ferry. He was carrying two suitcases with 45 kg of cannabis resin. 
He was on his way to Cordoba. Police estimated that the drugs were worth 9 million 
pesetas, or about EUR 1.20 per gram wholesale (El País, 12 September 1989).
Case 4 Small-scale smuggling from Spain into France
In November 1992, four women were arrested in Madrid’s Chamartín train station when 
they were boarding the Bordeaux train with 32 kg of hashish in their bags. It seems that 
they were related. Two of them were Spanish, a 54-year-old woman and her 26-year-
old daughter, and the other two were French nationals, a 26- and 19-year-old. They 
were travelling with two babies. They had arrived two days before, exchanged a large 
amount of French currency in the station bank, took a taxi to Madrid Airport, and flew to 
Malaga. Upon their return, their bags were searched by suspicious police officers. They 
had made similar trips in June and September of the same year (El País, 26 November 
1992).
This appears to be a case of small-scale smuggling from Spain to France. It is possible 
that these women were wholesalers or retailers in France. There was some continuity 
in their projects, and they may be an example of a family business, in the typology 
proposed by Natarajan and Belanger (1998).
Smugglers for multiregional distribution
The second type or level of drug trade organisation includes networks that smuggle 
hundreds of kilograms using boats, trucks, or even small aircraft. Often they work 
together with importers or regional distributors in other European countries, and 
maintain, at least for a period, some continuity in their operations.
Case 5 By air: importation and regional distribution
In February 2000, Spanish police forces were suspicious of wholesalers in four provinces 
that followed similar routines. They were able to trace a common contact in Seville, 
and learned of an incoming shipment arriving at a makeshift airfield in the Cadiz 
countryside. There they seized 639 kg of ‘pollen’ or high-quality resin, and five high-end 
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cars. A light aircraft made the three-hour round trips from a small airport in Seville to 
Morocco and back, with an intermediate landing in countryside locations. Seven people 
were arrested at the landing grounds. The financier and an aide were arrested on their 
return from Morocco. In the financier’s home the police found 40 million pesetas in 
cash (about EUR 240 000). All arrestees seemed mature, knowledgeable and careful. 
Their average age was 38. Police found that they had been conducting regular flights to 
Morocco, often at night, for several months.
This appears to be a case of importers linked to regional distributors and wholesalers, 
with a clear hierarchy and division of tasks based on resources, contacts and expertise. 
They seemed to work exclusively in Spanish regional distribution covering a large area. 
They exhibited some permanence and repeated the same modus operandi over several 
months.
Large-scale importers for an international market
A higher level of operations is reached when tonnes of hashish are smuggled into Spain 
and sent to other European countries for wider distribution.
Case 6 Middle-tier distribution network: smuggling to the wider 
Europe
In March 1977, the British yacht Cynosure was seized in Palma de Mallorca’s harbour. 
In the yacht’s stores the Spanish police found over 2000 kg of hash in sealed packages. 
Two French sailors were arrested on the spot. The captain and owner, a prominent 
businessman from the Balearic hotel trade, fled but was arrested in Amsterdam some 
weeks later and extradited. The cargo had been transferred to the yacht from a fishing 
boat in Betoya’s Bay in northern Morocco. The two French sailors had been hired in 
Ibiza to sail the yacht from Morocco to Southern France. Near Mallorca the engines 
failed, and in their search for help they provoked police suspicion. There was evidence 
of previous trips by the Cynosure from Moroccan ports to Southern France, with stops in 
the Costa del Sol, Costa Brava and Mallorca. Here we see a small organisation, linking 
Morocco and France, with a minimal hierarchy and distribution of work, and some 
recurrence in their operations.
The industrial level
The higher level of the cannabis resin export–import industry is composed of groups that 
deal with dozens of tonnes at a time in industrial scale operations.
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Case 7 Large-scale smuggling: an electric train in a cave
The sophistication of the higher echelons of the cannabis resin import industry was 
revealed in July 1988 when police discovered one of the largest stashes of hashish 
on record in a cove near the Costa Brava resort of Lloret de Mar in north-east Spain. 
Smugglers had constructed a 50-metre tunnel through a mountain that connected the 
beach to a cabin in a field via a small train. In the tunnel, police found 15 tonnes of 
cannabis resin. Another 2 tonnes were found in a farm nearby. Air conditioners and 
humidifiers maintained the hashish’s quality, and refrigerated trucks took the product 
to markets in France, Britain and West Germany. Six people were arrested, all in their 
40s and 50s. A Corsican and a Spaniard were the leaders of the group. The Spaniard 
had already been prosecuted in 1981 when found with 2.5 tonnes of hashish. Police 
claimed that ‘The Corsican’, as the second leader was known, was considered the chief 
of a ring of international smugglers (El País, 26 July 1988). He was a French citizen 
who owned several restaurants on the Costa Brava. One of these restaurants had been 
attacked with a bomb three years before. His arrest was world news, and he was related 
to the Corsican Mafia (see Time article, ‘Smugglers On Ice’, 8 August 1988). In 1992, 
when the trial took place, it became evident that the group had been operating for some 
time, and probably was responsible for the smuggling of hundreds of tonnes of hashish 
(El País, 16 July 1992). ‘The Corsican’ was arrested again in June 1997 in relation to 
another haul of 6 tonnes of hash seized near Barcelona. Six people were arrested. He 
had, at the time, been out of jail for less than a year (El País, 24 June 1997).
This is an example of a section of an international network, armed and well organised, 
with credit and capacity to invest in infrastructure and the trafficking of tonnes of 
cannabis resin in every operation. These traffickers had been in the business for over 15 
years, although it seems that much of this time they were inactive.
Case 8 A freight cargo with fish meal
Early in 1996, customs officers in Marín, a small harbour in the Galician coast of north-
western Spain unloaded thousands of 10-kg hashish packages hidden beneath fish meal 
in the storerooms of the Volga One, a 49-metre cargo ship registered in Panama that 
had arrived that day. Three months before, the same ship, with a different name, had 
unloaded a legal cargo of 260 tonnes of tuna fish. This time, 36 tonnes of Moroccan 
hashish were hidden beneath a cargo of 90 tonnes of fish meal. The ship picked up its 
cargo in Asilah, a small harbour in the Atlantic coast south of Tangier. Most of the eight 
crew members were Russians. This was the largest seizure of hashish on record, and 
11 people were charged. A highly indebted businessman from the Canary Islands, with 
experience in food imports, appeared to be the financier and the contact with Dutch 
and Moroccan distributors. A Galician entrepreneur linked to tobacco smuggling and 
cocaine importers seemed to have organised the shipment and local storage. A trade 
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union leader and a prison officer were also charged. The ‘Canario’ entrepreneur had 
USD 2.5 million in cash, mostly in Dutch currency, when apprehended.
Here, we see a coalition of entrepreneurs working together on a large project. 
Individuals from at least four countries were playing roles according to their expertise 
and capacity: financiers and buyers of the drug, organisers, wholesalers, ship crews, 
transporters and Dutch importers. The network they had developed, however, seemed 
transitory, project-oriented, and non-hierarchical.
In this simplified overview, we have shown the emergent lines of a pyramid that 
includes various actors performing different tasks in association or competition. Our 
sample reveals only failed schemes, and of those, only the portion operating in Spain. 
Obviously, the limitations of our sample are considerable. Further work is necessary to 
document networks operating in other countries at both ends of the commodity and the 
financial chains followed by hashish and the money that pays for it. Thus, much work 
remains to be done in Morocco, Gibraltar, Costa del Sol and in the receiving European 
countries.
Violence in the hashish market
Violence in the hashish market seems to be much less frequent and serious than in 
the cocaine and heroin markets, although perhaps in both cases its effects tend to be 
exaggerated. As Reuter observed, ‘there are many limitations on the use of violence as 
a tool for competition, that only in very narrowly defined circumstances can violence be 
used to suppress competition’ (Reuter, 1984). We found violent acts in three realms of 
the hashish trade: in connection with large networks in which some associates abandon 
their duties; in retailing, where some dealers (in Spanish: ‘camellos’) and clients fight 
over prices, money, thefts, etc., and when traffickers react violently against enforcement 
officers. Here we present some examples.
In June 1990, a suspected hashish dealer was arrested in Madrid when he knifed a 
client in a central square notorious for the drug scene (El País, 27 June 1993). In the 
Costa del Sol there have been some cases of murders related to hashish trafficking, 
apparently related to unpaid debts (see El País, 20 January 1993). In 1996, a ‘mule’ 
who did not deliver the drug he was given in Morocco to bring to Spain inside his body 
was kidnapped (El País, 6 June 1996). There was also the case of an international 
criminal network that poisoned two importers who had apparently sold adulterated 
hashish. Following this incident, one of the dealers attacked became a police informant 
(El País, 10 May 1994). In another case, a group was using 15-year-olds to smuggle 
hashish within their bodies from Ceuta, and used intimidation and violence to coerce the 
minors (El País, 11 October 1995).
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In our sample, episodes involving violent acts are few and far between, and the 
atmosphere in the hashish trade does not seem as threatening or violent as that of the 
cocaine industry. Violence and intimidation may be a means to solve disputes in the 
hashish market, and to enforce contracts and obligations. But, at least on the European 
side in Spain, there is little sign that it is used to maintaining monopoly or oligopoly 
conditions, which would prevent people from entering this trade.
Concluding comments
The market for hashish in Europe has grown substantially in the last three decades 
and has stimulated the spread of an illicit plantation and manufacturing economy on 
the other side of the Mediterranean. Today, 22.5 million Europeans are reported to 
have consumed cannabis in the last year (see Vicente, this monograph). Two major 
products dominate the European market: a relatively standardised cannabis resin, 
and domestically or Dutch-grown herbal cannabis. Most of Europe’s cannabis resin 
originates in Morocco and is imported through Spain, and then often taken to the 
Netherlands to be distributed in northern countries (UNODC, 2007).
Cannabis-related policies are contentious issues in international relations. European 
countries have often been accused of leniency regarding cannabis use and possession, 
as occurred in the meeting of the United Nations Commission on Narcotic Drugs 
(UNCND) held in May 2002. The growing links and transfers of people, commodities 
and ideas from both sides of the Mediterranean have facilitated the explosion in 
the production of hashish. The multiple transactions and displacements to and from 
Morocco facilitate the smuggling of hashish.
The rapid growth of cannabis resin production in Morocco is a dramatic phenomenon. 
Cannabis resin is the most successful Moroccan export of the last quarter of a century. 
For northern Morocco it has been a mixed blessing. In the short term, it may be helping 
to alleviate some social and political tensions, providing a source of foreign currency 
in a region in which underprivileged, forgotten and resentful citizens are pitted against 
their government. However, it is also increasing corruption, raising local prices, and 
cutting incentives for local production of legal crops and other goods. Long term, 
the drug trade could produce nastier effects if it leads to an increase in the local 
consumption of hashish and other drugs, or if the European demand for cannabis 
diminishes and the Rif turns to other crops, for instance opium poppies. Growing links 
between hashish and cocaine traders may prove ominous.
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The structure of drug export–import organisations
From our limited review of importers and distributors arrested in Spain, we will venture 
some observations concerning the types of organisations and networks involved in the 
trade.
First, the hashish trade, like most illegal markets, is a service industry and ‘the bulk of 
total cost of getting the final good to the consumer is not production but compensation 
to those involved in the distribution of the drug from production point to the final 
consumer’ (Reuter, 1984). Technologically, the hashish industry is very simple. There 
is little transnational cooperation in the manufacturing of the product, and chemical 
precursors are not needed. The hashish industry is mostly a storage and transport 
industry. Some initial investment is necessary for seeds and fertilisers, and to buy raw 
material from farmers. As in other drug industries, ‘capital in this business consists 
almost entirely of an inventory which is turned over very rapidly and the “goodwill” built 
up by knowing good suppliers and customers’ (Reuter and Haaga, 1989). Thus, the cost 
curve of cannabis resin distribution is likely to be determined by human factors (Reuter, 
1984).
Second, although our data are partial and preliminary, they echo the findings of authors 
who have been analysing drug dealing networks or organisations from a relational or 
industrial organisation perspective. For instance, Reuter and Haaga explored careers 
and organisations in the upper levels of the cocaine and herbal cannabis markets, and 
found that successful operations did not require ‘a large or enduring organisation’. 
More or less formal organisations may exist, but are not indispensable for ‘operational 
or financial success’. Relationships between partners ‘were more like networks than like 
hierarchical organisations’ (Reuter and Haaga, 1989). Therefore, the relational aspects 
of the drug industry may play a crucial role in its structure, although few studies have 
focused on this topic. Morselli (2001) has recently reviewed the operational methods 
of a long-term distributor of hashish, and found that he never worked within an 
organisation but was able to operate via his own strong and weak links within a very 
wide social network.
As we have shown, the major groups working in smuggling hashish present a 
hierarchical division of roles and tasks, but this structure seems to be transitory and 
informal. As Reuter and Haaga noted, asymmetries of information ‘would preclude 
formal organisation’ (Reuter and Haaga, 1989). Participants often work as independent 
specialists or salesmen, hired for one project, more like freelancers or specialists. Thus, 
Morselli concludes that ‘informal cooperation rather than formal organisation’ is a more 
suitable notion to describe the links of those participating in drug importing (Morselli, 
2001).
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In sum, hashish smuggling and distributing firms tend to be informal, changing 
and decentralised, more cooperative than corporative. As Zaitch (2002) has found 
concerning cocaine import groups in the Netherlands, hashish trading organisations 
are more flexible than the notion of a ‘cartel’ suggests. Some are individual enterprises. 
Others adopt the form of temporary partnerships between two or three persons who 
collaborate in a single project. Individuals who function as brokers play a central role 
in bringing about these coalitions for specific transactions or projects (Zaitch, 2002; 
Morselli, 2001; Korf and Verbraeck, 1993). Larger operating groups rarely involve 
more than nine persons, and the division of labour is not rigid or compartmentalised 
along vertical lines, and despite the importance of kinship ties and the frequent use of 
relatives, few of these enterprises are ‘family businesses’ (Zaitch, 2002).
Our results indicate that the organisations in this trade seemed more cooperative 
than hierarchical, and were based on network modes of resource allocation where 
transactions occur neither through discrete exchanges nor by administrative fiat, but 
through networks of individuals engaged in reciprocal, preferential, mutually supportive 
actions (Morselli, 2001). It is probable that the structure of drug organisations is 
somehow different in Europe and Morocco, for a number of reasons. One area of 
difference stems from the varying roles of the state institutions and officials on both sides 
of the Strait. Furthermore, the need to grow, harvest, collect, manufacture and store the 
product on a yearly basis may promote more stable transactions and, perhaps, networks 
and organisations in Morocco. However, we know very little direct information about 
groups based primarily in Morocco.
Competition and disorganised crime
The hashish trade seems relatively open and competitive, although competition seems 
greater at the lower echelons of the market. There is no evidence of smuggling cartels or 
oligopolies operating in the Spanish side of the trade, and even the existence of large, 
stable organisations is doubtful. This is more difficult to ascertain for the Moroccan side.
We know that some entrepreneurs have been able to remain involved in the cannabis 
trade for decades, but for long periods of their careers they were inactive for their own 
reasons, or because they suffered arrests, trials and incarceration. In any case, most 
entrepreneurs seem to work ‘without having the organizing force and support of a 
reputed and resource-yielding criminal organisation’ (Morselli, 2001). Instead, they may 
rely on legal enterprise for a more permanent business structure and stable contractual 
relationships for some of their associates.
In some cases, one small group, even a single individual, runs the whole pyramid, 
buying from Moroccan farmers, smuggling it into a European country and retailing 
the drug to consumers. But larger operations reveal considerable complexity and 
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coordination of people in Morocco, Spain and other European countries buying, storing 
and transporting the product through several frontiers and selling it to wholesalers and 
smaller distributors.
There are competing views of how drug markets are organised. Most studies 
assume that organised crime plays a major role in structuring these markets through 
organisations that are hierarchical, relatively permanent and bureaucratic. Some authors 
posit the existence of ‘corporations’ in the drug trade. In parallel, there are explanations 
in which ‘violence is typically regarded as the principal regulator of competition’ 
(Morselli, 2001). This model does not seem to apply to our data. It appears that hashish 
dealers face few barriers to entry in the low and middle levels of the market, and also 
in the higher levels if they have the right contacts and funds. A successful operation 
does not require the creation of a large or enduring organisation, and it is possible to 
function as a high-level dealer without recourse to violence (Reuter and Haaga, 1989). 
Moreover, violence and intimidation do not have as much of a presence in the European 
hashish trade as in the cocaine business. There are cases concerning kidnappings and 
killings in our sample, but they are rare and usually connected with rip-offs, fights at the 
retail level or reactions against enforcement officers.
Regarding the origin of the agents of this market, Moroccan hashish importers both 
compete and cooperate with native Spanish and other European importers, and to a 
lesser extent with traffickers of other nationalities, which is similar to what Zaitch (2002) 
has recently found concerning Colombian importers in the Netherlands. All traffickers 
experience conditions that both promote and limit their opportunities. While some 
Moroccans may have privileged access to hashish supply, local entrepreneurs tend to 
have better access to human resources and infrastructure in their countries.
Prices, standardisation of products and economies of scale
Price data are a potentially important research tool for understanding the workings of 
drug markets and the effects of law enforcement (Caulkins and Reuter, 1998), but its 
collection has not been a priority in Europe. Thus, we lack historical data on such a 
crucial variable, which makes it difficult to understand the evolution of drug markets. 
With regard to cannabis resin and other cannabis products, European evidence shows 
a clear decrease in real prices, at least from 1989 to 2004, a period in which there 
has been a clear increase in demand of cannabis products. This appears to have also 
happened in other European countries, such as the UK. It seems that international 
groups which operate in a European common market for cannabis have developed 
economies of scale, with declining costs per unit of output, and this has resulted in a 
decrease of prices, the standardisation of supply, and a reduction in the diversity of the 
final product both in quality, origin and type of derivative.
Multinational export–import ventures: Moroccan hashish into Europe through Spain
288
Bibliography
Adler, P. A. (1985), Wheeling and dealing. An ethnography of an upper-level drug dealing and 
smuggling community, Columbia University Press, New York.
Bowcott, O. (2003), ‘Morocco losing forests to cannabis’, The Guardian, 16 December.
Caulkins, J. P., Reuter, P. (1998), ‘What price data tell us about drug markets’, Journal of Drug Issues 
28(3): 593–612.
De Kort, M., Korf, D. (1992), ‘The development of drug trade and drug control in the Netherlands: a 
historical perspective’, Crime, Law and Social Change 17: 123–144.
Dorn, N., Murji, K., South, N. (1992), Traffickers. Drug markets and law enforcement, Routledge, 
London.
EMCDDA (2006), Annual report 2006, European Monitoring Centre for Drugs and Drug Addiction, 
Lisbon.
EMCDDA (2007), Annual report 2007, European Monitoring Centre for Drugs and Drug Addiction, 
Lisbon.
Franzosi, R. (1987), ‘The press as a source of socio-historical data: issues in the methodology of data 
collection from newspapers’, Historical Methods 20 (1): 5–16.
Franzosi, R. (1995), The puzzle of strikes: class and state strategies in postwar Italy, Cambridge 
University Press, Cambridge.
Gamella, J. F., Jiménez Rodrigo, M. L. (2003), El consumo prolongado de cánnabis: pautas, 
tendencias y consecuencias, Fundación de Ayuda contra la Drogadicción, Madrid.
Gamella, J. F., Jiménez Rodrigo, M. L. (2004), ‘A brief history of cannabis policies in Spain’, Journal 
of Drug Issues 34(3): 623–659.
Haller, M. H. (1990), ‘Illegal enterprise: a theoretical and historical interpretation’, Criminology 28(2): 
207–235.
Independent Drug Monitoring Unit (2005), ‘The cannabis market’, Drug survey 2005 
www.idmu.co.uk/ru5.htm
Ketterer, J. (2001), ‘Networks of discontent in Northern Morocco: drugs, opposition and 
urban unrest’, Middle East Report Online 218, special issue: Morocco in transition 
www.merip.org/mer/mer218/mer218.html
Kielbowicz, R. B., Scherer, C. (1986), ‘The role of the press in the dynamics of social movements’, 
Research in Social Movements, Conflict and Change 7: 203–233.
King, L. A., Carpentier, C., Griffiths, P. (2004), ‘An overview of cannabis potency in Europe’, Insights 
No. 6, European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
Kingery, P. M., Alford, A. A., Coggeshall, M. B. (1999), ‘Marijuana use among youth — epidemiological 
evidence from the US and other nations’, School Psychology International 20 (1): 9–21.
Korf, D. J., Verbraeck, H. (1993), Dealers en dienders: dynamiek tussen drugsbestrijding en de 
midden- en hogere niveaus van de cannabis, cocaine, amfetamine en ecstasyhandel in Amsterdam, 
Criminologisch Instituut Bonger, Universiteit van Amsterdam, Amsterdam.
Labrousse, A., Romero, Ll. (2001), Rapport sur la situation du cannabis dans Le Rif Marocain. OFDT, 
Paris.
MacCoun, R. J., Reuter, P. (2001), Drug war heresies: learning from other vices, times and places, 
Cambridge University Press, Cambridge.
Moore, M. H. (1977), Buy and bust. The effective regulation of an illicit market in heroin, Heath, 
Lexington.
Morselli, C. (2001), ‘Structuring Mr. Nice. Entrepreneurial opportunities and brokerage positioning in 
the cannabis trade’, Crime, Law and Social Change 35: 203–244.
Natarajan, M., Belanger, M. (1998), ‘Varieties of drug trafficking organisations: a typology of cases 
prosecuted in New York City’ Journal of Drug Issues 28 (4): 1005–1025.
Chapter 15
289
Observatoire Géopolitique des Drogues (OGD) (1996), Atlas mondial des drogues, Presses 
Universitaires de France, Paris.
Observatorio Español sobre Drogas (2003), Informe número 6, Noviembre 2003, Ministerio del 
Interior. Delegación del Gobierno para el Plan Nacional sobre Drogas, Madrid.
Olzak, S. (1989), ‘Analysis of events in studies of collective action’, Annual Review of Sociology 15: 
119–141.
Olzak, S. (1992), The dynamics of ethnic competition and conflict, Stanford University Press, 
Stanford.
Reuter, P. (1984), Disorganized crime: illegal markets and the mafia, MIT Press, Cambridge.
Reuter, P. (1985), ‘Eternal hope: America’s quest for narcotics control’, The Public Interest 79 (Spring): 
79–95.
Reuter, P., Haaga, J. (1989), The organisation of high-level drug markets: an exploratory study, Rand 
Corporation, Santa Monica.
Reuter, P., Kleinman, A. R. (1986), ‘Risk and prices: an economic analysis of drug enforcement’, Crime 
and Justice, An Annual Review of Research 7: 289–340, Chicago University Press, Chicago.
Reuter, P., MacCoun, R., Murphy, P. (1990), Money from crime. A study of the economics of drug 
dealing in Washington, D.C., RAND Drug Policy and Research Center, Santa Monica.
Ruggiero, V., South, N. (1995), Eurodrugs. Drug use, markets and trafficking in Europe, University 
College London Press, London.
Tilly, C., Tilly, L., Tilly, R. (1975), The Rebellious Century, 1830–1930, Harvard University Press, 
Cambridge.
UNODC (2003), Global illicit drug trends 2003, United Nations Office on Drugs and Crime, 
Vienna.
UNODC (2004), World drug report 2004, United Nations Office on Drugs and Crime, Vienna.
UNODC (2005), World drug report 2005, United Nations Office on Drugs and Crime, Vienna.
UNODC (2006), World drug report 2006, United Nations Office on Drugs and Crime, Vienna.
UNODC (2007), World drug report 2007, United Nations Office on Drugs and Crime, Vienna.
Wagstaff, A. (1989), ‘Economic aspects of illicit drug markets and drug enforcement policies’, British 
Journal of Addiction 84 (10): 1173–1182.
Wilkinson, I. (2003), ‘Morocco: cannabis profits “funding terrorism”, Daily Telegraph, 9 August.
Zaitch, D. (2002), Trafficking cocaine: Colombian drug entrepreneurs in the Netherlands, Kluwer Law 
International, The Hague.

291
Chapter 16
An analysis of the significance 
of supply and market factors for 
variations in European cannabis 
use
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Setting the context
The chapter by Carpentier et al. (this monograph) discussed the broad concept of 
‘availability’ as applied to the cannabis market in Europe. The chapters by Ballotta 
et al., Korf and Asmussen also suggest that governments across Europe are placing 
emphasis upon the stronger enforcement of the supply of cannabis. Despite this, our 
understanding of the cannabis market remains limited, as does our understanding of 
how variations in supply-side factors may influence demand. This short chapter provides 
a postscript to the previous chapter by Gamella and Jiménez Rodrigo on Moroccan 
cannabis resin, by describing an innovative approach to modelling the cannabis resin 
market. It analyses some recent initiatives that may increase our knowledge of supply-
side factors, and discusses some differences between the markets for cannabis and those 
for other illicit drugs, in particular heroin and cocaine.
While correlations can be identified, there remains considerable work to be done in 
the area of mapping availability. It may prove useful to identify whether there are any 
regional correlations between prevalence and resin seizures, and to determine any 
cross-border patterns that are linked to supply lines.
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An analysis of the significance 
of supply and market factors for 
variations in European cannabis 
use
Leif Lenke
Introduction
Various studies have noted that national cannabis policies, be they liberal or repressive, 
do not show a constant impact on demand (Reuband, 1998; Korf, 2002). It is therefore 
important to explore other factors that may contribute to the different patterns of 
cannabis use we find in Europe today. This chapter takes as its basis a co-authored 
study of heroin supply factors and market conditions, on which the author worked for 
the Council of Europe (Lenke and Olsson, 1998).
Developing a supply model for illicit psychoactive substances
The analysis for the Council of Europe study was based on a number of assumptions. 
These include:
the geographical distribution of seizures is not random;•	
some correlation exists between heroin consumption and distribution;•	
the accumulation of large amounts of heroin at distribution points is generally •	
avoided;
the seizure of large consignments of narcotics is given priority, irrespective of the •	
type of drug policy pursued; and
a positive correlation would be expected over the longer term between quantities •	
seized and quantities distributed.
The study suggested that it was possible to show a strong positive correlation for western 
Europe whereby increases in the amount of heroin seizures in a given country tended to 
be followed by an immediate increase in consumption, as measured by some indirect 
indicators, including fatal overdoses. Moreover, this model allowed conclusions to be 
drawn about the impact on these indicators of changes in the supply situation.
The development of a seizures-based model for analysing cannabis markets may not be 
as straightforward as that for heroin. The cannabis market is much broader than that 
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for heroin, and the profile of consumers more mixed. Further to this, important changes 
may be occurring in the nature of the European cannabis market. The long-term 
domination in many countries of Moroccan-produced resin trafficked through Spain is 
now called into question by data suggesting increases in home-grown or domestically 
cultivated herbal cannabis. This trend is likely to have shortened the distance between 
product source and consumer, and the extent to which cannabis is trafficked across 
borders. Nonetheless, cannabis resin still accounts for the bulk of the cannabis that is 
seized in Europe (Pietschmann and Legget, this monograph) and the analysis presented 
here focuses solely on resin and is therefore partial by definition.
In the Council of Europe heroin case study it was possible to show that the supply of 
heroin was a central factor for understanding consumption patterns. For example, 
proximity of different countries to the Balkan route was important: countries along the 
route had particularly serious heroin problems, while those at a greater distance, for 
example the Scandinavian countries, had been to some extent shielded. As cannabis 
resin consumed in Europe is largely produced in North Africa and imported via the 
Iberian peninsula, it is possible to explore the extent to which geographical proximity to 
resin trafficking routes is reflected in cannabis consumption indicators.
If the quantity of cannabis seized in proportion to the population size is analysed, it is 
possible to identify differences between countries, with those countries in Europe that 
have close contacts with Morocco tending to report larger seizures. For this purpose, 
‘close contact’ refers not only to geographical proximity, but also social proximity 
resulting from colonialism and migration. This has been referred to in the American 
literature as ‘pipelines’, with reference to the Colombian involvement in the American 
cocaine market (Reuter and Kleiman, 1986). For the purposes of this exploratory 
analysis, each country has been allocated an ‘exposure score’, which was found to 
have a strong positive correlation (approaching r = 0.90) with the population-adjusted 
seizure total. Spain was excluded from the analysis as it was an extreme outlier due to its 
atypically high values for both seizures and cannabis consumption.
Important differences exist between the organisation of the cannabis market and that of 
other drugs. Among these is the involvement of a large number of actors, lack of clear 
hierarchy, and relative ease in which new operations can be established (see Gamella 
and Jiménez Rodrigo, this monograph). Profits can be substantial and relatively low 
investment is required to establish new operations. This low degree of organisation 
and the absence of a monopoly may manifest itself in relatively low and stable prices 
found for cannabis resin (see Carpentier et al., this monograph). However, again a 
geographical effect is apparent: prices reported in Norway and Iceland are over four 
times higher than those found in Spain and Portugal, for example.
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Another important difference in the structural organisation of the cannabis market, as 
opposed to some other drug types, is that its operations tend to be European based, 
often involving nationals from or with good contacts in the target market. This means 
that trafficking networks have ‘natural’ contacts with the local distribution networks. This 
has often been a problem for the distributors on the heroin market where ‘outsiders’ 
can face difficulties in selling consignments of drugs directly on the local markets, and 
success is dependent on having reliable contacts with networks in both the production or 
trans-shipment country and the country of consumption.
How does drug supply impact on the consumption 
of cannabis?
In order to explore the question of how drug supply impacts on consumption an 
indicator of the extent of current or recent cannabis use is required. Methods to access 
the size and nature of the cannabis market are described elsewhere in this monograph 
(Vicente et al.). For the purposes of the exploratory analysis presented here, a good 
proxy measure, even if it is somewhat partial, is provided by the ESPAD data set (see 
Hibell et al., this monograph). The advantage of ESPAD is that it is conducted in a 
systematic fashion and guarantees anonymity to the participants and thus the level of 
comparability can be regarded as relatively high. The disadvantage is that the data is 
only available for 15–16 year-old students and patterns of use in the broader population 
may differ. However, as changes in deviant behaviour tend to manifest themselves 
earlier among the youngest age groups (Carlsson, 1972) this group may provide a 
useful window on changes in overall consumption patterns.
The result is that a clear — although not particularly strong — positive statistical 
correlation exists between last-month prevalence from the ESPAD studies and seizures. 
For 16 west European countries, the strength of the correlation lies at r = 0.56 
(F = 6.02). Given the uncertainties involved in the measure of supply in particular (i.e. 
quantities seized), this can be interpreted as providing support for the hypothesis on the 
significance of supply for cannabis consumption.
The correlation between the supply of cannabis and ‘recent use’ is relatively strong 
among students; in countries with high prevalence, the quantities of cannabis seized are 
also high. Spain has again been excluded from the analysis as an extreme outlier. It 
is not as easy to comment on the correlation between quantities seized and recent use 
over time. This is due in large part to the absence of robust and comparable time series 
in which contrasts can be made. However, a general impression that emerges from the 
data that are available does suggest a relationship between seizures and consumption. 
It can be noted that the most substantial increases in cannabis use appear to have 
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occurred during the first half of the 1990s (UNODC, 2004). This was also the period 
that saw the greatest increases in the production of cannabis in Morocco and also the 
greatest increases in the quantities seized in Spain (Gamella and Jiménez Rodrigo, this 
monograph).
Concluding remarks
To summarise, the correlations reported here support the conclusion that a relationship 
exists between indicators of cannabis supply and the extent of cannabis use in western 
Europe. This factor has relevance for the discussion on the significance of drug policy 
choices in influencing the extent and trends in cannabis use over time. As such, the 
analysis offered here, although preliminary, supports the conclusions made by Reuband 
(1998) and Korf (2002) that the ‘level of repression’ found in different national cannabis 
policies does not appear to be a consistent central factor for explaining the variations 
found in the epidemiological data on cannabis consumption patterns.
That said, in the context of a discussion on the factors that do determine national 
variations in levels of cannabis use, it is not helpful to simply shift the point of focus 
from drug policy to drug supply. Clearly other factors are also likely to be important. 
The structure of the correlations provides little if any support for the contention that 
cannabis use is determined by demand at the macro level, however.
One factor that is often presented as an explanation of variations in cannabis use is 
that the drug is associated with specific cultural patterns, and in particular with specific 
patterns of youth subculture. These subcultural patterns arguably then determine the 
patterns of demand and consumption. Testing a hypothesis of this kind is difficult, 
although some types of drug consumption, at some periods of time, do appear to be 
closely linked with particular subcultural groups, for example ecstasy (MDMA) was 
associated with the emergence of rave culture in Europe. Linking today’s widespread 
patterns of cannabis use to any specific subcultural group would appear, however, more 
problematic. A more reasonable interpretation of the relationships is that the supply of, 
and access to, drugs contributes to and intensifies the establishment of consumption 
behaviours. Such a relationship is exemplified by, for example, the drinking cultures 
described in the field of alcohol research, which are also, at least in part, determined by 
supply-side factors.
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The index below covers both volumes of this monograph. Volume number is denoted by the principal 
number in the index entry, e.g. ‘absorption’ can be found on p. 33 of Volume 1.
A
absorption 1.33
abuse 2.33–4
Acomplia see rimonabant
action plan on drugs see European Union
activist groups 1.88
adolescents 2.3–26, 2.79–95, 2.332
correlates of consumption 2.74–7
screening tests 2.39–40
treatment 2.209
see also ESPAD; students
advertising 2.224
Advisory Committee on Drug Dependence 1.44, 
1.46
advocacy 2.97–110
affordability 1.76–7
see also economic accessibility
age 2.287
agonists 1.19
AHOJ-G criteria 1.141
see also environmental strategies
ALAC 2.53
alcohol 2.79, 2.330–1
health effects 2.151
prevalence 2.85–6
see also harm indices
alcohol policy 1.122–3
alternatives to prohibition 1.125–6
consumption after legalisation 1.125
and potency 1.127–8
rationing system 1.126–7
Alcohol Use Disorders Identification Test 
(AUDIT) 2.36
Algeria 1.262
amotivational syndrome see psychological effects
amphetamines 1.54, 1.56, 1.74, 2.63, 2.79
prevalence 2.85–6
Amsterdam 1.138, 1.142, 1.143–5, 1.151, 
1.152, 1.204, 2.39
anandamide 1.19
anasha 1.67
antagonists 1.19
anthropology 2.97–110
antiemetic use 2.165
anxiety 2.133–4
see also mental health
2-arachidonoyl glycerol 1.19
Austria 1.232–3
consumption of cannabis products 1.250
potency of cannabis 1.245, 1.251
availability 1.75–6, 2.64
current indicators 1.218–20
definition of 1.218
Europe 1.215–36
global 1.218
perceived 1.230–1, 1.232–3, 2.72
street-level 1.218
see also supply
awareness 2.63–4
B
back door problem (coffee shops) 1.151–2
Baltic States 1.65, 1.68, 1.76, 1.78, 1.79, 
1.87–8, 1.90, 1.91
Balzac, Honoré de 1.6
Baudelaire, Charles 1.6
Beatles, the 1.44
Becker, Howard S. 2.109
Bedrocan 1.23
Index
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behaviour 2.97–110
behavioural effects 2.189–90
Belgium 1.232–3
consumption of cannabis products 1.250
Maat in de Shit programme 2.222
see also Flanders
Beron, Basilus 1.7
bhang 1.7
Bibra, Ernst Freiherr von 1.8
bongs see waterpipes
botanic classification 1.32
box-score reviews 2.205–7
Bromidia 1.9
buckets 1.178–9
bupropion 2.212
Burroughs, William 2.115
C
CAGE test 2.36, 2.39, 2.43, 2.48
Callaghan, James 1.47
Canada 1.22
CANDIS 2.212
cannabichromene 1.32
cannabidiol 1.32, 1.243
cannabigerol 1.32
cannabindon 1.9
cannabinoids 1.17–24
detection of 2.189
effects of 1.28
pharmacology 1.17–24, 1.27–37
cannabinol 1.243
Cannabinum tannicum Merck 1.8
Cannabis: the Scientific and Medical 
Evidence 1.20
cannabis
as medicine 1.3–14
psychoactive properties 1.5, 1.66–7
Cannabis Abuse Screening Test (CAST) 2.40, 
2.43, 2.53
cannabis clubs 1.23
cannabis flos 1.256
Cannabis indica 1.8
cannabism 1.10
cannabis oil 1.191
trafficking 1.279–80
cannabis plants
seizures 1.221
see also herbal cannabis
Cannabis Problems Questionnaire 2.40
cannabis resin 1.5, 1.30, 1.73, 1.84, 1.100
commodity chain 1.269–70
export 1.272–84
growth of trade 1.272–3
lifetime experience 2.66–7, 2.71
potency 1.228, 1.230
prices 1.225
production 1.199–203, 1.264
production/manufacture 1.265–71
seizures 1.221
sources of 1.200
trafficking 1.208–9, 1.278
see also Morocco
Cannabis sativa L. 1.30
Cannabis Use Disorders Identification Test 
(CUDIT) 2.38, 2.43, 2.47
Cannador 1.22
carcinogenicity 2.121–4
childhood cancers 2.123–4
respiratory cancer 2.121–3
CARED study 2.310
CB1 see receptors
CB2 see receptors
Cesamet capsules 1.21
charras 1.7
chemical structure 1.243
childhood cancers 2.123–4
Christchurch Health and Development 
Study 2.130–1
Christiania 1.157, 1.159
charges 1.164
Intelligence Service 1.162–3
pre-trial detention 1.163–4
Pusher Street 1.157, 1.159–60, 1.162–3
trials and sentences 1.165
classification 1.105, 1.110–11
clubbers see recreational settings
cocaine 1.74, 2.79
prevalence 2.85–6
Cocaine Craving Questionnaire 2.41
Cochrane Collaboration 2.251
coffee shops 1.113, 1.129, 1.137–58
back door problem 1.151–2
policy options 1.151–2
restricted role of 1.149–51
collision risk 2.177–88
communication 1.174–5
comorbidity 2.115–40
competition 1.286–7
Composite International Diagnostic Interview 
(CIDI) 2.36
concealed use 2.101–2
means of concealment 2.102–3
consumption 1.250
after legalisation 1.125
correlates in adolescents 2.74–7
and perceived availability 2.72–4
relative 1.253
and risk perception 2.74
consumption techniques see mode of 
administration
Index
313
contingency management 2.210–11
continuation (conversion) rate 2.16–17
controls see legislation
controlling use 2.103
Convention on Narcotic Drugs (1961) 1.11
convictions 1.41, 1.43
Copenhagen 1.157–72
Council of Europe 1.293–5
Courtive, Edmond de, Haschish 1.6
crack 1.74
crackdown 1.157–72
crime
disorganised 1.286–7
smuggling see trafficking
see also legislation
Criminal Justice Act (1977) 1.48
criminal justice system 2.232–3
culpability index 2.184
cultivation see production
culture of silence 2.104
current use 2.7, 2.11–12, 2.14, 2.15, 2.29
measurement of 2.7–8
medicinal 1.11–12, 1.17–24
Cyprus 1.232–3
availability 1.75
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalence 1.66, 1.68, 1.71
Czech Republic 1.232–3
availability 1.75
consumption of cannabis products 1.250
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalence 1.67, 1.68, 1.70
potency of cannabis 1.245, 1.251
D
Dangerous Drugs Act (1928) 1.41
data presentation 1.253–4
Daumier, Honoré 1.6
debut drugs 2.69–70
see also gateway theory, initiation
decriminalisation 1.97–117
and cannabis use 1.145–9
demand 1.273–4
demand reduction 1.85–7
Denmark 1.157–72, 1.232–3
Hash-Club Law 1.160
legislation 1.160–6
depenalisation 1.87, 1.88, 1.121, 1.125
dependence 2.16, 2.33, 2.37, 2.126–7, 2.150
physiological 2.34
psychological 2.34
depression 2.133–4
Deutsche Hauptstelle für Suchtfragen 
(Germany) 1.307
deviance 2.97–110
Diagnostic Interview for Genetic Studies 
(DIGS) 2.38
Dib, H’midou 1.270
discos and bars 2.65
distribution 1.275–6
middle-tier network 1.281
multiregional 1.280
smallest unit 1.279
divalproex 2.212
domestic production 1.253
Donovan 1.44
dopamine 1.31, 1.35
dopaminergic system 1.35
Dragendorff, Johan Georg 1.9
driving 2.173–98
assessment of behavioural effects 2.189–90
collision risk 2.177–88
effects on performance 2.175–7
dronabinol 1.20–1, 1.105, 1.106
drug policy 2.157–71
drug recognition experts 2.189
DrugScope 1.174
drug use progression 2.329–30
DSM-IV 2.33, 2.35, 2.37, 2.45–6
Dumas, Alexandre 1.6
Dunedin Multidisciplinary Health and 
Development Study 2.129–30
Dutch drug policy see Netherlands
Dutch National School Survey 2.79–95
dysphoria 1.28, 2.119
dysthymic disorder 2.316, 2.317
E
Early Developmental Stages of Psychopathology 
(EDSP) study 2.131
early intervention 2.279–95
early onset use 2.70
economic accessibility 1.76–7
economics 1.119–35
economies of scale 1.287
ecstasy 1.74, 2.63, 2.79
prevalence 2.85–6
polydrug use with cannabis 2.85–6
EDDRA database 2.234
education 1.174–5, 2.219–21
Egypt, legislation 1.100–1
EMCDDA 1.53, 1.111, 1.187, 2.3–26, 2.32, 
2.144
EDDRA database 2.234
PERK project 2.225, 2.227
Index
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endocannabinoids 1.19, 1.27, 1.30, 1.31, 
1.34–6
environmental prevention strategies 1.119–35, 
2.220, 2.223–4
see also alcohol, tobacco
epidemiology 1.66–77, 2.3–26, 2.59–77, 
2.79–95
ESPAD 1.67–9, 1.231, 1.294, 2.23, 2.59–77
Estonia 1.232–3
availability 1.75
consumption of cannabis products 1.250
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalence 1.67, 1.68, 1.71, 1.73
Europe
availability of cannabis 1.215–36
cannabis use 2.19–21
importing 1.272–84
legislation 1.97–117
medicinal use of cannabis 1.3–14
potency of cannabis 1.239–62
recent trends 2.21–4
supply and market factors 1.291–7
treatment demand 2.261–76
see also individual countries
European Union 1.110–12, 2.3–26
classification 1.110–11
new Member States 1.63–93
personal use 1.111–12
event analysis 1.274
Evidence-based Electronic Library for Drugs and 
Addiction 1.172
experimentation 2.7
expert knowledge 1.124–5, 2.349–53
export prices 1.268
exports see imports/exports
exposure score 1.294
Extractum Cannabis indicae 1.8
F
family approaches to prevention 2.230, 2.333–4
farm prices 1.268
Finland 1.232–3, 2.97–110
First International Opium Conference 1.101
Flanders 1.304
see also Belgium
Flaubert, Gustave 1.6
flower power 1.45
France 1.8, 1.9, 1.232–3
potency of cannabis 1.245, 1.248
free radicals 1.31
Fronmüller, Bernhard 1.8
G
ganglia 1.31
ganjah 1.7
see also herbal cannabis
gateway theory 1.77, 2.60, 2.92, 2.93, 2.223, 
2.329–31, 2.335
Gauthier, Théophile 1.6
gender 1.71, 2.287
and cannabis use 2.18–19, 2.69
and prevention programmes 2.228
and trafficking 1.278
generation effect 1.149, 2.22
genetic factors 2.338
Germany 1.8, 1.22, 1.232–3
consumption of cannabis products 1.250
Deutsche Hauptstelle für Suchtfragen 1.308
legislation 1.100
potency of cannabis 1.245, 1.247, 1.251
Quit the Shit programme 2.222
treatment demand 2.305–23
glaucoma 1.12
global availability 1.218
government monopoly system 1.126
effectiveness of 1.127
see also environmental prevention strategies
Greece 1.232–3
legislation 1.100–1
grey literature 12.300–10
GW Pharmaceuticals 1.21
H
Hachichins, Club des 1.6
Hahnemann, Samuel 1.7
hallucinogens 2.79
harmful use 2.33
harm indices see classification
harm potential 2.147–52
harm reduction 1.171–83
definition of 1.173–4
health-related 1.174–80
harm risk 2.146–7
Hash-Club Law 1.160, 1.161
hashish see cannabis resin
Hassela pedagogic 1.58
health benefits 2.164–5
health effects 1.106–7, 2.115–40, 2.157–71
acute 2.118–20, 2.160–1
carcinogenicity 2.121–4
cardiovascular 2.119
causal inferences 2.159–60, 2.162–3
chronic 2.120–1, 2.161–2
dependence 2.16, 2.33, 2.37, 2.126–7
immune system 2.120
improved assessments 2.166–7
Index
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mood 2.119–20
premature mortality 2.125–6
prenatal cannabis exposure 2.124–5
reproductive system 2.124
respiratory system 2.120
see also public health impact
health impact assessment 2.143
hemp 1.5, 1.6–7, 1.8
Hemp Seed Association 1.88
Herba Cannabis indicae 1.8
herbal cannabis 1.73, 1.76–7, 1.84
lifetime experience 2.66–7, 2.71
potency 1.228, 1.229, 1.230
prices 1.226
production 1.192–8
seizures 1.221–2
THC in 1.249
trafficking 1.206–7
heroin 2.79
health effects 2.151
prevalence 2.85–6
supply model 1.294
hippie era 1.45, 1.59, 1.67, 1.159
history 1.3–14, 1.99–100
new EU Member States 1.66
HIT 1.174
homeopathy 1.7
house dealers 1.141
Hugo, Victor 1.6
Hungarian Civil Liberties Union 1.88
Hungary 1.232–3
availability 1.75
drug seizures 1.82, 1.83, 1.84
herbal cannabis buying power 1.77
legislation 1.81
lifetime prevalence 1.67, 1.68, 1.70, 1.71
I
ICD-10 2.37, 2.313–14
immune effects 2.120
imports/exports 1.272–84
large-scale 1.281
see also trafficking
India 1.99–100
Indian hemp see hemp
Indian Hemp Report (1894) 1.9
indicated prevention 2.220, 2.235
information 1.174–5
inhalants 2.79
initiation (age of first use) 2.267–8, 2.331–2
intensive use 2.14–17, 2.34
continuation rates 2.16–17
current 2.14
daily 2.14–16
dependence/problematic use 2.16
international law 1.102–4
intoxication 2.148
Ireland 1.232–3
consumption of cannabis products 1.250
ISD-10 2.33
Italy 1.22, 1.232–3
Iversen, Leslie 1.20
J
Jagger, Mick 1.44, 1.45, 1.48
jazz scene 1.43, 1.44, 1.53, 1.55, 1.142–3
Jellinek Clinic (the Netherlands) 2.39
Jellinek self-screening test 1.171, 2.39
see also, Know Cannabis test 
Joseph Rowntree Foundation 1.302, 1.309
K
key indicators 2.24, 2.34
kif 1.265, 1.267
trafficking into Europe 1.272–84
see also cannabis resin, Morocco
Know Cannabis test 2.48–51
Kobert, Rudolf 1.9
L
laboratory analysis 1.254–5
Lapin, Leib 1.9
last month prevalence 1.51, 1.67–70, 1.144, 
1.295, 2.68–9
last year prevalence 1.69, 1.74, 1.144, 2.68–9
Latvia 1.232–3
availability 1.75
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalance 1.67, 1.68, 1.71
laws see legislation
law enforcement 1.82–5, 1.147
Denmark 1.157–72
law reform 1.109
legalisation 1.47
legislation 1.39–49, 1.63–93
consistency of 1.112–13
Denmark 1.160–6
driving 2.190–1
Europe 1.97–117
origins of 1.99–102
licensing 1.126
Lifeline 1.174
lifestyle 2.288–9
lifetime prevalence 1.67–9, 1.73, 2.9, 2.66–7
lifetime use 2.8
liposolubility 1.33
Index
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Lithuania 1.232–3
availability 1.75
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.80
lifetime prevalence 1.67, 1.68, 1.71, 1.72
lobbying 1.39–49
locations of use 1.129
London 2.209
LSD 1.44, 1.74
lung damage 2.115–40
Luxembourg 1.232–3
M
Maat in de Shit (Belgium) 2.222
McCartney, Paul 1.44–5, 1.48
Malta 1.232–3
availability 1.75
drug seizures 1.82, 1.83, 1.84
herbal cannabis buying power 1.77
legislation 1.81
lifetime prevalence 1.67, 1.68, 1.70
manufacture, cannabis resin 1.265–71
marihuana see herbal cannabis
marijuana see herbal cannabis
Marijuana Craving Questionnaire (MCQ) 2.40
Marijuana Effect Expectancy Questionnaire 
(MEEQ) 2.41
Marijuana Screening Inventory (MSI-X) 2.41
marinol see dronabinol
market sizing 1.291–7
Martius, Georg 1.7
mass media campaigns 2.224–8, 2.230–1
Maternal Health Practices and Child Development 
Study 2.125
media coverage 1.51–60
Medical Use of Marijuana 1.20
medicinal use 1.3–14, 1.256
current situation 1.11–12, 1.17–24
decline of 1.10–11
mental health 2.157–71, 2.316–17
dependence 2.16, 2.33, 2.37, 2.126–7, 
2.150
depression and anxiety 2.133–4
mood 2.119
positive benefits 2.165
psychological effects 2.115–40
meta-analysis 2.205–8
metabolism 1.33–4
Meurisse, Georges, Le Haschich 1.9
Million Marijuana March 1.88, 2.101, 2.105
MINI screening test 2.39, 2.43, 2.52
Misuse of Drugs Act (1971) 1.41, 1.47
mobile sale points 1.150
mode of administration 1.175–6
adoption of safer methods 1.178–9
comparative safety of 1.177–8
smoking 1.33, 1.128, 1.175, 1.178
snuff 1.128
vaporisers 1.177
waterpipes 1.177–8
monographs see grey literature
moral panic 1.51–60
Moreau de Tours, Jacques Joseph 1.6
Du Haschich et de L’aliénation mentale 1.6
Morocco 1.187–8, 1.190, 1.200–2
exporting cannabis 1.263–89
prices 1.268
production/manufacture 1.265–71
seizures 1.273
sociopolitical and ecological issues 1.271
MS see multiple sclerosis
multiple sclerosis 1.17–24
mushrooms 1.74
music scene 1.78
N
nabilone 1.20–1
naltrexone 2.212
National Household Survey on Drug 
Abuse 2.36–7
National Institute on Drug Abuse (USA) 2.253
nationalities of traffickers 1.276–8
nederwiet 1.151, 1.239, 1.246
nefazadone 2.212
Netherlands 1.22, 1.23, 1.137–58, 1.232–3
cannabis use 1.142–5
consumption of cannabis products 1.250
decriminalisation 1.145–9
Opium Acts 1.140, 1.141
potency of cannabis 1.245, 1.248, 1.251
Trimbos Institute 1.151, 2.349
Netherlands Mental Health Survey and Incidence 
Study (NEMESIS) 2.131
NIDA 
see also, Red book recommendations
neurones 1.31
neuroscience 1.27
neurotransmitters 1.31
nomenclature 1.252–3
normative beliefs 2.229–31
Norway 1.232–3
O
onset see initiation
Ontario alcohol and other drug opinion 
survey 2.48
Index
317
open activism 2.103–5
means of 2.105–6
opium 1.3, 1.10, 1.11, 1.101, 1.190, 1.192, 
1.199, 1.284
Opium Commission (Shanghai) 1.101
O’Shaughnessy, William 1.5–6
On the Preparations of the Indian Hemp or 
Gunjah, Cannabis indica 1.5
Ottawa Prospective Prenatal Study 2.125
overdose 2.148
P
patterns of use 1.73
peers 2.334–6
perceived availability 1.230–1, 1.232–3, 2.72
and cannabis consumption 2.72–4
perceptions of use 1.77–8
PERK project 2.225, 2.227
permit system 1.126
personal use 1.108–9, 1.111–12, 1.198
phagocytosis 1.31, 1.36
pharmaceutical use 1.3–14, 1.17–24
pharmacodynamics 1.31
pharmacokinetics 1.31, 1.33–4
pharmacological effects 1.28, 1.32
pharmacological treatment 2.212
pharmacology 1.17–24, 1.27–37, 1.255–6
pharmacy 1.2–14
physical effects 1.27–37
physiological dependence 2.34
phytocannabinoids 1.32–3
phytochemicals 1.31
pipelines 1.294
see also seizures
Plan Nacional Sobre Drogas (Spain) 1.301, 
1.307, 1.309
Poland 1.232–3
availability 1.75
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.81
lifetime prevalence 1.67, 1.68, 1.70, 1.72
political debate 1.87–8
polydrug prevention 2.219–21
polydrug use 1.74, 1.119–35, 2.79–95, 
2.266–7, 2.290–1
risk profiles 2.89–90
typography of users 2.88–9
Pompidou Group 2.230, 2.263, 2.264, 2.350
popular culture 1.79
population surveys 1.70–1, 2.29–57
Portugal 1.232–3
consumption of cannabis products 1.250
potency of cannabis 1.245, 1.251
possession laws 1.147
potency 1.197, 1.219, 1.227–30, 1.239–62
cannabis resin 1.228, 1.230
changes in 1.244–52
comparative 1.232–3
definition 1.242
herbal cannabis 1.228, 1.229, 1.230
increased 2.134
proxy measures 1.253
premature mortality 2.125–6
prenatal cannabis exposure 2.124–5
prescription drugs 2.79
prescription system 1.126
prevalence 2.3–26
comparative figures 2.12–13
current 2.11–12
Europe 2.19–21
and gender 2.18–19
increasing use 2.70–1
intensive use 2.14–17
lifetime 1.67–9, 1.73, 2.2, 2.9, 2.66–7
and perceived availability 2.72–4
recent 2.9–11, 2.68–9
students 2.59–77
substance use 2.85–6
prevention 2.217–44, 2.338–40
campaigns 1.85
classification systems 2.220
consistent approach 2.222
education 1.174–5, 2.219–21
environmental 2.220, 2.223–4
gender focus 2.228
heterogeneous settings 2.222–3
indicated 2.220, 2.235
informal and formalised 
programmes 2.221–2
polydrug 2.219–21
school-based 2.247–59
selective 2.220, 2.231–5
universal 2.220, 2.224–9
prices 1.76–7, 1.187–212, 1.219, 1.287
and availability 1.222–7
comparative 1.232–3
Europe 1.273–4
long-term trends 1.224–7
Morocco 1.268
PRISAM 1.23
problematic cannabis use 2.329
problematic use 2.16
definition of 2.31
production
cannabis resin 1.199–203, 1.265–71
herbal cannabis 1.192–8
prohibition 1.119–35
alternatives to 1.125–6
Index
318
protective factors 2.325–45
protest movements 1.39–49
Denmark 1.147–72
psychoactive properties 1.5, 1.66–7
psychoactive substances 2.79
psychological dependence 2.34
psychological effects 2.127–33
dependence 2.34
mood 2.119
psychological risk factors 2.336–7
psychometric screening 2.29, 2.242
psychosis see psychological effects
psychosocial intervention 2.279–95
psychotic disorders 1.47, 1.54, 1.239, 1.244, 
2.115–40, 2.326, 2.337
public debate 1.87–8
public health impact 2.143–54, 2.157–71
social and health harm 2.147–52
Pusher Street 1.157, 1.159–60, 1.162–3
Q
quality measures 2.35–6
Quit the Shit (Germany) 2.222
R
Rabelais, François 1.5
RAND Drug Policy Research Center 1.303, 1.309
rationing 1.126–7
recent use 2.9–11, 2.68–9
receptors 1.11–12, 1.19, 1.31, 1.34–6
reclassification 1.48
recreational settings 1.53, 1.119, 2.229
Red Book recommendations 2.227
reefers 1.251–2
Rees-Mogg, William 1.45
reference tests 2.35–6
referrals 1.82, 2.287–8, 2.319–20
reform movements 1.157–72
regulatory policies 1.119–35
location/circumstances of use 1.129
and potency 1.127–8
relative consumption 1.253
reproductive system 2.124
research 2.347–53
respiratory cancers 2.121–3
respiratory system 2.120–1
Richards, Keith 1.44, 1.45
Rif Mountains see Morocco
rimonabant 1.22
risk factors 2.325–45
psychological 2.336–7
risk magnitude 2.163–4
risk perception 2.74, 2.229–31
risk profiles 2.89–90
road safety 2.173–98
roadside testing 2.188–9
Rotterdam 1.153
rural areas 1.71
S
sampling 1.254
Sativex 1.21–2
Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN) 2.36
schizophrenia 2.132–3
school-based prevention programmes 2.247–59
dissemination of 2.256–7
effectiveness of 2.255–6
evidence-based 2.250–4
schools 2.65, 2.79–95, 2.224–8, 2.229–30
selective prevention 2.231–2
Schroff, Carl Damian Ritter von 1.7
screening 2.29–57
concepts 2.32–5
validation and quality measures 2.35–6
screening tests 2.36–8
adolescents 2.39–40
adults 2.38–9
long 2.40–1
Second League of Nations Opium 
Conference 1.101
seizures 1.82, 1.83, 1.195, 1.275, 1.276, 1.294
and availability 1.219, 1.220–2
cannabis plants 1.221
cannabis resin 1.221
comparative 1.232–3
Europe 1.205, 1.273
global 1.204
herbal cannabis 1.221–2
Morocco 1.273
regional breakdown 1.206
selective prevention 2.220, 2.231–2
criminal justice system 2.232–3
informal settings 2.233–5
school setting 2.231–2
Severity of Dependence (SDS) Scale 2.36, 2.38, 
2.46
sinsemilla 1.191, 1.195–6, 1.198, 1.246
potency 1.249, 1.250
skunk see sinsemilla
Slovakia 1.232–3
availability 1.75
drug seizures 1.82, 1.83
herbal cannabis buying power 1.77
legislation 1.81
lifetime prevalence 1.67, 1.68, 1.70, 1.71
outpatient treatment services 1.87
Slovenia 1.232–3
availability 1.75
drug seizures 1.82, 1.83
Index
319
herbal cannabis buying power 1.77
legislation 1.81
lifetime prevalence 1.67, 1.68
smoking 1.33, 1.128, 1.175, 1.178
safety of 1.177
smuggling see trafficking
snuff 1.128
social environment 2.334–6
social harm 2.147–52
social networks 1.75
social protest 1.39–49
social representations 1.77–9
social responses 1.79–85
social vulnerability 2.232
social withdrawal 2.106–7
as relationship to society 2.108
socio-economic factors 1.72
sociology 1.39–49, 2.97–110, 2.325–45
sociopolitical context 2.165–6
Softsecrets 2.224
Soma 1.39, 1.44
Soubeiran, Eugene 1.6
Spain 1.232–3
cannabis use 2.20
distribution 1.275–6
importing cannabis 1.263–89
Plan Nacional Sobre Drogas 1.301, 1.307, 
1.309
prices 1.273–4
seizures 1.273
trafficking into 1.275–6
spliffs 1.179
standardisation 1.287
stigmatisation 2.108
street-level availability 1.218
strength see potency
students 2.59–77
availability 2.64
awareness 2.63–4
lifetime use 2.66–7
recent use 2.68–9
supply channels 2.64–5
subcultures 2.97–110
summum 1.239
supply 1.63–93, 1.187–212, 1.273–4, 1.291–7, 
2.64–5
and consumption 1.295–6
see also availability; market sizing
supply model 1.293–5
supply reduction 1.79–85
surveys 1.70–1
Sweden 1.232–3
Bratt system 1.126
cannabis use 1.146
drug policy 1.51–60
Swedish conscript study 2.129
T
Talk to Frank (UK) 2.222
taxation 1.119–35
effectiveness of 1.127
tetrahydrocannabinol 1.11, 1.19, 1.32
chemical structure 1.243
decomposition 1.243–4
pharmacology 1.33–4
and potency 1.227
tetrahydrocannabinol acid 1.243
THC see tetrahydrocannabinol
therapeutic use see medicinal use
Therapeutic Uses of Cannabis 1.20
Tinctura Cannabis indicae 1.8
T lymphocytes 1.31
tobacco 2.79, 2.330–1
and cannabis 1.180
health effects 2.151
prevalence 2.85–6
tobacco policy 1.123–4
alternatives to prohibition 1.125–6
consumption after legalisation 1.125
cost-effectiveness 1.125
and potency 1.128
rationing system 1.126–7
tolerance 2.34
trade agreements/disputes 1.129
trafficking 1.203–9, 1.275–6
by air 1.280–1
by boat 1.282–3
by rail 1.282
cannabis resin 1.208–9
case histories 1.279–83
and gender 1.278
herbal cannabis 1.206–7
large-scale 1.282
for multiregional distribution 1.280
nationalities of traffickers 1.276–8
organisations and networks 1.279
see also distribution
treatment 1.58, 2.203–15
adolescents 2.209
adults 2.209–12
description of 2.284–6
pharmacological 2.212
service survey 2.279–95
treatment centres 2.283–4
treatment clients 2.266–8
treatment demand 2.261–76
data collection 2.264–6
Germany 2.305–23
incidence of 2.268–74
trends in 2.320–1
treatment referral 2.272–4
treatment response 1.85–7
Index
320
trends in use 2.212.4
by countries 2.22–4
Trimbos Institute (Netherlands) 1.151, 2.349
see also Netherlands
Turkey, legislation 1.100–1
U
United Kingdom 1.232–3
consumption of cannabis products 1.250
potency of cannabis 1.245, 1.246, 1.249, 
1.250, 1.251
Talk to Frank programme 2.222
United Nations Single Convention on Narcotic 
Drugs (1961) 1.102, 1.104
United States 1.8–9, 1.146
schools prevention programmes 2.247–59
universal prevention 2.220, 2.224–8
best practices 2.227–8
content 2.225–7
rationale 2.225
trends in 2.228–9
UNODC 1.187–212, 2.144
Morocco cannabis surveys 1.266
see also World Drugs Report
urban areas 1.71, 1.72
use see prevalence
V
validation 2.35–6
vaporisers 1.177
violence 1.283–4
visual arts 1.78
von Esenbeck, Friedrich Ludwig Nees 1.5
W
Warsaw 1.72
waterpipes 1.177–8
West Africa 1.187–8, 1.190, 1.200–2
WHO Expert Committee on Drug 
Dependence 1.105
Wootton Report 1.39–49, 1.106
World Drug Report 1.193
see also trafficking, UNODC
Z
zero tolerance 1.161, 1.162

European Monitoring Centre for Drugs and Drug Addiction
EMCDDA Scientific Monograph Series 8, Volume 1
A cannabis reader: global issues and local experiences
Lisbon: European Monitoring Centre for Drugs and Drug 
Addiction
2008 — 352 pp. — 16 x 24 cm
ISBN number: 978-92-9168-311-6
ISSN number: 1606-1691
DOI number: 10.2810/13807
Catalogue number: TD-32-07-001-EN-C
Price (excluding VAT) in Luxembourg: EUR 20 per volume
© European Monitoring Centre for Drugs and Drug Addiction, 
2008.
How to obtain EU publications
Our priced publications are available from the EU Bookshop 
(http://bookshop.europa.eu), where you can place an order 
with the sales agent of your choice.
The Publications Office has a worldwide network of sales 
agents. You can obtain their contact details by sending a fax to 
(352) 29 29-42758.
A cannabis reader: global issues and 
local experiences
IS
S
N
 1
6
0
6
-1
6
9
1
EMCDDA 
MONOGRAPHS
A
 cannabis reader: global issues and local experiences
E
M
C
D
D
A
 
M
O
N
O
G
R
A
PH
S
Price (excluding VAT) in Luxembourg: EUR 20 per volume
1
5
     1
7
     1
6
   T
D
-3
2
-0
7
-0
0
2
-E
N
-C
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) is one of the European Union’s decentralised 
agencies. Established in 1993 and based in Lisbon, it is the 
central source of comprehensive information on drugs and 
drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, 
objective, reliable and comparable information on drugs and 
drug addiction. In doing so, it provides its audiences with an 
evidence-based picture of the drug phenomenon at European 
level.
The Centre’s publications are a prime source of information 
for a wide range of audiences including policy-makers and 
their advisers; professionals and researchers working in the 
drugs field; and, more broadly, the media and general public.
EMCDDA monographs are comprehensive scientific 
publications containing thematic papers prepared in the 
context of the Centre’s activities. Topics cover a wide range 
of issues relating to science, policy, epidemiology and best 
practice.
88 VOLUME 
II
V
O
L.
 II
